

OSCIENT PHARMACEUTICALS CORP

Form 10-K

March 25, 2009

[Table of Contents](#)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

(Mark one)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended: December 31, 2008

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 0-10824

OSCIENT PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Massachusetts
(State or other jurisdiction)

04-2297484
(IRS employer

of incorporation or organization)
1000 Winter Street, Suite 2200

identification number)

Waltham, Massachusetts
(Address of principal executive offices)

02451
(Zip Code)

Registrant's telephone number: (781) 398-2300

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name of Each Exchange on Which Registered
Common Stock, \$.10 Par Value	NASDAQ Global Market

Securities registered pursuant to Section 12(g) of the Act:

None.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "accelerated filer," "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer (do not check if smaller reporting company)

Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of June 30, 2008, the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was \$16,647,721 as reported on the NASDAQ Global Market. The number of shares outstanding of the registrant's common stock as of March 20, 2009 was 39,003,978.

DOCUMENTS INCORPORATED BY REFERENCE

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Portions of the registrant's proxy statement for use at its 2009 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K.

Table of Contents

Oscient Pharmaceuticals Corporation

ANNUAL REPORT

ON FORM 10-K

INDEX

	PAGE
<u>PART I</u>	
Item 1. <u>Business</u>	1
Item 1A. <u>Risk Factors</u>	22
Item 2. <u>Properties</u>	47
Item 3. <u>Legal Proceedings</u>	48
Item 4. <u>Submission of Matters to a Vote of Security Holders</u>	48
<u>PART II</u>	
Item 5. <u>Market for the Registrant's Common Stock and Related Security Holder Matters</u>	49
Item 6. <u>Selected Financial Data</u>	51
Item 7. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	52
Item 7A. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	81
Item 8. <u>Financial Statements and Supplementary Data</u>	81
Item 9. <u>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u>	81
Item 9A. <u>Controls and Procedures</u>	81
Item 9B. <u>Other Information</u>	83
<u>PART III</u>	
Item 10. <u>Directors, Executive Officers and Corporate Governance</u>	83
Item 11. <u>Executive Compensation</u>	83
Item 12. <u>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u>	84
Item 13. <u>Certain Relationships and Related Transactions and Director Independence</u>	84
Item 14. <u>Principal Accountant Fees and Services</u>	84
<u>PART IV</u>	
Item 15. <u>Exhibits and Financial Statement Schedules</u>	85
<u>SIGNATURES</u>	90

Table of Contents

PART I

Forward-Looking Statements

Certain statements contained herein related to our anticipated cash utilization and the sufficiency of our cash resources, our actions taken to preserve financial resources and position the Company for partnership or acquisition, our engagement with Broadpoint Capital, Inc. to advise the Company on strategic options, including the potential sale of the Company, our ability to raise additional funds and/or refinance our maturing and existing debt and to fund operations, the availability and length of a FDA stay of approval of the ANDA referencing ANTARA and the timing of FDA approval of the generic drug product which is the subject of that ANDA, our discount and rebate programs for ANTARA and FACTIVE, the possible partnering or other strategic opportunities for the continued development of Ramoplanin, our plans to work with the FDA to implement any necessary changes to the FACTIVE labeling, the potential marketing approval of FACTIVE in Europe, the possibility of acquiring a third product, as well as other statements related to the progress and timing of product development, present or future licensing, collaborative or financing arrangements or that otherwise relate to future periods, are forward-looking statements. These statements represent, among other things, the expectations, beliefs, plans and objectives of management and assumptions underlying or judgments concerning the future financial performance and other matters discussed in this document. The words may, will, should, plan, believe, estimate, intend, anticipate, project, and expect and similar expressions are intended to identify forward-looking statements. All forward-looking statements involve certain risks, estimates, assumptions, and uncertainties with respect to future revenues, cash flows, expenses and the cost of capital, among other things.

Some of the important risk factors that could cause our actual results to differ materially from those expressed in our forward-looking statements are included under the heading Risk Factors in this Form 10-K. We encourage you to read these risks carefully. We caution investors not to place significant reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless another date is indicated) and we undertake no obligation to update or revise forward-looking statements.

Item 1. Business

OVERVIEW

Oscient Pharmaceuticals Corporation (we , us , or the Company) is a commercial-stage pharmaceutical company marketing Food and Drug Administration (FDA)-approved products in the United States. We have developed a commercial infrastructure, including a national sales force calling on targeted primary care physicians, cardiologists, endocrinologists and pulmonologists in the United States.

We currently market two products: ANTARA® (fenofibrate) capsules, a cardiovascular product, and FACTIVE® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is approved by the FDA to treat hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with a healthy diet. We license the rights to ANTARA from Ethypharm S.A. of France (Ethypharm) and began promoting ANTARA in late August 2006. In 2008, ANTARA generated approximately \$70 million in net revenues. FACTIVE is indicated for the treatment of community-acquired pneumonia of mild to moderate severity (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB). We license the rights to gemifloxacin, the active ingredient in FACTIVE tablets, from LG Life Sciences of the Republic of Korea (LG Life Sciences) and launched FACTIVE in the U.S. market in September 2004. In 2008, FACTIVE generated approximately \$16 million in net revenues.

Additionally, we have a novel, late-stage antibiotic candidate, Ramoplanin for the treatment of *Clostridium difficile*-associated disease (CDAD). To concentrate our financial resources on building our revenues for products promoted to community-based physicians in the United States, we have explored partnering and other strategic opportunities for the continued development of Ramoplanin.

Table of Contents

Our goal is to maximize the sales of our existing products and to gain access to new primary care products via transactions, including acquisition, in-licensing and co-promotion for the U.S. marketplace in order to leverage our existing sales force and commercial infrastructure. Our review of potential additions to our portfolio of marketed products is focused on those products which are commonly prescribed by those primary care physicians that we currently visit during the marketing of ANTARA and FACTIVE. As we currently direct our sales effort largely at those primary care physicians that treat older patients with co-morbidities, a range of therapeutic categories can be considered for our portfolio, including cardiovascular, diabetes, metabolic and anti-infectives, among others.

We have been pursuing privately raising additional capital from investors through equity financing, the incurrence of indebtedness, or a combination of equity and debt. We plan to use the additional capital if raised to fund operations and repay approximately \$17.7 million of indebtedness which comes due in December 2009, for operating cash and to execute our business strategy. As a result of our need for additional financing and our recurring operating losses, our auditors included a going concern explanatory paragraph in their audit opinion for the year ended December 31, 2008. Based on the current credit market turmoil and the inclusion of a going concern explanatory paragraph in our auditor's report on our consolidated financial statements, there can be no assurance that we will be able to raise additional capital in the future. If we are unable to secure additional financing or refinance or repay our indebtedness as it becomes due, we may be unable to continue operations as a going concern and will be materially and adversely affected.

In order to more aggressively preserve the Company's financial resources and position our organization for a potential partnership or acquisition, on February 11, 2009, we announced a reduction of approximately 32% in the size of our sales and marketing teams as well as a reduction in our office personnel.

Also on February 11, 2009, we announced that we have engaged Broadpoint Capital, Inc. to advise the Company on strategic options, including the potential sale of the Company. There can be no assurance that this engagement will enable the Company to identify and implement strategic options that will be of benefit to investors.

ANTARA

The Fenofibrate and Cholesterol-Treatment Markets

Nearly 37 million Americans have total cholesterol values above recommended levels and heart disease remains the number one cause of death in the U.S. Abnormal cholesterol and lipid levels, known as dyslipidemia, can lead to the development of atherosclerosis, a dangerous hardening of blood vessels and a primary cause of coronary heart disease. Managing cholesterol levels is a complex undertaking and several therapeutic options are available to treat different types of abnormalities. Statins are the standard of care for lowering high levels of LDL-C (low density lipoprotein cholesterol). Fenofibrate products have demonstrated their utility in managing atherogenic dyslipidemia or mixed dyslipidemia (also known as lipid abnormalities) which are characterized by high triglycerides, low HDL-C (high density lipoprotein cholesterol), high levels of remnant-like particle cholesterol and a high proportion of cholesterol carried by small, dense LDL particles. Other drugs commonly used to treat lipid abnormalities include niacin and omega-3 fatty acids.

In 2008, total U.S. sales of fenofibrate products were approximately \$2.3 billion, a 16% increase over 2007 sales. The fenofibrate market has experienced a 15% average annual growth in sales since 2004 with growth in 2008 over 2007 slowing to 10%.

ANTARA's sales accounted for approximately 5% of the U.S. fenofibrate sales for the year ending December 31, 2008.

Table of Contents

Indications and Efficacy

ANTARA is a once-daily formulation of fenofibrate approved for use in combination with a diet restricted in saturated fat and cholesterol to reduce elevated LDL-C (bad cholesterol), triglyceride and apolipoprotein B (free floating fats in the blood) levels and to increase HDL-C (good cholesterol) in adult patients with high cholesterol or an abnormal concentration of lipids in the blood. Fenofibrate products work primarily to lower triglycerides and increase HDL-C. ANTARA received FDA approval in November 2004 and is approved and marketed in 43 mg and 130 mg doses. The predominantly prescribed dose is 130 mg while the 43 mg dose is generally used for titration and in patients with impaired renal function. ANTARA was approved based in part on demonstrating its bioequivalence to Abbott Laboratories fenofibrate product TriCor®, meaning that, under FDA guidelines, the bioequivalence of the two products does not differ significantly when the two products are given under similar conditions. ANTARA was also studied in the Triglyceride Reduction in Metabolic Syndrome study, known as TRIMS, to measure the impact of ANTARA on cholesterol levels in patients with multiple cardiovascular risk factors and to assess the use of ANTARA without regard to meals.

In the treatment of hypercholesterolemia, ANTARA is approved as adjunctive therapy to diet to reduce elevated LDL-C, total cholesterol (total-C), triglycerides and apolipoprotein B (apo B) and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia. The effects of fenofibrate at a dose equivalent to 130 mg ANTARA per day were assessed in four randomized, placebo-controlled, double-blind, parallel-group studies. Fenofibrate therapy lowered LDL-C, total-C, and the LDL-C/HDL-C ratio. In these studies, fenofibrate therapy also lowered triglycerides, raised HDL-C and significantly reduced apo B as compared with placebo.

ANTARA is also indicated as an adjunctive therapy to diet for the treatment of hypertriglyceridemia, which affects an estimated 10% of American men over the age of 30 and 10% of American women over the age of 55. In clinical studies, the effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 hypertriglyceridemic patients for eight weeks. In patients with hypertriglyceridemia, treatment with fenofibrate at dosages equivalent to 130 mg ANTARA per day effectively decreased very low density lipoprotein (VLDL) triglycerides and VLDL cholesterol.

Mechanism of Action: ANTARA increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity). The resulting decrease in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. ANTARA also activates PPAR-alpha, which induces an increase in the synthesis of apoproteins A-I, A-II and HDL-cholesterol.

Competitive Advantages: The TRIMS study produced exclusive clinical data for ANTARA. In the study, ANTARA was evaluated in patients with elevated triglyceride levels and multiple cardiovascular risk factors. Of the 146 patients studied, 70% had hypertension and 32% had diabetes. The double-blind, placebo-controlled trial measured levels of total cholesterol, triglycerides, HDLs and LDLs, as well as other types of cholesterol, during eight weeks of therapy. In the study, ANTARA demonstrated the ability to reduce triglyceride and increase HDL-C levels after two weeks of therapy. At the end of therapy, patients treated with ANTARA had a statistically significant 37% reduction in their triglyceride levels and a statistically significant 14% increase in their HDL levels. ANTARA is distributed in 130 mg and 43 mg capsule formulations, as compared to the 145 mg and 48 mg tablet formulations of TriCor, which is marketed by Abbott Laboratories.

License Agreement

On August 18, 2006, we acquired rights to ANTARA in the United States from Reliant Pharmaceuticals Inc. (Reliant) for \$78.0 million plus approximately \$4.3 million for ANTARA inventory, excluding estimated transaction costs. Under the terms of our acquisition of ANTARA, we assumed certain of Reliant s liabilities

Table of Contents

related to ANTARA and we were assigned rights to an exclusive license from Ethypharm S.A. (Ethypharm). Pursuant to the Ethypharm license, in order to maintain the exclusivity of our rights, we must achieve minimum annual sales in the United States until February 2012 or alternatively Ethypharm may elect to convert our exclusive license to a non-exclusive; however, we would then have the option to compensate Ethypharm for any shortfall to maintain the exclusive license. On or about February 27, 2009, we received notice from Ethypharm that we had not achieved the minimum sales threshold, and accordingly within 60 days of receipt of such notice, on or approximately April 28, 2009, we may elect to maintain the exclusivity of the license by compensating Ethypharm for any shortfall, or to convert the exclusive license to a non-exclusive license. As of December 31, 2008, we have recorded approximately \$621,000 related to the potential minimum royalty obligation owed to Ethypharm and which would be payable in the event we elect to maintain the exclusivity of the license. During the term of the agreement with Ethypharm, we are obligated to pay a royalty on net sales of ANTARA in the U.S., including a royalty on other fenofibrate monotherapy products in formulations and dosage forms that may be substantially similar or identical to ANTARA developed by us. The license term expires in February 2020 and, absent notice of termination by either party, automatically renews for consecutive periods of two (2) years each. Under the terms of the agreement, at our option, Ethypharm is obligated to either manufacture and deliver to us finished fenofibrate product or deliver active pharmaceutical ingredient (API) to us for encapsulation and packaging. Ethypharm also has a right of first refusal on any divestiture of the ANTARA rights by us. Oscient also has other obligations under the Ethypharm agreement, including the funding of a portion of the API safety stock that Ethypharm is required to maintain.

Pursuant to the terms of our acquisition of ANTARA from Reliant, we also acquired the New Drug Application (NDA), and the Investigational New Drug application (IND), covering the ANTARA products in the United States, clinical data, inventory, the ANTARA trademark in the United States and certain related contracts and licenses covering intellectual property rights related to the ANTARA products. We also assumed certain of Reliant's liabilities relating to the ANTARA products.

In accordance with the terms of our asset purchase agreement with Reliant we assumed a third party license relating to ANTARA not including the Ethypharm license. Under the license we are obligated to make certain royalty payments based on sales of ANTARA, which royalty payments are subject to a low single digit increase in the event of a change in control of the Company. The third party license also limits our ability to co-promote ANTARA with companies other than contract sales organizations or similar companies. We have engaged the third party licensor to renegotiate the terms of that license and have suspended further royalty payments while the terms of such license are being renegotiated.

We are not required to pay Reliant a royalty on the sale of the ANTARA products; however, we are required to pay a low single-digit royalty to Reliant for a specified time period on net sales of any line extensions and improvements to the ANTARA products that we develop, which include any product containing fenofibrate as the active pharmaceutical ingredient. We currently do not pay royalties to Reliant. We also agreed that we would not, at any time prior to August 2016, develop or sell any product in the United States that is a combination of fenofibrate and an omega-3 compound without the prior written consent of Reliant. On December 19, 2007, Reliant was acquired by GlaxoSmithKline.

FACTIVE

Infectious Diseases Market

Infectious diseases represent the second leading cause of death worldwide accounting for over 14 million deaths each year, with lower respiratory tract infections alone causing 3.9 million deaths annually. Bacterial infections are the ninth leading cause of death in the U.S. Sales of antibiotics in the U.S. totaled approximately \$15 billion in 2008. Within the antibiotic market, fluoroquinolones, a product class with close to \$4.1 billion in annual sales in the U.S. in 2008, have been gaining market share at the expense of older classes of antibiotics, according to Wolters Kluwer, a leading provider of pharmaceutical market data.

Table of Contents

The principal classes of antibiotics include beta-lactams, fluoroquinolones, macrolides, tetracyclines, aminoglycosides, glycopeptides and trimethoprim combinations. Bacterial resistance to existing antibiotics has increased in recent years, leading to bacterial infection recurrences, treatment failures and higher costs. These factors have fueled a growing need for more effective products in existing antibiotic classes, as well as for products with new mechanisms of action.

Acute Bacterial Exacerbations of Chronic Bronchitis: Chronic bronchitis is a health problem associated with significant morbidity and mortality. It is estimated that chronic bronchitis affects approximately 9 million adults in the United States. Patients with chronic bronchitis are prone to frequent exacerbations, characterized by increased cough and other symptoms of respiratory distress. Longitudinal studies have estimated that 1 to 4 exacerbations occur each year in patients with chronic bronchitis; studies estimate that two-thirds are caused by bacteria. Exacerbations are estimated to account for approximately 12 million physician visits per year in the U.S. Antibiotic therapy, the standard treatment for acute bacterial exacerbations of chronic bronchitis (AECB), is typically effective in reducing the course of illness for patients. Fluoroquinolones are frequently used to treat AECB due to their activity versus *Haemophilus influenzae* and *Moraxella catarrhalis*, two of the most common causes of these infections. Newer fluoroquinolones have enhanced activity versus *Streptococcus pneumoniae* (*S. pneumoniae*), another common cause of these infections.

Community-Acquired Pneumonia: Community-acquired pneumonia (CAP), is a common and serious illness in the United States. Of the estimated 4 to 5 million cases per year of CAP, nearly 1 million cases occur in patients over the age of 65. CAP cases result in approximately 10 million physician visits and as many as 1 million hospitalizations annually. Antibiotics are the mainstay of treatment for most patients with pneumonia, and where possible, antibiotic treatment should be specific to the pathogen responsible for the infection on a case by case basis. However, since the responsible pathogen is not identified in a high proportion of patients with CAP, physicians usually take an empiric approach to treatment in the first instance. Over the last decade, resistance to penicillins and macrolides has increased significantly, and in many cases, fluoroquinolones are now recommended as a first line of therapy due to their efficacy against a wide range of respiratory pathogens, including many antibiotic resistant strains. The most recent treatment guidelines from the Infectious Diseases Society of America and the American Thoracic Society recommend fluoroquinolones as a first-line treatment for certain higher-risk patients with CAP and as therapy for treating patients with pneumonia in geographic regions of the U.S. with high levels of macrolide-resistant *S. pneumoniae*.

Indications and Efficacy

FACTIVE is a member of the fluoroquinolone class of antibiotics. In April 2003, FACTIVE was approved by the FDA for the five-day treatment of AECB and seven-day treatment of CAP of mild to moderate severity. In July 2003, FACTIVE was also approved by the FDA to treat CAP caused by multi-drug resistant *S. pneumoniae*, a growing clinical concern. Multi-drug resistant *S. pneumoniae* (MDRSP), is defined as *S. pneumoniae* resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins (such as cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. In May 2007, FACTIVE was approved by the FDA for the five-day treatment of CAP.

FACTIVE has potent *in vitro* activity against a wide range of Gram-positive, Gram-negative and atypical pathogens, including key respiratory pathogens, such as *S. pneumoniae*, *H. influenzae* and *M. catarrhalis*. FACTIVE is bactericidal at clinically achievable concentrations. Gemifloxacin, the active ingredient in FACTIVE, has minimum inhibitory concentrations (MICs), as low as 0.032 µg/ml for *S. pneumoniae*. In clinical trials, FACTIVE has been administered to approximately 8,000 patients and had a good overall safety and tolerability profile. FACTIVE has been the subject of over 200 scientific publications and has been mentioned in nearly 300 scientific articles. Among the research published are data from a study involving 438 subjects indicating that a statistically significant higher percentage of patients treated with FACTIVE (71%) remained free of AECB recurrences than those treated with a comparator agent (58.5%) over a six-month period following treatment.

Table of Contents

Mechanism of Action: FACTIVE tablets act by inhibiting bacterial DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, two enzymes essential for bacterial growth and survival. Strains of *S. pneumoniae* showing mutations in both DNA gyrase and topoisomerase IV (double mutants) are resistant to most fluoroquinolones. Since gemifloxacin has the ability to inhibit both target enzymes at therapeutically relevant drug levels, some of these *S. pneumoniae* double mutants remain susceptible to FACTIVE. FACTIVE is also active against many strains of *S. pneumoniae* that are resistant to other classes of antibiotics.

Clinical Efficacy: The clinical development program for FACTIVE included 19 Phase III trials in respiratory tract infections. FACTIVE was studied for the treatment of acute bacterial exacerbations of chronic bronchitis in three pivotal, non-inferiority, double-blind, randomized, active-controlled clinical trials using 320 mg once daily for five-days. In these principal Phase III AECB studies, FACTIVE given once daily for five-days was at least as effective as the comparators given for seven-days, with clinical response rates in the FACTIVE arms ranging from 85.4% to 93.6%. FACTIVE was also studied for the treatment of CAP in three double-blind, randomized, active-controlled clinical studies, one open, active-controlled study, and two uncontrolled studies. The results of these studies showed that gemifloxacin was effective in the treatment of mild to moderate CAP.

Safety and Tolerability: FACTIVE tablets have been studied in approximately 8,000 patients in clinical trials and we estimate that to date, approximately 1,000,000 prescriptions have been dispensed for FACTIVE since its launch in September 2004. In clinical trials, the incidence of adverse events reported for FACTIVE tablets was low and comparable to comparator drugs, namely beta-lactam antibiotics, macrolides and other fluoroquinolones. Most adverse events were described as mild to moderate. The most common adverse events reported in FACTIVE clinical trials were diarrhea, rash and nausea. In clinical trials across all durations of therapy, rash was reported in 2.8% of patients receiving gemifloxacin and was more commonly observed in patients with treatment durations greater than seven-days and patients less than 40 years of age, particularly females. In clinical trials conducted in 3,696 patients treated with five-days of FACTIVE therapy, the rate of rash reported was 1.1% vs. 0.7% for comparator antibiotics. Since the launch of the drug, the post-marketing adverse events reported have been consistent with those observed in the clinical development program, and with the fluoroquinolone class as a whole.

Competitive Advantages: We believe the competitive advantages of FACTIVE tablets include:

FACTIVE has been shown in *in vitro* studies to be active against many bacterial isolates resistant to other classes of antibiotics.

FACTIVE is the most active fluoroquinolone against *S. pneumoniae*, one of the most prevalent pathogens found in lower respiratory tract infections, compared to the currently marketed fluoroquinolones (MIC₉₀ 0.032 µg/mL).

FACTIVE has a dual mechanism of action in bacteria, targeting two enzymes essential for bacterial growth and survival at therapeutically relevant drug levels, and as a result we believe FACTIVE has low potential for generating bacterial resistance.

FACTIVE can be dosed once daily, with short courses of therapy (five-days) for both AECB and CAP.

FACTIVE is effective in the treatment of CAP due to penicillin-resistant *S. pneumoniae* and due to MDRSP. In clinical trials, of 22 patients with MDRSP treated with FACTIVE for seven-days, 19 (87%) achieved both clinical and bacteriological success at follow-up.

FACTIVE achieves high concentration levels in lung and bronchial tissues and in secretions.

FACTIVE has composition of matter patent protection which extends into 2018, longer than the composition of matter patent protection for any currently marketed fluoroquinolone or other antibiotic widely used to treat respiratory tract infections.

Post-Marketing Commitments: As a post-marketing commitment to the FDA, we completed a Phase IV trial of FACTIVE. This prospective, randomized study examined the activity of FACTIVE tablets (5,000 patients)

Table of Contents

versus an active comparator (2,500 patients) in treating patients with mild to moderate CAP or AECB. The study included patients of different ethnicities so that safety information in populations not substantially represented in the existing clinical trial program could be collected, specifically as it relates to rash. This Phase IV trial was initiated in the fall of 2004 and was completed in February 2007. The final report of the utilization study was submitted to the FDA in March of 2008. In the future, we need only to provide the FDA with annual reports containing safety information.

Recent developments: On July 7, 2008, we received notice from the FDA directing that the prescribing information for all fluoroquinolone products, including FACTIVE, be revised to include a Boxed Warning relating to the risk of tendonitis and tendon rupture associated with the use of fluoroquinolone product. Warnings regarding the risk of tendon related adverse events were already included in the prescribing information, as part of a class labeling, for all fluoroquinolones. The FDA has cautioned that such risk is increased in patients over the age of 60 and in those on concomitant corticosteroid therapy, as well as kidney, heart and lung transplant recipients. The FDA has also required that all manufacturers of fluoroquinolones submit a Medication Guide. The FDA has approved our changes to the package insert and Medication Guide as required by FDA to ensure patient safety and improve physician understanding of the risk-benefit profile for fluoroquinolone products, including FACTIVE. We have also submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) as required by FDA of all sponsors of fluoroquinolone products to ensure patients' safe and effective use of such products. We are working with the FDA to finalize certain details of the REMS.

Additional Development of FACTIVE

Five-Day Treatment of CAP: We completed a clinical trial to demonstrate that a five-day course of FACTIVE for the treatment of mild to moderate CAP is as effective as the previously approved seven-day course of treatment. On September 21, 2006, we received an approvable letter from the FDA for the supplemental New Drug Application (sNDA) seeking approval for the five-day treatment of CAP with FACTIVE tablets. In accordance with the letter, we provided clarification and additional interpretation regarding certain data included in the application to assist the FDA in its evaluation. On May 1, 2007, the FDA approved FACTIVE for the five-day treatment of CAP.

In the five-day CAP clinical trial, a five-day course of therapy with FACTIVE was shown to be as effective as the FDA-approved seven-day course of treatment, with both arms displaying excellent clinical response rates. Further, data showed that the bacteriological and radiologic success rates with five-days of therapy were also non-inferior to the success rates with seven-days of therapy. The multicenter, randomized, double-blind study enrolled 510 patients with CAP, with 469 patients comprising the per protocol group. Investigators measured clinical and bacteriological response at end of therapy as well as clinical, bacteriological and radiologic response at follow-up (two to three weeks post therapy). Clinical response at follow-up, the primary endpoint, in the per protocol group was 95% for the five-day treatment arm and 92% for the seven-day treatment arm (95% CI: -1.48, 7.42), demonstrating non-inferiority between the two groups. Further, clinical response at end of therapy in the per protocol group was 96% for the five-day group and 96% for the seven-day group (95% CI: -3.85, 3.42). The study also yielded encouraging results for bacteriological response. Bacteriological response in the per protocol population was 91% for the five-day and seven-day groups at follow-up (95% CI: -6.89, 7.93) and 94% for the five-day group and 96% for the seven-day group (95% CI: -8.27, 3.25) at end of therapy. The study demonstrated radiologic response at follow-up in the per protocol population of 98% for the five-day arm and 93% for the seven-day arm (95% CI: 0.35, 7.91). FACTIVE was well-tolerated in the study, with a low withdrawal rate due to adverse events: 1.2% for the five-day group and 2.0% for the seven-day group. The most common adverse event reported was a laboratory finding of elevated liver enzymes (increased ALT and increased AST). Analysis of all ALT/AST values demonstrated that the elevations were significantly associated with baseline ALT levels (elevated in many patients) with no significance or association with a particular treatment group. There was also no evidence of symptomatic hepatic events. In addition, the rate of drug-related rash in both treatment groups was low: 0.4% for the five-day arm and 2.8% for the seven-day arm. There were no withdrawals due to rash.

Table of Contents

Acute Bacterial Sinusitis: As part of the FACTIVE development program, several studies relating to acute bacterial sinusitis (ABS), were completed, and, in November 2005, we filed an sNDA for ABS. In September 2006, the FDA's Anti-Infective Drugs Advisory Committee voted not to recommend approval of this sNDA. In November 2006, we voluntarily withdrew our sNDA seeking approval of the ABS indication.

FACTIVE IV: An intravenous formulation of gemifloxacin has also been studied. If we elect to further pursue such a formulation, additional formulation development will be necessary before initiating a bioequivalence study.

License Agreement with LG Life Sciences

We license the rights to gemifloxacin, the active ingredient in FACTIVE tablets, from LG Life Sciences. We have the rights to commercialize gemifloxacin in North America, France, Germany, the United Kingdom, Luxembourg, Ireland, Italy, Spain, Portugal, Belgium, the Netherlands, Austria, Greece, Sweden, Denmark, Finland, Norway, Iceland, Switzerland, Andorra, Monaco, San Marino, Vatican City, Poland, Czech Republic, Slovakia, Slovenia, Hungary, Estonia, Latvia, Lithuania, Liechtenstein, Malta, Cyprus, Romania, Bulgaria, Croatia, Serbia and Montenegro, Bosnia and Herzegovina, Albania and the Former Yugoslav Republic of Macedonia. The term of the agreement with respect to each country extends at least through the life of the patents covering gemifloxacin in such country. In the United States, the last of the currently issued patents for composition of matter expires in 2018. The patent term could extend further in countries outside of the U.S. depending upon several factors, including whether we obtain patent extensions and the timing of our commercial sale of the product in a particular country.

Under the terms of the agreement, LG Life Sciences has agreed to supply and we are obligated to purchase from LG Life Sciences all of our anticipated commercial requirements for the FACTIVE active pharmaceutical ingredient (API). LG Life Sciences currently supplies the FACTIVE API from its manufacturing facility in South Korea.

The agreement with LG Life Sciences also required that we achieve a minimum gross sales level of \$30 million from our licensed territories over a 12-month period of time starting in approximately the third quarter of 2007 to the third quarter of 2008 which, if not met, LG Life Sciences could elect to terminate the agreement and have the technology be returned to LG Life Sciences. We believe that we have achieved the minimum gross sales threshold level. After LG Life Sciences' review of our financial information during the fourth quarter of 2008, it has accepted our analysis and concluded that it will not terminate the agreement based on the minimum gross sales level of \$30 million. Under this agreement, we are responsible, at our expense and through consultation with LG Life Sciences, for the clinical and commercial development of gemifloxacin in the countries covered by the license, including the conduct of clinical trials, the filing of drug approval applications with the FDA and other applicable regulatory authorities and the marketing, distribution and sale of gemifloxacin in our territory.

We are obligated to pay a royalty on sales of FACTIVE in North America and the territories covered by the license in Europe. These royalty obligations expire with respect to each country covered by the agreement on the later of (i) the expiration of the patents covering FACTIVE in such country or (ii) the expiration of data exclusivity in Mexico, Canada or the European Union respectively, or 2014 in the U.S. We are also obligated to make aggregate milestone payments of up to approximately \$40 million (not including payments to LG Life Sciences previously made pursuant to up-front obligations or achievements of certain milestones) including milestone payments required by the amendments described below upon achievement of additional regulatory approvals and sales thresholds.

Collaborations and Partnerships for FACTIVE

Pfizer, S.A. de C.V. On February 6, 2006, we entered into a Sublicensing and Distribution Agreement with Pfizer, S.A. de C.V. (Pfizer Mexico), pursuant to which we sublicensed our rights to market FACTIVE tablets

Table of Contents

in Mexico to Pfizer Mexico. In exchange for those rights, Pfizer Mexico has made an up-front payment and has agreed to pay milestone payments upon obtaining certain regulatory approvals and sales goals, as well as royalties on future sales. The up-front payment is being recognized as revenue over the term of our continuing obligations under the agreement. These royalty rates are subject to reduction upon expiration of certain patents in Mexico for FACTIVE or if a generic form of gemifloxacin has a material impact on Pfizer Mexico's sales volumes in Mexico. Pfizer Mexico is obligated to exclusively purchase from us, and we must exclusively supply, all API for FACTIVE. The agreement with Pfizer Mexico may be terminated by either party upon the occurrence of certain termination events, including Pfizer Mexico's right to terminate at any time after August 2007, the first anniversary of launch of FACTIVE tablets in Mexico upon six months prior written notice. Upon termination, Pfizer Mexico is obligated to assign any and all rights to regulatory approvals in Mexico to us or our designee.

In October 2006, Pfizer Mexico launched its promotion and marketing of FACTIVE-5 in Mexico for the five-day treatment of acute bacterial exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP). On December 9, 2008, Pfizer Mexico received regulatory approval to market FACTIVE tablets for the Uncomplicated Urinary Tract Infections (uUTI) indication with a 3 day course of treatment, from COFEPRIS, the pharmaceutical regulatory agency of Mexico.

Abbott Laboratories Ltd. On August 9, 2006, we granted the commercialization rights to FACTIVE tablets in Canada to Abbott Laboratories, Ltd. (Abbott Canada), the Canadian affiliate of Abbott. In exchange for those rights, Abbott Canada agreed to a transfer price on product purchases and to make certain payments to us upon achievement of certain regulatory and sales milestones. Our license agreement with Abbott Canada was terminated in December 2008 and Abbott Canada has ceased all development and commercialization of FACTIVE in Canada.

Menarini International Operation Luxembourg S.A. We entered into a License, Supply and Marketing Agreement with Menarini International Operation Luxembourg S.A. (Menarini), a wholly-owned subsidiary of Menarini Industrie Farmaceutiche Riunite S.r.l. dated December 28, 2006, whereby we sublicensed our rights to sell FACTIVE tablets in the European Union to Menarini. Under the terms of our agreement, Menarini is responsible for obtaining regulatory approval for FACTIVE in the European Union, and Oscient has agreed to reimburse Menarini for expenses associated with such regulatory development up to an agreed limit. Menarini has also paid us an up-front payment which is being recognized over the term of our continuing obligations under the agreement of approximately thirty-three months. Menarini has also agreed to pay us milestone payments upon obtaining certain regulatory and reimbursement approvals and upon achieving certain annual net sales goals, which could total up to \$23.0 million, if all the milestones are achieved. Menarini will pay us a transfer price on purchases of the active pharmaceutical ingredient (API), for FACTIVE, which is determined based on a percentage of quarterly sales of FACTIVE by Menarini in Europe. Menarini is also obligated to exclusively purchase from us, and we must exclusively supply, all API for FACTIVE to be sold in Europe for the earlier of (i) the expiration of the life of certain patents covering the product or (ii) expiration of data exclusivity. Our agreement with Menarini may be terminated by either party upon the occurrence of certain termination events, including Menarini's right to terminate if the European regulatory authorities do not recommend approval of FACTIVE at various stages of the approval process with a package insert, or label, that meets certain requirements as to the safety, dosing and indications for which FACTIVE may be prescribed. In recent years, the FDA has made the approval process for new antibiotics more challenging, sometimes requesting placebo-controlled or superiority design clinical studies for certain indications. It is possible that the European Medicines Agency (EMEA) could adopt a similar position regarding the approval of FACTIVE for certain indications, and as a result Menarini may not be able to secure regulatory approval of FACTIVE in Europe and accordingly could elect to terminate the agreement. Menarini may also terminate the agreement if it does not receive approval for reimbursement from European member countries that is above a certain minimum price per tablet. Upon termination, Menarini is obligated to assign any and all rights to regulatory approvals in the European Union to Oscient or its designee. In the first quarter of 2008, Menarini submitted a regulatory filing seeking approval of FACTIVE in Europe for the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.

Table of Contents

RAMOPLANIN

In October 2001, we in-licensed U.S. and Canadian rights to Ramoplanin from Vicuron Pharmaceuticals Inc. (Vicuron), a wholly-owned subsidiary of Pfizer Inc., and on February 3, 2006, acquired worldwide rights from Vicuron, assuming full control of Ramoplanin manufacturing, development and commercialization. Ramoplanin is a novel glycolipodepsipeptide antibiotic produced by fermentation of the bacteria *Actinoplanes*, with activity against Gram-positive aerobic and anaerobic microorganisms. In preclinical studies, Ramoplanin has been shown to be bactericidal against most Gram-positive species, including methicillin-resistant staphylococci, VRE and *C. difficile*, including the recent epidemic strains. Ramoplanin inhibits the bacterial cell wall peptidoglycan biosynthesis with a mechanism different from that of vancomycin, teicoplanin or other cell wall-synthesis inhibitors. No evidence of cross-resistance between Ramoplanin and other glycopeptide antibiotics has been observed *in vitro* to date. Ramoplanin has a unique profile that may make it particularly well-suited for killing bacteria in the GI tract.

In 2004, we completed a Phase II trial to assess the safety and efficacy of Ramoplanin in the treatment of CDAD. The open-label study enrolled 87 patients in 24 U.S. sites. The trial compared two doses of Ramoplanin (200 mg and 400 mg twice daily) to vancomycin (125 mg four times daily). Both agents were administered for ten days, during which data on Ramoplanin was collected to measure safety and efficacy. The primary endpoint of the study was response rate at the test-of-cure visit, 7 to 14 days post-therapy. For this trial, the response rates were 60% for Ramoplanin 200 mg, 71% for Ramoplanin 400 mg, and 78% for vancomycin 125 mg in the clinically evaluable population. While the study did not meet its primary endpoint, non-inferiority at the test-of-cure visit, the response rates for all three arms were comparable. A potentially more clinically relevant endpoint, response at the end of therapy, was also assessed. At the end of therapy, the response rates were 83% for Ramoplanin 200 mg, 85% for Ramoplanin 400 mg and 86% for vancomycin 125 mg.

In December 2005, we agreed with the FDA to a Special Protocol Assessment regarding the specific components of a Phase III program that, if completed successfully, would support regulatory approval for the indication. Because the Special Protocol Assessment was agreed to by the FDA in 2005, we cannot guarantee that the FDA will continue to regard it as a binding on the agency if and when we or a prospective partner reinitiates the Ramoplanin clinical development process. On January 8, 2008, the United States Patent and Trademark Office (USPTO) issued us a patent relating to methods of use of Ramoplanin for the treatment of CDAD.

Acquisition of Expanded Rights: In exchange for the assignment of the rights for Ramoplanin under the acquisition agreement with Pfizer, we made a one-time, up-front payment to Pfizer and agreed to make additional milestone payments for regulatory filings and approvals in various countries. We will also pay mid-single-digit to low double-digit royalties to Pfizer on net sales of Ramoplanin dependent upon the territory.

With the acquisition of ANTARA, we made the decision to concentrate our financial resources on building our revenues for products promoted to community-based physicians in the United States and have worked to out-license, co-develop or sell our rights to Ramoplanin to a partner. There can be no assurance that we will be able to license or divest Ramoplanin or to partner the development of Ramoplanin on acceptable terms, or at all.

SALES AND MARKETING

We market ANTARA and FACTIVE through our sales and marketing organization in the U.S. On February 11, 2009 we announced a reduction of approximately 32% in the size of our sales and marketing teams as well as a reduction in our office personnel. We have substantially completed the reduction of our sales and marketing organization, which at March 20, 2009 is comprised of approximately 168 field sales personnel, including 150 sales representatives, as well as district managers and regional sales directors. Sales and marketing functions are located within our New Jersey office. Our sales representatives focus on community-based physicians and opinion leaders who are potential high prescribers of fluoroquinolones and/or fenofibrate products. We have also built a team of professionals with experience in insurance and government

Table of Contents

reimbursement, medical affairs and marketing. Our strategy is to continue to leverage our existing commercial infrastructure through the acquisition, in-license or co-promotion of additional marketed products to market to community-based physicians in the United States.

Our strategy includes granting commercialization rights to FACTIVE tablets in territories outside of the U.S. to third parties to leverage the additional resources that a pharmaceutical marketing partner with expertise in such countries can provide. Thus, we have partnered with following entities:

On February 6, 2006, we sublicensed our rights to sell FACTIVE tablets in Mexico to Pfizer, S.A. de C.V. (Pfizer Mexico), the largest pharmaceutical company in Mexico. Pfizer Mexico is commercializing FACTIVE for community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis with three national field sales forces and one specialty field sales force. On December 9, 2008 Pfizer Mexico received regulatory approval to market FACTIVE tablets for Uncomplicated Urinary Tract Infections (uUTI) indication with a 3 day course of treatment, from COFEPRIS, the pharmaceutical regulatory agency of Mexico.

On December 27, 2006, we sublicensed our rights to sell FACTIVE tablets in Europe to Menarini International Operation Luxembourg SA (Menarini), the second largest primary care pharmaceutical company in Europe. Menarini is responsible for obtaining regulatory approval for FACTIVE in Europe and will leverage its regulatory and marketing experience to pursue approval and launch of FACTIVE in Europe. In the first quarter of 2008, Menarini submitted a regulatory filing seeking approval of FACTIVE in Europe for the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.

COMPETITION

The pharmaceutical industry generally is characterized by rapidly evolving technology and intense competition. Our competitors include pharmaceutical and biotechnology companies both in the United States and abroad. Many of our competitors have substantially greater capital resources, facilities and human resources than we do.

Competition with respect to our products and product candidates is and will be based on, among other things:

our sales and marketing expertise;

our clinical trial results and post marketing experience;

our ability to obtain appropriate regulatory approvals for our product candidates in a cost-efficient and timely manner and subsequently remain in regulatory compliance;

our ability to secure adequate reimbursement for our products from public and private healthcare payors;

our ability to attract and retain qualified personnel;

our ability to obtain patent protection and defend our patent challenges from generic companies including Lupin Limited and Orchid Healthcare;

our ability to in-license product candidates for clinical development;

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

our ability to gain access to new products via co-promotion or in-license agreements or product acquisitions;

our ability to secure sufficient capital resources to fund our clinical development and sales and marketing operations; and

our ability to secure sufficient capital resources to execute transactions to gain access to new products.

Table of Contents

Because we rely primarily on in-licensing, co-promotion and acquisitions of products and product candidates to expand our portfolio, it is important to note that we may also face increasing competition for in-licensing, co-promotion and acquisition opportunities from leading pharmaceutical and biotechnology companies. We cannot be certain that we will be able to in-license product opportunities in the future or acquire new products.

ANTARA

ANTARA is a fenofibrate product approved by the FDA to treat hypercholesterolemia and hypertriglyceridemia in combination with a healthy diet. The marketing of current and additional branded versions of fenofibrate could reduce our net sales of ANTARA and adversely impact our revenues. Currently, the primary competition for ANTARA in the fenofibrate market is TriCor[®] 145 mg, a product manufactured by Abbott Laboratories, which accounted for approximately 90% of U.S. fenofibrate sales for the twelve month period ended December 31, 2008. Additionally, Abbott Laboratories has recently introduced a new product, TriLipix[™], which the FDA approved in December 2008 whose active ingredient is fenofibric acid, the active metabolite of fenofibrate.

In addition to TriCor and TriLipix, there are several other branded fenofibrate products which compete with ANTARA. ANTARA competes with Triglide[®], a 160 mg fenofibrate product and Fenoglide[®], a 120 mg branded fenofibrate product, both which are marketed by Sciele Pharma, Inc., a wholly owned subsidiary of Shionogi & Co. Ltd. Triglide and Fenoglide accounted for approximately 2% of U.S. fenofibrate sales for the twelve month period ended December 31, 2008. ANTARA also competes with Lipofen[®], a 150 mg fenofibrate product, which is marketed by Kowa Pharmaceuticals America, Inc.

As described in Risk Factor Lupin Limited's and Orchid Healthcare's Paragraph IV certifications under the Hatch-Waxman Act related to ANTARA and FACTIVE respectively could have a material adverse effect on our financial condition and results of operations, as it could result in the introduction of a generic products prior to the expiration of the patents covering ANTARA and FACTIVE, as well as in significant legal expenses and diversion of management's time, we received notice of a Paragraph IV certification from Lupin Limited (Lupin), notifying us of the filing of an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of ANTARA. The final FDA approval of Lupin's ANDA and the commercialization of the drug product which is the subject of that ANDA would have a material adverse impact on the sales of ANTARA.

Additionally, several generic versions of fenofibrate in varying doses are also available for the treatment of dyslipidemias. Revenues from these products accounted for approximately 4% of total U.S. sales of fenofibrate in the twelve month period ended December 31, 2008. In May 2005, Teva Pharmaceutical Industries, Ltd. (Teva) obtained FDA approval to market a generic version of Abbott Laboratories' 160 mg TriCor tablet (which is no longer marketed or sold) and Par Pharmaceuticals and Impax Labs received FDA approval for similar generic products in October 2007 and March 2008, respectively. In addition, Solvay S.A., Abbott Laboratories' partner announced on January 23, 2008, that Teva had filed an ANDA with a Paragraph IV certification seeking the approval of a generic version of TriCor 145 mg. Additionally, Biovail Corporation announced on September 3, 2008 that it also has filed an ANDA seeking approval for a generic version of TriCor 145 mg. If a generic version of Abbott Laboratories' TriCor 145 mg product is approved by the FDA, the percentage of total revenues attributable to generic fenofibrate products would likely increase.

There are also several other FDA-approved products and products in development for similar indications as ANTARA which could compete with ANTARA, including statins, omega-3 fatty acids (including Lovaza[®] marketed by GlaxoSmithKline), niacin (including Niaspan[®] marketed by Abbott), ezetimibe and fixed-dose combination products. The growth of any of these branded products, the FDA approval of Lupin's ANDA and subsequent launch of a generic version of ANTARA or the marketing of generic fenofibrate products could result in a decrease in ANTARA sales, create pressure on the price at which we are able to sell ANTARA, reduce our profit margins, reduce our net sales of ANTARA and adversely impact our revenues.

Table of Contents

FACTIVE

FACTIVE tablets are approved for the treatment of community-acquired pneumonia of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis. There are several classes of antibiotics that are primary competitors for the treatment of these indications, including other fluoroquinolones (levofloxacin, ciprofloxacin and moxifloxacin), macrolides (clarithromycin and azithromycin) and penicillins (amoxicillin/clavulanate potassium).

Many generic antibiotics are also currently prescribed to treat these infections. Moreover, a number of the antibiotic products that are competitors of FACTIVE tablets have composition of matter patents which have gone or will be going off patent at dates ranging from 2003 to 2016. As these competitors lose patent protection, their manufacturers will likely decrease their promotional efforts. However, makers of generic drugs will likely begin to produce some of these competing products and this could result in pressure on the price at which we are able to sell FACTIVE tablets and reduce our profit margins.

In addition, as described in Risk Factor Lupin Limited's and Orchid Healthcare's Paragraph IV certifications under the Hatch-Waxman Act related to ANTARA and FACTIVE respectively could have a material adverse effect on our financial condition and results of operations, as it could result in the introduction of a generic products prior to the expiration of the patents covering ANTARA and FACTIVE, as well as in significant legal expenses and diversion of management's time. Orchid has recently filed an ANDA seeking approval to market a generic version of FACTIVE. Upon final FDA approval of Orchid's ANDA, the drug product which is the subject of that ANDA would have a material adverse impact on the sales of FACTIVE.

Ramoplanin

We have completed Phase II clinical trials studying Ramoplanin for the treatment of CDAD. We are aware of two products currently utilized in the marketplace for the treatment of this indication: Vancocin[®] pulvules (vancomycin), a product marketed by ViroPharma Inc., and metronidazole, a generic product. We are also aware of several other companies with products in development for the treatment of CDAD.

Due to strategic and financial considerations, we have suspended the clinical development of Ramoplanin pending identification of a partner, licensee or buyer for the product.

GOVERNMENT REGULATION

Regulation by governmental entities in the United States and other countries will be a significant factor in the development, manufacturing, distribution and marketing of any product candidates that we develop or commercialize. The extent to which such regulation may apply to us and our licensees will vary depending on the nature of the product. Virtually all of our pharmaceutical products, including expanded uses of our pharmaceutical products, will require regulatory approval by governmental agencies prior to commercialization. In particular, the FDA in the United States and similar health authorities in foreign countries subject human therapeutic and vaccine products to rigorous preclinical and clinical testing, and require review and approval of extensive data in order to permit commercial marketing.

Virtually all aspects of our activities are regulated by federal and state statutes and regulations, and government agencies. The research, development, manufacturing, processing, packaging, labeling, distribution, sale, advertising, promotion, import and export of our products, and disposal of waste products arising from these activities, are subject to regulation by one or more federal agencies and their state equivalents, including the FDA, the Consumer Product Safety Commission, the Occupational Safety and Health Administration and the Environmental Protection Agency, as well as by state and local governments and governmental authorities in those foreign countries in which we or our partners operate.

Table of Contents

Noncompliance with applicable regulatory policies or requirements of the FDA or other governmental authorities could subject us to enforcement actions, such as suspensions of product distribution, seizure of products, product recalls, civil monetary and other penalties, criminal prosecution and penalties, injunctions, whistleblower lawsuits, failure to approve pending drug product applications or total or partial suspension of product marketing approvals. Similar civil or criminal penalties could be imposed by other government agencies or the agencies of the states and localities in which our products are manufactured, sold or distributed, and could have ramifications for our contracts with government agencies. These enforcement actions would detract from management's ability to focus on our daily business and would have an adverse effect on the way we conduct our daily business, which could severely impact future profitability.

Product Approval

For innovative, or non-generic, new drugs, a FDA-approved new drug application (NDA) is required before the drugs may be marketed in the United States. The NDA must contain data to demonstrate that the drug is safe and effective for its labeled uses, and that it will be manufactured to appropriate quality standards. In order to demonstrate safety and effectiveness, an NDA typically must include or reference preclinical data from animal and laboratory testing and clinical data from controlled trials in humans. For a new chemical entity, this generally means that lengthy, uncertain and rigorous pre-clinical and clinical testing must be conducted. For compounds that have a record of prior or current use, it may be possible to utilize existing data or medical literature and limited new testing to support an NDA. Any preclinical laboratory and animal testing must comply with FDA's good laboratory practice and other requirements. Clinical testing in human subjects must be conducted in accordance with FDA's good clinical practice and other requirements. In order to initiate a clinical trial, the sponsor must submit an investigational new drug application (IND), to the FDA or meet one of the narrow exemptions that exist from the IND requirement. Clinical research must also be reviewed and approved by independent institutional review boards (IRBs), at the sites where the research will take place, and the study subjects must provide informed consent. The FDA also regulates and typically inspects manufacturing facilities, equipment and processes used in the manufacturing of pharmaceutical products before granting approval to market any drug. Each NDA submission requires a substantial user fee payment, unless a waiver or exemption applies. FDA has committed generally to review and make a decision concerning approval on an NDA within 10 months, and on a new priority drug within six months. However, final FDA action on the NDA can take substantially longer, and where novel issues are presented there may be review and recommendation by an independent FDA advisory committee. The FDA can also refuse to file and review an NDA it deems incomplete or not properly reviewable.

Clinical trial programs in humans generally follow a three-phase process. Typically, Phase I studies are conducted in small numbers of healthy volunteers or, on occasion, in patients afflicted with the target disease, to determine the metabolic and pharmacological action of the product candidate in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. In Phase II, studies are generally conducted in larger groups of patients having the target disease or condition in order to validate clinical endpoints, and to obtain preliminary data on the effectiveness of the product candidate and optimal dosing. This phase also helps determine further the safety profile of the product candidate. In Phase III, large-scale clinical trials are generally conducted in hundreds of patients having the target disease or condition to provide sufficient data for the statistical proof of effectiveness and safety of the product candidate as required by U.S. and foreign regulatory agencies. Federal law and the state of Maine require that clinical trial sponsors register most Phase II and Phase III studies and post results of such studies on a publicly funded internet website. Failure to comply with these requirements can result in civil and criminal penalties and, at the federal level, can render our products misbranded. We believe we are in compliance in all respects with federal clinical trial registration laws and are in the process of bringing the company into compliance with applicable Maine law.

Before proceeding with a study, sponsors may seek a written agreement from the FDA regarding the design, size, and conduct of a clinical trial. This is known as a Special Protocol Assessment (SPA). Among other things, Special Protocol Assessments can cover clinical studies for pivotal trials whose data will form the

Table of Contents

primary basis to establish a product's efficacy. Where the FDA agrees to a Special Protocol Assessment, the agreement may not be changed by either the sponsor or the FDA except if the sponsor and the FDA agree to a change, or a senior FDA official determines that a substantial scientific issue essential to determining the safety or effectiveness of the product was identified after the testing began. Special Protocol Assessments thus help establish up-front agreement with the FDA about the adequacy of the design of a clinical trial to support a regulatory approval, but the agreement is not binding if new circumstances arise. There is no guarantee that a study will ultimately be adequate to support an approval even if the study is subject to a Special Protocol Assessment.

The FDA can, and does, reject new drug applications, require additional clinical trials, grant approvals on only a restricted basis even when product candidates performed well in clinical trials, or require further studies as a condition of approval. In addition, the Food and Drug Administration Amendments Act of 2007 (FDAAA) permits the agency to require new drug applicants to submit a REMS with the NDA if the agency determines that a REMS is necessary to ensure that the benefits of the drug outweigh the risks.

Generic drugs are approved through an abbreviated process based on the submission to FDA of an abbreviated new drug application (ANDA). The ANDA must seek approval of a drug product that has the same active ingredient(s), dosage form, strength, route of administration, and labeling as a so-called reference listed drug approved under an NDA, although some limited exceptions may be permitted. The ANDA also generally contains limited clinical data to demonstrate that the product covered by the ANDA is absorbed in the body at the same rate and to the same extent as the reference listed drug. This is known as bioequivalence. In addition, the ANDA must contain information regarding the manufacturing processes and facilities that will be used to ensure product quality, and must contain certifications to patents listed with the FDA for the reference listed drug. Special procedures apply when an ANDA contains certifications stating that a listed patent is invalid or not infringed, and if the owner of the patent or the NDA for the reference listed drug brings a patent infringement suit within a specified time, an automatic stay bars FDA approval of the ANDA for a specified period of time pending resolution of the suit or other action by the court. The amount of testing and effort that is required to prepare and submit an ANDA is generally substantially less than that required for an NDA.

In addition to the NDA and ANDA procedures, there is an additional approval mechanism known as a 505(b)(2) application. A 505(b)(2) application is a form of an NDA where the applicant does not have a right to reference all or some of the data being relied upon for approval. Under current regulations and FDA policies, 505(b)(2) applications can be used where the applicant is relying in part on published literature or on findings of safety or effectiveness in another company's NDA. This might be done, for example, where the applicant is seeking approval for a new use for a drug that has already been approved for a different use or for a different formulation of the same drug that is already approved for the same use. FDA's interpretation of the 505(b)(2) pathway is controversial and has not been tested in the courts.

In European Union countries (where our partner, Menarini is currently attempting to gain marketing approval for certain indications of FACTIVE) and in Canada, regulatory requirements and approval processes are similar in principle to those in the United States and can be at least as rigorous, costly and uncertain. Additionally, depending on the type of drug for which an applicant is requesting approval, there are currently two potential tracks for marketing approval in European Union countries: the centralized procedure and a de-centralized process which requires requesting approval on a country-by-country basis. These review mechanisms may ultimately lead to approval in all European Union countries, but each method grants all participating countries some decision making authority in product approval.

Post-Approval Requirements

Products on the market are subject to continual review by the FDA. If previously unknown problems are discovered or if there is a failure to comply with applicable regulatory requirements, the FDA may restrict the marketing of an approved product, cause the withdrawal of the product from the market, or under certain circumstances seek recalls, seizures, injunctions or criminal sanctions. For example, the FDA may require a

Table of Contents

change in labeling for an approved marketing application or additional studies for any marketed drug product if new information reveals questions about a drug's safety or effectiveness. In addition, changes to the product, the manufacturing methods or locations, or labeling are subject to additional FDA approval, which may or may not be received, and which may be subject to a lengthy FDA review process.

Manufacturing facilities that produce drugs are subject to extensive regulation both by the FDA, state and local governments, and foreign regulatory authorities. These laws and regulations require, among other things, that our facilities and the facilities of third parties, such as LG Life Sciences, Ethypharm S.A. (Ethypharm), Patheon Pharmaceuticals Inc. (our third party finished-product manufacturer for FACTIVE tablets) and Catalent Pharma Solutions (our third party packager of ANTARA capsules), be registered with the FDA and other regulatory authorities, comply with current good manufacturing practices requirements, and pass periodic inspections by the FDA and other regulators. Facilities in foreign countries may be subject to inspection by the FDA, local regulators or both. Current good manufacturing practices (cGMP), require extensive recordkeeping, quality control, documentation and auditing to ensure that products meet applicable specifications. Failure to comply with these requirements can result in warning letters, requirements of remedial action, and, in the case of more serious failures, suspension of manufacturing, seizure, injunctions or recall of product and fines and other penalties. Compliance with these requirements can be time consuming, costly and can result in delays in product approval or product sales.

In addition to cGMP requirements, certain of our products must also be packaged with child-resistant and senior friendly packaging under the Poison Prevention Packaging Act and Consumer Product Safety Commission regulations. Products that do not comply with these requirements can be considered misbranded and subject to seizure, recall, monetary fines, and other penalties.

The distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA), which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. States require the registration of manufacturers and distributors who provide pharmaceuticals, including in certain states even if these manufacturers or distributors have no place of business within the state but satisfy other nexus requirements, for example, the shipment of products into such state. States also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that are requiring manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Both the PDMA and state laws limit the distribution of prescription drug product samples to licensed practitioners and impose other requirements to ensure accountability in the distribution of samples.

Other reporting and recordkeeping requirements also apply for marketed drugs, including for most products requirements to review and report cases of adverse events. Product advertising and promotion are subject to FDA and state regulation, including requirements that promotional claims conform to any applicable FDA approval, and be appropriately balanced and substantiated. We are also subject to various federal and state laws pertaining to health care fraud and abuse, including the anti-kickback provisions of the Social Security Act, the False Claims Act, the Veterans Healthcare Act, and the implementing regulations and policies of the United States Health and Human Services Office of Inspector General and United States Department of Justice, as well as similar state laws. Anti-kickback laws make it illegal for a prescription drug manufacturer or marketer to solicit, offer, receive, or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase, recommendation or prescription of a particular drug, covered by a federal healthcare program, unless one of several narrow safe harbors or other exceptions applies. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third-party government payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Many states have their own versions of the False Claims Act, some of which apply regardless of whether the relevant payors are government or private.

Table of Contents

Similar laws apply in other countries, including anti-bribery prohibitions in the European Union and member countries of the European Union.

Other Regulatory and Compliance Requirements

Under the laws of the United States, the countries of the European Union and other nations, we and the institutions where we sponsor research are subject to obligations to ensure the protection of personal information of human subjects participating in our clinical trials. In the United States, these laws include the privacy provisions of the Health Insurance Portability and Accountability Act (HIPAA), the implementing regulations of the United States Department of Health and Human Services, and state medical records privacy laws. We have instituted procedures that we believe will enable us to comply with these requirements and the contractual requirements of our data sources. The laws and regulations in this area are evolving and further regulation, if adopted, could affect the timing and the cost of future clinical development activities.

We are subject to the United States Foreign Corrupt Practices Act, which prohibits corporations and individuals from engaging in specified activities to obtain or retain business or to influence a person working in an official capacity. Under this act, it is illegal to pay, offer to pay, or authorize the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. Our present and future business has been and will continue to be subject to various other laws and regulations.

Pricing and Third-Party Reimbursement

In the United States and elsewhere, sales of therapeutic and other pharmaceutical products are dependent in part on the availability of reimbursement to the consumer from third party payors, such as government and private insurance plans. Increasingly, third party payors are challenging the prices charged for medical products and services. As a result, in the future, reimbursement to the consumer could become unavailable or could be insufficient to allow us to sell our products on a competitive and profitable basis, either because our products are deemed to be not cost effective or for some other reason. For example, in some foreign markets, pricing reimbursement or profitability of therapeutic and other pharmaceutical products is subject to governmental control. In Canada this practice has led to lower priced products than in the United States. As a result, importation of products from Canada into the United States may result in reduced product revenues. In the United States there have been, and we expect that there will continue to be, a number of federal and state proposals to implement similar governmental pricing reimbursement controls. For example, Congress may give the federal government authority to negotiate drug prices for the Medicare Part D outpatient prescription drug benefit. Currently under Part D, prices are negotiated by the manufacturer with individual Part D plan sponsors or their administrators. Medicare Part B provides separate reimbursement for a limited universe of prescription drugs (primarily physician administered drugs). Currently, reimbursement for most Part B drugs is set at 106% of average sales price (which a manufacturer must report quarterly). Congress may consider proposals to reduce reimbursement for Part B drugs.

In many foreign markets, including the countries in the European Union, pricing of pharmaceutical products is subject to governmental control. In the United States, there have been, and we expect that there will continue to be, a number of federal and state proposals to implement similar governmental pricing controls. While we cannot predict whether such legislative or regulatory proposals will be adopted, the adoption of such proposals could have a material adverse effect on our business, financial condition and results.

Through the commercialization of ANTARA and FACTIVE, we became a participant in the Medicaid rebate program established by the Omnibus Budget Reconciliation Act of 1990, and most recently amended under the Deficit Reduction Act of 2005. Under the Medicaid rebate program, we pay a rebate for each unit of our product reimbursed by Medicaid. The amount of the rebate for each product is set by law as a minimum of 15.1% of the average manufacturer price (AMP), of that product, or if it is greater, the difference between

Table of Contents

AMP and the best price available from us to any commercial customer. The rebate amount also includes an inflation adjustment if AMP increases faster than inflation. The rebate amount is recomputed each quarter based on our reports of our current average manufacturer price and best price for each of our products to the Centers for Medicare & Medicaid Services (CMS). In order to meet the requirements of the Deficit Reduction Act of 2005, the AMP for each product must now be reported to CMS monthly in addition to quarterly, and CMS will publish the monthly AMP data on its website.

Participation in the Medicaid rebate program requires participation in the Public Health Service (PHS), pharmaceutical pricing program. The PHS pricing program extends discounts comparable to the Medicaid rebate to a variety of community health clinics and other entities that receive health services grants from the PHS, as well as hospitals that serve a disproportionate share of low-income Medicare and Medicaid beneficiaries.

ANTARA and FACTIVE are available to authorized users of the Federal Supply Schedule of the General Services Administration. Since 1993, as a result of the Veterans Health Care Act of 1992 (VHC Act), federal law has required that product prices for purchases by the Veterans Administration, the Department of Defense, Coast Guard, and the PHS, including the Indian Health Service, be discounted by a minimum of 24% off the non-federal average manufacturer price (non-FAMP). Our computation and report of non-FAMP is used in establishing the price, and the accuracy of the reported non-FAMP may be audited by the government under applicable federal procurement laws.

PATENTS AND PROPRIETARY TECHNOLOGY

Our success will depend, in part, on our ability to obtain commercially valuable patent claims and protect our intellectual property. We currently own or license approximately 64 issued U.S. patents, approximately 36 pending U.S. patent applications, approximately 60 issued foreign patents and approximately 109 pending foreign patent applications. These patents and patent applications primarily relate to (1) the chemical composition, use, and method of manufacturing FACTIVE, (2) pharmaceutical compositions, methods of their use and treatment, and methods of manufacturing ANTARA, (3) anti-infective compounds and their uses, and (4) the field of human and pathogen genetics. Our material patents are as follows:

U.S. Patent No. 5,633,262 granted May 27, 1997, relating to quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent; licensed from LG Life Sciences; expiring June 15, 2015;

U.S. Patent No. 5,776,944 granted July 7, 1998, relating to 7-(4-aminomethyl-3-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1, 8-naphthyridine-3-carboxylic acid; licensed from LG Life Sciences; expiring April 4, 2017;

U.S. Patent No. 5,869,670 granted February 9, 1999, relating to 7-(4-aminomethyl-3-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1, 8-naphthyridine-3-carboxylic acid; licensed from LG Life Sciences; expiring June 15, 2015;

U.S. Patent No. 5,962,468 granted October 5, 1999, relating to 7-(4-aminomethyl-3-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1, 8-naphthyridine-3 carboxylic acid; licensed from LG Life Sciences; expiring June 15, 2015;

U.S. Patent No. 6,340,689 granted January 22, 2002, relating to methods of using quinolone compounds against atypical upper respiratory pathogenic bacteria; licensed from LG Life Sciences; expiring September 14, 2019;

U.S. Patent No. 6,262,071 granted July 17, 2001, relating to methods of using antimicrobial compounds against pathogenic Mycoplasma bacteria; licensed from LG Life Sciences; expiring September 21, 2019;

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

U.S. Patent No. 6,331,550 granted December 18, 2001, relating to methods of using quinolone compounds against anaerobic pathogenic bacteria; licensed from LG Life Sciences; expiring September 21, 2019;

Table of Contents

U.S. Patent No. 6,455,540 granted September 24, 2002, relating to methods of use of quinolone compounds against anaerobic pathogenic bacteria; licensed from LG Life Sciences; expiring September 21, 2019;

U.S. Patent No. 6,723,734 granted April 20, 2004, relating to the salt of naphthyridine carboxylic acid derivative; licensed from LG Life Sciences; expiring March 20, 2018;

U.S. Patent No. 6,803,376 granted October 12, 2004, relating to methods of use of quinolone compounds against pneumococcal pathogenic bacteria; licensed from LG Life Sciences; expiring September 21, 2019;

U.S. Patent No. 7,101,574 granted September 5, 2006, relating to pharmaceutical compositions containing fenofibrate and methods of preparing the same; licensed from Ethypharm, S.A.; expiring August 20, 2020; and

U.S. Patent No. 7,317,001 granted January 8, 2008, relating to methods of use of Ramoplanin for the treatment of *Clostridium difficile*-Associated Disease (CDAD); expiring December 20, 2024.

Our patent position involves complex legal and factual questions, and legal standards relating to the issuance, scope, validity and enforceability of claims in the applicable technology fields are still evolving. Therefore, the degree of future protection for our proprietary rights is uncertain.

Under our development, license and supply agreement with Ethypharm, S.A. (Ethypharm), we assumed all of the rights and obligations related to the development, manufacturing, marketing and sale of ANTARA in the United States. This license includes one issued U.S. patent and several pending patent applications. In conjunction with the financing of our acquisition of ANTARA, we entered into a Security Agreement with Paul Royalty Fund Holdings II, LP (Paul Capital), an affiliate of Paul Capital Partners, under which our wholly-owned subsidiary, Guardian II Acquisition Corporation granted Paul Capital a security interest in substantially all of its assets, including all rights to ANTARA intellectual property, in order to secure its performance under the financing agreements with Paul Capital. These patents and applications include claims that relate to pharmaceutical compositions containing fenofibrate using the drug delivery technologies incorporated in ANTARA, methods of their use and treatment, and methods of preparing the same.

On December 2, 2008, we received notice of a Paragraph IV certification from Lupin Limited (Lupin), notifying us of the filing of an ANDA with the FDA for a generic version of ANTARA. We received the certification as the holder of the New Drug Application for ANTARA. Lupin 's certification notice alleges that U.S. Patent No. 7,101,574 (the 574 Patent), owned by Ethypharm, exclusively licensed to Oscient and listed in the FDA Orange Book for ANTARA, is invalid and/or will not be infringed by Lupin 's commercial manufacture, use or sale of the drug product described in Lupin 's ANDA. The 574 Patent will expire in 2020.

In response to the filing of Lupin 's ANDA, on January 14, 2009, we, along with our wholly owned subsidiary Guardian II Acquisition Corporation and our licensor Ethypharm, filed a lawsuit in the United States District Court for the District of Maryland against Lupin and its subsidiary Lupin Pharmaceuticals, Inc. for infringement of the 574 Patent.

In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Lupin, FDA approval of Lupin 's ANDA will be stayed until the earlier of thirty months from the date of receipt of the Paragraph IV certification notice, or the date of a District Court decision finding that the 574 Patent is either invalid, unenforceable or not infringed by the drug product which is the subject of Lupin 's ANDA. We have agreed to share the costs incurred during the litigation against Lupin with our licensor Ethypharm. There can be no assurance that our suit against Lupin will be successful.

Under our license agreement with LG Life Sciences, we obtained an exclusive license to develop and market gemifloxacin in certain territories. This license covers 18 issued U.S. patents and a broad portfolio of corresponding foreign patents and pending patent applications. These patents include claims that relate to the

Table of Contents

chemical composition of FACTIVE, methods of manufacturing and its use for the prophylaxis and treatment of bacterial infections. We have received a Notice of Final Determination from the U.S. Patent and Trademark Office on our patent term extension application for U.S. Patent No. 5,776,944 extending its patent term 659 days to April 4, 2017. The principal U.S. patents are currently set to expire at various dates, ranging from 2015 to 2019.

On May 30, 2008 we received notice of a Paragraph IV certification from Orchid Healthcare, a Division of Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), notifying us of the filing of an ANDA with the FDA for a generic version of FACTIVE. Orchid s notice sets forth allegations that eight of the nine FDA Orange Book listed patents are invalid and/or will not be infringed by Orchid s manufacture, importation, use, or sale of the product for which the ANDA was submitted. The notice does not, however, include a Paragraph IV certification with respect to U.S. Patent No. 5,633,262, which is also listed in the FDA Orange Book. Accordingly, the FDA cannot finally approve Orchid s ANDA until the expiry of U.S. Patent No. 5,633,262 in June 2015.

We have not commenced a lawsuit against Orchid relating to these eight patents and are continuing to evaluate whether to commence litigation in response to Orchid s Paragraph IV certification. In the event Orchid elects to amend its ANDA to include a Paragraph IV certification with respect to the ninth patent, U.S. Patent No. 5,633,262, we believe that we will be entitled to an automatic thirty-month stay of FDA approval of the ANDA if either we and/or LG Life Sciences initiate a timely patent infringement lawsuit against Orchid, which could be a substantial cost and there are no assurances that we would be successful.

The patents relating to Ramoplanin include claims relating to methods of manufacturing Ramoplanin as well as methods of increasing the yield of the active compound. On January 8, 2008, the United States Patent and Trademark Office (USPTO) issued us a U.S. patent relating to methods of use of Ramoplanin for the treatment of *Clostridium difficile*-associated disease (CDAD). We also have applications pending relating to various novel uses of Ramoplanin as well as a formulation containing Ramoplanin. The patent covering the chemical composition of Ramoplanin has expired. To provide additional protection for Ramoplanin, we rely on proprietary know-how relating to maximizing yields in the manufacture of Ramoplanin, and intend to rely on the five years of data exclusivity we believe we would receive under the Hatch-Waxman Act in the U.S. and the ten years of market exclusivity in Europe available through the European Medicines Agency (EMEA), because Ramoplanin would be a new chemical entity not previously marketed commercially.

We also have the exclusive right to use FACTIVE trademarks, trade names, domain names and logos in conjunction with the use or sale of the product in the territories covered by the license. We acquired exclusive rights to ANTARA trademarks, trade names, domain names and logos. After becoming aware that Antara Biosciences, Inc. filed trademark applications with the USPTO for the ANTARA and ANTARA BIOSCIENCES marks in connection with biotechnology related goods and services we filed a complaint in Federal District Court alleging, among other things, trademark infringement seeking to enjoin ANTARA BIOSCIENCES from using the ANTARA mark. We have reached a settlement with ANTARA BIOSCIENCES whereby they have agreed to abandon their ANTARA trademark applications and cease using the ANTARA marks. Accordingly we have dismissed our complaint before the Federal District Court.

We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. We generally protect this information with confidentiality agreements that provide that all confidential information developed or made known to others during the course of the employment, consulting or business relationship shall be kept confidential except in specified circumstances. Agreements with employees provide that all inventions conceived by the individual while employed by us are our exclusive property. We cannot guarantee, however, that these agreements will be honored, that we will have adequate remedies for breach if they are not honored or that our trade secrets will not otherwise become known or be independently discovered by competitors.

Table of Contents

MANUFACTURING

Currently, our source of supply of bulk capsules of ANTARA is Ethypharm, S.A (Ethypharm), which produces the capsules at its facilities in France. Ethypharm is able to receive ANTARA API from two vendors in Spain and Italy. We also have an agreement with Catalent Pharma Solutions (formerly Cardinal Health) to package finished ANTARA capsules.

Under the terms of our agreement with LG Life Sciences, LG Life Sciences has agreed to supply and we are obligated to purchase from LG Life Sciences all of our anticipated commercial requirements for FACTIVE API. LG Life Sciences supplies the FACTIVE API from its manufacturing facility in South Korea. Patheon Pharmaceuticals Inc. currently manufactures the finished tablets. With respect to our sublicense of commercialization rights to FACTIVE in ex-US territories:

Pfizer Mexico must purchase all of its commercial requirements in Mexico for FACTIVE API from us, but has the option to receive FACTIVE product from us or to fill and finish the final tableted FACTIVE product at its manufacturing facilities in Mexico. We have transferred the required technology to Pfizer Mexico so that it can start its fill and finish activities;

With respect to the anticipated commercialization of FACTIVE in Europe, Menarini must purchase all of its requirements for FACTIVE active pharmaceutical ingredient from us, but may request that we supply finished FACTIVE product to it for an interim period of time while the technology transfer process is completed.

Pursuant to our acquisition of worldwide rights to Ramoplanin from Pfizer (formerly Vicuron), we are responsible for the manufacture of both the active pharmaceutical ingredient and finished dosage form of Ramoplanin. Although we plan to seek a partner for Ramoplanin, a contract manufacturer or the partner would be required to produce both the active pharmaceutical ingredient and the final dosage form to support related manufacturing activities.

HUMAN RESOURCES

As of December 31, 2008, we had 316 full-time equivalent employees, with 257 field employees across the United States and 59 employees in our Waltham, Massachusetts and Skillman, New Jersey offices. On February 11, 2009 we announced a reduction of approximately 32% in the size of our sales and marketing teams as well as reductions in our office personnel to more aggressively preserve the Company's financial resources and position our organization for a potential partnership or acquisition.

We have substantially completed the reduction and as of March 20, 2009, we have 213 full-time equivalent employees. None of our employees are covered by a collective bargaining agreement, and we consider our relations with our employees to be good.

AVAILABILITY OF INFORMATION

We maintain a website with the address www.oscient.com. We are not including the information contained on our website as a part of, or incorporating it by reference into, this Annual Report on Form 10-K. We make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the Securities and Exchange Commission.

Table of Contents

Item 1A. Risk Factors

The following are significant factors known to us that could materially adversely affect our business, financial condition, or operating results. The risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

RISKS RELATED TO OUR BUSINESS

We will need to monitor our expenses and raise additional funds in the near future or refinance our existing debt due in December 2009 to fund our operations, repay our debt and support sales and marketing activities and if sufficient funds are not available or we are unable to refinance our debt, it will have a material affect on our business.

Based on the recent extension of the maturity date of approximately \$16.7 million of the approximately \$17.0 million outstanding principal and accrued interest of our 5% Convertible Promissory Note now due on December 1, 2009, we believe our existing funds, anticipated cash used in operations and our ability to continue to manage expenses after certain cost reduction measures discussed below are in effect will be sufficient to support our current operations and obligations into the third quarter of 2009. In an effort to aggressively preserve the Company's financial resources and position the organization for a potential partnership or acquisition, on February 11, 2009 we announced plans to substantially reduce the size of our sales and marketing teams as well as our office personnel. Our revenue will likely decline as a result of this decrease. In the next several months, we will need to raise additional capital and/or refinance or amend the terms of our existing debt due in December 2009, to fund our operations for the remainder of 2009, fund other potential commercial or development opportunities and support our sales and marketing activities. We intend to pursue privately raising additional capital from investors through equity financing, the incurrence of indebtedness or a combination of equity and debt. Based on the current credit market turmoil and the inclusion of a going concern explanatory paragraph in the auditor's report of our consolidated financial statements as discussed below, additional financing may not be available to us, or, if available, may not be available on favorable terms. If we cannot obtain adequate financing on acceptable terms when such financing is required or lower our expenses as expected through certain cost reduction measures, we may have to further scale back our operations, take other measures to significantly reduce our expenses which will have a material adverse effect on our business and/or we may seek bankruptcy protection.

For the year ended December 31, 2008, our auditors included a going concern explanatory paragraph in their audit opinion. A going concern explanatory paragraph is included when the auditor concludes there is substantial doubt about our ability to continue as a going concern for at least 12 months following the balance sheet date. If we are unable to refinance or repay our indebtedness as it becomes due, we may be materially and adversely affected and we may be unable to continue operations as a going concern. If we are unable to continue as a going concern it is likely that investors will lose all or a part of their investment. On February 11, 2009, we engaged Broadpoint Capital, Inc. to advise us on strategic options, including the potential sale of the Company. There can be no assurance that this engagement will enable us to identify and implement strategic options, including a potential sale, that will be of benefit to investors. In addition, if we are unable to meet our payment obligations to third parties as they come due, we may be subject to litigation claims and/or may seek bankruptcy protection. Even if we are successful in defending against these claims, litigation could result in substantial costs, be a distraction to management and may result in unfavorable results that could further adversely impact our financial condition and may impact our ability to continue operations.

We have a history of significant operating losses and expect losses to continue for some time.

We have a history of significant operating losses and expect losses to continue for some time. We expect to continue to have net losses in the near future and we had an accumulated deficit of approximately \$511 million as of December 31, 2008. These losses are primarily a result of costs incurred in research and development, including our clinical trials and product acquisitions, from sales and marketing, and from general and

Table of Contents

administrative costs associated with our operations and product sales. These costs have exceeded our revenues which to date have been generated principally from sales of ANTARA and FACTIVE, sublicensing agreements, and our legacy collaborations, government grants and sequencing services.

We anticipate that we will incur additional losses in the current year and in future years. These losses are expected to continue, principally due to the expenses in the sales and marketing area, as we seek to grow sales of ANTARA capsules and FACTIVE tablets and as we seek to acquire additional approved products or product candidates.

Failure to regain compliance with The NASDAQ Global Market continued listing requirements may result in our common stock being delisted from The NASDAQ Global Market.

Our common stock is currently listed on The NASDAQ Global Market under the symbol `OSCI`. Currently, we are not compliant with the continued listing requirements of the NASDAQ Global Market. In the event that we do not regain compliance and/or fail to satisfy any of the additional listing requirements, our common stock may be delisted from The NASDAQ Global Market.

On October 3, 2008, we received a notification from The NASDAQ Listings Qualifications Department of The NASDAQ Stock Market LLC (`NASDAQ`) that, as of October 2, 2008, the Company's market value of publicly held shares (`MVPHS`) had closed below the minimum \$15 million threshold set forth in Marketplace Rule 4450(b)(3) for the previous thirty (30) consecutive business days, a requirement for continued listing. For NASDAQ purposes, `MVPHS` is the market value of the Company's publicly held shares, which is calculated by subtracting all shares held by officers, directors or beneficial owners of 10% or more of an issuer's common stock from the issuer's total shares outstanding.

On October 23, 2008 we received notification from NASDAQ that, given the current extraordinary market conditions, NASDAQ has suspended the enforcement of the rules requiring a `MVPHS` and a minimum \$1 closing bid price (`Rule Suspension`). On December 23, 2008 we received a second notification from NASDAQ that the Rule Suspension period had been extended an additional ninety (90) days and that the minimum bid price and `MVPHS` requirements would be reinstated on April 20, 2009. On March 23, 2009 we received a third notification from NASDAQ that the Rule Suspension period had been extended an additional ninety (90) days and that the minimum bid price and `MVPHS` requirements will be reinstated on July 20, 2009. As a result of the Rule Suspension, all companies presently in the compliance process will remain at that same stage of the process; however, companies can regain compliance during the Rule Suspension period. NASDAQ will not take any action to delist any security for these concerns during the Rule Suspension period, which will remain in effect through Friday, July 17, 2009. These rules will be reinstated on Monday, July 20, 2009. Under the Rule Suspension, we believe that we will now have until approximately October 6, 2009 to regain compliance by evidencing a minimum \$15 million `MVPHS` for ten (10) consecutive business days. If we do not regain compliance with the `MVPHS` requirement by October 6, 2009, we will receive written notification of delisting from NASDAQ and at that time will be entitled to request a hearing before a NASDAQ Listing Qualifications Panel (`Panel`) to present our plan to regain compliance with the `MVPHS` requirement.

If our efforts to regain compliance are successful and the `MVPHS` exceeds \$15 million for ten (10) consecutive business days before October 6, 2009, we will regain compliance with respect to the `MVPHS` requirement. In the event we do not regain compliance, we may appeal the staff determination to the Panel. In the event that we fail to regain compliance and are unsuccessful in an appeal to the Panel, our securities will be delisted from The NASDAQ Global Market. In the event that our securities are delisted from The NASDAQ Global Market, we may not be able to meet the requirements necessary for our common stock (i) to transfer to, or list on, a U.S. national securities exchange, including The NASDAQ Capital Market or (ii) be approved for listing on a U.S. system of automated dissemination of quotations. If such event in (i) or (ii) above occurred, holders of our 2011 Notes (as defined below) have the right to require us to repurchase for cash the outstanding principal amount of the 2011 Notes, as applicable, plus accrued and unpaid interest through such date. As of

Table of Contents

December 31, 2008, there were approximately \$86.7 million principal amount of 12.50% Convertible guaranteed senior notes due 2011 (the 12.50% Notes), approximately \$12.7 million principal amount of 3.50% Senior convertible promissory notes due 2011 and approximately \$0.8 million principal amount of 3 1/2% Senior convertible promissory notes due 2011 (collectively, the 2011 Notes). If the 12.50% Notes become due and are accelerated, this could trigger a Put Event under the Paul Capital Revenue Interest Assignment Agreement as amended. We do not have sufficient cash or may not be able raise sufficient additional capital to repay the 2011 Notes and repurchase the RIAA at the Put/Call Price and the amounts outstanding under the Note Purchase Agreement, as applicable, if requested to be repurchased by the holders and Paul Capital.

Our business is very dependent on the commercial success of ANTARA and FACTIVE.

ANTARA capsules and FACTIVE tablets are currently our only commercial products and we expect that they will likely account for substantially all of our product revenues until we are able to acquire and successfully market additional FDA approved products through acquisitions, in-licensing or co-promotion agreements.

ANTARA is approved by the FDA to treat hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with a healthy diet. FACTIVE tablets have FDA marketing approval for the treatment of community-acquired pneumonia of mild to moderate severity (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB).

The commercial success of ANTARA and FACTIVE will depend upon their continued acceptance by regulators, physicians, patients and other key decision-makers as a safe, therapeutic and cost-effective alternative to other products used, or currently being developed, to treat CAP and AECB, in the case of FACTIVE tablets, or hypercholesterolemia and hypertriglyceridemia, in the case of ANTARA capsules. In addition, if concerns should arise about the safety or efficacy of our products, regardless of whether or not such concerns have a basis in generally accepted science or peer-reviewed scientific research, such concerns could adversely affect the market for these products. Furthermore, regulatory authorities may withdraw the approval of our products, or require the addition of restrictive safety labeling statements, to our products.

On July 7, 2008, we received notice from the FDA directing that the prescribing information for all fluoroquinolone products, including FACTIVE, be revised to include a Boxed Warning relating to the risk of tendonitis and tendon rupture associated with the use of fluoroquinolone product. Warnings regarding the risk of tendon related adverse events were already included in the prescribing information, as part of a class labeling, for all fluoroquinolones. The FDA has cautioned that such risk is increased in patients over the age of 60 and in those on concomitant corticosteroid therapy, as well as kidney, heart and lung transplant recipients. The FDA has also required that all manufacturers of fluoroquinolones submit a Medication Guide. The FDA has approved our changes to the package insert and Medication Guide as required by FDA to ensure patient safety and improve physician understanding of the risk-benefit profile for fluoroquinolone products, including FACTIVE. We have also submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) as required by FDA of all sponsors of fluoroquinolone products to ensure patients safe and effective use of such products. We are working with the FDA to finalize certain details of the REMS.

We cannot predict what further action, if any, the FDA may take, including, among others things, further label restrictions in the fluoroquinolone class or even the removal of indications or products from the market. Any of these events could prevent us from achieving or maintaining market acceptance of our products or could substantially increase the costs and expenses of commercializing our products, which in turn could delay or prevent us from generating significant revenues from their sales.

If ANTARA and FACTIVE are not commercially successful, we will have to find additional sources of funding or curtail or cease operations.

Table of Contents

Lupin Limited's and Orchid Healthcare's Paragraph IV certifications under the Hatch-Waxman Act related to ANTARA and FACTIVE respectively could have a material adverse effect on our financial condition and results of operations, as it could result in the introduction of a generic products prior to the expiration of the patents covering ANTARA and FACTIVE, as well as in significant legal expenses and diversion of management's time.

On December 2, 2008, we and our licensor, Ethypharm, S.A. (Ethypharm), received notice of a Paragraph IV certification from Lupin Limited (Lupin), notifying us of the filing of an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market a generic version of ANTARA prior to the August 2020 expiration date of U.S. Patent No. 7,101,574 (the 574 Patent). The 574 Patent, which is owned by Ethypharm, exclusively licensed to Oscient and listed in the FDA Orange Book for ANTARA relates to pharmaceutical compositions containing fenofibrate and methods of preparing the same. Lupin's certification notice alleges that the 574 Patent, is invalid and/or will not be infringed by Lupin's commercial manufacture, use or sale of the drug product described in Lupin's ANDA.

In response to the filing of Lupin's ANDA, on January 14, 2009, we, along with our wholly owned subsidiary Guardian II Acquisition Corporation and licensor Ethypharm, filed a lawsuit in the United States District Court for the District of Maryland against Lupin and its subsidiary Lupin Pharmaceuticals, Inc., for infringement of the 574 Patent. We and our licensor Ethypharm have agreed to equally share the costs incurred during such litigation. In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Lupin, FDA approval of Lupin's ANDA will be stayed until the earlier of thirty months from the date of receipt of the Paragraph IV certification notice, or the date of a District Court decision finding that the 574 Patent is either invalid, unenforceable or not infringed by the drug product which is the subject of Lupin's ANDA. If the litigation is still ongoing after thirty months, the termination of the stay could result in the introduction of one or more generic products to ANTARA prior to resolution of the litigation.

On May 30, 2008 we received notice of a Paragraph IV certification from Orchid Healthcare, a Division of Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), notifying us of their filing of an ANDA for a generic version of FACTIVE. The certification alleges that eight of the nine FDA Orange Book listed patents are invalid and/or will not be infringed by Orchid's manufacture, importation, use, or sale of the product for which the ANDA was submitted. The certification does not, however include a Paragraph IV certification with respect to U.S. Patent No. 5,633,262 which is listed in the Orange Book and expires in June 2015. We are continuing to evaluate whether to commence litigation in response to Orchid's Paragraph IV certification.

Any legal action taken to defend our patent rights relating to ANTARA or FACTIVE will likely be costly, time consuming and distracting to management, could have a material adverse effect on our business, and could result in a finding that either Orchid's or Lupin's proposed generic product does not infringe the claims of our patents or that our patents are invalid and/or unenforceable. An adverse outcome in any such legal action could result in one or more generic versions of ANTARA or FACTIVE being launched before the expiration of the patents covering the products. Since ANTARA and FACTIVE are currently our only marketed products, the introduction of a generic version of either ANTARA or FACTIVE could have a material adverse affect on our ability to successfully execute our business strategy, to maximize the value of our products and therefore could have a material negative impact on our financial condition and results of operations.

If third parties challenge the validity of the patents or proprietary rights of our marketed products or assert that we have infringed their patents or proprietary rights, we may become involved in intellectual property disputes and litigation that would be costly, time consuming, and prevent the commercialization of ANTARA, FACTIVE and/or any other products that we acquire.

The intellectual property rights of pharmaceutical companies, including us, are generally uncertain and involve complex legal, scientific and factual questions. Our success in developing and commercializing pharmaceutical products may depend, in part, on our ability to operate without infringing on the intellectual

Table of Contents

property rights of others and to prevent others from infringing on our intellectual property rights. There has been substantial litigation regarding patents and other intellectual property rights in the pharmaceutical industry.

As further discussed under, Lupin Limited's and Orchid Healthcare's Paragraph IV certifications under the Hatch-Waxman Act related to ANTARA and FACTIVE respectively could have a material adverse effect on our financial condition and results of operations, as it could result in the introduction of a generic product prior to the expiration of the patents covering ANTARA and FACTIVE, as well as in significant legal expenses and diversion of management's time. Lupin and Orchid are seeking to market generic versions of our products.

If additional ANDA filings are made referencing either ANTARA or FACTIVE, we may need to defend and/or assert our patents, including filing lawsuits alleging patent infringement. If we were unsuccessful in such a proceeding and the FDA approved a generic version of any one or both of our products, such an outcome would have a material adverse effect on our business.

We may also become party to patent litigation or proceedings at the U.S. Patent and Trademark Office or a foreign patent office to determine our patent rights with respect to third parties which may include competitors in the pharmaceutical industry. Interference proceedings in the U.S. Patent and Trademark Office or opposition proceedings in a foreign patent office may be necessary to establish which party was the first to discover such intellectual property. The cost to us of any patent litigation or similar proceeding could be substantial, and it may absorb significant management time.

We do not expect to maintain separate insurance to cover intellectual property infringement. Our general liability insurance policy does not cover our infringement of the intellectual property rights of others. If infringement litigation against us is resolved unfavorably, we may be enjoined from manufacturing or selling certain of our products or services and be liable for damages. In certain cases, a license may be available, although we may not be able to obtain such a license on commercially acceptable terms, or at all. Even if we were able to obtain such a license to a third party's intellectual property, the license may be non-exclusive and thereby accessible to our competitors. We may be forced to reformulate, rebrand or rename our products to avoid infringing the intellectual property rights of third parties, which, if possible, could be costly and time-consuming. The commercialization of our products or product candidates may be delayed or discontinued as a result of patent infringement claims against us or due to our failure to license necessary intellectual property, which could adversely affect our business.

We are aware of United States patents that are controlled by third parties that may be construed to encompass ANTARA. However, we believe that, if these patents were asserted against us, we would have valid defenses that ANTARA does not infringe any valid claims of these patents or that the patents would be found to be unenforceable. Nonetheless, in order to successfully challenge the validity of any United States patent, we would need to overcome the presumption of validity which is accorded to issued patents in the United States. If any of these patents were found to be valid and enforceable and we were found to infringe any of them, or any other patent rights of third parties, we would be required to pay damages, cease the sale of ANTARA or pay additional royalties on manufacture and sales of ANTARA. If we are unable to market or sell ANTARA, or if we are obligated to pay significant damages or additional royalties, our earnings attributable to ANTARA would be reduced and our business would be materially adversely affected. Even if we prevail, the cost to us of any patent litigation would likely be substantial, and it may absorb significant management time. If the other party in any such litigation has substantially greater resources than us, we may be forced, due to cost constraints, to seek to settle any such litigation on terms less favorable to us than we might be able to obtain if we had greater resources.

Table of Contents

Our debt obligations expose us to risks that could adversely affect our business, operating results and financial condition.

We have a substantial level of debt. As of December 31, 2008, we had approximately \$207.4 million of indebtedness outstanding (including accrued interest and excluding a bond discount of approximately \$1.9 million), which includes approximately \$41.1 million in revenue interest that entitles Paul Capital to receive a royalty on the sales of both ANTARA and FACTIVE. Approximately \$16.9 million of outstanding indebtedness will mature on December 1, 2009, approximately \$23.4 million of outstanding indebtedness will mature in 2010 or may be extended at our option to 2012 through issuance of warrants and approximately \$126.0 million of indebtedness will mature in 2011. The level and nature of our indebtedness, among other things, could:

make it difficult for us to make payments on our debt outstanding from time to time or to refinance it;

make it difficult for us to obtain any necessary financing in the future for working capital, capital expenditures, debt service, product and company acquisitions or general corporate purposes;

limit our flexibility in planning for or reacting to changes in our business including life cycle management;

reduce funds available for use in our operations;

impair our ability to incur additional debt because of financial and other restrictive covenants;

make us more vulnerable in the event of a downturn in our business;

place us at a possible competitive disadvantage relative to less leveraged competitors and competitors that have better access to capital resources;

restrict the operations of our business as a result of provisions in the Revenue Interests Agreement with Paul Capital that restrict our ability to (i) amend, waive any rights under, or terminate any material license agreements, including the agreements relating to ANTARA and FACTIVE, (ii) enter into any new agreement or amend or fail to exercise any of our material rights under existing agreements that would materially adversely affect Paul Capital's royalty interest, and (iii) sell any material assets related to ANTARA or FACTIVE; or

impair our ability to merge or otherwise effect the sale of the Company due to the right of the holders of certain of our indebtedness to accelerate the maturity date of the indebtedness in the event of a change of control of the Company.

We will need to raise additional capital to pay our indebtedness as it comes due. If we are unable to obtain funds necessary to make required payments, or if we fail to comply with the various requirements of our indebtedness, we would be in default, which would permit the holders of our indebtedness to accelerate the maturity of the indebtedness and could cause defaults under any indebtedness we may incur in the future. Any default under our indebtedness would have a material adverse effect on our business, operating results and financial condition. If we are unable to refinance or repay our indebtedness as it becomes due, we may be unable to continue operations and/or may seek bankruptcy protection.

Future fundraising could adversely affect the value of the conversion right of our convertible securities and dilute the ownership interests of our shareholders.

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

In order to raise additional funds, we may issue equity or convertible debt securities in the future. Depending upon the market price of our shares at the time of any transaction, we may be required to sell a significant percentage of the authorized and unissued shares of our common stock in order to fund our operating plans, potentially requiring a shareholder vote, which we may not be able to obtain. In addition, we may have to sell securities at a discount to the prevailing market price, which could adversely affect the value of the conversion right of any outstanding convertible securities and result in further dilution to our shareholders.

Table of Contents

Our products and product candidates face significant competition in the marketplace.

ANTARA

ANTARA is a fenofibrate product approved by the FDA to treat hypercholesterolemia and hypertriglyceridemia in combination with a healthy diet. The marketing of current and additional branded versions of fenofibrate by competitors could reduce our net sales of ANTARA and adversely impact our revenues.

The primary competition for ANTARA in the fenofibrate market is TriCor[®] 145 mg, a product manufactured by Abbott Laboratories, which accounted for approximately 90% of U.S. fenofibrate sales for the year ended December 31, 2008. Additionally, Abbott Laboratories has recently launched a new product, TriLipix[™], which was approved by the FDA in December 2008 and its active ingredient is fenofibric acid, the active metabolite of fenofibrate.

In addition to TriCor and TriLipix, there are several other branded fenofibrate products which compete with ANTARA. ANTARA competes with Triglide[®], a 160 mg fenofibrate product and Fenoglide[®], a 120mg branded fenofibrate product, both of which are marketed by Sciele Pharma, Inc., a wholly owned subsidiary of Shionogi & Co. Ltd. Triglide and Fenoglide accounted for approximately 2% of U.S. fenofibrate sales for the year ended December 31, 2008. Additionally, ANTARA also competes with Lipofen[®], a 150 mg fenofibrate product, which is marketed by Kowa Pharmaceuticals America, Inc.

As described under Lupin Limited's and Orchid Healthcare's Paragraph IV certifications under the Hatch-Waxman Act related to ANTARA and FACTIVE respectively could have a material adverse effect on our financial condition and results of operations, as it could result in the introduction of a generic products prior to the expiration of the patents covering ANTARA and FACTIVE, as well as in significant legal expenses and diversion of management's time, we received notice of Paragraph IV certification from Lupin Limited (Lupin), notifying us of the filing of an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of ANTARA. Upon final FDA approval of Lupin's ANDA, the drug product which is the subject of that ANDA would have a material adverse impact on the sales of ANTARA.

Additionally, several generic versions of fenofibrate in varying doses are also available for the treatment of dyslipidemias. Revenues from these products accounted for approximately 4% of total U.S. sales of fenofibrate sales for the year ended December 31, 2008. In May 2005, Teva Pharmaceutical Industries, Ltd. (Teva) obtained FDA approval to market a generic version of Abbott Laboratories' 160 mg TriCor tablet (which is no longer marketed or sold) and Par Pharmaceuticals and Impax Labs received FDA approval for similar generic products in October 2007 and March 2008, respectively. In addition, Solvay S.A., Abbott Laboratories' partner announced on January 23, 2008, that Teva had filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification seeking the approval of a generic version of TriCor 145 mg. Additionally, Biovail Corporation announced on September 3, 2008 that it also has filed an ANDA seeking approval for a generic version of TriCor 145 mg. If a generic version of Abbott Laboratories' TriCor 145 mg product is approved by the FDA, the percentage of total revenues attributable to generic fenofibrate products would likely increase and adversely impact the sales of ANTARA. There are also several other FDA-approved products and products in development for similar indications as ANTARA which could compete with ANTARA, including statins, omega-3 fatty acids (including Lovaza[®] marketed by GlaxoSmithKline), niacin, (including Niaspan[®] marketed by Abbott), ezetimibe and fixed-dose combination products.

The growth of any of these competitive branded products, the approval of Lupin's ANDA, the marketing of generic fenofibrate products or the FDA approval and subsequent marketing of products with similar indications, including combination therapy products currently in development could result in a decrease in ANTARA sales, place pressure on the price at which we are able to sell ANTARA, reduce our profit margins, reduce our net sales of ANTARA and adversely impact our revenues.

Table of Contents

FACTIVE

FACTIVE tablets are approved for the treatment of community-acquired pneumonia of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis. There are several classes of antibiotics that are primary competitors for the treatment of these indications, including other fluoroquinolones (levofloxacin, ciprofloxacin and moxifloxacin), macrolides (clarithromycin and azithromycin), cephalosporins (cefdinir) and penicillins (amoxicillin/clavulanate potassium).

Many generic antibiotics are also currently prescribed to treat these infections. Moreover, a number of the antibiotic products that are competitors of FACTIVE tablets have composition of matter patents which have expired or will expire at dates ranging from 2003 to 2016. As these competitors lose patent protection, their manufacturers will likely decrease their promotional efforts. However, manufacturers of generic drugs will likely begin to produce some of these competing products and this could result in pressure on the price at which we are able to sell FACTIVE tablets and reduce our profit margins.

In addition, as described under Lupin Limited's and Orchid Healthcare's Paragraph IV certifications under the Hatch-Waxman Act related to ANTARA and FACTIVE respectively could have a material adverse effect on our financial condition and results of operations, as it could result in the introduction of a generic product prior to the expiration of the patents covering ANTARA and FACTIVE, as well as in significant legal expenses and diversion of management's time. Orchid has recently filed an ANDA seeking approval to market a generic version of FACTIVE. The final FDA approval of Orchid's ANDA, the drug product which is the subject of that ANDA, would have a material adverse impact on the sales of FACTIVE.

Ramoplanin

We have completed Phase II clinical trials studying the use of Ramoplanin for the treatment of *Clostridium difficile*-associated disease (CDAD). We are aware of two products currently utilized in the marketplace for the treatment of this indication: Vancocin® pulvules (vancomycin), a product marketed by ViroPharma Inc., and metronidazole, a generic product. We are also aware of several companies with products in development for the treatment of CDAD, as well as the potential approval of generic vancomycin. Due to strategic and financial considerations, we have suspended the clinical development of Ramoplanin pending identification of a partner, licensee, or buyer for the product candidate.

Many of our competitors have substantially greater capital resources and human resources than us. Furthermore, many of those competitors are more experienced than us in drug discovery, clinical development and commercialization, and in obtaining regulatory approvals. As a result, those competitors may discover, develop and commercialize pharmaceutical products or services before us. In addition, our competitors may discover, develop and commercialize products or services that are more effective than, or otherwise render non-competitive or obsolete, the products or services that we or our collaborators are seeking to develop and commercialize. Moreover, these competitors may obtain patent protection or other intellectual property rights that would limit our rights or the ability of our collaborators to develop or commercialize pharmaceutical products or services.

Our failure to in-license, co-promote or acquire and develop additional product candidates or approved products will negatively affect our business.

As part of our business strategy, we intend to acquire, develop and commercialize additional product candidates or approved products. The success of this strategy depends upon our ability to identify, select and acquire products that meet our criteria. We may not be able to acquire the rights to additional product candidates and approved products on terms that we find acceptable, or at all. The acquisition of rights to additional products would likely require us to make significant up-front cash payments, which could adversely affect our liquidity and/or may require us to raise additional capital and/or secure external sources of financing. We may seek funding for product acquisitions through equity or debt offerings, through royalty-based financings or by a

Table of Contents

combination of these methods, such as the financing we completed with Paul Capital to fund the ANTARA acquisition. There is no assurance that we will be able to raise the funds necessary to complete any product acquisitions on acceptable terms or at all. In addition, as announced on February 11, 2009 the reduction in our sales force to conserve capital will negatively impact our ability to acquire new products. If we raise funds it could dilute shareholders, or if we use existing resources it could adversely affect our liquidity and increase the amount of capital which we would need.

New product candidates acquired or in-licensed by us may require additional research and development efforts prior to commercial sale, including extensive preclinical and/or clinical testing and approval by the FDA and corresponding foreign regulatory authorities. All product candidates are prone to the risks of failure inherent in pharmaceutical product development, including the possibility that the product candidate will not be safe, effective or approved by regulatory authorities. In addition, it is uncertain whether any approved products that we develop or acquire will be:

manufactured or produced economically;

successfully commercialized; or

widely accepted in the marketplace.

We, as well as our partners, are subject to numerous complex regulatory requirements and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business.

Virtually all aspects of our and our partners' activities are subject to regulation by numerous governmental authorities in the U.S., Europe, Canada, Mexico and elsewhere. These regulations govern or affect the testing, manufacture, safety, effectiveness, labeling, storage, record-keeping, approval, distribution, advertising and promotion of ANTARA, FACTIVE, Ramoplanin and any other product candidates we may acquire, as well as safe working conditions and the experimental use of animals. We are required to report any serious and unexpected adverse experiences with our products to the FDA and other similar regulatory authorities in other jurisdictions. Noncompliance by us or our commercial partners with any applicable regulatory requirements or failure to obtain adequate documentation from any governmental agency can result in refusal of the government to approve products for marketing, criminal prosecution and fines, recall or seizure of products, injunctions, total or partial suspension of production, whistleblower lawsuits, prohibitions or limitations on the commercial sale of products or refusal to allow the entering into of federal and state supply contracts. These enforcement actions would detract from management's ability to focus on our daily business and would have an adverse effect on the way we conduct our daily business, which could severely impact future profitability. Our corporate compliance program cannot fully ensure that we are in compliance with all applicable laws and regulations, and a failure to comply with such regulations by us or our commercial partners could harm our business.

For instance, we, along with many other pharmaceutical companies, received correspondence in 2007 from the FDA stating that it had some concerns over the reliability of studies conducted by MDS Pharma Services between 2000 and 2004. The predecessor owner of the rights to ANTARA, Reliant Pharmaceuticals, had engaged MDS Pharma to perform certain bioequivalence studies for ANTARA, including some studies that were submitted in support of the original approval of ANTARA. The FDA suggested that we take one of the following steps to assess the accuracy of such data: conduct an independent audit of the trials to verify the data, re-assay samples or repeat the studies. The FDA also stated that it has not detected any signals or any evidence that the products mentioned in its correspondence pose a safety risk or that there has been any impact on efficacy. On May 30, 2007, we responded to the FDA informing the FDA that we do not believe that these steps are necessary because the FDA audited the pivotal MDS Pharma study at issue prior to its approval of ANTARA, and further because there are other non-MDS Pharma data that support the safety and effectiveness of ANTARA. To date, the FDA has not responded to our response. As a result, the outcome of this issue is uncertain, and we cannot predict whether this issue will have a material impact on our results of operations.

Table of Contents

New legal and regulatory requirements could make it more difficult for us to obtain expanded or new product approvals, and could limit or make more burdensome our ability to commercialize our approved products.

Numerous proposals have been made in recent years to impose new requirements on drug approvals, expand post-approval requirements, and restrict sales and promotional activities. Without limiting the generality of the foregoing, Congress has recently enacted, and the President has signed into law, the Food and Drug Administration Amendments Act of 2007 (FDAAA). The recently enacted amendments authorize the FDA, among other things, to require submission of REMS with new drug applications, or post-approval upon the discovery of new safety information, to monitor and address potential safety issues for products upon approval. The FDAAA also grants the FDA the authority to mandate labeling changes in certain circumstances and establishes new requirements for registering and disclosing the results of clinical trials. For example, as discussed under Our business is very dependent on the commercial success of ANTARA and FACTIVE the FDA has informed us, along with the other sponsors of all marketed fluoroquinolone products of the need to have a Boxed Warning with respect to tendonitis and tendon rupture in certain patients. The FDA has also informed us that, based on new safety information, we (along with other sponsors of marketed fluoroquinolone products) must submit a proposed Medication Guide and a proposed REMS to ensure patients safe and effective use of all fluoroquinolones, including FACTIVE. Such changes may increase our costs and adversely affect our operations.

Additional measures have also been enacted to address the perceived shortcomings in the FDA s handling of drug safety issues, and to limit pharmaceutical company sales and promotional practices. The implementation of the recently enacted amendments or other proposed legal or regulatory changes may make it more difficult or burdensome for us to obtain extended or new product approvals, and our current approvals may be restricted or subject to onerous post-approval requirements.

Failure to comply with or changes to the regulatory requirements that are applicable to ANTARA, FACTIVE or our other product candidates may result in a variety of consequences, including the following:

restrictions on our products or manufacturing processes;

notice of violation letters regarding promotional and marketing materials and activities;

withdrawal of the product from the market;

voluntary or mandatory recall of the product;

fines against us or our partners;

suspension or withdrawal of regulatory approvals for ANTARA, FACTIVE or a product candidate which subsequently receives regulatory approval;

suspension or termination of any of our ongoing clinical trials of a product candidate;

refusal to permit import or export of our products;

refusal to approve pending applications or supplements to approved applications that we or our partners submit;

denial of permission to file an application or supplement in a jurisdiction;

product seizure; and

injunctions or the imposition of civil or criminal penalties against us or our partners.

If we market or distribute products in a manner that violates federal or state healthcare fraud and abuse, marketing disclosure or drug pedigree laws, we may be subject to civil or criminal penalties.

In addition to FDA and related regulatory requirements, we are subject to health care fraud and abuse laws, such as the federal False Claims Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. Federal and state anti-kickback laws prohibit, among other things,

Table of Contents

knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally or state financed health care programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, patients, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing, or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor.

Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Numerous pharmaceutical companies have been investigated, prosecuted or entered into settlement agreements in connection with a variety of allegedly impermissible promotional and marketing activities, such as allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; promoting uses that the FDA has not approved (i.e., off-label uses) that caused claims to be submitted to Medicaid for non-covered off-label uses; and submitting inflated best price information to the Medicaid Drug Rebate Program.

The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer's products from reimbursement under government programs, criminal fines, and imprisonment. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which would also harm our financial condition. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws.

In recent years, several states and localities, including California, the District of Columbia, Maine, Massachusetts, Minnesota, Nevada, New Mexico, Texas, Vermont, and West Virginia, have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs that comply with the PhRMA Code and OIG Guidelines with respect to interactions with health care providers, and/or file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Similar legislation is being considered by Congress and other states. Many of these requirements are new and uncertain, and the penalties for failure to comply with these requirements are unclear. We are not aware of any companies against which fines or penalties have been assessed under these special state reporting and disclosure laws to date. Nonetheless, while we have established a compliance program, we may face enforcement, fines and other penalties, and could receive adverse publicity if this program is found not to be in full compliance with these laws.

In recent years, some states have passed or have proposed laws and regulations obligating pharmaceutical manufacturers and distributors to provide prescription drug pedigrees that are intended to protect the safety of the drug supply channel. For example, the Florida Prescription Drug Pedigree laws and regulations that became effective in July 2006 imposed obligations upon us to deliver prescription drug pedigrees to various categories of customers. Also, effective January 1, 2011, California will require the implementation of costly track and trace chain of custody technologies. At the federal level, a bill was recently introduced that would establish national standards for the drug supply chain (H.R. 5839). Overall, compliance with these pedigree laws requires implementation of extensive tracking systems as well as heightened documentation and coordination with distributors and customers. While we fully intend to comply with these laws, there is uncertainty around the interpretation of the recently passed laws, future changes in legislation and government enforcement of these laws. Failure to comply could result in fines or penalties, as well as loss of business that could have a material adverse effect on our business.

Table of Contents

We depend on third parties to manufacture and distribute our products and product candidates.

We do not have the internal capability to manufacture pharmaceutical products. Under our agreement with LG Life Sciences, LG Life Sciences manufactures the active pharmaceutical ingredient (API) of FACTIVE and is our only source of supply. We use Patheon Inc. (Patheon) to produce the finished FACTIVE tablets and it is currently our only source of FACTIVE tablets. Currently, our only source of supply of bulk capsules of ANTARA is Ethypharm which manufactures the bulk capsules in France and is able to receive ANTARA API from two vendors in Spain and Italy. Further, we have an agreement with Catalent Pharma Solutions to package finished ANTARA capsules and FACTIVE tablets.

If Ethypharm, LG Life Sciences, Patheon or Catalent Pharma Solutions experience any significant difficulties in their respective manufacturing processes for our products, including the API or finished product, or is found otherwise not to be in compliance with applicable legal and regulatory requirements, we could experience significant interruptions in the supply of ANTARA and FACTIVE. Our inability to coordinate the efforts of our third party manufacturing partners, or the lack of capacity available at our third party manufacturing partners, could impair our ability to supply ANTARA and FACTIVE at required levels. Such an interruption could cause us to incur substantial costs and our ability to generate revenue from ANTARA and FACTIVE may be adversely affected. We may not be able to enter into alternative supply arrangements at commercially acceptable rates, if at all. Also, if we change the source or location of supply or modify the manufacturing process, regulatory authorities will require us to demonstrate that the new process or source meets applicable legal and regulatory requirements and that the product manufactured by the new source or from the modified process is equivalent to the product used in any clinical trials that we had conducted. Due to these regulatory requirements, we could incur substantial expenses or experience significant interruptions in the supply of ANTARA and FACTIVE if we decided to transfer the manufacture of our products to one or more suppliers in an effort to deal with such difficulties.

As the ANTARA bulk capsules and FACTIVE API are manufactured in France and South Korea, respectively, we must ship our products to the United States for finishing, packaging and labeling, and manufacturing in the case for FACTIVE. While in transit, our API and product, each shipment of which is of significant value, could be lost or damaged. Moreover, at any time after shipment to the United States, our API or finished product could be lost or damaged as our FACTIVE API is stored at Patheon and our ANTARA and FACTIVE finished product is stored at our third party logistics provider, Integrated Commercialization Solutions, Inc. (ICS). Appropriate risk mitigation steps have been taken and insurance is in place. However, depending on when in the process the API or finished product is lost or damaged, we may have limited recourse for recovery against our manufacturers or insurers. As a result, our financial performance could be impacted by any such loss or damage to our API or finished product.

We may also experience interruption or significant delay in the supply of ANTARA and FACTIVE due to natural disasters, acts of war or terrorism, shipping embargoes, labor unrest or political instability in France or South Korea. In any such event, the supply of our products stored at Ethypharm or LG Life Sciences could also be impacted.

Pursuant to our acquisition of worldwide rights to Ramoplanin from Vicuron, a wholly-owned subsidiary of Pfizer Inc., we are responsible for the manufacture of both the active pharmaceutical ingredient and finished dosage form of Ramoplanin. Although we plan to seek a partner for Ramoplanin, a contract manufacturer or the partner would be required to produce both the active pharmaceutical ingredient and the final dosage form to support related manufacturing activities. If there is a significant delay in securing a qualified supplier on commercially favorable terms, we could experience a supply shortage of Ramoplanin bulk drug, possibly affecting our ability to consummate partnering arrangements for the commercialization of Ramoplanin.

Moreover, while we may choose to manufacture products in the future, we have no experience in the manufacture of pharmaceutical products for clinical trials or commercial purposes. If we decide to manufacture

Table of Contents

products, it would be subject to the regulatory requirements described above. In addition, we would require substantial additional capital and would be subject to delays or difficulties encountered in manufacturing pharmaceutical products.

We depend on third parties to assist in the management and execution of our product supply chain for ANTARA capsules and FACTIVE tablets.

We do not have the internal capability to perform product supply chain services including warehousing, inventory management, storage and distribution of commercial and sample quantities of ANTARA capsules and FACTIVE tablets. We have an exclusive arrangement with Integrated Commercialization Solutions, Inc. (ICS) to perform such supply chain services with respect to commercial product through the second quarter of 2010.

We cannot be certain that ICS will be able to perform uninterrupted supply chain services. If ICS were unable to perform their services for any period, we may incur substantial loss of sales to wholesalers and other purchasers of our products. If we are forced to find an alternative supply chain service provider for ANTARA and FACTIVE, in addition to loss of sales, we may also incur costs in establishing a new arrangement.

Wholesalers, pharmacies and hospitals may not maintain adequate inventory for the distribution for our products.

We sell ANTARA and FACTIVE to wholesale drug distributors who generally sell products to retail pharmacies and other institutional customers. We do not promote ANTARA and FACTIVE to these wholesalers, and they do not determine such products prescription demand. However, approximately 92% of our product shipments during the year ended December 31, 2008 was to only three wholesalers. Our ability to commercialize ANTARA and/or FACTIVE will depend, in part, on the extent to which we maintain adequate distribution of ANTARA capsules and FACTIVE tablets via wholesalers, pharmacies and hospitals, as well as other customers. Although a majority of the larger wholesalers and retailers distribute and stock ANTARA and FACTIVE, they may be reluctant to do so in the future if demand is not established. Further, it is possible that wholesalers could decide to change their policies or fees, or both, at some time in the future. This could result in their refusal to distribute smaller volume products, or cause higher product distribution costs, lower margins or the need to find alternative methods of distributing products. Such alternative methods may not exist or may not be economically viable. If we do not maintain adequate distribution of ANTARA capsules or FACTIVE tablets, the commercialization of ANTARA and/or FACTIVE and our anticipated revenues and results of operations could be adversely affected.

Under our financing arrangement with Paul Capital, upon the occurrence of certain events, Paul Capital may require us to repurchase the right to receive revenues that we assigned to it, repay the outstanding principal and interest on the note or may foreclose on certain assets that secure our obligations to Paul Capital. Any exercise by Paul Capital of its right to cause us to repurchase the assigned right, repay the note or any foreclosure by Paul Capital would adversely affect our results of operations and our financial condition.

On August 18, 2006, we and our subsidiary Guardian II Acquisition Corporation (Guardian II), entered into a revenue interests assignment agreement with Paul Royalty Fund Holdings II, LP (Paul Capital), an affiliate of Paul Capital Partners pursuant to which we assigned to Paul Capital the right to receive a portion of our net revenues from FACTIVE tablets and Guardian II assigned to Paul Capital the right to receive a portion of its net revenue from ANTARA capsules. To secure its obligations to Paul Capital, Guardian II also granted Paul Capital a security interest in substantially all of its assets, including the U.S. rights to ANTARA.

Under our arrangement with Paul Capital, upon the occurrence of certain events (the Put Events), including if we experience a change of control, undergo certain bankruptcy events of us or our subsidiary, transfer any or substantially all of our rights in ANTARA or FACTIVE, transfer all or substantially all of our

Table of Contents

assets, breach certain of the covenants, representations or warranties under the Revenue Interests Assignment Agreement, or sales of ANTARA are suspended due to an injunction or if we elect to suspend sales of ANTARA as a result of a lawsuit filed by certain third parties, Paul Capital may (i) require us to repurchase the rights we assigned to it at the price in cash which equals the greater of (a) 200% of cumulative payments made by Paul Capital under the Revenue Interests Assignment Agreement less the cumulative royalties previously paid to Paul Capital; or (b) the amount which will provide Paul Capital, when taken together with the royalties previously paid, a 22% internal rate of return (the Put/Call Price) in effect on the date such right is exercised or (ii) foreclose on the ANTARA assets that secure our obligations to Paul Capital. Except in the case of certain bankruptcy events, if Paul Capital exercises its right to cause us to repurchase the rights we assigned to it, Paul Capital may not foreclose unless we fail to pay the Put/Call Price as required. In the event of a Put Event, the outstanding principal and interest in the \$20 million note will become immediately due and payable to Paul Capital.

On November 5, 2008 we entered into a first amendment to the Revenue Interests Assignment Agreement. The amendment provides, among other things, that Paul Capital consented to the grant by Guardian II of a second-ranking security interest in and to the assets of Guardian II to secure Guardian II's guarantee of the 12.50% Notes that were issued in our November 2008 exchange. The amendment provides that any acceleration or failure to pay the 12.50% Notes would be considered a Put Event whereby Paul Capital could have the right to demand that we repurchase the Revenue Interest Assignment at the Put/Call Price and the amounts outstanding under the Note Purchase Agreement would immediately become due and payable.

If Paul Capital were to exercise its right to cause us to repurchase the right we assigned to it, there can be no assurance that we would have sufficient funds available to pay the Put/Call Price in effect at that time. Even if we have sufficient funds available, we may have to use funds that we planned to use for other purposes and our results of operations and financial condition could be adversely affected. If Paul Capital were to foreclose on the ANTARA assets that secure our obligations to Paul Capital, our results of operations and financial condition could also be adversely affected. The existence of Paul Capital's rights that it may exercise upon a Put Event could discourage us or a potential acquirer from entering into a business transaction that would result in the occurrence of any of those events.

The development and commercialization of our products may be terminated or delayed, and the costs of development and commercialization may increase, if third parties upon whom we rely to support the development and commercialization of our products do not fulfill their obligations.

In addition to using third parties to fulfill our manufacturing, distribution and supply chain services, our development and commercialization strategy entails entering into arrangements with corporate collaborators, contract research organizations, licensors, licensees and others to conduct development work, manage our clinical trials and market and sell our products outside of the United States. We do not have the expertise or the resources to conduct such activities on our own and, as a result, we are particularly dependent on third parties in these areas. For instance, we have entered into exclusive arrangements granting rights to Pfizer, S.A. de C.V and Menarini International Operation Luxembourg S.A. to develop and sell FACTIVE in Mexico and Europe, respectively. We had previously entered into an exclusive arrangement granting rights to Abbott Laboratories, Ltd. (Abbott Canada) to develop and sell FACTIVE in Canada, however our agreement with Abbott Canada was terminated in December 2008, and Abbott Canada ceased all development and commercialization of FACTIVE in Canada. FACTIVE sales in Canada accounted for approximately 4% of all FACTIVE revenues recorded by the Company in the two years ended December 31, 2008.

We may not be able to maintain our existing arrangements with respect to the commercialization of our existing products, ANTARA and FACTIVE, or establish and maintain arrangements or partnerships to develop and commercialize Ramoplanin or any additional product candidates or products we may acquire on terms that are acceptable to us. Any current or future arrangements for development and commercialization may not be successful. If we are not able to establish or maintain agreements relating to our current products, Ramoplanin,

Table of Contents

our other product candidates or any additional products we may acquire on terms which we deem favorable, our results of operations would be materially adversely affected.

Third parties may not perform their obligations as expected. The amount and timing of resources that third parties devote to developing and commercializing our products are not within our control. Furthermore, our interests may differ from those of third parties that commercialize our products. Disagreements that may arise with these third parties could delay or lead to the termination of the development or commercialization of our product candidates, or result in litigation or arbitration, which would be time consuming and expensive.

If any third party that supports the development or commercialization of our products breaches or terminates its agreement with us, or fails to conduct its activities in a timely and regulatory compliant manner, such breach, termination or failure could:

delay or otherwise adversely impact the development or commercialization of ANTARA capsules, FACTIVE tablets, Ramoplanin, our other product candidates or any additional product candidates that we may acquire or develop;

require us to undertake unforeseen additional responsibilities or devote unforeseen additional resources to the development or commercialization of our products; or

result in the termination of the development or commercialization of our products.

We bear substantial responsibilities under our license agreements for ANTARA and FACTIVE and our sublicense agreements to Pfizer, S.A. de C.V., Abbott Laboratories, Ltd. and Menarini International Operation Luxembourg S.A., and there can be no assurance that we will successfully fulfill our responsibilities.

ANTARA

Our exclusive rights to ANTARA are licensed to us by Ethypharm, S.A. (Ethypharm). If we breach the obligations in any of our license agreements relating to ANTARA including the development, license and supply agreement with Ethypharm, the licensor may be entitled to terminate the agreement. Further, in order to maintain our exclusive rights, we must achieve certain minimum annual sales of ANTARA until February 2012 or make payments to Ethypharm to compensate for the difference. On or about February 27, 2009, we received notice from Ethypharm that we had not achieved the minimum sales threshold, and accordingly within 60 days of receipt of such notice, on or approximately April 28, 2009, we may elect to maintain the exclusivity of the license by compensating Ethypharm for any shortfall, or to convert the exclusive license to a non-exclusive license. As of December 31, 2008, we have recorded approximately \$621,000 related to the potential minimum royalty obligation owed to Ethypharm and which would be payable in the event we elect to maintain the exclusivity of the license. Ethypharm also has a right of first refusal on any divestiture of our rights to ANTARA, which may adversely affect our ability to effect a change of control or sale of our assets.

In accordance with the terms of our asset purchase agreement with Reliant we assumed a third party license relating to ANTARA not including the Ethypharm license. Under the license we are obligated to make certain royalty payments based on sales of ANTARA, which royalty payments are subject to a low single digit increase in the event of a change in control of the Company. The third party license also limits our ability to co-promote ANTARA with companies other than contract sales organizations or similar companies. We have engaged the third party licensor to renegotiate the terms of that license and have suspended further royalty payments while the terms of such license are being renegotiated. This decision could lead to litigation and have a material impact on our operations and sales of ANTARA.

Table of Contents

FACTIVE

We have an exclusive license from LG Life Sciences to develop and market FACTIVE in North America, France, Germany, the United Kingdom, Luxembourg, Ireland, Italy, Spain, Portugal, Belgium, the Netherlands, Austria, Greece, Sweden, Denmark, Finland, Norway, Iceland, Switzerland, Andorra, Monaco, San Marino, Vatican City, Poland, Czech Republic, Slovakia, Slovenia, Hungary, Estonia, Latvia, Lithuania, Liechtenstein, Malta, Cyprus, Romania, Bulgaria, Croatia, Serbia and Montenegro, Bosnia and Herzegovina, Albania and the Former Yugoslav Republic of Macedonia. Under this agreement, we are responsible, at our expense and through consultation with LG Life Sciences, for the clinical and commercial development of FACTIVE in the countries covered by the license, including the conduct of clinical trials, the filing of drug approval applications with the FDA and other applicable regulatory authorities and the marketing, distribution and sale of FACTIVE in our territory. The agreement with LG Life Sciences also required that we achieve a minimum gross sales level of \$30 million from our licensed territories over a 12-month period of time starting in approximately the third quarter of 2007 to the third quarter of 2008 which, if not met, LG Life Sciences could elect to terminate the agreement and have the technology be returned to LG Life Sciences. After LG Life Sciences' review of our financial information it has accepted our analysis and concluded that it will not terminate the agreement based on the minimum gross sales level of \$30 million. We believe that we are currently in compliance with our obligations under the agreement with LG Life Sciences, but there can be no assurance that we will be able to remain in compliance and meet all of our obligations due to the limitations on our resources and the challenges inherent in the commercialization of new products as described above in Our product and product candidates face significant competition in the marketplace.

LG Life Sciences has the obligation under the agreement to diligently maintain its patents and the patents of third parties to which it has rights that, in each case relating to gemifloxacin, the active ingredient in FACTIVE tablets. We have the right, at our expense, to control any litigation relating to suits brought by a third party alleging that the manufacture, use or sale of gemifloxacin in its licensed field in the territories covered by the license infringes upon our rights. We also have the primary right to pursue actions for infringement of any patent licensed from LG Life Sciences under the license agreement within the territories covered by the license. If we elect not to pursue any infringement action, LG Life Sciences has the right to pursue it. The costs of any infringement actions are first paid out of any damages recovered. If we are the plaintiff, the remainder of the damages are retained by us, subject to our royalty obligations to LG Life Sciences. If LG Life Sciences is the plaintiff, the remainder of the damages are divided evenly between us and LG Life Sciences, subject to our royalty obligations to LG Life Sciences. The costs of pursuing any such action could substantially diminish our resources. To date, we have no pending litigation relating to FACTIVE.

In February 2006, we entered into a Sublicensing and Distribution Agreement with Pfizer, S.A. de C.V. (Pfizer Mexico) whereby we sublicensed our rights to commercialize FACTIVE tablets in Mexico to Pfizer Mexico. Under this agreement, we are obligated to exclusively supply all active pharmaceutical ingredient for FACTIVE required by Pfizer Mexico in Mexico. The agreement with Pfizer Mexico may be terminated by either party upon the occurrence of certain termination events, including Pfizer Mexico's right to terminate at any time after August 2007, the first anniversary of launch of FACTIVE tablets in Mexico upon six-months prior written notice.

In August 2006, we entered into a Supply, Development and Marketing Agreement with Abbott Laboratories, Ltd. (Abbott Canada), the Canadian affiliate of Abbott. Under this agreement, we were obligated to exclusively supply all finished packaged FACTIVE product required by Abbott Canada. The agreement also provided that we could terminate the agreement at any time with prior notice to Abbott Canada and Abbott Canada could terminate with prior notice to us after November 30, 2008. On December 18, 2008 the agreement with Abbott Canada was terminated.

In December 2006, we entered into a License, Supply and Marketing Agreement with Menarini International Operation Luxembourg S.A. (Menarini), whereby we sublicensed our rights to sell FACTIVE tablets in Europe to Menarini. Under the terms of our agreement with Menarini, Menarini is also obligated to exclusively purchase from us, and we must exclusively supply, all API for FACTIVE to be sold in Europe for the

Table of Contents

earlier to occur of the expiration of the life of certain patents covering the product or expiration of data exclusivity. We believe that, together with our manufacturing partners, we will be able to meet such supply and other obligations under these sublicense and supply agreements but can make no assurances that we will be able to remain in compliance with such responsibilities, which would result in our breach of such agreement. Our agreement with Menarini may be terminated by either party upon the occurrence of certain termination events, including Menarini's right to terminate if the European regulatory authorities do not recommend approval of FACTIVE at various stages of the approval process with a package insert, or label, that meets certain requirements as to the safety, dosing and indications for which FACTIVE may be prescribed. In recent years, the FDA has made the approval process for new antibiotics more challenging, sometimes requesting placebo-controlled or superiority design clinical studies for certain indications. It is possible that the European Medicines Agency (EMEA) could adopt a similar position regarding the approval of FACTIVE for certain indications, and as a result Menarini may not be able to secure regulatory approval of FACTIVE in Europe and accordingly could elect to terminate the agreement. Menarini may also terminate the agreement if it does not receive approval for reimbursement from European Union member countries that is above a certain minimum price per tablet.

Our intellectual property protection and other protections may be inadequate to protect our products.

Our success will depend, in part, on our ability to obtain commercially valuable patent claims and protect our intellectual property. The degree of protection afforded by a patent varies on a country-by-country and a product-by-product basis and depends upon many factors, including the scope of the patent's claims, the availability of regulatory-related patent term extensions, the validity and enforceability of the patent and the availability of legal remedies in a particular country. We currently own or license approximately 64 issued U.S. patents, approximately 36 pending U.S. patent applications, approximately 60 issued foreign patents and approximately 109 pending foreign patent applications. We are not currently involved in any litigation, settlement negotiations, or other legal action regarding patent issues and we are not aware of any patent litigation threatened against us. Our patent position involves complex legal and factual questions, and legal standards relating to the issuance, scope, validity and enforceability of claims in the applicable technology fields are still evolving. Therefore, the degree of future protection for our proprietary rights is uncertain.

Under our Development, License and Supply Agreement with Etypharm, S.A. (Etypharm), we assumed all of the rights and obligations related to the development, manufacturing, marketing and sale of ANTARA in the United States. This license includes one issued U.S. patent and several pending patent applications. In conjunction with the financing of our acquisition of ANTARA, we entered into a Security Agreement with Paul Royalty Fund Holdings II, LP (Paul Capital), an affiliate of Paul Capital Partners, under which our wholly-owned subsidiary granted Paul Capital a security interest in substantially all of its assets, including all rights to the ANTARA intellectual property, in order to secure its performance under the financing agreements with Paul Capital. In connection with the issuance of the 2011 notes, Guardian II and the collateral agent for the 2011 note holders entered into a Security Agreement under which Guardian II granted the collateral agent a second priority security interest in substantially all of the assets of Guardian II to secure Guardian's guarantee of our obligations with respect to the 2011 notes. The patents and applications include claims that relate to pharmaceutical compositions containing fenofibrate using the drug delivery technologies incorporated in ANTARA, methods of their use and treatment, and methods of preparing the same. The patent issued to Etypharm which is listed in the FDA Orange Book is set to expire in 2020.

As discussed under, Lupin Limited's and Orchid Healthcare's Paragraph IV certifications under the Hatch-Waxman Act related to ANTARA and FACTIVE respectively could have a material adverse effect on our financial condition and results of operations, as it could result in the introduction of a generic products prior to the expiration of the patents covering ANTARA and FACTIVE, as well as in significant legal expenses and diversion of management's time, we received notice of a Paragraph IV certification from Lupin Limited (Lupin), notifying us of the filing of an ANDA with the FDA for a generic version of ANTARA and in response to the filing of Lupin's ANDA, on January 14, 2009, we, along with our wholly owned subsidiary Guardian II Acquisition Corporation and licensor Etypharm, filed a lawsuit in the United States District Court for the District of Maryland against Lupin and its subsidiary Lupin Pharmaceuticals, Inc.

Table of Contents

Under our license agreement with LG Life Sciences, we obtained an exclusive license to develop and market gemifloxacin in certain territories. This license covers 18 issued U.S. patents and a broad portfolio of corresponding foreign patents and pending patent applications. These patents include claims that relate to the chemical composition of FACTIVE, methods of manufacturing and its use for the prophylaxis and treatment of bacterial infections. We have received a Notice of Final Determination from the U.S. Patent and Trademark Office on our patent term extension application for U.S. Patent No. 5,776,944 extending its patent term 659 days to April 4, 2017. The principal U.S. patents for FACTIVE are currently set to expire at various dates, ranging from 2015 to 2019. As discussed under, Lupin Limited's and Orchid Healthcare's Paragraph IV certifications under the Hatch-Waxman Act related to ANTARA and FACTIVE respectively could have a material adverse effect on our financial condition and results of operations, as it could result in the introduction of a generic product prior to the expiration of the patents covering ANTARA and FACTIVE, as well as in significant legal expenses and diversion of management's time. We received notice of a Paragraph IV certification from Orchid Healthcare, a Division of Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), notifying us of their filing of an ANDA for a generic version of FACTIVE.

On January 8, 2008 the United States Patent and Trademark Office (USPTO) issued us U.S. Patent No. 7,317,001 relating to the treatment of *Clostridium difficile* associated disease (CDAD) using Ramoplanin. We received a patent term adjustment of 565 days thus extending the term through December 20, 2024. In addition to the recently issued patent, we have an additional patent which includes claims relating to methods of manufacturing Ramoplanin. We also have several applications pending relating to additional novel uses of Ramoplanin as well as formulations containing Ramoplanin. The patent covering the chemical composition of Ramoplanin has expired. To provide additional protection for Ramoplanin, we rely on proprietary know-how relating to maximizing yields in the manufacture of Ramoplanin, and intend to rely on the five years of data exclusivity we believe we would receive under the Hatch-Waxman Act in the U.S. and the ten years of market exclusivity in Europe available through the European Medicines Agency (EMA), because Ramoplanin would be a new chemical entity not previously marketed commercially.

We also have the exclusive right to use FACTIVE trademarks, trade names, domain names and logos in conjunction with the use or sale of the product in the territories covered by the license. We acquired exclusive rights to ANTARA trademarks, trade names, domain names and logos. After becoming aware that Antara Biosciences, Inc. filed trademark applications with the USPTO for the ANTARA and ANTARA BIOSCIENCES marks in connection with biotechnology related goods and services we filed a complaint in Federal District Court alleging, among other things, trademark infringement seeking to enjoin ANTARA BIOSCIENCES from using the ANTARA mark. We have reached a settlement with ANTARA BIOSCIENCES whereby they have agreed to abandon their ANTARA trademark applications and cease using the ANTARA marks. Accordingly we have dismissed our complaint before the Federal District Court.

The risks and uncertainties that we will face with respect to our patents and other proprietary rights include the following:

the pending patent applications that we have filed or to which we have exclusive rights may not result in issued patents, may result in issued patents with narrower claims than anticipated or may take longer than expected to result in issued patents;

the claims of any patents which are issued may be limited from those in the patent applications and may not provide meaningful protection;

U.S. Patents may be subject to reexamination or reissue proceedings before the USPTO, and foreign patents may be subject to comparable proceedings in corresponding patent offices;

we may not be able to develop additional proprietary technologies that are patentable;

the patents licensed or issued to us or our partners may not provide a competitive advantage;

other companies, such as Lupin or Orchid may challenge patents licensed or issued to us or our partners;

Table of Contents

patents issued to other companies may harm our ability to do business;

the April 30, 2007 U.S. Supreme Court decision in *KSR International Co. vs. Teleflex, Inc.* may raise the standard for patentability for both patent applications and holders, thus making it more difficult to either obtain patents or withstand challenges to patentability based on a determination of obviousness;

other companies may independently develop similar or alternative technologies or duplicate our technologies; and

the patents may be narrow in scope and accordingly other companies may design around technologies we have licensed or developed.

International patent protection is uncertain.

Patent law outside the United States is uncertain and is currently undergoing review and revision in many countries. Further, the laws of some foreign countries may not protect our intellectual property rights to the same extent as U.S. laws. We may participate in opposition proceedings to determine the validity of our or our competitors' foreign patents, which could result in substantial costs and diversion of our efforts.

Our proprietary position may depend on our ability to protect our proprietary confidential information and trade secrets.

We rely upon certain proprietary confidential information, trademarks, unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. We generally protect this information with confidentiality agreements that provide that all confidential information developed or made known to others during the course of the employment, consulting or business relationship shall be kept confidential except in specified circumstances. Agreements with employees provide that all inventions conceived by an individual while employed by us are our exclusive property. We cannot guarantee, however, that these agreements will be honored, that we will have adequate remedies for breach if they are not honored or that our proprietary confidential information and trade secrets will not otherwise become known or be independently discovered by competitors.

Seasonal fluctuations in demand for FACTIVE, and even possibly ANTARA may cause our operating results to vary significantly from quarter to quarter.

We expect demand for FACTIVE to be highest between December 1 and March 31 as the incidence of respiratory tract infections, including CAP and AECB, tends to increase during the winter months. In addition, fluctuations in the duration and severity of the annual respiratory tract infection season may cause our product sales to vary from year to year. Due to these seasonal fluctuations in demand, our results in one quarter may not be indicative of the results for any other quarter or for the entire year. Although not related to seasonal weather changes, wholesaler buying patterns may fluctuate for ANTARA during the year and possibly increase toward year end and decrease early in the year. There can be no assurance that the demand for our products or the wholesaler buying pattern will not change.

Clinical trials are costly, time consuming and unpredictable, and we have limited experience conducting and managing necessary preclinical and clinical trials for product candidates.

To obtain FDA approval to market a new drug product or to expand the approved uses of an existing product, we or our partners must demonstrate proof of safety and efficacy in humans. To meet these requirements, we or our partners will have to conduct extensive testing, including potentially preclinical testing and adequate and well-controlled clinical trials. Conducting clinical trials is a lengthy, time-consuming and expensive process. The length of time required to conduct required studies may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per trial. Delays associated with products for which clinical trials are required may cause us to incur additional operating expenses.

Table of Contents

The Phase II trial for our product candidate, Ramoplanin, to assess the safety and efficacy of treating *Clostridium difficile*-associated disease (CDAD), was completed in 2004 but did not meet its primary endpoint. Prior clinical and preclinical trials for Ramoplanin were conducted by Vicuron and its licensees, from whom we acquired rights to Ramoplanin. In December 2005 we agreed with the FDA to a Special Protocol Assessment regarding specific components of a Phase III program that, if completed successfully, would support regulatory approval for the indication. However, due to the nature of Special Protocol Assessments and the fact that our Special Protocol Assessment was agreed to by the FDA in 2005, we can give no assurance that as clinical trials proceed or as part of an NDA review process, if any, the FDA will not determine that a previously approved Special Protocol Assessment for a particular protocol is no longer valid. Additionally, in October 2007, the FDA issued draft guidance on the use of non-inferiority studies to support approval of antibiotics. Under this draft guidance, the FDA recommends that for some antibiotic indications, sponsor companies carefully consider study designs other than non-inferiority, such as placebo-controlled trials demonstrating the superiority of a drug candidate to placebo. While the indications identified by the FDA in the draft guidance are not indications which we are currently pursuing, the draft guidance does not articulate clear standards or policies for demonstrating the safety and efficacy of antibiotics generally. The lack of clear guidance from the FDA creates uncertainties about the standards for the approval of antibiotics and could delay or ultimately prevent commercialization of new antibiotic product candidates such as Ramoplanin or additional indications for FACTIVE. If the trials or the filings are delayed or not approved by the FDA, our business may be adversely affected. Currently, we have suspended the clinical development program for Ramoplanin pending identification of a partner, licensee, or buyer for the product.

If we choose to pursue additional indications or expand the label for ANTARA or FACTIVE, or are required to conduct additional clinical trials, we may not be able to demonstrate the safety and efficacy of FACTIVE or ANTARA for those indications to the satisfaction of the FDA, or other regulatory authorities. We may also be required to demonstrate that our proposed products represent an improved form of treatment over existing therapies and we may be unable to do so without conducting further clinical studies. Negative, inconclusive or inconsistent clinical trial results could prevent regulatory approval, increase the cost and timing of regulatory approval or require additional studies or a filing for a narrower indication or label expansion.

In addition, the cost of human clinical trials varies dramatically based on a number of factors, including the order and timing of clinical indications pursued, the extent of development and financial support from alliance partners, the number of patients required for enrollment, the difficulty of obtaining clinical supplies of the product candidate, and the difficulty in obtaining sufficient patient populations and clinicians.

We have limited experience in conducting and managing the preclinical and clinical trials necessary to obtain regulatory marketing approvals. We may not be able to obtain the approvals necessary to conduct clinical studies. Also, the results of our clinical trials may not be consistent with the results obtained in preclinical studies or the results obtained in later phases of clinical trials may not be consistent with those obtained in earlier phases. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after experiencing promising results in early animal and human testing.

Even if a product gains regulatory approval, the product and the manufacturer of the product will be subject to continuing regulatory review, including the requirement to conduct post-approval clinical studies, post-approval adverse event reporting requirements and potentially a REMS. We may be restricted or prohibited from marketing or manufacturing a product, even after obtaining product approval, if previously unknown problems with the product or its manufacture are subsequently discovered.

Table of Contents

We could experience delays in clinical development which could delay anticipated product launches.

The speed with which we are able to complete clinical trials for future product candidates, when and if we, or any third party with whom we partner, elects to commence Phase III development of Ramoplanin, and our applications for marketing approval will depend on several factors, including the following:

the rate of patient enrollment, which is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study and the nature of the protocol;

fluctuations in the disease incidence for patients available to enroll in our trials;

compliance of patients and investigators with the protocol and applicable regulations;

prior regulatory agency review and approval of our applications and procedures;

Institutional Review Board (IRB) review and monitoring;

analysis of data obtained from preclinical and clinical activities which are susceptible to varying interpretations, which interpretations could delay, limit or prevent regulatory approval;

changes in the policies of regulatory authorities for drug approval during the period of product development including the FDA's recent draft guidance released in October 2007 relating to Antibacterial Drug Products: Use of Noninferiority Studies to Support Approval; and

the availability of skilled and experienced staff to conduct and monitor clinical studies, to accurately collect data and to prepare the appropriate regulatory applications.

We depend on key personnel, including members of our direct sales force, in a highly competitive market for such skilled personnel.

We are highly dependent on the principal members of our senior management and key scientific, sales and technical personnel. The loss of any of our personnel could have a material adverse effect on our ability to achieve our goals. We currently maintain employment agreements with the following executive officers: Steven M. Rauscher, President and Chief Executive Officer and Philippe M. Maitre, Executive Vice President and Chief Financial Officer. The term of each employment agreement continues until it is terminated by the officer or Oscient.

Our future success is dependent upon our ability to attract and retain additional qualified sales and marketing, clinical development, scientific and managerial personnel. Like others in our industry, we may face, and in the past we have faced from time to time, difficulties in attracting and retaining certain employees with the requisite expertise and qualifications. We believe that our historical recruiting periods and employee turnover rates are similar to those of others in our industry; however, we cannot be certain that we will not encounter greater difficulties in the future.

With routine employee turnover, we also face the risk of being unable to enforce our rights under non-compete and non-solicitation provisions as well as confidentiality obligations that protect the Company. We also need to guard against the same obligations that our employees or our potential employees have with their former employers, otherwise we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers and disputes may arise as to rights in related or resulting know-how and inventions. Litigation may be necessary to defend against these claims, which may result in substantial costs, be a distraction to management, require payment of money claims, and result in a loss of valuable intellectual property or personnel.

Table of Contents

Failure to obtain or maintain regulatory approvals in foreign jurisdictions will prevent us from marketing FACTIVE abroad.

We have entered into commercialization relationships with Pfizer Mexico and Menarini whereby we sublicensed our rights to sell FACTIVE tablets in Mexico to Pfizer Mexico and in Europe to Menarini. We had previously sublicensed our rights to commercialize FACTIVE tablets in Canada to Abbott Laboratories, Inc. (Abbott Canada) whereby Abbott Canada was responsible for the development and commercialization of FACTIVE in Canada, however our license agreement with Abbott Canada was terminated in December 2008, and Abbott Canada has ceased all development and commercialization activities relating to FACTIVE in Canada. Further, in order to market FACTIVE in Europe, we or our distribution partners may need to obtain multiple regulatory approvals. For instance, in the first quarter of 2008, Menarini, submitted a regulatory filing seeking approval of FACTIVE in Europe. Menarini is seeking approval of FACTIVE for the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. The regulatory review time in Europe is approximately twelve (12) months. Obtaining foreign approvals may require additional trials and expense. In recent years, the FDA has made the approval process for new antibiotics more challenging, sometimes requesting placebo-controlled or superiority design clinical studies for certain indications. It is possible that the European Medicines Agency (EMEA) could adopt a similar position regarding the approval of new antibiotics for certain indications. Menarini may not be able to obtain regulatory approval for FACTIVE, which could delay or prevent us from receiving revenue from sales of FACTIVE in Europe, and/or may require additional expenditures. Moreover, our predecessor's original regulatory filing in the United Kingdom was rejected.

If our partners are unsuccessful in their efforts to obtain and/or expand their respective marketing approvals, the revenues that we expect to obtain from the sales of FACTIVE could be significantly limited.

We rely on operational data obtained from third party vendors which could be inaccurate.

We rely on prescription and wholesaler data obtained from industry-accepted, third-party data sources. These third-party data projections may not accurately reflect actual prescriptions or trade levels of inventory. If this data turns out to be inaccurate or unreliable and our controls are not effective, there could be an adverse effect on our ability to properly manage inventory and our financial performance.

RISKS RELATED TO OUR INDUSTRY

Health care insurers, the government and other payers may not pay for our products or may impose limits on reimbursement.

Our ability to commercialize ANTARA capsules, FACTIVE tablets, Ramoplanin and our future products will depend, in part, on the extent to which reimbursement for such products will be available from third-party payers, such as Medicare, Medicaid, health maintenance organizations, health insurers and other public and private payers. We cannot assure you that third-party payers will pay for such products or will establish and maintain price levels sufficient for realization of an appropriate return on our investment in product development. If government and private payers do not cover our products or do not reimburse for use of our products at adequate reimbursement levels, our products may fail to achieve market acceptance and our results of operations may be materially adversely affected. Under the Medicare Part D outpatient prescription drug benefit, Medicare beneficiaries (primarily the elderly over 65 and the disabled) may enroll in private drug plans. There are multiple types of Part D plans and numerous plan sponsors, each with its own formulary and product access requirements. The plans have considerable discretion in establishing formularies and tiered co-pay structures and in placing prior authorization and other restrictions on the utilization of specific products. In addition, Part D plan sponsors are permitted and encouraged to negotiate rebates with manufacturers. The profitability of our products may depend on the extent to which they enjoy preferred status on the formularies of a significant portion of the largest Part D prescription drug plans. Our ability to obtain such preferred status on favorable economic terms cannot be assured. Additionally, the Part D program has been the subject of much controversy since its enactment in 2003,

Table of Contents

and significant amendments, including an amendment to authorize the Federal Government to directly negotiate drug prices with manufacturers, are possible. Such amendments could adversely affect our anticipated revenues and results of operations, possibly materially.

Most state Medicaid programs have established preferred drug lists (PDLs), and the process, criteria and timeframe for obtaining placement on the PDL varies from state to state. Under the Medicaid drug rebate program, a manufacturer must pay a rebate for Medicaid utilization of a product. The rebate for an innovator product is based on the greater of (i) 15.1% of the product s average manufacturer price (AMP) or (ii) the difference between the product s AMP and the best price offered by the manufacturer, plus an inflation adjustment if AMP increases faster than inflation. In addition, many states have established supplemental rebate programs as a condition for including a drug product on a PDL. The profitability of our products may depend on the extent to which they appear on the PDLs of a significant number of state Medicaid programs and the amount of the rebates that must be paid to such states. In addition, there is significant fiscal pressure on the Medicaid program, and amendments to lower the pharmaceutical costs of the program and/or lower manufacturers rebate liability are possible. Such amendments could adversely affect our anticipated revenues and results of operations, possibly materially.

As part of the effort to control the costs of prescription drugs, many health maintenance organizations and other third-party payers use formularies, or lists of drugs for which coverage is provided under their benefit plans. Each payer that maintains a drug formulary makes its own determination as to whether a drug will be included in the formulary and whether particular drugs in a therapeutic class will have preferred status over other drugs in the same class. This determination often involves an assessment of the clinical appropriateness of the drug and sometimes the cost of the drug in comparison to alternative products. We cannot assure you that ANTARA capsules, FACTIVE tablets, Ramoplanin or any of our future products will be added to payers formularies, whether our products will have preferred status over alternative therapies, nor whether the formulary decisions will be made in a timely manner. We may also decide to enter into discount or formulary fee arrangements with payers, which could result in our receiving lower or discounted prices for our products.

If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, we could be forced to pay substantial damage awards.

The use of any of our product candidates in clinical trials, and the sale of any approved products, might expose us to product liability claims. We currently maintain, and we expect that we will continue to maintain, product liability insurance coverage in the amount of \$10.0 million per occurrence and \$10.0 million in the aggregate. Such insurance coverage might not protect us against all of the claims to which we might become subject. We might not be able to maintain adequate insurance coverage at a reasonable cost or in sufficient amounts or scope to protect us against potential losses. Additionally, as a result of the March 4, 2009 U.S. Supreme Court decision in *Wyeth v. Levine*, we may potentially be exposed to state common law product liability claims for inadequately disclosing risks related to our products use and we cannot predict the impact of this decision at this time. In the event a claim is brought against us, we might be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim brought successfully against us. Furthermore, whether or not we are ultimately successful in defending any such claims, we might be required to direct financial and managerial resources to such defense and adverse publicity could result, all of which could harm our business. In addition, a product recall or excessive warranty claims (in any such case, whether arising from manufacturing deficiencies, labeling errors or other safety or regulatory reasons) could have an adverse effect on our product sales or require a change in the indications for which our products may be used.

Table of Contents

RISKS RELATED TO THE SECURITIES MARKET AND OUR 12.50% NOTES

The price of our common stock and our 12.50% Notes is highly volatile.

The market price of our stock and 12.50% Notes has been and is likely to continue to be highly volatile due to the risks and uncertainties described herein, as well as other factors, including:

our ability to obtain financing necessary to meet future operating cash flow requirements;

our ability to service our debt obligations as they become due;

the revenues that we may derive from the sale of ANTARA capsules and FACTIVE tablets, as compared to analyst estimates or to our own guidance;

our ability to enter into transactions to acquire, license or co-promote additional products;

our ability to defend our products from generic attack and litigation relating to such matters;

whether we will be able to successfully integrate any additional products that we acquire, license or co-promote into our sales and marketing efforts;

the timing of the achievement of development milestones and other payments under our strategic alliance agreements;

termination of, or an adverse development in, our strategic alliances;

conditions and publicity regarding the pharmaceutical industry generally;

our ability to meet the continued listing requirements for The NASDAQ Global Market;

price and volume fluctuations in the stock market at large which do not relate to our operating performance;

variations in our rates of product returns, allowances and rebates and discounts;

sales of shares of our common stock in the public market; and

comments by securities analysts, or our failure to meet market expectations, including our projected financial performance.

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Over the two-year period ending December 31, 2008 the closing price of our stock as reported on The NASDAQ Global Market ranged from a high of \$8.07 to a low of \$0.18. The stock market has from time to time experienced extreme price and volume fluctuations that are unrelated to the operating performance of particular companies. In the past, companies that have experienced volatility have sometimes been the subject of securities class action litigation. If litigation were instituted on this basis, it could result in substantial costs and a diversion of management's attention and resources. These broad market fluctuations may adversely affect the price of our securities, regardless of our operating performance.

Any investment in our 12.50% Notes is subject to a very high degree of risk.

Any investment in our 12.50% Notes is subject to a very high degree of risk. At maturity or upon an acceleration of the 12.50% Notes, the entire outstanding principal amount of our 12.50% Notes will become due and payable and we may not have sufficient funds or may be unable to arrange for additional financing to pay the principal amount when due. Although the 12.50% Notes are guaranteed by our subsidiary Guardian II Acquisition Corporation (Guardian II) and this guarantee is secured by a second priority lien on substantially all of the assets of Guardian II, there is a substantial amount of uncertainty regarding both the value of the collateral and the ability of a holder of 12.50% Notes to realize value from the collateral. In the event of

Table of Contents

foreclosure on the collateral, the proceeds from the sale of the collateral would be distributed first to satisfy indebtedness secured by the first priority lien held by Paul Capital. The value of the collateral and the amount to be received upon a sale of the collateral will depend upon many factors including, among others, the condition of the collateral and our industry, the ability to sell the collateral in an orderly sale, the condition of the international, national and local economies, the availability of buyers, the availability of credit to a buyer and similar factors all of which are subject to increased risk given recent turmoil in the credit markets. In addition to the foregoing, the 12.50% Notes are subject to risk and uncertainties, including that:

the 12.50% Notes are not listed on national exchange or quotation system and you may not be able to sell the 12.50% Notes at a price acceptable to you or at all;

bankruptcy laws may place additional limits on your ability to realize value from the collateral;

federal and state statutes allow courts, under specific circumstances, to void guarantees and could require holders of the 12.50% Notes to return payments received from the guarantor;

the market price of our common stock into which the 12.50% Notes are convertible may fluctuate significantly, causing additional volatility in the price of the 12.50% Notes; and

investments in the 12.50% Notes may result in adverse tax consequences to you and you should consult you tax advisor before making any investment in the 12.50% Notes.

Conversion of our convertible notes will dilute the ownership interests of existing stockholders.

The conversion of some or all of our convertible notes will dilute the ownership interest of our existing stockholders. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of our convertible notes may encourage short selling by market participants because the conversion of notes could depress the price of our common stock and short selling by holders of 12.50% Notes engaging in hedging transactions which could further depress the price of our common stock.

Multiple factors beyond our control may cause fluctuations in our operating results and may cause our stock price or the price of our 12.50% Notes to fall.

Our revenues and results of operations may fluctuate significantly, depending on a variety of factors, including the following:

the pace of our commercialization of ANTARA capsules and FACTIVE tablets, and in the case of FACTIVE, seasonal fluctuations in the duration and severity of the annual respiratory tract infection season;

the level of acceptance by physicians and third party payers of ANTARA and FACTIVE;

expenses related to, and the results of, litigation and other proceedings relating to intellectual property rights including the Lupin litigation;

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

our success in concluding transactions to acquire additional approved products and product candidates, and the pace of our commercialization of such additional products;

the introduction of new products and services by our competitors;

regulatory actions;

the progress of any future clinical trials for our products; and

the progress of any clinical trials conducted by partners for Ramoplanin or products developed through our legacy alliances.

Table of Contents

We will not be able to control many of these factors. In addition, if our revenues in a particular period do not meet expectations, we may not be able to adjust our expenditures in that period, which could cause our business to suffer and may cause our stock price to fall. We believe that period-to-period comparisons of our financial results will not necessarily be meaningful. You should not rely on these comparisons as an indication of our future performance. If our operating results in any future period fall below the expectations of securities analysts and investors, our stock price may fall, possibly by a significant amount.

Item 2. Properties

Our executive offices are located at 1000 Winter Street, Suite 2200, Waltham, Massachusetts. We lease approximately 36,000 square feet of space at our Winter Street facility and our lease expires on March 31, 2012.

During 2008, 2007 and 2006, we incurred aggregate rental costs, excluding maintenance and utilities, for our leased facilities of approximately \$1,017,000, \$833,000 and \$833,000 respectively. Additionally, in 2006 we incurred approximately \$1.8 million in rental costs which included obligations under a lease for approximately 81,000 square feet of space at our former executive offices located at 100 Beaver Street, Waltham, Massachusetts, which expired on November 15, 2006. We subleased approximately 47,000 square feet at our former Beaver Street facility, and we received approximately \$1.6 million in sublease income in 2006.

In 2007, we expanded our commercial sales and marketing capabilities by adding offices in New Jersey. Our commercial sales and marketing offices are located at 23 Orchard Road, Suite B103, Skillman, New Jersey. We lease approximately 10,000 square feet of space at the Orchard Road facility and our lease term, which extends five years, began on February 11, 2008 and expires in 2013.

We also maintain a west coast lease at 7300 Shoreline Court, South San Francisco, California, for approximately 68,000 square feet of laboratory and administrative space. The remaining average yearly base rent for the west coast facility is approximately \$4.7 million. The lease for this facility expires on February 28, 2011 and we have subleased to third parties approximately 61,300 square feet of the facility through various dates ranging from July 31, 2009 to February 28, 2011. In 2008, we received approximately \$2.8 million in sublease income from the west coast subleases.

Table of Contents

Item 3. Legal Proceedings

ANTARA Paragraph IV Litigation

On December 2, 2008, we and our licensor, Ethypharm, S.A. (Ethypharm) received notice of a Paragraph IV certification from Lupin Limited (Lupin), notifying us of the filing of an ANDA with the FDA seeking approval to market a generic version of ANTARA prior to the August 2020 expiration date of U.S. Patent No. 7,101,574 (the 574 Patent). The 574 Patent, which is owned by Ethypharm, exclusively licensed to Oscient and listed in the FDA Orange Book for ANTARA relates to pharmaceutical compositions containing fenofibrate and methods of preparing the same. Lupin's certification notice alleges the 574 Patent, is invalid and/or will not be infringed by Lupin's commercial manufacture, use or sale of the drug product described in Lupin's ANDA. The 574 Patent will expire in 2020. The Paragraph IV certification sets forth allegations that the 574 Patent will not be infringed by Lupin's manufacture, use or sale of the product for which their ANDA was submitted.

On January 14, 2009, we, along with our wholly owned subsidiary Guardian II Acquisition Corporation and our licensor Ethypharm, filed a lawsuit in the United States District Court for the District of Maryland against Lupin and its subsidiary Lupin Pharmaceuticals, Inc., for infringement of the 574 Patent. We have agreed to share the costs incurred during the litigation with our licensor Ethypharm. In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Lupin, FDA approval of Lupin's ANDA will be stayed until the earlier of thirty months from the date of receipt of the Paragraph IV certification notice, or the date of a District Court decision finding that the 574 Patent is either invalid, unenforceable or not infringed by the drug product which is the subject of Lupin's ANDA. If the litigation is still ongoing after thirty months, the termination of the stay could result in the introduction of one or more generic products to ANTARA prior to resolution of the litigation.

Other Litigation

From time to time we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. These actions, when finally concluded and determined, will not, in our opinion, have a material adverse effect on our financial position, results of operations or cash flows. We believe that we have obtained adequate insurance or, where appropriate, have established adequate reserves in connection with these legal proceedings.

Item 4. Submission of Matters to a Vote of Security Holders

None

Table of Contents**PART II****Item 5. Market for the Registrant's Common Stock and Related Security Holder Matters**

Our common stock is traded on the NASDAQ Global Market under the symbol OSCI. The table below sets forth the range of high and low sale prices for each fiscal quarter during 2008 and 2007 as reported by the NASDAQ Global Market.

	2008		2007	
	High	Low	High	Low
First Quarter	\$ 2.30	\$ 1.06	\$ 5.50	\$ 4.10
Second Quarter	2.84	1.38	7.78	4.45
Third Quarter	1.53	0.70	4.75	2.48
Fourth Quarter	1.15	0.15	3.27	1.16

As of March 20, 2009, there were approximately 471 shareholders of record of our common stock.

We have not paid any dividends since our inception and presently anticipate that all earnings, if any, will be retained for development of our business and that no dividends on our common stock will be declared in the foreseeable future. Any future dividends will be subject to the discretion of our Board of Directors and will depend upon, among other things, future earnings, the operating and financial condition of our company, our capital requirements and general business conditions.

Equity Compensation Plan Information

Plan category	(a) Number of securities to be issued upon exercise of outstanding options	(b) Weighted-average exercise price of outstanding options	(c)
			Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans approved by security holders	1,327,177	\$ 17.23	1,057,558
Equity compensation plans not approved by security holders (1)	265,282	1.99	107,956
Total	1,592,459	\$ 14.50	1,165,514

- (1) As described on the Company's Form S-8 filed on October 1, 2007, the Board of Directors approved the Company's 2007 Employment Inducement Award Plan (the "2007 Inducement Plan") on August 13, 2007, and authorized 500,000 shares of common stock for issuance under the 2007 Inducement Plan. The 2007 Inducement Plan provides for the grant of non-qualified stock options and restricted stock to new employees.

Table of Contents

Company Purchases of Equity Securities

We did not make any purchases of our common stock during the year ended December 31, 2008.

* \$100 invested on 12/31/03 in stock or index, including reinvestment of dividends.
Fiscal year ending December 31.

Notwithstanding anything to the contrary set forth in any of the Company's previous or future filings made under the Securities Act or the Exchange Act that might incorporate by reference this annual report or future filings made by the Company under those statutes, the preceding Stock Performance Graph and the information relating to it is not soliciting material and is not deemed filed with the Securities and Exchange Commission, and shall not be deemed incorporated by reference into any of those such prior filings or into any future filings made by the Company under those statutes.

Copyright © 2009, S&P, a division of The McGraw-Hill Companies, Inc. All rights reserved.

Table of Contents**Item 6. Selected Financial Data**

You should read carefully the financial statements included in this report, including the notes to the financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations. The selected financial data in this section are not intended to replace the financial statements.

We derived the statement of operations data for the years ended December 31, 2008, 2007 and 2006 and the balance sheet data as of December 31, 2008 and 2007 from our audited financial statements, which are included elsewhere in this report. We derived the statement of operations data for the years ended December 31, 2005 and 2004 and the balance sheet data as of December 31, 2006, 2005 and 2004 from our audited financial statements which are not included herein. Historical results are not necessarily indicative of future results. See the notes to the financial statements for an explanation of the method used to determine the number of shares used in computing basic and diluted net loss per common share (in thousands, except per share data).

	For the Year Ended December 31,				
	2008	2007	2006(5)	2005	2004(6)
Revenues (net):					
Product sales	\$ 86,325	\$ 78,458	\$ 38,244	\$ 20,458	\$ 4,067
Co-promotion			6,890	2,954	
Other	523	1,511	1,018	197	2,546
Total net revenues (1)	86,848	79,969	46,152	23,609	6,613
Costs of product sales and operating expenses (2)	167,210	117,965	118,071	112,281	97,229
Loss from operations	(80,362)	(37,996)	(71,919)	(88,672)	(90,616)
Net other income (expense) (3)	16,027	8,527	(6,379)	79	(2,863)
Loss from continuing operations before income tax	(64,335)	(29,469)	(78,298)	(88,593)	(93,479)
Provision for income tax	(420)	(384)	(179)		
Net loss from continuing operations	(64,755)	(29,853)	(78,477)	(88,593)	(93,479)
Income (loss) from discontinued operations					208
Net loss	\$ (64,755)	\$ (29,853)	\$ (78,477)	\$ (88,593)	\$ (93,271)
Net loss per common share basic and diluted (4)	\$ (4.03)	\$ (2.19)	\$ (6.58)	\$ (9.26)	\$ (10.61)
Weighted average basic and diluted common shares outstanding (4)	16,051	13,601	11,925	9,569	8,794

(1) Does not include income (loss) from discontinued operations related to our genomics business.

(2) For the year ended December 31, 2008, includes charge for impairment of intangible assets of \$50,759.

(3) For the years ended December 31, 2008 and 2007, includes \$35,357 and \$30,824 as gains on exchange of convertible notes, respectively, and includes \$10,480 and \$3,023 as gains on derivatives, respectively.

(4) Adjusted to account for the effect of the one-for-eight reverse stock split effective on November 15, 2006.

(5) We acquired the ANTARA assets on August 18, 2006.

(6) We completed a merger with GeneSoft Pharmaceuticals on February 6, 2004.

	As of December 31,				
	2008	2007	2006	2005	2004
Cash and cash equivalents, restricted cash, and long and short-term marketable securities	\$ 17,193	\$ 52,466	\$ 44,808	\$ 80,044	\$ 176,628

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Working capital	(208,352)	42,011	40,444	77,750	156,021
Total assets	174,033	274,184	279,407	241,095	340,560
Long-term liabilities	5,371	268,906	250,977	191,289	193,397
Shareholders (deficit) equity	(81,184)	(28,715)	(1,996)	28,101	114,400

Table of Contents

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

Oscient Pharmaceuticals Corporation (we , us , the Company or Oscient) is a commercial-stage pharmaceutical company marketing Food and Drug Administration (FDA)-approved products in the United States. Our strategy is to maximize the sales of our existing products and to gain access to new products via transactions, including acquisition, in-licensing and co-promotion. We have developed a commercial infrastructure, including a national sales force calling on targeted primary care physicians, cardiologists, endocrinologists and pulmonologists in the United States.

We currently market two products: ANTARA® (fenofibrate) capsules, a cardiovascular product, and FACTIVE® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is approved by the FDA to treat hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with a healthy diet. We license the rights to ANTARA from Ethypharm S.A. of France (Ethypharm) and began promoting ANTARA in late August 2006. FACTIVE is indicated for the treatment of community-acquired pneumonia of mild to moderate severity (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB). We license the rights to gemifloxacin, the active ingredient in FACTIVE tablets, from LG Life Sciences of the Republic of Korea (LG Life Sciences) and launched FACTIVE in the U.S. market in September 2004.

We have incurred significant operating losses in the past. As of December 31, 2008, we had an accumulated deficit of approximately \$511 million. Our independent registered public accounting firm has included a going concern explanatory paragraph in its report for fiscal year ended December 31, 2008. This indicates that our recurring losses from operations and current lack of sufficient funds to sustain operations through the end of the following fiscal year raise substantial doubt about our ability to continue as a going concern. We will require additional funding to remain a going concern and to fund operations. The inclusion of a going concern explanatory paragraph in the fiscal year 2008 report of our registered public accounting firm may materially and adversely affect our ability to raise new capital and there are no assurances that adequate additional financing will be available to us on acceptable terms, if at all. If we are unsuccessful in obtaining financing or reducing costs, we may be unable to continue operations and/or may seek bankruptcy protection.

In order to more aggressively preserve the Company's financial resources and position our organization for a potential partnership or acquisition, on February 11, 2009, we announced plans to substantially reduce the size of our sales and marketing teams as well as our office personnel. We also announced on February 11, 2009 that we have engaged Broadpoint Capital, Inc. to advise us on strategic options, including the potential sale of the Company. There can be no assurance that this engagement will enable us to identify and implement strategic options, including the potential sale, that will be of benefit to investors.

Notice of Delisting

On October 3, 2008, we received a notification from The NASDAQ Listings Qualifications Department of The NASDAQ Stock Market LLC (NASDAQ) that, as of October 2, 2008, our market value of publicly held shares (MVPHS) had closed below the minimum \$15 million threshold set forth in Marketplace Rule 4450(b)(3) for the previous thirty (30) consecutive business days, a requirement for continued listing. For NASDAQ purposes, MVPHS is the market value of the Company's publicly held shares, which is calculated by subtracting all shares held by officers, directors or beneficial owners of 10% or more of an issuer's common stock from the issuer's total shares outstanding.

On October 23, 2008, we received notification from NASDAQ that given the current extraordinary market conditions, NASDAQ has suspended the enforcement of the rules requiring a MVPHS and a minimum \$1 closing bid price (Rule Suspension). On December 23, 2008 we received a second notification from NASDAQ that the

Table of Contents

Rule Suspension period had been extended an additional ninety (90) days and that the minimum bid price and MVPHS requirements would be reinstated on April 20, 2009. On March 23, 2009 we received a third notification from NASDAQ that the Rule Suspension period had been extended an additional ninety (90) days and that the minimum bid price and MVPHS requirements will be reinstated on July 20, 2009. As a result of the Rule Suspension, all companies presently in the compliance process will remain at that same stage of the process; however, companies can regain compliance during the Rule Suspension period. NASDAQ will not take any action to delist any security for these concerns during the Rule Suspension period, which will remain in effect through Friday, July 17, 2009. These rules will be reinstated on Monday, July 20, 2009. Under the Rule Suspension, we believe we will now have until approximately October 6, 2009 to regain compliance by evidencing a minimum \$15 million MVPHS for ten (10) consecutive business days. If we do not regain compliance with the MVPHS requirement by October 6, 2009, we will receive written notification of delisting from NASDAQ and at that time will be entitled to request a hearing before a NASDAQ Listing Qualifications Panel (Panel) to present our plan to regain compliance with the MVPHS requirement.

If our efforts to regain compliance are successful and the MVPHS exceeds \$15 million for ten (10) consecutive business days before October 6, 2009, we will regain compliance with respect to the MVPHS requirement. In the event we do not regain compliance, we may appeal the staff determination to the Panel. In the event that we fail to regain compliance and are unsuccessful in an appeal to the Panel, our securities will be delisted from The NASDAQ Global Market. In the event that our securities are delisted from The NASDAQ Global Market, we may not be able to meet the requirements necessary for our common stock (i) to transfer to, or list on, a U.S. national securities exchange, including The NASDAQ Capital Market or (ii) be approved for listing on a U.S. system of automated dissemination of quotations. If such event in (i) or (ii) above occurred, holders of our 2011 Notes (as described below) would have the right to require us to repurchase for cash the outstanding principal amount of the 2011 Notes as applicable, plus accrued and unpaid interest through such date. As of December 31, 2008, there was \$86,684,000 principal amount of 12.50% Guaranteed convertible senior notes due 2011 (12.50% Notes), \$12,687,000 principal amount of 3.50% Senior convertible promissory notes due 2011 (3.50% Notes) and \$829,000 principal amount of 3% Senior convertible promissory notes due 2011 (3% Notes) (collectively, the 2011 Notes). If the 12.50% Notes become due and are accelerated, this could trigger a Put Event under the Paul Capital Revenue Interest Assignment Agreement as amended. We do not have sufficient cash and may not be able to raise sufficient additional capital to repay the 2011 Notes as applicable, if requested by the holders to repurchase the notes and/or Paul Capital.

ANTARA

ANTARA is a once-daily formulation of fenofibrate approved for use in combination with a diet restricted in saturated fat and cholesterol to reduce elevated LDL-C (bad cholesterol), triglyceride and apolipoprotein B (free floating fats in the blood) levels and to increase HDL-C (good cholesterol) in adult patients with high cholesterol or an abnormal concentration of lipids in the blood. Following oral administration, fenofibrate is rapidly hydrolyzed to its active metabolite, fenofibric acid. Fenofibrate products work primarily to lower triglycerides and increase HDL-C, which makes the drug an attractive alternative for those patients whose LDL-C is well controlled. ANTARA received FDA approval in November 2004. We began marketing ANTARA in 43 mg and 130 mg doses in August 2006.

On August 18, 2006, we acquired rights to ANTARA in the United States from Reliant Pharmaceuticals Inc. (Reliant) for \$78 million plus approximately \$4.3 million for ANTARA inventory, excluding estimated transaction costs. Under the terms of our acquisition of ANTARA, we assumed certain of Reliant's liabilities related to ANTARA, including obligations to make certain royalty and milestone payments on sales of ANTARA.

We were assigned rights to an exclusive license from Ethypharm, S.A. (Ethypharm). Pursuant to the Ethypharm license, in order to maintain the exclusivity of our rights, we must achieve minimum annual sales in

Table of Contents

the United States until February 2012 or alternatively Ethypharm may elect to convert our exclusive license to a non-exclusive; however, we would then have the option to compensate Ethypharm for any shortfall to maintain the exclusive license. On or about February 27, 2009, we received notice from Ethypharm that we had not achieved the minimum sales threshold, and accordingly within 60 days of receipt of such notice, on or approximately April 28, 2009, we may elect to maintain the exclusivity of the license by compensating Ethypharm for any shortfall, or to convert the exclusive license to a non-exclusive license. As of December 31, 2008, we have recorded approximately \$621,000 related to the potential minimum royalty obligation owed to Ethypharm which would be payable in the event we elect to maintain the exclusivity of the license. During the term of the agreement with Ethypharm, we are obligated to pay a royalty on net sales of ANTARA in the U.S., including a royalty on other fenofibrate monotherapy products in formulations and dosage forms that may be substantially similar or identical to ANTARA developed by us. The license term expires in February 2020 and, absent notice of termination by either party, automatically renews for consecutive periods of two (2) years each. Under the terms of the agreement, at our option, Ethypharm is obligated to either manufacture and deliver to us finished fenofibrate product or deliver active pharmaceutical ingredient (API) to us for encapsulation and packaging. Ethypharm also has a right of first refusal on any divestiture of the ANTARA rights by us. Additional Oscient obligations under the Ethypharm agreement include funding a portion of the API safety stock that Ethypharm is required to maintain.

In addition, under the terms of one of the licenses we assumed related to ANTARA, not including the Ethypharm license, we are obligated to make certain royalty payments to a third party licensor based on sales of ANTARA, which royalty payments are subject to a low single digit increase in the event of a change in control of the Company. The third party license also limits our ability to co-promote ANTARA with companies other than contract sales organizations or similar companies. We have engaged the third party licensor to renegotiate the terms of that license and have suspended further royalty payments while the terms of such license are being renegotiated.

Pursuant to the terms of our acquisition of ANTARA from Reliant, we also acquired the New Drug Application (NDA) and the Investigational New Drug application (IND), covering the ANTARA products in the United States, clinical data, inventory, the ANTARA trademark in the United States and certain related contracts and licenses covering intellectual property rights related to the ANTARA products. We also assumed certain of Reliant's liabilities relating to the ANTARA products.

We are not required to pay Reliant a royalty on the sale of the ANTARA products; however, we are required to pay a low single-digit royalty to Reliant for a specified time period on net sales of any line extensions and improvements to the ANTARA products that we develop, which include any product containing fenofibrate as its API. We currently do not pay royalties to Reliant. We also agreed that we would not, at any time prior to August 2016, develop or sell any product in the United States that is a combination of fenofibrate and an omega-3 compound without the prior written consent of Reliant. On December 19, 2007, Reliant was acquired by GlaxoSmithKline.

ANTARA capsules are covered by a U.S. patent relating to formulations containing fenofibrate and methods of preparing the same that extends through August 2020. In addition, Ethypharm has filed additional patent applications which relate to the formulation and we were assigned a patent application which was filed by Reliant relating to methods of treatment. If issued, we believe these patents may provide ANTARA additional patent protection. On December 2, 2008, we received notice of a Paragraph IV certification from Lupin Limited (Lupin), notifying us of the filing of an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of ANTARA. We received the certification as the holder of the New Drug Application for ANTARA. Lupin's certification notice alleges that U.S. Patent No. 7,101,574 (the 574 Patent), owned by Ethypharm, exclusively licensed to Oscient and listed in the FDA Orange Book for ANTARA, is invalid and/or will not be infringed by Lupin's commercial manufacture, use or sale of the drug product described in Lupin's ANDA.

Table of Contents

In response to the filing of Lupin's ANDA, on January 14, 2009, we, along with our wholly owned subsidiary Guardian II Acquisition Corporation and our licensor, Ethypharm, filed a lawsuit in the United States District Court for the District of Maryland against Lupin and its subsidiary Lupin Pharmaceuticals, Inc. for infringement of the 574 Patent.

In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Lupin, FDA approval of Lupin's ANDA will be stayed until the earlier of thirty months from the date of receipt of the Paragraph IV certification notice, or the date of a District Court decision finding that the 574 Patent is either invalid, unenforceable or not infringed by the drug product which is the subject of Lupin's ANDA.

FACTIVE

Overview

FACTIVE was approved by the FDA in 2003 for the treatment of community-acquired pneumonia of mild to moderate severity (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB).

We license from LG Life Sciences of the Republic of Korea (LG Life Sciences) the right to develop and commercialize FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic, in North America, France, Germany, the United Kingdom, Luxembourg, Ireland, Italy, Spain, Portugal, Belgium, the Netherlands, Austria, Greece, Sweden, Denmark, Finland, Norway, Iceland, Switzerland, Andorra, Monaco, San Marino, Vatican City, Poland, Czech Republic, Slovakia, Slovenia, Hungary, Estonia, Latvia, Lithuania, Liechtenstein, Malta, Cyprus, Romania, Bulgaria, Croatia, Serbia and Montenegro, Bosnia and Herzegovina, Albania and the Former Yugoslav Republic of Macedonia. The term of the agreement with respect to each country extends at least through the life of the patents covering gemifloxacin in such country.

In the United States, the last of the issued patents for composition of matter expires in 2018. The patent term could extend further in countries outside of the U.S. depending upon several factors, including whether we obtain patent extensions and the timing of our commercial sale of the product in a particular country. On May 30, 2008, we received notice of a Paragraph IV certification from Orchid Healthcare, a Division of Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) notifying us of the filing of an Abbreviated New Drug Application (ANDA) with the FDA to market a generic version of FACTIVE in the U.S. As part of its ANDA, filing Orchid submitted a Paragraph IV certification alleging that eight of the nine FDA Orange Book listed patents relating to FACTIVE are invalid and/or will not be infringed by Orchid's manufacture, importation, use, or sale of the generic version of the product. Orchid has not, however, included a Paragraph IV certification with respect to U.S. Patent No. 5,633,262, which is also listed in the Orange Book and expires in June 2015. Accordingly the FDA cannot finally approve Orchid's ANDA until the expiry of U.S. Patent No. 5,633,262 in June 2015. We have not commenced a lawsuit against Orchid relating to these eight patents and are continuing to evaluate whether to commence litigation in response to Orchid's Paragraph IV certification. In the event Orchid elects to amend its ANDA to include a Paragraph IV certification with respect to the ninth patent, U.S. Patent No. 5,633,262, we believe that we will be entitled to an automatic thirty-month stay of FDA approval of the ANDA if either we and/or LG Life Sciences initiate a timely patent infringement lawsuit against Orchid at that time.

Under the terms of the agreement, LG Life Sciences has agreed to supply and we are obligated to purchase from LG Life Sciences all of our anticipated commercial requirements for the FACTIVE API. LG Life Sciences currently supplies the FACTIVE API from its manufacturing facility in South Korea.

The agreement with LG Life Sciences also required that we achieve a minimum gross sales level of \$30 million from our licensed territories over a 12-month period of time starting in approximately the third quarter of 2007 to the third quarter of 2008 which, if not met, LG Life Sciences could elect to terminate the agreement and have the technology be returned to LG Life Sciences. We believe that we have achieved the

Table of Contents

minimum gross sales threshold level. After LG Life Sciences' review of our financial information during the fourth quarter of 2008, it has accepted our analysis and concluded that it will not terminate the agreement based on the minimum gross sales level of \$30 million. Under this agreement, we are responsible, at our expense and through consultation with LG Life Sciences, for the clinical and commercial development of gemifloxacin in the countries covered by the license, including conducting clinical trials, filing drug approval applications with the FDA and other applicable regulatory authorities and marketing, distributing and selling of gemifloxacin in our territory.

We are obligated to pay a royalty on sales of FACTIVE in North America and the territories covered by the license in Europe. These royalty obligations expire with respect to each country covered by the agreement on the later of (i) the expiration of the patents covering FACTIVE in such country or (ii) the expiration of data exclusivity in Mexico, Canada or the European Union respectively, or 2014 in the U.S. We are also obligated to make aggregate milestone payments of up to \$40 million to LG Life Sciences (including milestone payments required by the amendments described below) upon achievement of additional regulatory approvals and sales thresholds.

On March 31, 2005, we amended our license and option agreement with LG Life Sciences which included a payment and additional milestones as well as a reduction of future royalties payable to LG Life Sciences at certain FACTIVE revenue levels in territories covered by the agreement.

We further amended our agreement with LG Life Sciences on February 3, 2006, pursuant to which LG Life Sciences agreed to a reduction of future royalties payable for sales of FACTIVE tablets in Mexico and Canada and the termination of LG Life Sciences' co-promotion rights in these countries. The modified agreement also calls for additional milestone payments to be made to LG Life Sciences upon consummation of sublicense agreements in Mexico and Canada (which payments were made to LG Life Science in February 2006 and August 2006, respectively) as well as upon receipt of regulatory approval of FACTIVE in each of such countries. Additionally, on December 27, 2006, we amended our agreement with LG Life Sciences to reduce future royalties payable to LG Life Sciences for sales of FACTIVE tablets in Europe and to provide for a reduction in the supply price for the API for FACTIVE for product to be sold in Europe. In lieu of milestone payments previously agreed to by the parties, this amendment also requires us to pay LG Life Sciences a portion of any milestone or license fee payments we receive from our European partner.

Commercialization and Development

With respect to additional development initiatives, we completed a clinical trial designed to demonstrate that a five-day course of FACTIVE for the treatment of mild to moderate CAP is as effective as the previously approved seven-day course of treatment. On September 21, 2006, we received an approvable letter from the FDA for the supplemental New Drug Application (sNDA) seeking approval for the five-day treatment of CAP with FACTIVE tablets. In accordance with the letter, we provided clarification and additional interpretation regarding certain data included in the application to assist the FDA in its evaluation. On May 1, 2007, the FDA approved FACTIVE for the five-day treatment of CAP.

As part of the FACTIVE development program, several studies relating to acute bacterial sinusitis (ABS) were completed, and, in November 2005, we filed an sNDA for ABS. In September 2006, the FDA's Anti-Infective Drugs Advisory Committee voted not to recommend approval of this sNDA. In November 2006, we voluntarily withdrew our sNDA seeking approval of the ABS indication.

On February 6, 2006, we entered into a Sublicensing and Distribution Agreement with Pfizer, S.A. de C.V. (Pfizer Mexico), pursuant to which we sublicensed our rights to sell FACTIVE tablets in Mexico to Pfizer Mexico. In exchange for those rights, Pfizer Mexico has paid us an up-front payment and has agreed to pay us milestone payments upon obtaining certain regulatory approvals and sales goals as well as royalties on future

Table of Contents

sales. The up-front payment has been recognized as revenue over the term of our continuing obligations under the agreement. The royalty rates are subject to reduction upon expiration of certain patents in Mexico for FACTIVE or if a generic form of gemifloxacin has a material impact on Pfizer Mexico's sales volumes in Mexico. Pfizer Mexico is obligated to exclusively purchase from us, and we must exclusively supply, all API for FACTIVE. The agreement with Pfizer Mexico may be terminated by either party upon the occurrence of certain termination events, including Pfizer Mexico's right to terminate at any time after August 2007, the first anniversary of launch of FACTIVE tablets in Mexico upon six months prior written notice. Upon termination, Pfizer Mexico is obligated to assign any and all rights to regulatory approvals in Mexico to us or our designee. Pfizer Mexico is currently marketing FACTIVE-5 in Mexico for the treatment of CAP, AECB and ABS. On December 9, 2008, Pfizer Mexico received regulatory approval to market FACTIVE tablets for the Uncomplicated Urinary Tract Infections (uUTI) indication with a 3-day course of treatment, from COFEPRIS, the pharmaceutical regulatory agency of Mexico.

On August 9, 2006, we granted the commercialization rights to FACTIVE tablets in Canada to Abbott Laboratories, Ltd. (Abbott Canada), the Canadian affiliate of Abbott. In exchange for those rights, Abbott Canada agreed to a transfer price on product purchases and to make certain payments to us upon achievement of certain regulatory and sales milestones. We subsequently amended the agreement on January 31, 2008 whereby Abbott Canada's development and commercialization obligations were substantially reduced. Our license agreement with Abbott Canada was terminated in December 2008, and Abbott Canada has ceased all development and commercialization of FACTIVE in Canada.

On December 28, 2006, we entered into a License, Supply and Marketing Agreement with Menarini International Operation Luxembourg S.A. (Menarini), a wholly-owned subsidiary of Menarini Industrie Farmaceutiche Riunite S.r.l., whereby we sublicensed our rights to sell FACTIVE tablets in the European Union to Menarini. Under the terms of our agreement with Menarini, Menarini is responsible for obtaining regulatory approval for FACTIVE in the European Union. We have agreed to reimburse Menarini for expenses associated with such regulatory development up to an agreed limit. Menarini has paid us an up-front payment and agreed to pay us milestone payments upon obtaining certain regulatory and reimbursement approvals and upon achieving certain annual net sales goals, which could total up to \$23 million if all the milestones are achieved. Menarini will pay us a transfer price on purchases of the API, for FACTIVE, which is determined based on a percentage of quarterly sales of FACTIVE by Menarini in Europe. Menarini is also obligated to exclusively purchase from us, and we must exclusively supply, all API for FACTIVE to be sold in Europe for the earlier of (i) the expiration of the life of certain patents covering the product or (ii) expiration of data exclusivity. Our agreement with Menarini may be terminated by either party upon the occurrence of certain termination events, including Menarini's right to terminate if the European regulatory authorities do not recommend approval of FACTIVE at various stages of the approval process with a package insert, or label, that meets certain requirements as to the safety, dosing and indications for which FACTIVE may be prescribed. Menarini may also terminate the agreement if it does not receive approval for reimbursement from European Union member countries that is above a certain minimum price per tablet. Upon termination, Menarini is obligated to assign any and all rights to regulatory approvals in the European Union to us or our designee. In the first quarter of 2008, Menarini submitted a regulatory filing seeking approval of FACTIVE in Europe for the treatment of community-acquired pneumonia (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB).

On July 7, 2008, we received notice from the FDA directing that the prescribing information for all fluoroquinolone products, including FACTIVE, be revised to include a Boxed Warning relating to the risk of tendonitis and tendon rupture associated with the use of fluoroquinolone products. Warnings regarding the risk of tendon related adverse events were already included in the prescribing information, as part of a class labeling, for all fluoroquinolones. The FDA has cautioned that such risk is increased in patients over the age of 60 and in those on concomitant corticosteroid therapy, as well as kidney, heart and lung transplant recipients. The FDA has also required that all manufacturers of fluoroquinolones submit a Medication Guide. The FDA has approved our changes to the package insert and Medication Guide as required by FDA to ensure patient safety and improve

Table of Contents

physician understanding of the risk-benefit profile for fluoroquinolone products, including FACTIVE. We have also submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) as required by FDA of all sponsors of fluoroquinolone products to ensure patients' safe and effective use of such products. We are working with the FDA to finalize certain details of REMS.

Research and Development Programs

FACTIVE

As a condition to the approval to sell FACTIVE tablets, the FDA required, as a post-marketing study commitment, that we conduct a prospective, randomized study examining the activity of FACTIVE tablets (5,000 patients) versus an active comparator (2,500 patients) in patients with AECB and CAP of mild to moderate severity. This study included patients of different ethnicities to gain safety information in populations not substantially represented in the existing clinical trial program. This Phase IV trial was initiated in the fall of 2004 and was completed in February 2007. The final report of the utilization study was submitted to the FDA in March of 2008. In the future, we only need to provide the FDA with annual reports containing safety information.

Additionally, in April 2005, we completed a Phase III trial examining the potential use of FACTIVE tablets for the five-day treatment of mild to moderate CAP. Based on the results of this study, in November 2005 we submitted an sNDA to the FDA for approval to promote the five-day treatment of FACTIVE tablets for this indication. On September 21, 2006, we received an approvable letter from the FDA for the sNDA seeking approval for the five-day treatment of CAP with FACTIVE tablets. In accordance with the letter, we provided clarification and additional interpretation regarding certain data included in the application to assist the FDA in its evaluation. On May 1, 2007, the FDA approved FACTIVE for the five-day treatment of CAP.

Ramoplanin

We have a novel, late-stage investigational antibiotic candidate, Ramoplanin, for the treatment of *Clostridium difficile*-associated disease (CDAD). In October 2001, we in-licensed Ramoplanin from Vicuron Pharmaceuticals Inc. (Vicuron), a wholly-owned subsidiary of Pfizer Inc., and on February 3, 2006, acquired worldwide rights from Vicuron, assuming full rights to the manufacturing, development and commercialization of Ramoplanin.

In December 2005, we agreed with the FDA to a Special Protocol Assessment (SPA) regarding the specific components of a Phase III program that, if completed successfully, would support regulatory approval for the indication. With the acquisition of ANTARA, we have made the strategic decision to concentrate our financial resources on building revenues for our products promoted to community-based physicians in the United States and have explored partnering and other strategic opportunities for the continued development of Ramoplanin. Because the Special Protocol Assessment was agreed to by the FDA in 2005, we cannot guarantee that the FDA will continue to regard it as binding on the agency if and when we or a prospective partner re-initiates the Ramoplanin clinical development process.

Critical Accounting Policies & Estimates

We have identified the policies below as critical to our business operations and the understanding of our results of operations. The impact and any associated risks related to these policies on our business operations is discussed throughout Management's Discussion and Analysis of Financial Condition and Results of Operations where such policies affect our reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see Note 2 in the Notes to the Consolidated Financial Statements of this Annual Report on Form 10-K. Our preparation of our financial statements requires us to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent

Table of Contents

assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our critical accounting policies include the following:

Revenue Recognition

Our principal source of revenue is the sale of ANTARA capsules and FACTIVE tablets. In the second quarter of 2005, we began recognizing co-promotion revenue in connection with our co-promotion agreement with Auxilium Pharmaceuticals, Inc. (Auxilium), which terminated on August 31, 2006. ANTARA revenue results are anticipated to be non-seasonal, although the wholesaler buying patterns tend to increase toward the end of the fiscal year. We expect demand for FACTIVE to be highest from December to March as the incidence of respiratory tract infections, including CAP and AECB, tends to increase during the winter months. In addition, fluctuations in the severity of the annual respiratory tract infection season may cause our product sales to vary from year to year. Due to these seasonal fluctuations in demand for FACTIVE, our results in any particular quarter may not be indicative of the results for any other quarter or for the entire year.

Product Sales

We follow the provisions of Staff Accounting Bulletin (SAB) No. 104, Revenue Recognition (a replacement of SAB 101) (SAB No. 104) and recognize revenue from product sales upon delivery of product to wholesalers, when persuasive evidence of an arrangement exists, the fee is fixed or determinable, title to product and associated risk of loss has passed to the wholesaler and collectability of the related receivable is reasonably assured. All revenues from product sales are recorded net of applicable allowances for sales returns, rebates, special promotional programs, and discounts. For arrangements where the risk of loss has not passed to wholesalers or pharmacies, we defer the recognition of revenue by recording deferred revenue until such time that risk of loss has passed. For one product sale to a new customer in 2008, we were unable to estimate product returns. Accordingly, we are recognizing revenue on the sell-through method for this transaction. As of December 31, 2008, we have \$3,653,000 of deferred revenue related to this transaction. The cost of ANTARA and FACTIVE associated with amounts recorded as deferred revenue is recorded in inventory until such time as risk of loss has passed or other criteria for revenue recognition have been met.

Other Revenues

Other revenues primarily consist of sublicensing revenues related to FACTIVE. We recognize revenue in accordance with SAB No. 104 and Emerging Issues Task Force (EITF) Issue No. 00-21, Revenue Arrangements with Multiple Deliverables (EITF No. 00-21). In accordance with EITF No. 00-21, the up-front license payments related to the various sublicense agreements will be recognized as revenue over the term of our continuing obligations under the arrangements which range from eighteen months to thirty-three months. Substantive milestones achieved are recognized as revenue when earned and when payment is reasonably assured. We expense incremental direct costs associated with sublicense agreements in the period in which the expense is incurred.

Sales Rebates, Discounts and Incentives

In the U.S., we sell ANTARA and FACTIVE to pharmaceutical wholesalers for further distribution through pharmacies to the ultimate consumers of the product. When we deliver our product, we reduce the amount of gross revenue recognized from such product sales based primarily on estimates of four categories of discounts and allowances that suggest that all or part of the revenue should not be recognized at the time of the delivery product returns, cash discounts, rebates, and special promotional programs.

Table of Contents

Product Returns

Factors that are considered in our estimate of future ANTARA and FACTIVE product returns include an analysis of the amount of product in the wholesaler and pharmacy channel, review of consumer consumption data as reported by external information management companies, actual and historical return rates for expired lots, the remaining time to expiration of our product, and our forecast of future sales of our product. Consistent with industry practice, we offer contractual return rights that allow our customers to return product within six months prior to, and twelve months subsequent to, the expiration date of our product. ANTARA capsules and FACTIVE tablets each have a 36-month expiration period from the date of manufacturing. As of December 31, 2008 and 2007, our product return reserve was approximately \$4,687,000 and \$3,169,000, respectively. This reserve is evaluated on a quarterly basis, assessing each of the factors described above, and adjusted accordingly. Based on the factors noted above, we believe our estimate of product returns is reasonable, and changes, if any, from this estimate would not have a material impact to our financial statements.

Cash Discounts

Our standard invoice includes a contractual cash 2% discount, net 30 days terms. Based on historical experience, we estimate that most of our customers deduct a 2% discount from their balance. The cash discount reserve is presented as an allowance against trade receivables in the consolidated balance sheets. As of December 31, 2008 and 2007, the balance of the cash discounts reserve was approximately \$331,000 and \$343,000, respectively.

Rebates

The liability for commercial managed care rebates is calculated based on historical and current rebate redemption and utilization rates with respect to each commercial contract. The liability for Medicaid rebates is calculated based on historical and current rebate redemption and utilization rates contractually submitted by each state. As of December 31, 2008 and 2007, the balance of the accrual for managed care and Medicaid rebates for ANTARA and FACTIVE in total was approximately \$5,917,000 and \$4,263,000, respectively. Considering the estimates made by us, as well as estimates reflected in third party utilization reports that are used in evaluating the required liability balance, we believe our estimates are reasonable.

Special Promotional Programs

From time to time, we offer certain promotional incentives to our customers for both ANTARA and FACTIVE and will continue this practice in the future. Such programs include: sample cards to retail consumers, certain product incentives to pharmacy customers, and other sales stocking allowances. We account for these programs in accordance with EITF No. 01-09, Accounting for Consideration Given by a Vendor to a Customer (EITF No. 01-09). Examples of programs utilized to date are as follows:

Voucher Rebate Programs for ANTARA

Since acquiring ANTARA in August 2006, we have initiated four voucher rebate programs for ANTARA whereby we offered a point-of-sale rebate to retail consumers. The liabilities we recorded for the current voucher rebate programs were estimated based upon the historical rebate redemption rates for similar completed programs by other pharmaceutical companies as reported to us by a third party claims processing organization and actual redemption rates on our similar completed programs. This reserve is evaluated on a quarterly basis, assessing each of the factors described above and adjusted accordingly. The first program expired on December 31, 2006, the second program expired on September 30, 2007, the third program expires on February 28, 2009 and the fourth program expires on March 31, 2010. As of December 31, 2008 and 2007, the balance of the liabilities for these voucher programs totaled approximately \$2,131,000 and \$491,000, respectively.

Table of Contents

Voucher Rebate Programs for FACTIVE

We periodically initiate voucher rebate programs for FACTIVE whereby we offer mail-in rebates and point-of-sale rebates to retail consumers. The liabilities we record for these voucher rebate programs are estimated based upon the historical rebate redemption rates for similar completed programs. This reserve is evaluated on a quarterly basis, assessing each of the factors described above and adjusted accordingly. In April 2007, we initiated a voucher rebate program whereby we offered a point-of-sale rebate to retail consumers. In October 2007, we initiated another voucher rebate program whereby we offered a point-of-sale rebate to retail customers. This program expired on April 30, 2008. In April 2008 and July 2008, we initiated additional voucher rebate programs whereby we offered a point-of-sale rebate to retail consumers. These programs expire or expired on October 15, 2008 and April 30, 2009, respectively. As of December 31, 2008 and 2007, the balance of the liabilities for these voucher programs totaled approximately \$1,978,000 and \$1,396,000, respectively.

Accounts Receivable

Trade accounts receivable consists of amounts due from wholesalers for the purchase of ANTARA and FACTIVE. Ongoing credit evaluations of customers are performed and collateral is generally not required. As of December 31, 2008 and 2007, we reserved approximately \$33,000 and \$35,000, respectively, for bad debts related to the sale of ANTARA or FACTIVE. We continuously review all customer accounts to determine if an allowance for uncollectible accounts is necessary. We currently provide substantially all of our distributors with payment terms of up to 30 days on purchases of ANTARA and FACTIVE. Amounts past due from customers are determined based on contractual payment terms. Through December 31, 2008, payments have generally been made in a timely manner and the company has not written off any customer account receivable balances.

Inventories

Inventories are stated at the lower of cost or market value, with cost determined under the average cost method which approximates actual cost. Products are removed from inventory on a first-in-first-out basis and recognized as cost of goods sold on an average cost basis which approximates actual cost. For ANTARA, inventories consist of raw material and work-in-process of approximately \$1,166,000 and \$2,363,000 as of December 31, 2008 and 2007, respectively, and ANTARA finished capsules of approximately \$2,967,000 and \$1,268,000 as of December 31, 2008 and 2007, respectively. For FACTIVE, inventories consist of raw material in powder form and work-in-process of approximately \$2,641,000 and \$3,505,000 as of December 31, 2008 and 2007, respectively, and FACTIVE finished tablets of approximately \$926,000 and \$1,923,000 as of December 31, 2008 and 2007, respectively.

On a quarterly basis, we analyze our inventory levels, and provide a reserve for inventory and marketing samples that have become obsolete, have a cost basis in excess of its expected net realizable value or are in excess of forecast requirements to cost of product revenues and marketing expense, respectively. During 2007, approximately \$1,204,000 of ANTARA inventory obtained in the product acquisition became obsolete and was expensed. Expired inventory is disposed of and the related costs are written off against the previously established reserves.

At December 31, 2008 and 2007, there was approximately \$592,000 and \$1,088,000 in ANTARA sample product to be used for ANTARA marketing programs and there was approximately \$1,191,000 and \$655,000 in FACTIVE sample product to be used for FACTIVE marketing programs. These are classified as other current assets in the consolidated balance sheets.

Table of Contents

Long-Lived Assets

We follow the provisions of Statement of Financial Accounting Standards (SFAS) No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (SFAS No. 144). Under SFAS No. 144, long-lived assets and identifiable intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, recoverability of assets to be held and used is assessed by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating the undiscounted cash flows are each done at the lowest possible level for which there are identifiable assets. If the aggregate undiscounted cash flows are less than the carrying value of the asset, then the resulting impairment charge to be recorded is calculated based on the amount by which the carrying amount of the asset exceeds its fair value. Any write-downs are recorded as permanent reductions in the carrying amount of the asset.

During the fourth quarter of 2008, events and circumstances, primarily a significant reduction in projected worldwide long-term revenues and the associated cash flows indicated that the ANTARA and FACTIVE intangible assets could be impaired. The decrease in forecasted long-term revenues and cash flows was related to the planned reduction in the sales force, the receipt of the Paragraph IV Notice from Lupin Limited (as described in Note 10 (c)) and the overall negative economic and regulatory conditions and developments in the United States and abroad. Our estimate of undiscounted cash flows performed during the quarter ended December 31, 2008 indicated that the carrying amount of the ANTARA intangible assets are expected to be recovered and therefore the intangible assets are not impaired. Our estimate of undiscounted cash flows performed during the quarter ended December 31, 2008 indicated that the carrying amount of the FACTIVE intangible assets are not expected to be recovered and therefore the assets are impaired. The estimate of undiscounted cash flows is based upon several significant assumptions including, but not limited to, estimated worldwide sales levels, forecasted size of our sales force and our strategic plans to control costs, including a significant reduction of our sales force. We calculated the fair value of the FACTIVE intangible assets by using a relief from royalty method. The relief from royalty method is based on the assumption that, in lieu of ownership of an intangible asset, a company would be willing to pay a royalty in order to enjoy the benefits of the asset. Under this method, fair value is estimated by discounting the hypothetical royalty payments to their present value over the economic life of the assets. We have recorded a non-cash impairment charge of approximately \$50,759,000 in the accompanying consolidated statements of operations for the year ended December 31, 2008 in order to write-down the FACTIVE intangible assets to fair value.

We also follow the provisions of SFAS No. 142, Goodwill and Other Intangible Assets, (SFAS No. 142). Under SFAS No. 142, goodwill and purchased intangible assets with indefinite lives are not amortized but are reviewed periodically for impairment. We perform an annual evaluation of goodwill at the end of each fiscal year to test for impairment or more frequently if events or circumstances indicate that goodwill may be impaired. Because we have a single operating segment, which is our sole reporting unit, we perform this test by comparing the fair value of the entity with our book value, including goodwill. If the fair value exceeds the book value, goodwill is not impaired. If the book value exceeds the fair value, then we would calculate the potential impairment loss by comparing the implied fair value of goodwill with the book value. If the implied fair value of goodwill is less than the book value, then an impairment charge would be recorded. Because our book value, as represented by stockholders' deficit, is negative as of December 31, 2008, we do not believe that any of our goodwill is impaired.

Stock-Based Compensation

Effective January 1, 2006, we adopted SFAS No. 123 (Revised 2004), Share-Based Payment (SFAS No. 123R) using the modified prospective transition method. SFAS No. 123R requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. Such amounts have been reduced by our estimate of forfeitures on all unvested awards.

Table of Contents

Stock-based compensation expense primarily relates to stock options, restricted stock, and stock issued under our employee stock purchase plan (ESPP).

The fair value of each stock option award is estimated on the grant date using the Black-Scholes-Merton option-pricing model based on the assumptions of volatility, risk-free interest rate, expected life of the option, and expected dividends (if any). The expected life of the stock options granted was estimated based on the historical exercise patterns over the option lives while considering employee exercise strategy and cancellation behavior. The expected volatility is determined based on historical volatility data of our common stock from the period of time beginning with our merger with Genesoft in February 2004 and other factors through the month of grant. Our expected volatility for the year ended December 31, 2008 was between 60.86% and 71.66%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Our risk-free interest rate for the year ended December 31, 2008 was between 1.71% and 3.61%. The expected life of options used for the year ended December 31, 2008 ranged from 5.59 to 5.84 years. We have not paid and do not expect to pay any dividends; as a result, our expected dividend yield is assumed to be 0%.

Our policy is to recognize compensation cost for awards with service conditions and graded vesting using the straight-line method. Additionally, our policy is to issue authorized but previously unissued shares to satisfy share option exercises, the issuance of restricted stock and stock issued under the ESPP. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. In addition, the requisite service period is generally equal to the vesting term. SFAS No. 123R requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term forfeitures is distinct from cancellations or expirations and represents only the unvested portion of the surrendered option. We have estimated forfeitures based on historical data, adjusted for known trends. We have applied an annual forfeiture rate of 21.39% to all unvested options as of December 31, 2008. This analysis is re-evaluated annually and the forfeiture rate will be adjusted as necessary. Ultimately, the actual expense recognized over the vesting period will only be for those shares that vest.

The compensation expense under SFAS No. 123R is recorded in cost of product sales, research and development expense, selling and marketing expense, and general and administrative expense based on the specific allocation of employees receiving the equity awards. Stock compensation expense recorded in the years ended December 31, 2008, 2007 and 2006 was approximately \$1,324,000, \$2,713,000 and \$3,876,000, respectively.

As of December 31, 2008, there is approximately \$1,967,000 of total unrecognized compensation cost related to unvested share based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 1.45 years. We expect approximately 484,000 in unvested options to vest at some point in the future. Options expected to vest are calculated by applying an estimated forfeiture rate to the unvested options.

Recent Accounting Pronouncements

Fair Value Measurement

In February 2008, the Financial Accounting Standards Board (FASB) issued FASB Staff Position No. SFAS 157-2, Effective Date of FASB Statement No. 157, which deferred the effective date of SFAS 157 for all non-financial assets and non-financial liabilities to fiscal years beginning after November 15, 2008. The implementation of SFAS 157 for financial assets and financial liabilities, effective for the Company on January 1, 2008, did not have a material effect on the Company's consolidated financial statements. We are currently evaluating the effect of SFAS 157 for non-financial assets and non-financial liabilities on our consolidated financial statements.

Table of Contents

In October 2008, the FASB issued FASB Staff Position No. SFAS 157-3, *Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active*, (FSP 157-3), to clarify the application of the provisions of SFAS 157 in an inactive market and how an entity would determine fair value in an inactive market. FSP 157-3 was effective upon issuance, including prior periods for which financial statements had not been issued. The implementation of FSP 157-3 did not have a material effect on our consolidated financial statements.

Accounting for Convertible Debt Instruments that may be Settled Upon Conversion

In May 2008, the FASB issued Staff Position No. APB 14-1 *Accounting for Convertible Debt Instruments that may be Settled in Cash Upon Conversion* (FSP APB14-1). FSP APB 14-1 requires the issuer of certain convertible debt instruments that may be settled in cash (or other assets) on conversion to separately account for the liability and equity components of the instrument in a manner that reflects the issuer's nonconvertible debt borrowing rate. Further, FSP APB 14-1 clarifies the appropriate economics of the conversion options as borrowing costs and their potential dilutive effects in earnings per share. FSP APB 14-1 is effective for fiscal years beginning after December 15, 2008. We have not yet completed our evaluation of FSP APB 14-1, but we do not currently believe that it will have a material impact on our results of operations, financial position or cash flows.

Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133

In March 2008, the FASB issued FASB Statement No. 161, *Disclosures about Derivative Instruments and Hedging Activities* (SFAS No. 161). SFAS No. 161 requires entities to provide greater transparency about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133 *Accounting for Derivatives and Hedging Activities* and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity's financial position, results of operations, and cash flows. SFAS No. 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. We are currently in the process of studying the impact of this standard on our financial accounting and reporting.

Business Combinations

In December 2007, the FASB issued Statement No. 141R, *Business Combinations* (SFAS No. 141R). SFAS No. 141R improves consistency and comparability of information about the nature and effect of a business combination by establishing principles and requirements for how an acquirer (a) recognizes and measures in its financial statements the identifiable assets acquired, liabilities assumed and any non-controlling interest in the acquiree; (b) recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and (c) determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS No. 141R applies prospectively to all business combination transactions for which the acquisition date is on or after January 1, 2009. The impact of our adoption of SFAS No. 141R will depend upon the nature and terms of business combinations, if any, that we consummate on or after January 1, 2009.

Accounting for Collaborative Arrangements

In November 2007, EITF issued EITF Issue No. 07-01 *Accounting for Collaborative Arrangements* (EITF No. 07-01). EITF No. 07-01 requires collaborators to present the results of activities for which they act as the principal on a gross basis and report any payments received from (made to) other collaborators based on other applicable generally accepted accounting principles (GAAP) or, in the absence of other applicable GAAP, based on analogy to authoritative accounting literature or a reasonable, rational, and consistently applied accounting policy election. Further, EITF No. 07-01 clarified that the determination of whether transactions within a

Table of Contents

collaborative arrangement are part of a vendor-customer (or analogous) relationship subject to Issue No. 01-09, Accounting for Consideration Given by a Vendor to a Customer . EITF No. 07-01 is effective for fiscal years beginning after December 15, 2008. We have not yet completed our evaluation of EIFT No. 07-01, but do not currently believe that it will have a material impact on our results of operations, financial position or cash flows.

RESULTS OF OPERATIONS

Years Ended December 31, 2008 and 2007

Revenues

On February 11, 2009, we announced a significant reduction of our sales force. This reduction of our sales force will have a significant impact on our revenue growth in 2009 and should also result in lower operating expenses.

Total net revenues increased 9% to approximately \$86,848,000 for the year ended December 31, 2008 from \$79,969,000 for the year ended December 31, 2007. Product sales increased 10% to approximately \$86,325,000 for the year ended December 31, 2008 from \$78,458,000 for the year ended December 31, 2007. This increase was due to higher ANTARA sales of approximately \$11,558,000, offset by lower FACTIVE sales of approximately \$4,039,000 due to lower gross shipments in connection with emphasis in sales focus and promotional efforts toward ANTARA in 2008 as well as lower sales in Mexico and the termination of the agreement with Abbott Canada.

Other revenues decreased 65% to \$523,000 for the year ended December 31, 2008 from \$1,511,000 for the year ended December 31, 2007. During 2007, the Company received a milestone payment of \$1,000,000 from Abbott Canada relating to regulatory approval of FACTIVE in Canada. In 2008, the Company received a \$150,000 milestone payment from Pfizer Mexico for the approval of Factive for urinary tract infections in Mexico, and amortization of upfront license fees from each of Pfizer Mexico and Menarini, respectively. The Company does not believe that other revenues will be a significant contributor to revenues in the future.

Costs and Expenses

Total costs and expenses increased 42% to \$167,210,000 for the year ended December 31, 2008 from \$117,965,000 for the year ended December 31, 2007.

Cost of product sales decreased 7% to approximately \$29,013,000 for the year ended December 31, 2008 from \$31,269,000 for the year ended December 31, 2007. Our overall gross product margin, including amortization of intangible assets, was approximately 67% and 60% for the years ended December 31, 2008 and 2007, respectively. The increase in gross margin is the result of an increase in shipments for ANTARA capsules, which have a higher gross margin than FACTIVE. Included in the cost of product sales is approximately \$4,766,000 of amortization of intangibles assets associated with FACTIVE for each of the years ended December 31, 2008 and 2007, respectively, as well as approximately \$4,341,000 of amortization of intangible assets associated with ANTARA for each of the years ended December 31, 2008 and 2007, respectively. For the year ended December 31, 2008, we wrote off \$50,759,000 of our intangible assets associated with FACTIVE. As a result we expect amortization expense to significantly decrease in 2009.

Research and development expenses decreased 51% to approximately \$2,875,000 for the year ended December 31, 2008 from approximately \$5,845,000 for the year ended December 31, 2007. This decrease is primarily due to completion of the enrollment of the 7,500 patients in February 2007 in a FACTIVE post-marketing trial. The Company's total costs related to this trial were completed by the end of the second quarter of 2007. Research and development expenses primarily consist of salaries and related expenses for regulatory personnel. Other research and development expenses include fees paid to consultants and outside service

Table of Contents

providers. As of December 31, 2008, there were no ongoing clinical trials and we do not believe there will be significant costs associated with clinical trials in the immediate future.

Selling and marketing expenses increased 7% to approximately \$71,150,000 for the year ended December 31, 2008 from \$66,278,000 for the year ended December 31, 2007. This increase is primarily a result of increased costs relating to publication and physician meetings as they relate to the promotion of ANTARA and FACTIVE of approximately \$3,525,000, increased costs associated with travel and meeting expenses of approximately \$2,183,000 associated with marketing and promoting ANTARA and FACTIVE as well as regional and national sales and training programs and increased consulting expense of \$299,000. The increases were offset by decreases in payroll and related costs of \$721,000, expenses associated with special promotional programs for ANTARA and FACTIVE of approximately \$278,000, lower sample costs of \$51,000 and a decrease in miscellaneous expenses of \$85,000.

General and administrative expenses decreased 8% to approximately \$13,413,000 for the year ended December 31, 2008 from approximately \$14,573,000 for the year ended December 31, 2007. The decrease is a result of decreases in payroll and related expenses of \$945,000, stock based compensation of \$539,000, depreciation of \$319,000, and insurance of \$202,000. The decreases were offset by increases in professional fees of \$647,000, facilities of \$379,000 and an decrease of miscellaneous expenses of \$180,000.

During the fourth quarter of 2008, events and circumstances, primarily a significant reduction in projected worldwide long-term revenues and the associated cash flows indicated that the ANTARA and FACTIVE intangible assets could be impaired. The decrease in forecasted long-term revenues and cash flows was related to the planned reduction in the sales force, the receipt of the Paragraph IV Notice from Lupin Limited (as described in Note 10 (c)) and the overall negative economic and regulatory conditions and developments in the United States and abroad. Our estimate of undiscounted cash flows performed during the quarter ended December 31, 2008 indicated that the carrying amount of the ANTARA intangible assets are expected to be recovered and therefore the intangible assets are not impaired. Our estimate of undiscounted cash flows performed during the quarter ended December 31, 2008 indicated that the carrying amount of the FACTIVE intangible assets are not expected to be recovered and therefore the assets are impaired. The estimate of undiscounted cash flows is based upon several significant assumptions including, but not limited to, estimated worldwide sales levels, forecasted size of our sales force and our strategic plans to control costs, including a significant reduction of our sales force. We calculated the fair value of the FACTIVE intangible assets by using a relief from royalty method. The relief from royalty method is based on the assumption that, in lieu of ownership of an intangible asset, a company would be willing to pay a royalty in order to enjoy the benefits of the asset. Under this method, fair value is estimated by discounting the hypothetical royalty payments to their present value over the economic life of the assets. We have recorded a non-cash impairment charge of approximately \$50,759,000 in the accompanying consolidated statements of operations for the year ended December 31, 2008 in order to write-down the FACTIVE intangible assets to fair value.

Other Income and Expense

Interest income decreased significantly to approximately \$650,000 for the year ended December 31, 2008 from approximately \$2,541,000 for the year ended December 31, 2007 reflecting lower overall cash balances and lower interest rate yields on investments.

Interest expense increased 9% to approximately \$30,882,000 for the year ended December 31, 2008 from approximately \$28,206,000 for the year ended December 31, 2007 primarily due to higher costs related to non-cash interest expense of approximately \$3,573,000, lower interest expense related to financing with Paul Capital of approximately \$730,000 and lower interest expense related to lower convertible debt balances of

Table of Contents

approximately \$165,000. For the year ended December 31, 2008, interest expense primarily consisted of the following:

3.50% Convertible senior promissory notes	\$ 7,089
Accretion of note discount	11,290
5% Convertible promissory notes	817
Revenue interest assignment	7,138
12% Senior secured note	2,642
Amortization of deferred financing costs	1,417
Other	489
	\$ 30,882

Gain on disposition of investment increased 79% to approximately \$413,000 for the year ended December 31, 2008 from approximately \$231,000 for the year ended December 31, 2007 due to additional proceeds related to Agencourt Bioscience Corporation which was acquired by Beckman Coulter.

We recorded a one-time non-cash gain on exchange of convertible notes of approximately \$35,357,000 resulting from the issuance of approximately \$85,184,000 of 12.50% Notes due 2011 and 21,310,549 shares of common stock in connection with the exchange completed in November of 2008. The exchange was accounted for as a troubled-debt restructuring and a gain has been recognized resulting from the difference between the carrying value of the 3.50% Notes due 2011 that were exchanged (including related unamortized debt issuance costs and embedded derivatives) and the sum of carrying value of the 12.50% Notes due 2011 (which will be equal to the sum of all future cash flows on the notes, including interest payments) related debt issuance costs, and the common stock issued in the Exchange Offer. As the exchange of convertible notes is being accounted for as a troubled debt restructuring, we will recognize no interest expense in future periods related to the notes issued during November 2008. Such gain is calculated as follows (in thousands):

Write-off of carrying value of 3.50% Notes due 2011 exchanged	\$ 179,957
Decreases to gain:	
Value of equity issued in exchange	9,803
Carrying value of 12.50% Notes due 2011	110,478
Write-off of unamortized deferred financing fees	3,475
Amendment of RIAA	2,884
Fair value of embedded derivative in 12.50% Notes due 2011	12,474
Exchange transaction costs	5,486
	\$ 35,357

Gain on derivatives related to long-term debt increased significantly to approximately \$10,480,000 for the year ended December 31, 2008 from approximately \$3,023,000 for the year ended December 31, 2007. This is a non-cash gain resulting from changes in the fair value of the interest make-whole derivative included in our 3.50% convertible senior notes due 2011 which were issued in May 2007 of approximately \$64,000, approximately \$333,000 related to a non-cash gain from changes in the fair value of the derivative related to the financing associated with the acquisition of ANTARA issued in August 2006 and approximately \$10,083,000 related to a non-cash gain from changes in fair value of the derivative related to the 12.50% convertible guaranteed senior notes due 2011.

Table of Contents

Years Ended December 31, 2007 and 2006

Revenues

Total net revenues increased 73% to \$79,969,000 for the year ended December 31, 2007 from \$46,152,000 for the year ended December 31, 2006.

Net product sales increased 105% to \$78,458,000 for the year ended December 31, 2007 from \$38,244,000 for the year ended December 31, 2006. This increase was primarily due to the promotion of ANTARA, which was acquired in August 2006, which resulted in a net increase of approximately \$41,793,000, partially offset by lower FACTIVE sales of approximately \$1,579,000 due to higher returns as a result in the shift of product demand from seven-day course of treatment to five-day course of treatment and returns associated with the initial stocking of FACTIVE.

Co-promotion revenue decreased 100% for the year ended December 31, 2007 from \$6,890,000 for the year ended December 31, 2006 due to the termination of the co-promotion arrangement with Auxilium in August 2006.

Other revenues increased 48% to \$1,511,000 for the year ended December 31, 2007 from \$1,018,000 for the year ended December 31, 2006, primarily due to recognition of a milestone achievement of \$1,000,000 from Abbott Laboratories, Ltd., (Abbott Canada) the Canadian Affiliate of Abbott, relating to the approval to sell FACTIVE tablets in Canada as well as the amortization of upfront license fees from our agreements with Pfizer Mexico and Menarini. We do not believe that other revenues will be a significant contributor to revenues in the future.

Costs and Expenses

Total costs and expenses decreased slightly to \$117,965,000 for the year ended December 31, 2007 from \$118,071,000 for the year ended December 31, 2006.

Cost of product sales increased 59% to approximately \$31,269,000 in 2007 from \$19,613,000 in 2006 as a result of increased product costs of approximately \$11,656,000 associated with an increase in shipments of ANTARA capsules. Our overall gross product margin for the year ended December 31, 2007 and 2006 was 60% and 49%, respectively. The increase in gross margin is the result of an increase in shipments for ANTARA capsules offset by higher returns of FACTIVE tablets associated with the combination of the shift in product demand from seven day course of treatment to five day course of treatment and returns associated with initial stocking of FACTIVE. Additionally, in 2007, we recorded approximately \$1,296,000 of obsolete inventory related to the initial product obtained upon the acquisition of ANTARA and also recorded approximately \$471,000 related to a minimum royalty obligation to Ethypharm. In addition, included in the cost of product sales is approximately \$4,767,000 of amortization of intangible assets associated with FACTIVE for each of the years ended December 31, 2007 and 2006 and approximately \$4,341,000 and \$1,447,000, respectively, of amortization of intangible assets associated with ANTARA for each of the years ended December 31, 2007 and 2006.

Research and development expenses decreased 53% to \$5,845,000 in 2007 from \$12,406,000 in 2006. This decrease is primarily due to the completion of the FACTIVE five-day treatment of CAP trial in 2006 and the completion of the enrollment of the 7,500 patients in the FACTIVE post-marketing trials in February 2007. Our total costs related to this clinical trial were completed by the end of the second quarter of 2007. At December 31, 2007, there was no clinical trial accrual balance remaining and we do not believe there will be significant costs associated with clinical trials in the immediate future.

Selling and marketing expenses decreased slightly to \$66,278,000 in 2007 from \$69,211,000 in 2006. This decrease is a result of decreases in co-promotion expenses relative to our arrangement with Auxilium which

Table of Contents

terminated in 2006 of approximately \$2,482,000 along with overall cost control efforts during the year ended December 31, 2007 resulting in lower conference and meeting expenses of approximately \$667,000, and lower publication, media, and market research costs of approximately \$712,000. The decrease was also attributable to decreases in payroll and payroll-related costs of approximately \$610,000 and stock-based compensation costs of approximately \$263,000, offset by increases in other selling and marketing expenses of approximately \$683,000 and costs associated with travel and entertainment of approximately \$1,118,000 related to sales personnel.

General and administrative expenses decreased 13% to approximately \$14,573,000 in 2007 from approximately \$16,841,000 in 2006. This decrease is a result of a decrease in technology license fees of approximately \$1,250,000, as well as overall cost control efforts during 2007 which resulted in decreases in payroll and payroll related costs of approximately \$317,000, decreases in stock-based compensation expense of approximately \$788,000, as well as decreases in other general and administrative expenses of approximately \$573,000. These decreases were partially offset by an increase in legal fees and settlement costs associated with a legal dispute.

Other Income and Expense

Interest income decreased 15% to approximately \$2,541,000 in 2007 from approximately \$2,995,000 in 2006 reflecting higher yields on cash balances in 2007, offset by lower overall cash balances in 2007.

Interest expense significantly increased 155% to approximately \$28,206,000 in 2007 from approximately \$11,056,000 in 2006. For the year ended 2007, interest expense imputed using the effective interest rate method primarily consisted of approximately \$10,645,000 related to financing with Paul Capital, approximately \$7,649,000 due to accretion of the bond discount associated with newly exchanged debt, approximately \$5,331,000 related to approximately \$225,666,000 of 3.50% convertible senior notes, resulting from the exchange of previously-outstanding 3 1/2% convertible promissory notes, exchange of previously outstanding 5% convertible promissory notes and issuance of new notes in May of 2007. Additionally, interest expense included approximately \$1,787,000 related to approximately \$152,700,000 of 3 1/2% senior convertible promissory notes issued in the second quarter of 2004, of which approximately \$829,000 remains after the debt exchange completed in May 2007, approximately \$954,000 related to approximately \$22,310,000 of 5% convertible promissory notes assumed in the Genesoft merger, of which approximately \$13,300,000 remains after the debt exchange completed in May 2007, approximately \$1,325,000 related to amortization of deferred financing costs, as well as approximately \$515,000 of non-cash interest expense related to the facility lease liability.

Gain on disposition of investment for the year ended December 31, 2007 of approximately \$231,000 resulted from milestones achieved by Agencourt Biosciences. The gain on disposition of investment of approximately \$1,617,000 for the year ended December 31, 2006 resulted from the sale of our investment in Agencourt Biosciences.

We recorded a one-time non cash gain on exchange of convertible notes of approximately \$30,824,000 in the year ended December 31, 2007 resulting from the issuance of approximately \$225,666,000 of 3.50% convertible senior notes due 2011 in connection with the exchange and tender of approximately \$151,921,000 of our previously-outstanding 3 1/2% senior convertible promissory notes due 2011 and the exchange and tender of approximately \$9,010,000 of our previously outstanding 5% convertible promissory notes due 2009. The gain arose due to the fact that fair value of the previously outstanding 3 1/2% senior convertible promissory notes exceeded that of the newly issued 3.50% convertible senior notes.

Gain on derivative related to convertible notes was approximately \$3,023,000 for the year ended December 31, 2007. This gain consists of a non-cash gain resulting from changes in the fair value of the interest make-whole derivative included in our 3.50% convertible senior notes due 2011 which were issued in May 2007 of approximately \$3,004,000 and also approximately \$19,000, related to a gain from changes in the fair value of derivative related to the financing associated with the acquisition of ANTARA issued in August 2006.

Table of Contents

Liquidity and Capital Resources

Our primary sources of cash have been from the sale of debt and equity securities, the sale of ANTARA capsules and FACTIVE tablets and co-promotion revenues based on the sale of TESTIM. The TESTIM co-promotion agreement was terminated on August 31, 2006.

At December 31, 2008, we had total cash and cash equivalents of approximately \$17,193,000, which included \$4,598,000 in restricted cash, and an accumulated deficit of approximately \$510,513,000. We have also generated significant operating losses for the last several years and expect to continue to generate significant operating losses for the foreseeable future. Based on the extension of the maturity date of approximately \$13,150,000 of the approximately \$13,300,000 outstanding principal and accrued interest of approximately \$3,645,000 of our 5% Convertible Promissory Note due in 2009, our available capital, our current operating plan and management's ability to manage expenses, we believe that the unrestricted cash on hand as of December 31, 2008, is sufficient to fund continuing operations into the third quarter of 2009. In an effort to aggressively preserve the Company's financial resources and position the organization for a potential partnership or acquisition, on February 11, 2009 we announced plans to substantially reduce the size of our sales and marketing teams as well as our office personnel. Our revenues will likely decline as a result of this decrease. In the next several months, we will need to raise additional capital and/or refinance or amend the terms of our existing debt due in December 2009, to fund our operations for the remainder of 2009, fund other potential commercial or development opportunities, and support our sales and marketing activities. We intend to pursue privately raising additional capital from investors through equity financing, the incurrence of indebtedness or a combination of equity and debt. Based on the current credit market turmoil and the inclusion of a going concern explanatory paragraph in our auditor's report of our consolidated financial statements as discussed below, additional financing may not be available to us, or, if available, may not be available on favorable terms. If we cannot obtain adequate financing on acceptable terms when such financing is required or lower our expenses as expected through certain cost reduction measures, we may have to further scale back our operations, take other measures to significantly reduce our expenses which will have a material adverse effect on our business and/or we may seek bankruptcy protection.

As a result of our recurring operating losses and need for additional financing, our auditors included an explanatory paragraph regarding our ability to continue operations as a going concern in their audit report relating to our consolidated financial statements for the year ended December 31, 2008. A going concern explanatory paragraph is included when the auditor concludes there is a substantial doubt about our ability to continue as a going concern for at least 12 months following the balance sheet date. If we are unable to continue as a going concern it is likely that investors will lose all or a part of their investment. On February 11, 2009, we engaged Broadpoint Capital, Inc. to advise the Company on strategic options, including the potential sale of the Company. There can be no assurance that this engagement will enable the Company to identify and implement strategic options, including a potential sale, that will be of benefit to investors. In addition, if we are unable to meet our payment obligations to third parties as they come due, we may be subject to litigation claims and/or may seek bankruptcy protection. Even if we are successful in defending against these claims, litigation could result in substantial costs, be a distraction to management and may result in unfavorable results that could further adversely impact our financial condition and may impact our ability to continue operations.

Cash Flows

Our operating activities used cash of approximately \$31,181,000, \$34,661,000 and \$63,635,000 in 2008, 2007 and 2006, respectively.

Cash used in our operating activities for 2008 of approximately \$31,181,000 was primarily a result of our net loss of approximately \$64,755,000 along with non-cash items such as a non-cash gain on exchange of convertible notes of approximately \$35,357,000, non-cash impairment charge of approximately \$50,759,000

Table of Contents

related to the write down of the FACTIVE intangible assets, non-cash interest expense of approximately \$13,196,000, non-cash depreciation and amortization expense of approximately \$9,485,000, stock based compensation of approximately \$1,324,000, provision for excess and obsolete inventory of approximately \$511,000, and non-cash gain on the derivative related to the convertible notes of approximately \$10,480,000. Additionally, cash used in our operating activities includes an increase of approximately \$2,570,000 in accounts receivable due to higher shipments of ANTARA capsules and FACTIVE tablets, increases in prepaid and other current assets of approximately \$710,000, and a decrease in accrued facilities impairment charge of approximately \$2,390,000 related to our west coast facility

Cash used in our operating activities was partially offset by an increase in deferred revenue of approximately \$3,289,000 due to the addition of a significant new customer offset by the amortization of the upfront license fees from our agreement with Menarini, an increase in accounts payable of approximately \$1,717,000 due to timing of vendor payments, an increase in accrued expenses and other current liabilities of approximately \$3,755,000 due to the timing of vendor invoices, decrease in inventory of approximately \$848,000 due to the timing of shipments to customers and wholesalers, as well as an increase in other long-term liabilities of approximately \$610,000 due to accrued interest on long-term debt.

Cash used in our operating activities for 2007 was primarily a result of our net loss of approximately \$29,853,000 along with non-cash items such as a non-cash gain on exchange of convertible note of approximately \$30,824,000, non-cash depreciation and amortization expenses of approximately \$9,847,000, non-cash interest expenses of approximately \$9,623,000, a non-cash gain from the change in the fair value of derivatives of approximately \$3,023,000, stock-based compensation of approximately \$2,713,000, and provision for excess and obsolete inventories of approximately \$793,000. Additionally, cash used in our operating activities includes an increase of approximately \$2,922,000 in accounts receivable due to higher shipments of ANTARA capsules and FACTIVE tablets and an increase in prepaid and other current assets of approximately \$96,000 along with decreases in accounts payable of approximately \$141,000 as a result of timing of vendor payments, decreases in accrued facilities impairment charges of approximately \$2,618,000 related to our west coast facility, recovery of bad debt of approximately \$172,000, a gain on disposition of investment of approximately \$231,000, as well as decreases in deferred revenue of approximately \$750,000 as a result of the amortization of upfront license fees from our agreements with Pfizer Mexico and Menarini.

These uses of cash were partially offset by increases in accrued expenses and other liabilities of approximately \$4,915,000 relating to timing of vendor invoices, decreases in inventory of approximately \$4,386,000 as a result of increased sales of ANTARA, as well as increases in other long-term liabilities of approximately \$3,692,000 related to accrued interest on long-term debt.

Cash used in our operating activities for 2006 was primarily a result of our net loss of approximately \$78,477,000, adjusted for the gains of approximately \$1,617,000 on the disposition of investment, an increase in inventories of approximately \$1,796,000 due to increased demand of ANTARA capsules and FACTIVE tablets, and an increase in accounts receivable of approximately \$6,080,000 as a result of the acquisition of ANTARA, as well as decreases in accrued facilities impairment charge of approximately \$2,826,000 related to our west coast facility.

These uses of cash were partially offset by decreases in prepaid expenses and other current assets of approximately \$2,134,000 resulting from decreases in net samples inventory and decreased costs associated with the utilization of a contracted third party sales organization, as well as, increases in accounts payable of approximately \$3,955,000 primarily resulting from the acquisition of ANTARA, including royalties payable on the net sales of ANTARA and FACTIVE sold in the U.S. and accounts payable and other accrued expenses acquired as part of the ANTARA acquisition. Additional offsets include increases in accrued expenses and other current liabilities of approximately \$3,335,000 resulting primarily from increases in sales reserves and allowances and royalty interest payable as a result of the acquisition of ANTARA, increases in deferred revenue

Table of Contents

of approximately \$1,386,000 pertaining to up-front license fees in relation to sublicense agreements with Pfizer Mexico, Abbott Canada, and Menarini, increases in other long-term liabilities of approximately \$1,869,000 resulting from accrued interest on the \$22.0 million convertible note and the \$20.0 million note payable to Paul Capital, as well as non-cash items such as depreciation and amortization expenses which includes amortization of intangible assets, stock based compensation, and non-cash interest expense of approximately \$12,502,000 as well as provision for excess and obsolete inventories and provision for accounts receivables of approximately \$1,980,000.

Our investing activities provided cash of approximately \$277,000 in 2008, provided cash of approximately \$3,906,000 in 2007 and used cash of approximately \$68,119,000 in 2006, respectively.

Our investing activities provided cash of approximately \$277,000 in 2008 primarily related to proceeds on the disposition of investments of approximately \$413,000, and proceeds from notes receivable of approximately \$486,000 offset by an increase in restricted cash of approximately \$400,000, purchases of property and equipment of approximately \$190,000 and an increase in other assets of approximately \$35,000.

Our investing activities provided cash of approximately \$3,906,000 in 2007 primarily related to a decrease of approximately \$2,414,000 in restricted cash, proceeds from notes receivable of approximately \$1,373,000 and proceeds from the disposition of investment of approximately \$231,000. These cash proceeds were partially offset by an increase in other assets of approximately \$63,000.

Cash used in our investing activities in 2006 were primarily related to the acquisition of ANTARA of approximately \$77,563,000, and increases in other assets of approximately \$329,000 and net purchases of property and equipment of approximately \$263,000. These uses of cash were partially offset by proceeds from maturities of marketable securities of approximately \$2,696,000, decreases in restricted cash associated with interest payments on debt of approximately \$5,118,000, proceeds from the disposition of an investment of approximately \$1,617,000 and net proceeds from notes receivable of approximately \$604,000.

Our financing activities used cash of approximately \$4,769,000 in 2008 and provided cash of approximately \$40,827,000 and \$104,332,000 in 2007 and 2006, respectively.

Our financing activities used cash of approximately \$4,769,000 in 2008 primarily related to the transaction costs related to the exchange of the long-term notes of approximately \$4,924,000 offset primarily by proceeds from the issuance of 150,611 shares of stock under the employee stock purchase plan of approximately \$193,000.

Our financing activities provided cash of approximately \$40,827,000 in 2007 primarily due to the net proceeds from the issuance of new notes in May 2007 of approximately \$40,444,000, exercise of 4,980 stock options for approximately \$17,000, and proceeds from the issuance of 95,045 shares of stock under the employee stock purchase plan of approximately \$404,000, offset by payments on long-term obligation of approximately \$38,000.

Our financing activities provided cash of approximately \$104,332,000 in 2006. This was primarily due to the issuance of 2,254,402 shares of common stock in connection with the completion of a private placement which generated net proceeds of approximately \$33,477,000; proceeds of \$20,000,000 from the issuance of a note in connection with the financing of the ANTARA acquisition; proceeds of \$40,000,000 from an assignment of revenue interest in connection with the financing of the ANTARA acquisition and net proceeds of approximately \$9,958,000 from the issuance of 1,388,889 shares of common stock in connection with financing the acquisition of ANTARA. In addition, we received approximately \$166,000 from the exercise of 89,456 stock options and proceeds of approximately \$740,000 from the issuance of 78,987 shares of stock under the employee stock purchase plan, offset by payments made on capital lease obligations of approximately \$9,000.

Table of Contents

At December 31, 2008, we had net operating loss carryforwards of approximately \$11,956,000 and \$7,149,000 available to reduce federal and state taxable income, if any, respectively. We also had tax research credit carryforwards of approximately \$244,000 to reduce federal and state income tax, if any. Net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may be limited in the event of certain cumulative changes in ownership interests of significant shareholders over a three-year period in excess of 50%.

Our Outstanding Debt Obligations and Equity Financings

5% Convertible five-year promissory notes due December 1, 2009

On February 6, 2004, we issued approximately \$22,310,000 in principal amount of 5% convertible five year promissory notes due February 2009 (the "5% Notes"). Following the exchange offer completed in May 2007 described below, there are approximately \$13,300,000 principal amount of the 5% Notes outstanding at December 31, 2008. As of December 31, 2008, the 5% Notes are convertible into our common stock at the option of the holders, at a conversion price of \$53.13 per share. The maturity of these notes was extended to December 1, 2009 and the conversion price was reduced to approximately \$1.10 effective on the date of the January 2009 Extension and Exchange offer.

3 1/2% Senior Convertible Promissory Notes and 3.50% Convertible Senior Notes due 2011

On June 26, 2004, we issued \$152,750,000 in principal amount of 3 1/2% senior convertible promissory notes due in April 2011 (the "3 1/2% Notes"). Following the exchange offer completed in May 2007 described below, there are approximately \$829,000 principal amount of the 3 1/2% Notes outstanding at December 31, 2008. These notes are convertible into our common stock at the option of the holders at a conversion price of \$53.14 per share. We may not redeem the outstanding 3 1/2% Notes at our election before May 10, 2010. After this date, we can redeem all or part of the 3 1/2% Notes for cash at a price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest. The holders' right of repurchase under the 3 1/2% Notes is identical to the right of repurchase under the 3.50% Notes (defined below) and is described below.

In May 2007, we completed (i) an exchange offer with certain holders of the 3 1/2% Notes in which we exchanged \$151,921,000 aggregate principal amount of our new 3.50% Convertible Senior Notes due 2011 (the "3.50% Notes") for \$151,921,000 aggregate principal amount of our then outstanding 3 1/2% Notes; and (ii) an exchange offer with holders of the 5% Notes in which we exchanged approximately \$10,574,000 aggregate principal and accrued interest amount of our then outstanding 5% Notes for approximately \$13,746,000 aggregate principal amount of the 3.50% Notes. We also issued an additional \$60,000,000 of 3.50% Notes to the public for cash at a public offering price of 77.50% of principal, resulting in \$46,500,000 in gross proceeds.

The 3.50% Notes are initially convertible at a conversion price of approximately \$13.50 per common share. The 3.50% Notes are convertible at any time by the holder. In the event of a fundamental change, holders of the 3 1/2% Notes and the 3.50% Notes have the right to require us to repurchase all or any portion of their notes at a price equal to 100% of the principal amount plus accrued and unpaid interest. Under the indenture for the 3 1/2% Notes and the 3.50% Notes, a fundamental change will be deemed to occur if (i) a change of control transaction occurs in which substantially all of our common stock is exchanged either for consideration other than common stock that is listed on a U.S. national securities exchange or is exchanged for consideration other than common stock that is approved for quotation on a U.S. system of automated dissemination of quotations of securities or (ii) our common stock is neither listed for trading on a U.S. national securities exchange nor approved for listing on any U.S. system of automated dissemination of quotations of securities prices. In the event that our shares are delisted from the NASDAQ Global Market, this event may be considered a fundamental change and the holders of the 3.50% Notes and the 3 1/2% Notes could have the ability to demand that we repurchase the outstanding Notes.

Table of Contents

Before May 10, 2010, we may not redeem the 3.50% Notes. On or after May 10, 2010, we may redeem any or all of the 3.50% Notes at 100% of the principal amount, plus accrued and unpaid interest. In addition, we may automatically convert some or all of the 3.50% Notes on or prior to the maturity date if the closing price of our common shares has exceeded 130% of the conversion price then in effect for at least 20 trading days during any consecutive 30 trading day period ending within five trading days prior to the notice of auto-conversion (the auto-conversion feature). If a holder elects to voluntarily convert their 3.50% Notes or we elect to automatically convert some or all of the 3.50% Notes on or prior to May 10, 2010, we will pay additional interest to holders of 3.50% Notes being converted. This additional interest will be equal to the amount of interest that would have been payable on the 3.50% Notes from the last day interest was paid on the 3.50% Notes, through and including May 10, 2010. Additional interest, if any, will be paid in cash or in our common shares, at our option. If we pay additional interest upon a voluntary conversion with our common shares, such shares will be valued at the conversion price that is in effect at that time. If we pay additional interest upon an automatic conversion with our common shares, such shares will be valued at 90% of the automatic conversion price that is in effect at that time.

We have accounted for the 3.50% Notes in accordance with the guidance as set forth in EITF No. 96-19, *Debtor's Accounting for a Modification or Exchange of Debt Instruments* (EITF No. 96-19), SFAS No. 133, *Accounting for Derivative Instruments and Hedging Activities*, as amended (SFAS No. 133), EITF No. 05-7, *Accounting for Modifications to Conversion Options Embedded in Debt Instruments and Related Issues* (EITF No. 05-7), EITF No. 00-19, *Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock* (EITF No. 00-19), EITF No. 05-02, *Meaning of Conventional Convertible Debt Instrument* (EITF No. 05-02) and EITF No. 01-6, *The Meaning of Indexed to a Company's Own Stock* (EITF No. 01-6), and determined that the exchange represents an extinguishment of existing debt rather than a modification. Accordingly, we recorded a gain of approximately \$30,824,000 upon the extinguishment of debt, which was a result of exchanging a majority of the 3 1/2% Notes and a portion of the 5% Notes that were issued at par value, for the 3.50% Notes that were issued at 77.50% of par (i.e. a 22.50% discount). The gain arose due to the fact that the fair value of the 3 1/2% Notes exceeded that of the 3.50% Notes. The debt issuance costs related to the 3 1/2% Notes in the amount of approximately \$3,285,000 are netted against the gain. The additional 3.50% Notes generated gross proceeds of \$46,500,000.

12.50% Convertible Guaranteed Senior Notes due 2011

On November 25, 2008, we completed our 2008 Exchange Offer (the 2008 Exchange Offer) in which we issued an aggregate principal amount of \$85,184,000 12.50% Convertible Guaranteed Senior Notes due 2011 (the 12.50% Notes) and 21,310,549 shares of our common stock in exchange for \$212,979,000 in aggregate principal amount of the 3.50% Notes. We also issued \$2,000,000 of 12.50% Notes due 2011 to Paul Capital Partners as part of the Amendment to the Revenue Interest Assignment Agreement discussed below.

The 12.50% Notes will mature on January 15, 2011. Interest on the 12.50% Notes is payable at a rate of 12.50% per year, payable semiannually on April 15 and October 15 of each year, commencing April 15, 2009, except that the final interest payment date will be payable January 15, 2011. We may elect to pay interest on the 12.50% Notes in cash or by increasing the principal amount of the 12.50% Notes or by issuing additional 12.50% Notes in an amount equal to the amount of interest for the applicable interest payment period.

The 12.50% Notes are guaranteed by our wholly-owned subsidiary, Guardian II Acquisition Corporation (Guardian II) and this guarantee is secured by a second priority lien on substantially all of the assets of Guardian II. The second priority lien is subject to the first priority lien on substantially all of the assets of Guardian II which is held by Paul Royalty Fund Holdings II, LP (Paul Capital), an affiliate of Paul Capital Partners and secures our and Guardian II's payment obligations to Paul Capital under the First Lien Obligations (as defined below).

The 12.50% Notes are convertible, at the option of the holder, at anytime on or prior to maturity, into shares of our common stock at an initial conversion rate equal to a conversion price of approximately \$1.10 per share. If

Table of Contents

a holder of 12.50% Notes elects to voluntarily convert some or all of its 12.50% Notes on or prior to November 25, 2010, we will pay additional interest to such holder. This additional interest will be equal to the amount of interest that would have been payable on the 12.50% Notes from the last day interest was paid on the 12.50% Notes, through and including November 25, 2010. Additional interest, if any, will be paid in cash or, solely at our option, in common shares or a combination of cash and common shares. If we pay additional interest upon a voluntary conversion with our common shares, such shares will be valued at the conversion price that is in effect at that time.

We also have the right to automatically convert some or all of the 12.50% Notes on or prior to January 15, 2011 if the closing price of our common shares has exceeded 130% of the conversion price then in effect for at least 20 trading days during any consecutive 30 trading day period ending within five trading days prior to the notice of automatic conversion. If we elect to automatically convert some or all of the 12.50% Notes on or prior to November 25, 2009, we will pay additional interest to holders of 12.50% Notes being converted. This additional interest will be equal to the amount of interest that would have been payable on the 12.50% Notes from the last day interest was paid on the 12.50% Notes, through and including November 25, 2009. Additional interest, if any, will be paid in cash or, solely at our option, in common shares or a combination of cash and common shares. If we pay additional interest upon an automatic conversion with our common shares, such shares will be valued at 90% of the automatic conversion price that is in effect at that time.

Prior to October 15, 2010, the 12.50% Notes are not redeemable. On or after October 15, 2010, we may redeem some or all of the 12.50% Notes for cash at 100% of the principal amount of the 12.50% Notes to be redeemed, plus accrued and unpaid interest, to but excluding the redemption date.

In the event of a fundamental change, holders of the 12.50% Notes have the same right as holders of the 3.50% Notes to require us to repurchase all or any portion of their notes at a price equal to 100% of the principal amount plus accrued and unpaid interest. In the event that our shares are delisted from the NASDAQ Global Market, this event may be considered a fundamental change and the holders of the 12.50% Notes could have the ability to demand that we repurchase the outstanding Notes. If holders of our 12.50% Notes elect to convert their notes in connection with a fundamental change that occurs on or prior to January 15, 2011, pursuant to which 10% or more of the consideration for our common stock (other than cash payments for fractional shares) in such fundamental change transaction consists of cash or securities (or other property) that are not traded immediately following such transaction on a United States national securities exchange, we will increase the conversion rate for the 12.50% Notes surrendered by the applicable amount as set forth in the Indenture. In some circumstances, this adjusted conversion rate may entitle the holders of the 12.50% Notes to receive more common shares than are authorized. In the event that we are required to issue more shares than are authorized, shareholder approval would be required to increase the amount of our authorized shares. In no event should the conversion rate be less than \$0.47. The definition of fundamental change is the same as under the indenture which governs the 3.50% Notes described above.

The Indenture also provides that we may not incur additional indebtedness in excess of \$50 million (Permitted Indebtedness) from the earlier of (i) the date that is one year from the date on which our common stock has traded at a price which exceeds the conversion price then in effect for at least 20 trading days during any consecutive 30 trading day period, and (ii) the first anniversary of the maturity date of the 12.50% Notes. Any indebtedness incurred to finance new product acquisitions or in connection with refinancing Permitted Indebtedness, our existing indebtedness or obligations or the 12.50% Notes would not be counted toward the aforementioned limit.

If an event of default occurs under the Indenture, the Trustee or the holders of at least 25% in principal amount of the notes may declare 100% of the principal of and accrued and unpaid interest on all the notes to be due and payable immediately.

Table of Contents

The 2008 Exchange Offer is being accounted for as a troubled debt restructuring in accordance with EITF Issue No. 02-4 Determining Whether a Debtor's Modification or Exchange of Debt Instruments is within the Scope of FASB Statement No. 15 and Statement of Financial Accounting Standards No. 15, Accounting by Debtors and Creditors for Troubled Debt Restructurings (SFAS No. 15). As a result, the carrying value of the 12.50% Notes due 2011 is equal to the sum of all future cash flows on the notes due, including interest payments. Accordingly, all future interest expense and debt issuance costs were accrued upon the date of the Exchange Offer as a reduction to the gain on extinguishment of the 3.50% Notes due 2011 and no future interest or amortization expense associated with the 12.50% Notes due 2011 will be recognized. We recognized a gain of approximately \$35,357,000 associated with the debt restructuring approximately \$2.20 per weighted average common share outstanding. As of December 31, 2008, the carrying value of the 12.50% Notes due 2011 consisted of \$86,684,000 of principal and approximately \$25,740,000 of future interest payable on these notes. As a result of the exchange being accounted for as a troubled debt restructuring, we will recognize no interest expense related to the 12.50% notes in future periods.

On December 5, 2008 one holder of the 12.50% Notes exercised the conversion feature of their notes for approximately 454,500 shares of common stock. Additionally, we elected to pay the additional interest upon conversion by issuing 113,636 common shares.

Embedded Derivatives Related to Convertible Notes

In accordance with SFAS No. 133, we have separately accounted for the additional interest payment features of the 3.50% Notes as an embedded derivative instrument. We are also accounting for the conversion option and the additional interest payment feature of the 12.50% Notes as a compound embedded derivative. Embedded derivatives are measured at fair value and classified in the consolidated balance sheets as other long term liabilities. Changes in the fair value of the embedded derivatives are recognized in earnings. The derivative liabilities are revalued quarterly and changes in their fair value are recorded as other expense or income. For the purpose of accounting for the 3.50% Notes issued in the exchange offer, the fair value of the embedded derivative upon issuance was subtracted from the carrying value of the debt and reflected as a debt discount. The debt discount is amortized as interest expense using the effective interest method through the date the notes are scheduled to mature. The embedded derivative contained in the 12.50% Notes was initially valued at \$12,474,000 on November 25, 2008 and was recorded as a component to the gain on exchange of convertible notes. As of December 31, 2008, the fair value of the derivatives for the 3.50% Notes and the 12.50% Notes are approximately \$0 and \$2,370,000, respectively, which reflects a change in the fair value of approximately \$10,104,000 for the year ended December 31, 2008 which is included as gain on derivative in the consolidated statements of operations.

Security Agreements

Guardian II and Paul Capital previously entered into a security agreement in August 2006 under which Guardian II granted to Paul Capital a senior security interest in and to substantially all assets owned by Guardian II (the First Priority Lien) in order to secure our and Guardian II's payment obligations (the First Lien Obligations) to Paul Capital under the Revenue Interests Assignment Agreement dated as of July 21, 2006 by and among us, Guardian II and Paul Capital and Guardian II's obligations of payment under the \$20,000,000 aggregate principal amount of 12% senior secured note issued to Paul Capital at the time we entered into the Revenue Interests Assignment Agreement.

On November 25, 2008, Guardian II and the Trustee, in its capacity as collateral agent for the holders of 12.50% Notes entered into a Security Agreement under which Guardian II granted to the Trustee a second priority security interest in and to substantially all assets owned by Guardian II (the Second Priority Lien) in order to secure Guardian II's guarantee of the Company's obligations with respect to the 12.50% Notes, the 2008 Paul Capital Note (as defined below) and any additional 12.50% Notes that may be issued under the Indenture (the Second Lien Obligations).

Table of Contents

For the year ended December 31, 2008, we incurred approximately \$7,907,000 in interest expense on our convertible debt. Additionally, we amortized approximately \$11,290,000 as non-cash interest expense related to the accretion of the bond discount and approximately \$1,416,000 in amortization of debt issuance costs.

Other Financial Arrangements

In August 2006, we, together with Guardian II, entered into several financing agreements with Paul Capital including the Revenue Interests Assignment Agreement, the Note Purchase Agreement and the Common Stock and Warrant Purchase Agreement, in consideration for an aggregate amount of \$70 million.

Revenue Interests Assignment Agreement

We and Guardian II entered into the Revenue Interests Assignment Agreement (the Revenue Agreement), pursuant to which the Company sold to Paul Capital the right to receive specified royalties on Oscient's net sales in the United States (and the net sales of its affiliates and licensees) of FACTIVE tablets and Guardian II sold to Paul Capital the right to receive specified royalties on Guardian II's net sales in the United States (and the net sales of its affiliates and licensees) of ANTARA capsules, in each case until December 31, 2016 in exchange for an aggregate of \$40 million from Paul Capital. The royalty payable to Paul Capital on net sales of ANTARA and FACTIVE are tiered as follows: 9% for the first \$75 million in annual net revenues, 6% for annual net revenues in excess of \$75 million, but less than \$150 million, and 2% for annual net revenues which exceed \$150 million. Once the cumulative royalty payments to Paul Capital exceed \$100 million, the royalties become nominal. In November of 2008, we entered into an amendment to the Revenue Agreement which is discussed in detail below under the subheading Amendment to Revenue Interests Assignment Agreement.

In connection with the Revenue Agreement, we recorded a liability, referred to as the revenue interest liability, of approximately \$40 million in accordance with EITF No. 88-18, Sales of Future Revenues (EITF No. 88-18). We impute interest expense associated with this liability using the effective interest rate method and have recorded a corresponding accrued interest liability. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of ANTARA and FACTIVE sales. Payments made to Paul Capital as a result of ANTARA and FACTIVE sales levels will reduce the accrued interest liability and the principal amount of the revenue interest liability. We currently estimate that the imputed interest rate associated with this liability will be approximately 17.39%. We recorded approximately \$7,138,000 and \$8,020,000 in interest expense related to this agreement in 2008 and 2007, respectively.

In the event of (i) a change of control of Oscient or Guardian II, (ii) a bankruptcy of Oscient or Guardian II, (iii) a transfer by Oscient or any of its subsidiaries of substantially all of either ANTARA or FACTIVE, (iv) subject to a cure period, breach of certain material covenants and representations in the Revenue Agreement and (v) in the event the sale of ANTARA is suspended due to a court issued injunction or the Company elects to suspend sales of ANTARA, in each case as a result of a lawsuit by certain third parties (each a Put Event), Paul Capital has the right to require us and Guardian II to repurchase from Paul Capital its royalty interest at a price in cash which equals the greater of (a) 200% of cumulative payments made by Paul Capital under the Revenue Agreement less the cumulative royalties previously made to Paul Capital; or (b) the amount which will provide Paul Capital, when taken together with the royalties previously paid, a 22% internal rate of return (the Put/Call Price). During the term of the agreement through December 31, 2008, we and Guardian II have paid approximately \$16,313,000 in royalty payments to Paul Capital. Upon a bankruptcy event, we and Guardian II are automatically required to repurchase the Paul Capital royalty interest at the Put/Call Price. In the event of a change of control of Oscient, we have the right to repurchase the Paul Capital royalty interest for an amount equal to the Put/Call Price. We have determined that Paul Capital's put option and the Company's call option meet the criteria to be considered an embedded derivative and should be accounted for as such. In 2006, we

Table of Contents

initially recorded a net liability of \$1,005,000 related to the put/call option to reflect its estimated fair value as of the date of the agreement, in accordance with SFAS No. 133. This liability is revalued on a quarterly basis to reflect any changes in the fair value and any gain or loss resulting from the revaluation is recorded in earnings. As of December 31, 2008, the fair value of the derivative is approximately \$653,000 which reflects a change in the fair value of approximately \$333,000 for the year ended December 31, 2008 which has been recorded as a gain on derivative in the consolidated statements of operations.

During the first two fiscal years immediately following the fiscal year in which combined annual net sales of ANTARA and FACTIVE are equal to or greater than \$125 million, we and Guardian II have the right, but not the obligation, to reduce the royalty percentages due under the Revenue Agreement to Paul Capital by fifty percent (50%) by paying Paul Capital a price in cash which will provide Paul Capital, when taken together with the royalties previously paid, a 22% internal rate of return. During the first two fiscal years immediately following the fiscal year in which combined annual net sales of ANTARA and FACTIVE are equal to or greater than \$250 million, we and Guardian II have the right, but not the obligation, to repurchase the Paul Capital royalty interest at a price in cash which will provide Paul Capital, when taken together with the royalties previously paid, a 22% internal rate of return.

Note Purchase Agreement

Guardian II entered into a Note Purchase Agreement (the *Note Purchase Agreement*) with Paul Capital pursuant to which Guardian II issued and sold a \$20,000,000 aggregate principal amount of 12% senior secured note (the *Note*), due on the fourth anniversary of the closing date, subject to Guardian II's option to extend the maturity to the sixth anniversary of the closing date, provided (i) there are no defaults under the Note at the time, and (ii) we issue to Paul Capital, at the time of the exercise of such option, a warrant for a number of shares of common stock equal to 10% of the principal balance plus accrued interest divided by \$6.94, with an exercise price of \$6.94 per share. If we exercise such option, the number of shares subject to the warrant issuable to Paul Capital would be between 288,018 shares and 367,529 shares, depending upon the amount, if any, of the interest payable on the Note we elect to have added to the principal of the Note rather than paid in cash as described below.

Interest is payable semi-annually in arrears on the last day of each of March and September. Guardian II has the option to pay interest in cash or to have 50% of the interest paid in cash and 50% of the interest added to principal. In the event of a change of control of Oscient or on or after the second anniversary of the closing, we may at our option prepay all or any part of the Note at a premium which declines over time. In the event of default, with *event of default* defined as a continuing Put Event under the Revenue Agreement as described in more detail above, the outstanding principal and interest in the Note will become immediately due and payable. As of December 31, 2008, we have exercised our option to add approximately \$3,015,000 of interest expense payable to the principal of the Note. This amount is recorded as accrued expenses and other current liabilities in the consolidated balance sheets.

Subject to the Revenue Agreement and the Note Purchase Agreement, without the prior written consent of Paul Capital, we have agreed not to (i) amend, waive any rights under, or terminate any material license agreements, including the agreements relating to the ANTARA products and FACTIVE products, (ii) enter into any new agreement or amend or fail to exercise any of its material rights under existing agreements that would adversely affect Paul Capital's royalty interest, and (iii) sell any material assets related to ANTARA or FACTIVE.

Pursuant to the terms of the Revenue Agreement and the Note Purchase Agreement, Guardian II and Paul Capital entered into a Security Agreement (the *Security Agreement*) under which Guardian II granted to Paul Capital a security interest in and to substantially all assets owned by Guardian II (including rights to the ANTARA products) in order to secure our performance under each of the Revenue Agreement, the Note

Table of Contents

Purchase Agreement and the Note. To the extent the indebtedness under certain of our pre-existing debt obligations is refinanced or replaced and such replacement or refinancing indebtedness is secured, we have agreed to equally and ratably secure our obligations under the Revenue Agreement.

Amendment to Revenue Interests Assignment Agreement

On November 25, 2008 the First Amendment (the Amendment) by and among us, Guardian II and Paul Capital dated November 5, 2008 to the Revenue Interests Assignment Agreement dated as of July 21, 2006 and restated August 18, 2006 became effective in accordance with its terms upon the completion of the 2008 Exchange Offer. The Amendment was entered into in order to secure Paul Capital's consent to the grant of the Second Priority Lien.

In accordance with the terms of the Amendment, we issued Paul Capital (i) a \$2.0 million aggregate principal amount note (the 2008 Paul Capital Note) with terms substantially identical to our 12.50% Notes issued in the 2008 Exchange Offer, and (ii) 500,000 shares of our common stock. We also granted certain registration rights to Paul Capital with respect to the 2008 Paul Capital Note and the common shares issued. Additionally, we agreed to amend the exercise price of the Common Stock Purchase Warrant dated August 18, 2006 issued to Paul Capital to purchase 288,018 shares of our common stock from \$6.94 to \$0.45, the closing price of our common stock on the NASDAQ Global Market on the date immediately preceding the closing of the 2008 Exchange Offer.

Under the terms of the Amendment, in the event that the sum of the net sales of ANTARA and FACTIVE in the U.S. and the gross margin received by us from sales of FACTIVE within our territory outside of the U.S. (for which the definition of Net Revenues has been expanded to be included in the Amendment) is less than 85% of certain specified annual sales thresholds, then Paul Capital can be entitled to a (i) 3% increase in the applicable royalty percentage payable on the first \$75 million of sales of such products in the applicable year and (ii) 2% increase in the applicable royalty percentage payable on net sales of such products in excess of \$75 million and less than \$150 million in the applicable year. The specified sales thresholds are \$115 million in 2009, \$135 million in 2010, \$150 million in 2011 and \$175 million thereafter through the term. Furthermore, the Amendment provides that in the event that we fail to achieve the specified sales threshold in any applicable year, the increased applicable royalty percentage shall also be payable on the net sales of any future drug products acquired or in-licensed by us or our subsidiaries. The increase in the applicable percentage payable on net sales shall be limited to a maximum payment to Paul Capital of \$2.25 million per year and \$15 million during the term of the Revenue Agreement, and in no event shall such payment exceed the amount which Paul Capital would have received in the applicable year had the specified sales threshold for that year been achieved.

The Amendment also provides that in the event that we or our subsidiaries acquire or in-license additional drug products, we shall make a one-time milestone payment to Paul Capital of \$1.25 million on the second anniversary of our first commercial sale of any such product.

Under the terms of the Amendment, in the event that Paul Capital and we determine that the fair market value of the collateral in which Paul Capital has been granted a security interest by Guardian II is less than the Put/Call Price (as defined in the Revenue Agreement), we will elect, in our sole discretion, to either grant Paul Capital a security interest in 25% of each additional drug product acquired or in-licensed us or our subsidiaries, or pay Paul Capital \$1.5 million on the second year anniversary of our first commercial sale of each such product.

Both the \$1.25 million milestone payment on the second anniversary of an acquired or in-licensed additional drug product and the \$1.5 million payment for any additional drug product acquired or in-licensed in which Paul Capital is not granted at least a 25% security interest are considered to be free standing financial instruments. These items are required to be recorded at fair value on the Company's balance sheet. As of December 31, 2008, we have determined that the fair value of these financial instruments is \$0. We will evaluate the valuation of these financial instruments at each balance sheet date.

Table of Contents

The Amendment also provides that any acceleration or failure to pay the 12.50% Notes would be considered a Put Event as further described above whereby Paul Capital could have the right to demand that we repurchase the revenue interest assignment at the Put/Call Price and the amounts outstanding under the Note Purchase Agreement would immediately become due and payable.

Common Stock and Warrant Purchase Agreement

As part of the financing, we and Paul Capital also entered into a Common Stock and Warrant Purchase Agreement (the "Stock and Warrant Purchase Agreement"), pursuant to which, in exchange for \$10 million, we sold to Paul Capital 1,388,889 shares (the "Shares") of our Common Stock, at a price of \$7.20 per share (the "Private Placement") and issued Paul Capital a warrant (the "Warrant") to purchase 288,018 shares of Common Stock (the "Warrant Shares") at an exercise price of \$6.94 per share. In accordance with the Amendment noted above, we amended the exercise price on the Warrant Shares to \$0.45 per share, the closing price of our common stock on the NASDAQ Global Market on the date immediately preceding the closing of the 2008 Exchange Offer. The Warrant is exercisable for seven years from the date of closing. The Warrant contains a net share settlement feature and penalties if the Company does not deliver the applicable amount of Warrant Shares within three trading days of exercise of a Warrant by Paul Capital. The Warrant also contains provisions providing that, at Paul Capital's election, we must repurchase the Warrant from Paul Capital upon a sale of the Company in which the consideration for such sale is solely cash. The warrant has not been exercised as of December 31, 2008.

Contractual Obligations

Our major outstanding contractual obligations relate to our convertible promissory notes, our facility leases and our financing agreements with Paul Royalty Fund Holdings II, LP, through which we funded our acquisition of ANTARA. The following table summarizes our significant contractual obligations as of December 31, 2008 and the effect such obligations are expected to have on our liquidity and cash flow in future periods (in thousands).

	2009	2010	2011	2012	2013	Thereafter	Total
Operating leases	\$ 5,820	\$ 6,011	\$ 2,003	\$ 467	\$ 112	\$ 112	\$ 14,525
Sublease contracted income	(1,990)	(1,797)	(305)				(4,092)
Current sublease forecasts (a)							
	3,830	4,214	1,698	467	112	112	10,433
Convertible promissory notes, including interest (b)	17,498	473	126,825				144,796
Term Loan (c)	1,402	26,625					28,027
Total forecasted contractual obligations	\$ 22,730	\$ 31,312	\$ 128,523	\$ 467	\$ 112	\$ 112	\$ 183,256

Note: The above contractual obligation table excludes amounts payable to Paul Capital in relation to the Revenue Agreement.

(a) The current market reflects lower demand and cost for space, as well as shorter term leases.

(b) See Note 11 of our consolidated financial statements for a description of our convertible promissory notes.

(c) See Note 11 of our consolidated financial statements for a description of our \$20 million term loan with Paul Capital.

In addition to the amounts reflected in the table above, in the future, we may owe royalties and other contingent payments to our collaborators and licensors, based on the achievement of product sales and specified other objectives and milestones, including a minimum annual product purchase commitment to Ethypharm pursuant to the ANTARA license agreement.

Table of Contents

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

As of December 31, 2008, we did not have any investments.

As of December 31, 2008 we did not have any financing arrangements that were not reflected in our consolidated balance sheet.

The interest rates on the Note to Paul Capital and our 5% Notes, 3 1/2% Notes, 3.5% Notes and 12.5% Notes are fixed and therefore not subject to interest rate risk.

Item 8. Financial Statements and Supplementary Data

Financial statements and supplementary data required by Item 8 are set forth at the pages indicated in Item 15(a) below.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Conclusion Regarding The Effectiveness Of Disclosure Controls And Procedures

We currently have in place systems relating to disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934). Our principal executive officer and principal financial officer evaluated the effectiveness of these disclosure controls and procedures as of the end of our fiscal year ended December 31, 2008 in connection with the preparation of this annual report. They concluded that the disclosure controls and procedures were effective as of the end of the period covered by this annual report.

MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). All internal controls over financial reporting, no matter how well designed, have inherent limitations. As a result of these inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those internal controls determined to be effective can provide only reasonable assurance with respect to reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2008 based on the framework in *Internal Control - Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in *Internal Control - Integrated Framework*, our management concluded that our internal control over financial reporting was effective as of December 31, 2008.

Ernst & Young LLP, the registered public accounting firm that audited the financial statements included in this annual report, has issued an attestation report on our internal control over financial reporting.

Table of Contents

Report of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders of

Oscient Pharmaceuticals Corporation

We have audited Oscient Pharmaceuticals Corporation's internal control over financial reporting as of December 31, 2008, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Oscient Pharmaceuticals Corporation's management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Oscient Pharmaceuticals Corporation maintained, in all material respects, effective internal control over financial reporting as of December 31, 2008, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Oscient Pharmaceuticals Corporation as of December 31, 2008 and 2007, and the related consolidated statements of operations, shareholders' (deficit) equity and comprehensive loss, and cash flows for each of the three years in the period ended December 31, 2008 of Oscient Pharmaceuticals Corporation and our report dated March 23, 2009 expressed an unqualified opinion thereon that included an explanatory paragraph regarding Oscient Pharmaceutical Corporation's ability to continue as a going concern.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 23, 2009

Table of Contents

Item 9B. OTHER INFORMATION

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

Executive Officers and Board of Directors

Information regarding our directors and executive officers may be found under the captions Election of Directors and Executive Officers in the Proxy Statement for our 2009 Annual Meeting of Shareholders. Such information is incorporated herein by reference.

Audit Committee

Information regarding our Audit Committee and identification of an Audit Committee financial expert may be found under the caption Board Meetings and Committees Audit Committee in the Proxy Statement for our 2009 Annual Meeting of Shareholders. Such information is incorporated herein by reference.

Section (16A) Beneficial Ownership Reporting Compliance

Pursuant to General Instruction G(3) to Form 10-K, the information regarding Section 16(a) Beneficial Ownership Reporting Compliance may be found under the caption Section 16(a) Beneficial Ownership Reporting Compliance in the Proxy Statement for our 2009 Annual Meeting of Shareholders. Such information is incorporated herein by reference.

Code of Ethics

We have adopted a code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer and controller. That code is part of our code of ethics and conduct which is available free of charge on our website (www.oscient.com), by sending a written request to Investor Relations, Oscient Pharmaceuticals Corporation, 1000 Winter Street, Suite 2200, Waltham, MA 02451, or by emailing investors@oscient.com. We intend to include on our website any amendment to, or waiver from, a provision of our code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer and controller that relates to any element of the code of ethics definition enumerated in Item 406(b) of Regulation S-K.

Item 11. Executive Compensation

Information with respect to this item may be found under the captions Report of the Compensation Committee, Executive Compensation, Directors Compensation and Compensation Committee Interlocks and Insider Participation, in the Proxy Statement for our 2009 Annual Meeting for Shareholders. Such information is incorporated herein by reference.

Table of Contents

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Information with respect to this item may be found under the caption Security Ownership of Certain Beneficial Owners and Management in the Proxy Statement for our 2009 Annual Meeting of Shareholders. Such information is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions and Director Independence

Information with respect to this item may be found under the caption Director Compensation Certain Relationships in the Proxy Statement for our 2009 Annual Meeting of Shareholders. Such information is incorporated herein by reference.

Item 14. Principal Accountant Fees and Services

Information with respect to this item may be found under the caption Principal Accountant Fees and Services in the Proxy Statement for our 2009 Annual Meeting of Shareholders. Such information is incorporated herein by reference.

Table of Contents**PART IV****Item 15. Exhibits and Financial Statement Schedules**

- (a) (1) Financial Statements See Index to Consolidated Financial Statements appearing on page F-1.
 (2) Schedule 2

Valuation and Qualifying Accounts**December 31, 2008****(in thousands)**

	Balance at Beginning of Period	Charged to Costs and Expenses	Charged to Product Sales	Deductions	Balance at End of Period
Year Ended December 31, 2008					
Deducted from assets accounts:					
Allowance for doubtful accounts	\$ 35	\$	\$	\$ (2)(*)	\$ 33
Reserve for cash discounts	343		2,400	(2,412)**	331
Total	\$ 378	\$	\$ 2,400	\$ (2,414)	\$ 364
Year Ended December 31, 2007					
Deducted from assets accounts:					
Allowance for doubtful accounts	\$ 349	\$	\$	\$ (314)(*)	\$ 35
Reserve for cash discounts	202		1,980	(1,839)**	343
Total	\$ 551	\$	\$ 1,980	\$ (2,153)	\$ 378
Year Ended December 31, 2006					
Deducted from assets accounts:					
Allowance for doubtful accounts	\$ 50	\$ 349	\$	\$ ()(*)	\$ 349
Reserve for cash discounts	50		953	(801)**	202
Total	\$ 50	\$ 349	\$ 953	\$ (801)	\$ 551

(*) Uncollectible accounts written off, net of recoveries.

(**) Discounts taken by customers during year.

- (3) List of Exhibits

Exhibit

No.	Description
2.1	Agreement and Plan of Merger and Reorganization dated November 17, 2003(11)
2.2	Asset Purchase Agreement by and among Reliant Pharmaceuticals, Inc., Guardian II Acquisition Corporation and Oscient Pharmaceuticals Corporation dated July 21, 2006 *(24)
3.1	Articles of Organization (as amended through November 15, 2006)(26)

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

- 3.2 By-Laws (as amended to date)(19)
- 4.1 Form of Purchase Warrant issued to Smithfield Fiduciary LLC and the Tail Wind Fund Ltd.(9)
- 4.2 Form of Common Stock Purchase Warrant dated as of September 29, 2003(10)
- 4.3 Registration Rights Agreement dated November 17, 2003, by and between Genome Therapeutics Corp. and certain creditors of GeneSoft Pharmaceuticals, Inc.(12)

Table of Contents

Exhibit No.	Description
4.4	Form of Indenture dated as of May 10, 2004(17)
4.5	Registration Rights Agreement dated May 10, 2004(17)
4.6	Form of Indenture dated as of May 10, 2004(17)
4.7	Registration Rights Agreement dated May 10, 2004(17)
4.8	Form of Common Stock Purchase Warrant dated April 5, 2006(20)
4.9	Form of Common Stock Purchase Warrant dated August 18, 2006(26)
4.10	Registration Rights Agreement dated August 18, 2006(26)
4.11	Form of Indenture dated as of May 1, 2007(27)
10.1	Incentive Stock Option Plan and Form of Stock Option Certificate(1)
10.2	Genome Therapeutics Corp. (f/k/a Collaborative Research) Incentive Savings Plan(2)
10.3	Amendment dated November 4, 1986 to the Genome Therapeutics Corp. (f/k/a Collaborative Research) Incentive Savings Plan dated March 1, 1985(3)
10.4	1991 Stock Option Plan and Form of Stock Option Certificate(4)
10.5	Lease dated June 23, 2004 relating to certain property in Waltham, Massachusetts(26)
10.6	1993 Stock Option Plan and Form of Stock Option Certificate(5)
10.7	1997 Directors' Deferred Stock Plan(6)
10.8	1997 Stock Option Plan(6)
10.9	Amended and Restated 2001 Incentive Plan(23)
10.10	Stock Option Agreements with Steven M. Rauscher(7)
10.11	Employment Letter with Steven M. Rauscher(8)
10.12	Amendment, Redemption and Exchange Agreement between the Company and The Tail Wind Fund, dated June 4, 2003(9)
10.13	Note Amendment and Exchange Agreement dated November 17, 2003, by and between Genome Therapeutics Corp. and certain creditors of GeneSoft Pharmaceuticals, Inc.(12)
10.14	Amendment to Employment Agreement dated as February 5, 2004 between Genome Therapeutics Corp. and Steven M. Rauscher(13)
10.15	Employment letter with Gary Patou, M.D. dated January 11, 2004(13)
10.16	License and Option Agreement dated October 22, 2002 between GeneSoft Pharmaceuticals, Inc. and LG Life Sciences, Ltd.*(13)
10.17	Amendment No. 1 to License and Option Agreement dated November 21, 2002 by and between GeneSoft Pharmaceuticals, Inc. and LG Life Sciences, Ltd.*(13)
10.18	Amendment to No. 2 to License and Option Agreement dated December 6, 2002 by and between GeneSoft Pharmaceuticals, Inc. and LG Life Sciences, Ltd.*(13)
10.19	Amendment No. 3 to License and Option Agreement dated October 16, 2004 by and between GeneSoft Pharmaceuticals, Inc. and LG Life Sciences, Ltd.*(13)
10.20	Genome Therapeutics Corp. Employee Stock Purchase Plan as amended through April 13, 2004(16)

Table of Contents

Exhibit No.	Description
10.21	Genome Therapeutics Corp. 2001 Incentive Plan as amended through April 13, 2004(16)
10.22	Employment Letter with Dominick C. Colangelo dated January 3, 2005(14)
10.23	Amendment to Employment Agreement for Philippe Maitre dated April 18, 2008(32)
10.24	Amendment No. 4 to License and Option Agreement dated March 31, 2005 by and between GeneSoft Pharmaceuticals, Inc. and LG Life Sciences, Ltd.*(15)
10.25	Form of Incentive Stock Option(18)
10.26	Form of Nonstatutory Stock Option(18)
10.27	Form of Restricted Stock Award(18)
10.28	Amended and Restated Employee Stock Purchase Plan (as amended through June 8, 2006)(23)
10.29	Amendment No. 5 to License and Option Agreement dated February 3, 2006 by and between Oscient Pharmaceuticals Corporation and LG Life Sciences, Ltd.*(21)
10.30	Assignment and Termination Agreement dated February 3, 2006 between Vicuron Pharmaceuticals, Inc. and Oscient Pharmaceuticals Corporation(21)
10.31	Sublicensing and Distribution Agreement dated February 6, 2006 by and between Pfizer S.A. de C.V. and Oscient Pharmaceuticals Corporation*(21)
10.32	Form of Purchase Agreement dated April 5, 2006(20)
10.33	Amendment to Employment Agreement for Dominick C. Colangelo dated May 5, 2006(22)
10.34	Employment Agreement with Philippe M. Maitre dated May 5, 2006(22)
10.35	Amendment to Employment Agreement for Steven M. Rauscher dated May 12, 2006(22)
10.36	Amended and Restated Development, Licensing and Supply Agreement dated July 31, 2006 by and between Ethypharm S.A. and Reliant Pharmaceuticals, Inc.*(24)
10.37	Common Stock and Warrant Purchase Agreement dated July 21, 2006 by and between Oscient Pharmaceuticals Corporation and Paul Royalty Fund Holdings II(25)
10.38	Note Purchase Agreement dated July 21, 2006 by and between Guardian Acquisition Corporation and Paul Royalty Fund Holdings II*(25)
10.39	Revenue Interests Assignment Agreement dated August 18, 2006 by and between Oscient Pharmaceuticals Corporation, Guardian II Acquisition Corporation and Paul Royalty Fund Holdings II*(25)
10.40	Amendment No. 7 to License and Option Agreement dated December 27, 2006 by and between Oscient Pharmaceuticals Corporation and LG Life Sciences, Ltd.*(26)
10.41	License, Supply and Marketing Agreement dated December 28, 2006 by and between Oscient Pharmaceuticals Corporation and Menarini International Operation Luxembourg, S.A.*(26)
10.42	2007 Employment Inducement Award Plan(28)
10.43	Employment Agreement with Mark Glickman dated August 16, 2007 (29)
10.44	Amendment to Employment Agreement with Mark Glickman dated August 22, 2007 (29)
10.45	Amendment to Employment Agreement with Mark Glickman dated July 28, 2008 (29)

Table of Contents

Exhibit

No.	Description
10.46	First Amendment to the Revenue Interests Assignment Agreement dated November 5, 2008 by and among Oscient Pharmaceuticals Corporation, Paul Royalty Fund Holdings II and Guardian II Acquisition Corporation(30)
10.47	First Amendment dated January 28, 2009 to the Note Amendment and Exchange Agreement dated November 17, 2003 by and between Oscient Pharmaceuticals Corporation and certain creditors of Oscient Pharmaceuticals Corporation(31)
12.1	Statement re: Computation of Ratios
21.1	Subsidiaries of the Registrant(26)
23.1	Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
31.1	Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
31.2	Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
32.1	Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act

Filed herewith.

- * Confidential treatment requested with respect to a portion of this Exhibit
- (1) Filed as an exhibit to the Company s Registration Statement on Form S-1 (No. 2-75230) dated December 8, 1981 and incorporated herein by reference.
 - (2) Filed as an exhibit to the Company s Annual Report on Form 10-K for the fiscal year ended August 31, 1985 and incorporated herein by reference.
 - (3) Filed as exhibits to the Company s Annual Report on Form 10-K for the fiscal year ended August 31, 1986 and incorporated herein by reference.
 - (4) Filed as an exhibit to the Company s Annual Report on Form 10-K for the fiscal year ended August 31, 1992 and incorporated herein by reference.
 - (5) Filed as exhibits to the Company s Annual Report on Form 10-K for the fiscal year ended August 31, 1994 and incorporated herein by reference.
 - (6) Filed as exhibits to the Company s Registration Statement on Forms S-8 (333-49069) dated April 1, 1998 and incorporated herein by reference.
 - (7) Filed as an exhibit to the Company s Registration Statement on Form S-8 (333-58274) on April 4, 2001 and incorporated herein by reference.
 - (8) Filed as an exhibit to the Company s Quarterly Report on Form 10-Q for the quarter ended September 29, 2001 and incorporated herein by reference.
 - (9) Filed as an exhibit to the Company s Current Report on Form 8-K on June 5, 2003 and incorporated herein by reference.
 - (10) Filed as an exhibit to the Company s Current Report on Form 8-K on October 1, 2003 and incorporated herein by reference.
 - (11) Filed as an exhibit to the Company s Current Report on Form 8-K on November 18, 2003 and incorporated herein by reference.
 - (12) Filed as an exhibit to the Company s Registration Statement on Form S-4 (No. 333-111171) on December 15, 2003 and incorporated herein by reference.
 - (13) Filed as an exhibit to the Company s Quarterly Report on Form 10-Q for the quarter ended March 27, 2004 and incorporated herein by reference.
 - (14) Filed as an exhibit to the Company s Annual Report on Form 10-K for the year-ended December 31, 2005 and incorporated herein by reference.
 - (15) Filed as an exhibit to the Company s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 and incorporated herein by reference.

Table of Contents

- (16) Filed as an exhibit to the Company's Registration Statement on Form S-8 (333-116707) on June 21, 2004 and incorporated herein by reference.
- (17) Filed as an exhibit to the Company's Registration Statement on Form S-3 (333-118026) on August 9, 2004 and incorporated herein by reference.
- (18) Filed as an exhibit to the Company's Current Report on Form 8-K on December 27, 2005 and incorporated herein by reference.
- (19) Filed as an exhibit to the Company's Registration Statement on Form S-3 (333-137596) on September 26, 2006 and incorporated herein by reference.
- (20) Filed as an exhibit to the Company's Current Report on Form 8-K on April 12, 2006 and incorporated herein by reference.
- (21) Filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2006 and incorporated herein by reference.
- (22) Filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 and incorporated herein by reference.
- (23) Filed as an exhibit to the Company's Registration Statement on Form S-8 (333-138309) on October 30, 2006 and incorporated herein by reference.
- (24) Filed as an exhibit to the Company's Current Report on Form 8-K on November 1, 2006 and incorporated herein by reference.
- (25) Filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 and incorporated herein by reference.
- (26) Filed as an exhibit to the Company's Annual report on Form 10-K for the year ended December 31, 2007 and incorporated herein by reference.
- (27) Filed as an exhibit to the Company's Current Report on Form 8-K on May 4, 2007 and incorporated herein by reference.
- (28) Filed as an exhibit to the Company's Registration Statement on Form S-8 on October 1, 2007 and incorporated herein by reference.
- (29) Filed as exhibits to the Company's Registration Statement on Forms S-4 (333-153394) dated September 10, 2008 and incorporated herein by reference.
- (30) Filed as exhibits to the Company's Registration Statement on Forms S-4 (333-153394) dated November 7, 2008 and incorporated herein by reference.
- (31) Filed as an exhibit to the Company's Current Report on Form 8-K on February 3, 2008 and incorporated herein by reference.
- (32) Filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and incorporated herein by reference.

The following Oscient-owned or licensed trademarks are used in this Annual Report on Form 10-K: Oscient, Oscient Pharmaceuticals, Antara[®] and Factive[®]. All are covered by registrations or pending applications for registration in the U.S. Patent and Trademark Office and other countries. Other trademarks used in this Annual Report on Form 10-K are the property of their respective owners.

Table of Contents**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OSCIENT PHARMACEUTICALS**CORPORATION**

By: /s/ STEVEN M. RAUSCHER
Steven M. Rauscher

President and Chief Executive Officer

Dated: March 25, 2009

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ STEVEN M. RAUSCHER Steven M. Rauscher	Director, President and Chief Executive Officer (Principal Executive Officer)	March 25, 2009
/s/ PHILIPPE M. MAITRE Philippe M. Maitre	Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)	March 25, 2009
/s/ DAVID K. STONE David K. Stone	Director and Chairman of the Board	March 25, 2009
/s/ GREGORY B. BROWN Gregory B. Brown	Director	March 25, 2009
/s/ ROBERT J. HENNESSEY Robert J. Hennessey	Director	March 25, 2009
/s/ JOHN R. LEONE John R. Leone	Director	March 25, 2009
/s/ WILLIAM R. MATTSON William R. Mattson	Director	March 25, 2009
/s/ WILLIAM S. REARDON William S. Reardon	Director	March 25, 2009

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

/s/ NORBERT G. RIEDEL

Director

March 25, 2009

Norbert G. Riedel

90

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page
<u>Report of Independent Registered Public Accounting Firm</u>	F-2
<u>Consolidated Balance Sheets as of December 31, 2008 and 2007</u>	F-3
<u>Consolidated Statements of Operations for the Years Ended December 31, 2008, 2007 and 2006</u>	F-4
<u>Consolidated Statements of Shareholders' (Deficit) Equity and Comprehensive Loss for the Years Ended December 31, 2008, 2007 and 2006</u>	F-5
<u>Consolidated Statements of Cash Flows for the Years Ended December 31, 2008, 2007 and 2006</u>	F-6
<u>Notes to Consolidated Financial Statements</u>	F-8

F-1

Table of Contents

Report of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders of

Oscient Pharmaceuticals Corporation

We have audited the accompanying consolidated balance sheets of Oscient Pharmaceuticals Corporation as of December 31, 2008 and 2007, and the related consolidated statements of operations, shareholders' (deficit) equity and comprehensive loss, and cash flows for each of the three years in the period ended December 31, 2008. Our audits also included the financial statement schedule listed in the index as Item 15(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Oscient Pharmaceuticals Corporation at December 31, 2008 and 2007, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2008, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material aspects the information as set forth therein.

As discussed in Note 1 to the consolidated financial statements, the Company's recurring losses from operations, declining cash balance, maturing debt, working capital and shareholders' deficit raise substantial doubt about its ability to continue as a going concern. Management's plans as to these matters are also described in Note 1. The 2008 consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As discussed in Note 2(s) to the consolidated financial statements, on January 1, 2006, the Company adopted the provisions of Statement of Financial Accounting Standards No. 123 (Revised 2004), *Share-Based Payment*, which requires the Company to recognize expense for all share-based payments based on their fair values.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Oscient Pharmaceuticals Corporation's internal control over financial reporting as of December 31, 2008, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 23, 2009 expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 23, 2009

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****CONSOLIDATED BALANCE SHEETS****(in thousands, except per share data)**

	December 31, 2008	December 31, 2007
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 12,595	\$ 48,268
Notes receivable		486
Accounts receivable (net of allowance for bad debts of \$33 and \$35 in 2008 and 2007, respectively)	17,602	15,032
Inventories	7,700	9,059
Prepaid expenses and other current assets	3,597	2,886
Total current assets	41,494	75,731
Property and Equipment, at cost:		
Manufacturing and computer equipment	4,589	4,695
Equipment and furniture	656	564
Leasehold improvements	183	138
	5,428	5,397
Less Accumulated depreciation	4,660	4,590
	768	807
Restricted cash	4,598	4,198
Other assets	729	5,585
Intangible assets, net	51,036	110,903
Goodwill	75,408	76,960
	\$ 174,033	\$ 274,184
LIABILITIES AND SHAREHOLDERS DEFICIT		
Current Liabilities:		
Current maturities of long-term debt	\$ 13,413	\$ 38
Debt obligations (Note 1)	183,278	
Accounts payable	11,979	10,262
Accrued expenses and other current liabilities	34,098	20,928
Current portion of accrued facilities impairment charge	3,152	2,128
Deferred revenue	3,926	364
Total current liabilities	249,846	33,720
Long-term Liabilities:		
Long-term debt, net of current maturities	132	252,859
Noncurrent portion of accrued facilities impairment charge	4,255	8,831
Other long-term liabilities	984	7,216
Deferred revenue		273
Commitments and Contingencies (Note 10)		
Shareholders Deficit:		
Common stock, \$0.10 par value Authorized 174,375 shares, Issued and Outstanding 36,640 and 13,892 in 2008 and 2007, respectively	3,664	1,389
Series B restricted common stock, \$0.10 par value Authorized 625 shares, Issued and Outstanding none		
Additional paid-in-capital	425,665	415,654
Accumulated deficit	(510,513)	(445,758)

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Total shareholders' deficit	(81,184)	(28,715)
	\$ 174,033	\$ 274,184

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

	2008	Year Ended December 31, 2007	2006
Revenues (net):			
Product sales	\$ 86,325	\$ 78,458	\$ 38,244
Co-promotion			6,890
Other	523	1,511	1,018
Total net revenues	86,848	79,969	46,152
Costs and expenses (1):			
Cost of product sales	29,013	31,269	19,613
Research and development	2,875	5,845	12,406
Selling and marketing	71,150	66,278	69,211
General and administrative	13,413	14,573	16,841
Impairment of intangible assets	50,759		
Total costs and expenses	167,210	117,965	118,071
Loss from operations	(80,362)	(37,996)	(71,919)
Other income (expense):			
Interest income	650	2,541	2,995
Interest expense	(30,882)	(28,206)	(11,056)
Gain on disposition of investment	413	231	1,617
Gain on exchange of convertible notes	35,357	30,824	
Gain on derivative	10,480	3,023	
Other income	9	114	65
Net other income (expense)	16,027	8,527	(6,379)
Loss from operations before income tax	(64,335)	(29,469)	(78,298)
Provision for income tax	(420)	(384)	(179)
Net loss	\$ (64,755)	\$ (29,853)	\$ (78,477)
Net loss per common share:			
Basic and diluted	\$ (4.03)	\$ (2.19)	\$ (6.58)
Weighted average common shares outstanding:			
Basic and diluted	16,050,707	13,600,787	11,925,485

(1) Includes non-cash stock-based compensation as follows:

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Cost of product sales	\$ 36	\$ 40	\$ 67
Research and development	(109)	50	136
Selling and marketing	287	972	1,236
General and administrative	1,110	1,651	2,437

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

CONSOLIDATED STATEMENTS OF SHAREHOLDERS (DEFICIT) EQUITY AND COMPREHENSIVE LOSS

(in thousands, except share data)

	Common Stock		Additional Paid- In Capital	Accumulated Deficit	Note Receivable From Officer	Total Shareholders (Deficit) Equity	Comprehensive Loss
	Shares	\$0.10 Par Value					
Balance at December 31, 2005	9,669	\$ 967	\$ 364,736	\$ (337,439)	\$ (163)	\$ 28,101	\$ (88,593)
Exercise of stock options	90	9	157			166	
Issuance of stock under employee stock purchase plan	79	8	732			740	
Issuance of common stock in private placement	2,254	225	33,252			33,477	
Issuance of common stock to Paul Capital	1,389	139	9,819			9,958	
Issuance of restricted stock	78	8	(8)				
Reversal of deferred compensation			(11)	11			
Stock based compensation expense			3,876			3,876	
Settlement of note receivable					163	163	
Net loss				(78,477)		(78,477)	(78,477)
Balance at December 31, 2006	13,559	1,356	412,553	(415,905)		(1,996)	
Exercise of stock options	5	1	16			17	
Issuance of stock under employee stock purchase plan	95	9	395			404	
Net issuance of restricted stock	233	23	(23)				
Stock based compensation expense			2,713			2,713	
Net loss				(29,853)		(29,853)	(29,853)
Balance at December 31, 2007	13,892	1,389	415,654	(445,758)		(28,715)	
Exercise of stock options							
Issuance of stock under employee stock purchase plan	151	15	178			193	
Net issuance of restricted stock	218	21	(21)				
Stock based compensation expense			1,324			1,324	
Issuance of common stock in connection with the convertible debt exchange (Note 11)	21,811	2,181	7,847			10,028	
Re-pricing of Paul Capital Warrants (Note 11)			65			65	
Conversion of 12.50% Notes	568	58	618			676	
Net loss				(64,755)		(64,755)	(64,755)
Balance at December 31, 2008	36,640	\$ 3,664	\$ 425,665	\$ (510,513)	\$	\$ (81,184)	

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

	Year Ended December 31,		
	2008	2007	2006
Cash Flows from Operating Activities:			
Net Loss	\$ (64,755)	\$ (29,853)	\$ (78,477)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	9,485	9,847	7,158
Provision for excess and obsolete inventories	511	793	1,631
(Recovery of) provision for bad debts		(172)	349
Non-cash interest expense	13,196	9,623	1,468
Gain on exchange of notes	(35,357)	(30,824)	
Gain on derivatives	(10,480)	(3,023)	
Gain on disposition of investment	(413)	(231)	(1,617)
Stock-based compensation	1,324	2,713	3,876
Impairment of intangible assets	50,759		
Changes in assets and liabilities, net of acquisition			
Accounts receivable	(2,570)	(2,922)	(6,080)
Inventories	848	4,386	(1,796)
Prepaid expenses and other current assets	(710)	(96)	2,134
Accounts payable	1,717	(141)	3,955
Accrued expenses and other liabilities	3,755	4,915	3,335
Deferred revenue	3,289	(750)	1,386
Accrued facilities impairment charge	(2,390)	(2,618)	(2,826)
Accrued other long-term liabilities	610	3,692	1,869
Net cash used in operating activities	(31,181)	(34,661)	(63,635)
Cash Flows from Investing Activities:			
Proceeds from disposition of investment	413	231	1,617
Purchases of property and equipment	(190)	(56)	(263)
Proceeds from sale of property and equipment	3	7	1
(Increase) decrease in restricted cash	(400)	2,414	5,118
Increase in other assets	(35)	(63)	(329)
Proceeds from notes receivable	486	1,373	790
Proceeds from maturities of marketable securities			2,696
Issuance of notes receivable			(186)
Cash flows related to acquisition of ANTARA			(77,563)
Net cash provided by (used in) investing activities	277	3,906	(68,119)

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)**

(in thousands)

	Year Ended December 31,		
	2008	2007	2006
Cash Flows from Financing Activities:			
Payments of convertible debt exchange costs	(4,924)		
Proceeds from issuance of notes, net of issuance costs		40,444	
Proceeds from private placement of common stock, net of issuance costs			33,477
Proceeds from issuance of stock in connection with acquisition of ANTARA, net of issuance costs			9,958
Proceeds from exercise of stock options		17	166
Proceeds from issuance of stock under the employee stock purchase plan	193	404	740
Proceeds from issuance of notes			20,000
Proceeds from assignment of revenue interest			40,000
Payments on long-term obligations	(38)	(38)	(9)
Net cash (used in) provided by financing activities	(4,769)	40,827	104,332
Net (Decrease) Increase in Cash and Cash Equivalents	(35,673)	10,072	(27,422)
Cash and Cash Equivalents, beginning of year	48,268	38,196	65,618
Cash and Cash Equivalents, end of year	\$ 12,595	\$ 48,268	\$ 38,196
Supplemental Disclosure of Cash Flow Information:			
Interest paid during period	\$ 9,978	\$ 14,925	\$ 6,053
Income tax paid during period	\$ 18	\$ 18	\$ 25

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements

(1) Operations

Oscient Pharmaceuticals Corporation (the Company) is a commercial-stage pharmaceutical company marketing Food and Drug Administration (FDA)-approved products in the United States. The Company's strategy is to maximize the sales of its existing products and to gain access to new products via transactions, including acquisition, in-licensing and co-promotion. Oscient has developed a commercial infrastructure, including a national sales force calling on targeted primary care physicians, cardiologists, endocrinologists and pulmonologists in the United States.

Oscient currently markets two products; ANTARA® (fenofibrate) capsules, a cardiovascular product and FACTIVE® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is approved by the FDA to treat hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with a healthy diet. The Company licenses the rights to ANTARA from Ethypharm S.A. of France (Ethypharm). The Company began promoting ANTARA in late August 2006. FACTIVE is indicated for the treatment of community-acquired pneumonia of mild to moderate severity (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB). The Company licenses the rights to gemifloxacin, the active ingredient in FACTIVE tablets, from LG Life Sciences of the Republic of Korea (LG Life Sciences). The Company launched FACTIVE in the U.S. market in September 2004.

Additionally, the Company has a novel, late-stage antibiotic candidate, Ramoplanin, for the treatment of *Clostridium difficile*-associated disease (CDAD). The Company has made the strategic decision to concentrate its financial resources on building its revenues for products promoted to community-based physicians in the United States and has explored partnering and other strategic opportunities for the continued development of Ramoplanin.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As shown in the consolidated financial statements, at December 31, 2008, the Company had total cash and cash equivalents of approximately \$17,193,000, which includes \$4,598,000 in restricted cash, negative working capital of \$208,352,000 and an accumulated deficit of approximately \$510,513,000. The Company has also generated significant operating losses for the last several years and expects to continue to generate significant operating losses for the foreseeable future. In an effort to preserve the Company's financial resources and position the organization for a potential partnership or acquisition, on February 11, 2009, the Company announced plans to substantially reduce the size of its sales and marketing teams as well as its office personnel and also announced that it had engaged a third party to advise the Company on strategic options, including sale of the Company. As a result of this reduction in its sales and marketing teams, the Company believes its product sales could decrease in 2009 as compared to 2008.

As more fully described below, the Company is subject to a possible delisting from the NASDAQ Global Market. In the event that the Company is not able to maintain such listing and meet the requirements to list its common stock on another national securities exchange or be approved for listing on a system of automated dissemination of quotations, the holders of a substantial portion of the Company's debt obligations can require the Company to repurchase the principal amount of such debt.

Based on the January 25, 2009 extension of the maturity date of approximately \$13,150,000 of the approximately \$13,300,000 outstanding principal of the Company's 5% Convertible Promissory Note due in 2009 and related accrued interest of approximately \$3,645,000, the Company's available capital, its current operating plan and management's ability to manage expenses, the Company believes that the unrestricted cash on

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

hand as of December 31, 2008, is sufficient to fund continuing operations only into the third quarter of 2009. In the next several months, the Company will need to, raise additional capital and/or refinance or amend the terms of its existing debt due in December 2009 in order to fund its operations for the remainder of 2009, repay its debt that is maturing in December 2009, fund other potential commercial or development opportunities, and support its sales and marketing activities. The Company intends to pursue privately raising additional capital from investors through equity financing, the incurrence of indebtedness or a combination of equity and debt.

Based on the financial condition of the Company, as discussed above, a strategic sale of the Company or additional financing may not be available to the Company, or, if available may not be available on favorable terms. If the Company cannot sell itself or obtain adequate financing on acceptable terms prior to exhausting its available cash when such sales or financing is required or lower its expenses as expected through certain cost reduction measures, it will have to scale back its operations even further or take other measures to significantly reduce its expenses which will have a material adverse effect on its business and/or may cause the Company to cease operations. Further, if the Company is unsuccessful in identifying and implementing strategic options, including a strategic sale of itself, if it fails to raise additional capital, or if it fails to meet payment obligations to third parties as they come due, the Company may be subject to litigation claims and/or may seek bankruptcy protection. Litigation could result in substantial costs, be a distraction to management and may result in unfavorable results that could further adversely impact the Company's financial condition and impact its ability to continue operations.

All of these conditions raise substantial doubt about the Company's ability to continue as going concern through the end of 2009. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as an ongoing enterprise.

Notice of Delisting

On October 3, 2008, the Company received a notification from The NASDAQ Listings Qualifications Department of The NASDAQ Stock Market LLC (NASDAQ) that, as of October 2, 2008, the Company's market value of publicly held shares (MVPHS) had closed below the minimum \$15 million threshold set forth in Marketplace Rule 4450(b)(3) for the previous thirty (30) consecutive business days, a requirement for continued listing. For NASDAQ purposes, MVPHS is the market value of the Company's publicly held shares, which is calculated by subtracting all shares held by officers, directors or beneficial owners of 10% or more of an issuer's common stock from the issuer's total shares outstanding.

On October 23, 2008, the Company received notification from NASDAQ that given the current extraordinary market conditions, NASDAQ has suspended the enforcement of the rules requiring a MVPHS and a minimum \$1 closing bid price (Rule Suspension). On December 23, 2008, the Company received a second notification from NASDAQ that the Rule Suspension period had been extended an additional ninety (90) days and that the minimum bid price and MVPHS requirements will be reinstated on April 20, 2009. On March 23, 2009 the Company received a third notification from NASDAQ that the Rule Suspension period had been extended an additional ninety (90) days and that the minimum bid price and MVPHS requirements will be reinstated on July 20, 2009. As a result of the Rule Suspension, all companies presently in the compliance process will remain at that same stage of the process; however, companies can regain compliance during the Rule Suspension period. NASDAQ will not take any action to delist any security for these concerns during the Rule Suspension period, which will remain in effect through Friday, July 17, 2009. These

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

rules will be reinstated on Monday, July 20, 2009. Under the Rule Suspension, the Company believes it will now have until approximately October 6, 2009 to regain compliance by evidencing a minimum \$15 million MVPHS for ten (10) consecutive business days. If the Company does not regain compliance with the MVPHS requirement by July 6, 2009, the Company will receive written notification of delisting from NASDAQ and at that time will be entitled to request a hearing before a NASDAQ Listing Qualifications Panel (Panel) to present its plan to regain compliance with the MVPHS requirement.

If the Company's efforts to regain compliance are successful and the MVPHS exceeds \$15 million for ten (10) consecutive days before July 6, 2009 the Company will regain compliance with respect to the MVPHS requirement. In the event the Company does not regain compliance, it may appeal the staff determination to the Panel. In the event that the Company fails to regain compliance and is unsuccessful in an appeal to the Panel, the Company's securities will be delisted from The NASDAQ Global Market. In the event that the Company's securities are delisted from The NASDAQ Global Market, the Company may not be able to meet the requirements necessary for its common stock (i) to transfer to, or list on, a U.S. national securities exchange, including The NASDAQ Capital Market or (ii) be approved for listing on a U.S. system of automated dissemination of quotations. Given the current economic markets and the Company's financial position, it is improbable that the Company will achieve an MVPHS of \$15 million before July 6, 2009.

If such event in (i) or (ii) above occurred, holders of the 2011 Notes (as described below) have the right to require the Company to repurchase for cash the outstanding principal amount of the 2011 Notes, as applicable, plus accrued and unpaid interest through such date. As of December 31, 2008, there were outstanding principal amounts of: (i) \$86,684,000 of 12.50% Convertible guaranteed senior notes due 2011 (12.50% Notes); (ii) \$12,687,000 of 3.50% Senior convertible promissory notes due 2011 (3.50% Notes); and (iii) \$829,000 of 3% Senior convertible promissory notes due 2011 (3% Notes) (collectively, the 2011 Notes). The Company does not have sufficient cash and may not be able to raise sufficient additional capital to repay the 2011 Notes as applicable, if requested to be repurchased by the holders.

In the event the holders of the 12.50% Notes require the Company to repurchase the notes and such payment is accelerated, this event could be considered a Put Event under the Revenue Interest Assignment Agreement, as amended with Paul Capital, and the related Note Purchase Agreement (the 12% Senior Secured Note) (See Note 11(b)). The Company does not have sufficient cash and may not be able to raise sufficient additional capital to repay these obligations if requested to be repurchased by the holders. As a result of the probable delisting of the Company's common stock, the potential right of the 12.50% Notes to require the Company to repurchase the notes and the potential Paul Capital Put Event, the Company reclassified all of the 2011 Notes, the \$39.2 million Revenue Interest Assignment agreement and the \$20 million 12% Senior Secured Note (including any related accrued interest payable and embedded derivative liabilities) to current liabilities at December 31, 2008 in accordance with SFAS No. 78, Classification of Obligations That Are Callable by the Creditor An Amendment to ARB 43, Chapter 3A, as of December 31, 2008. See Note 11 for additional description of the Company's outstanding debt obligations.

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

(2) Summary of Significant Accounting Policies

The accompanying consolidated financial statements reflect the application of certain accounting policies, as described in this note and elsewhere in the accompanying notes to the consolidated financial statements.

(a) Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Guardian II Acquisition Corporation, Collaborative Genetics, Inc., Collaborative Securities Corp. (a Massachusetts Securities Corporation), Oscient Pharmaceuticals U.K. Ltd., and GeneSoft Pharmaceuticals LLC. All intercompany accounts and transactions have been eliminated in consolidation.

(b) Revenue Recognition

The Company's principal source of revenue is the sale of ANTARA capsules and FACTIVE tablets. In the second quarter of 2005, the Company began recognizing co-promotion revenue in connection with its co-promotion agreement with Auxilium Pharmaceuticals, Inc. (Auxilium), which terminated on August 31, 2006. ANTARA revenue results are anticipated to be non-seasonal, although the wholesaler buying patterns tend to increase toward the end of the fiscal year. The Company expects demand for FACTIVE to be highest from December to March as the incidence of respiratory tract infections, including CAP and AECB, tends to increase during the winter months. In addition, fluctuations in the severity of the annual respiratory tract infection season may cause product sales to vary from year to year. Due to these seasonal fluctuations in demand for FACTIVE, the Company's results in any particular quarter may not be indicative of the results for any other quarter or for the entire year.

Product Sales

The Company follows the provisions of Staff Accounting Bulletin (SAB) No. 104, Revenue Recognition (a replacement of SAB 101) (SAB No. 104) and recognizes revenue from product sales upon delivery of product to wholesalers, when persuasive evidence of an arrangement exists, the fee is fixed or determinable, title to product and associated risk of loss has passed to the wholesaler and collectability of the related receivable is reasonably assured. All revenues from product sales are recorded net of applicable allowances for sales returns, rebates, special promotional programs, and discounts. For arrangements where the risk of loss has not passed to wholesalers or pharmacies, the Company defers the recognition of revenue by recording deferred revenue until such time that risk of loss has passed. For one product sale to a new customer in 2008, the Company was unable to estimate product returns. Accordingly, the Company is recognizing the revenue on the sell-through method for this transaction. As of December 31, 2008, the Company had approximately \$3,653,000 of deferred revenue related to this transaction. The cost of ANTARA and FACTIVE associated with amounts recorded as deferred revenue is recorded in inventory until such time as risk of loss has passed or other criteria for revenue recognition have been met.

Co-Promotion Revenue

On August 31, 2006, the Company and Auxilium mutually agreed to conclude the co-promotion arrangement and agreed to share profits from primary care sales, as provided for under the co-promotion agreement, through August 31, 2006. Amounts earned under the Company's co-promotion agreement with Auxilium from the sale of TESTIM gel, a product developed by Auxilium, are classified as co-promotion revenue in the accompanying consolidated statements of operations. Auxilium was obligated to pay the Company

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

a co-promotion fee based on a specified percentage of the gross profit from TESTIM sales attributable to primary care physicians in the U.S. that exceeded a specified cumulative sales threshold, determined on an annual basis. The specific percentage was based upon TESTIM sales levels attributable to primary care physicians and the marketing expenses incurred by the Company in connection with the promotion of TESTIM under the co-promotion agreement. Such co-promotion revenue was earned when TESTIM units were dispensed through patient prescriptions. There was no cost of goods sold associated with co-promotion revenue, and the selling and marketing expenses incurred with respect to the co-promotion arrangement are classified as selling and marketing expenses in the accompanying consolidated statements of operations. As part of the termination of the co-promotion agreement, the Company received \$1,800,000 from Auxilium as additional compensation for commercialization efforts by the Company's sales force through August 31, 2006, which was recognized as revenue during the year ended December 31, 2006. The Company does not expect any future co-promotion revenue in association with its agreement with Auxilium.

Other Revenues

Other revenues primarily consist of sublicensing revenues related to FACTIVE. The Company recognizes revenue in accordance with SAB No. 104 and Emerging Issues Task Force (EITF) Issue No. 00-21, Revenue Arrangements with Multiple Deliverables (EITF No. 00-21). In accordance with EITF No. 00-21, the up-front license payments related to the various sublicense agreements will be recognized as revenue over the term of the Company's continuing obligations under the arrangements which range from eighteen months to thirty-three months. Substantive milestones achieved are recognized as revenue when earned and when payment is reasonably assured. The Company expenses incremental direct costs associated with sublicense agreements in the period in which the expense is incurred.

On August 1, 2006, the Company announced that it received notice from Pfizer Mexico that FACTIVE was approved by the Ministry of Health in Mexico to be marketed as FACTIVE-5 for the treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis which generated a milestone payment recognized as revenue in 2006. On December 9, 2008, Pfizer Mexico received regulatory approval to market FACTIVE tablets for the Uncomplicated Urinary Tract Infections (uUTI) indication with a 3-day course of treatment, from COFEPRIS, the pharmaceutical regulatory agency of Mexico. On January 4, 2007, the Company announced that it had granted commercialization rights to FACTIVE in Europe to Menarini International Operation Luxembourg SA (Menarini), a wholly-owned subsidiary of Menarini Industrie Farmaceutiche Riunite S.r.l. Part of this arrangement included an up-front license payment which the Company is recognizing over the term of the Company's obligations under the arrangement. On March 2, 2007, the Company announced that Abbott Laboratories, Ltd. (Abbott Canada), the Canadian affiliate of Abbott Laboratories, had received approval to begin the promotion of FACTIVE in Canada. In connection with the terms of the agreement with Abbott, a milestone payment related to regulatory approval of the Company's manufacture of FACTIVE for Canada was recorded as other revenue during 2007. On January 31, 2008, Abbott Canada's development and commercialization obligations were substantially reduced. In accordance with the terms of the amendment, Abbott Canada continued to maintain FACTIVE tablets in its current product price list and it continued to pay the Company a transfer price on FACTIVE tablets purchases. Additionally, the amendment provided that the Company could terminate the agreement at any time with prior notice to Abbott Canada and Abbott Canada could terminate with prior notice to the Company after November 30, 2008. In December 2008, the Company's license agreement with Abbott Canada was terminated. Abbott Canada has ceased all development and commercialization of FACTIVE in Canada.

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

(c) Sales Rebates, Discounts and Incentives

The Company's sales of ANTARA and FACTIVE are made to pharmaceutical wholesalers for further distribution through pharmacies to the ultimate consumers of the product. When the Company delivers its product, the Company reduces the amount of gross revenue recognized from such product sales based primarily on estimates of four categories of discounts and allowances that suggest that all or part of the revenue should not be recognized at the time of the delivery product returns, cash discounts, rebates, and special promotional programs.

Product Returns

Factors that are considered in the Company's estimate of future ANTARA and FACTIVE product returns include an analysis of the amount of product in the wholesaler and pharmacy channel, review of consumer consumption data as reported by external information management companies, actual and historical return rates for expired lots, the remaining time to expiration of the product, and the forecast of future sales of the Company's product. Consistent with industry practice, the Company offers contractual return rights that allow its customers to return product within six months prior to, and twelve months subsequent to, the expiration date of its product. ANTARA capsules and FACTIVE tablets each have a 36-month expiration period from the date of manufacturing. As of December 31, 2008 and 2007, the Company's product return reserve was approximately \$4,687,000 and \$3,169,000, respectively. This reserve is evaluated on a quarterly basis, assessing each of the factors described above, and adjusted accordingly. Based on the factors noted above, the Company believes its estimate of product returns is reasonable, and changes, if any, from this estimate would not have a material impact to the Company's financial statements.

Cash Discounts

The Company's standard invoice includes a contractual 2% cash discount, for payments within 30 days. Based on historical experience, the Company estimates that most of its customers deduct a 2% discount from their balance. The cash discount reserve is presented as an allowance against trade receivables in the accompanying consolidated balance sheets. As of December 31, 2008 and 2007, the balance of the cash discounts reserve was approximately \$331,000 and \$343,000, respectively.

Rebates

The liability for commercial managed care rebates is calculated based on historical and current rebate redemption and utilization rates with respect to each commercial contract. The liability for Medicaid rebates is calculated based on historical and current rebate redemption and utilization rates contractually submitted by each state. As of December 31, 2008 and 2007, the balance of the accrual for managed care and Medicaid rebates for ANTARA and FACTIVE in total was approximately \$5,917,000 and \$4,263,000, respectively. Considering the estimates made by the Company, as well as estimates reflected in third party utilization reports that are used in evaluating the required liability balance, the Company believes its estimates are reasonable.

Special Promotional Programs:

The Company, from time to time, offers certain promotional incentives to its customers for both ANTARA and FACTIVE and will continue this practice in the future. Such programs include: sample cards to retail consumers, certain product incentives to pharmacy customers, and other sales stocking allowances. The

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

Company accounts for these programs in accordance with EITF No. 01-09, *Accounting for Consideration Given by a Vendor to a Customer* (EITF No. 01-09). Examples of programs utilized to date are as follows:

Voucher Rebate Programs for ANTARA

Since acquiring ANTARA in August 2006, the Company has initiated four voucher rebate programs for ANTARA whereby the Company offered a point-of-sale rebate to retail consumers. The liabilities the Company recorded for these voucher rebate programs were estimated based upon the historical rebate redemption rates for similar completed programs by other pharmaceutical companies as reported to the Company by a third party claims processing organization and actual redemption rates on completed programs by the Company. The first program expired on December 31, 2006, the second program expired on September 30, 2007, the third program expires on February 28, 2009 and the fourth program expires on March 31, 2010. As of December 31, 2008 and 2007, the balance of the liabilities for these voucher programs totaled approximately \$2,131,000 and \$491,000, respectively.

Voucher Rebate Programs for FACTIVE

The Company periodically initiates voucher rebate programs for FACTIVE whereby the Company offers mail-in rebates and point-of-sale rebates to retail consumers. The liabilities the Company records for these voucher rebate programs are estimated based upon the historical rebate redemption rates for similar completed programs. In April 2007, the Company initiated a voucher rebate program whereby the Company offered a point-of-sale rebate to retail consumers. This program expired on December 31, 2007. In October 2007, the Company initiated another voucher rebated program whereby the Company offered a point-of-sale rebate to retail consumers. This program expired on April 30, 2008. In April 2008 and July 2008, the Company initiated additional voucher rebate programs whereby the Company offered a point-of-sale rebate to retail consumers. These programs expired or expire on October 15, 2008 and April 15, 2009, respectively. As of December 31, 2008 and 2007, the balance of the liabilities for these voucher programs totaled approximately \$1,978,000 and \$1,396,000, respectively.

(d) Cash, Cash Equivalents and Marketable Securities

The Company applies the provisions of the Statement of Financial Accounting Standards (SFAS) No. 115, *Accounting for Certain Investments in Debt and Equity Securities* (SFAS No. 115). At December 31, 2008 and 2007, the Company held cash and cash equivalents. Cash equivalents are short-term, highly liquid investments with original maturities of 90 days or less. Cash equivalents are carried at cost, which approximates fair value. At December 31, 2008 and 2007, cash and cash equivalents consisted of money market funds. At December 31, 2008 and 2007, the Company did not hold investments, and as a result, had no net unrealized loss. The fair value of the Company's cash equivalents is determined based on market value.

(e) Accounts Receivable

Trade accounts receivable consists of amounts due from wholesalers for the purchase of ANTARA and FACTIVE. Accounts receivable related to sales of FACTIVE are the accounts receivable of the Company and accounts receivable related to sales of ANTARA are the accounts receivable of Guardian II Acquisition Corporation (Guardian II) (the entity which holds all of the ANTARA assets), a wholly-owned subsidiary of the Company. Guardian II granted Paul Royalty Fund Holdings II, LP (Paul Capital), an affiliate of Paul Capital Partners, a first security interest and the holders of the 12.50% Notes a second security interest in substantially all of its assets, including its accounts receivable, to secure these obligations. See Note 11.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

The Company performs ongoing credit evaluations on its customers and collateral is generally not required. As of December 31, 2008 and 2007, the Company reserved approximately \$33,000 and \$35,000, respectively, for bad debts related to the sale of ANTARA or FACTIVE. The Company continuously reviews all customer accounts to determine if an allowance for uncollectible accounts is necessary. The Company currently provides substantially all of its distributors with payment terms of up to 30 days on purchases of ANTARA and FACTIVE. Amounts past due from customers are determined based on contractual payment terms. Through December 31, 2008, payments have generally been made in a timely manner and the Company has not written off any customer accounts receivable balances.

The following table represents accounts receivable (in thousands):

	December 31,	
	2008	2007
Trade, net	\$ 17,042	\$ 14,950
Other	560	82
Total	\$ 17,602	\$ 15,032

(f) Restricted Cash

At December 31, 2008, approximately \$3,697,000 of cash is restricted in connection with a letter of credit issued for the building lease at the Company's South San Francisco, California facility, approximately \$433,000 of cash is restricted in connection with a letter of credit issued for the building lease at the Company's Waltham, Massachusetts facility, \$400,000 of cash is restricted in connection with a letter of credit issued to a credit card company and approximately \$68,000 of cash is restricted in connection with a letter of credit issued for the building lease at the Company's Skillman, New Jersey facility. The restriction related to the credit card company expires on October 2, 2009. The Company expects to extend this cash restriction beyond this date. The restrictions related to the South San Francisco facility, the Waltham facility and the Skillman facility expire on February 28, 2011, March 31, 2012 and February 2013, respectively.

(g) Property and Equipment

The Company records property and equipment at cost. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred. The Company depreciates its property and equipment over the estimated useful life of the assets using the straight-line method starting when the asset is placed in service. The estimated useful life for leasehold improvements is the term of the lease (which is lesser than the useful life of the assets).

	Estimated Useful Life
Manufacturing and computer equipment	3-5 Years
Equipment and furniture	3-5 Years
Leasehold improvements	7 Years

As of December 31, 2008 and 2007, the Company recorded approximately \$338,000 and \$188,000, respectively, as a capital lease obligation with accumulated depreciation of \$84,000 and \$47,000, respectively. The related asset is being depreciated using the straight-line method over the term of the lease and is being classified as computer equipment in the accompanying consolidated balance sheets.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

Depreciation expense was approximately \$377,000, \$738,000 and \$781,000 for the fiscal years ended December 31, 2008, 2007 and 2006, respectively.

(h) Inventories

Inventories are stated at the lower of cost or market value, with cost determined under the average cost method which approximates actual cost. Products are removed from inventory on a first-in-first-out basis and recognized as cost of goods sold on an average cost basis which approximates actual cost.

On a quarterly basis, the Company analyzes inventory levels, and provides a reserve for inventory and marketing samples that have become obsolete, have a cost basis in excess of their expected net realizable value or are in excess of forecast requirements to cost of product revenues and marketing expense, respectively. During 2007, approximately \$1,204,000 of ANTARA inventory obtained in the product acquisition became obsolete and was expensed. Expired inventory is disposed of and the related costs are written off against the previously established reserves.

At December 31, 2008 and 2007, there was approximately \$592,000 and \$1,088,000 in ANTARA sample product to be used for ANTARA marketing programs and approximately \$1,191,000 and \$655,000 in FACTIVE sample product to be used for FACTIVE marketing programs. These are classified as other current assets in the accompanying consolidated balance sheets.

The following table represents net trade inventories (in thousands):

	As of December 31	
	2008	2007
Raw material	\$ 2,041	\$ 2,846
Work-in-process	1,766	3,022
Finished goods	3,893	3,191
Total	\$ 7,700	\$ 9,059

(i) Net Loss Per Share

Basic and diluted net loss per share was determined by dividing net loss by the weighted average shares outstanding during the period. Diluted loss per share is the same as basic loss per share for all periods presented, as the effect of the potential common stock is anti-dilutive.

Anti-dilutive common stock equivalents which consist of stock options, securities sold under the Company's employee stock purchase plan, convertible notes, warrants and unvested restricted stock that are not included in diluted net loss per share totaled 83,418,510, 20,447,015, and 6,316,089 shares (prior to the application of the treasury stock method and the if-converted method) during the years ended December 31, 2008, 2007 and 2006, respectively.

(j) Single Source Suppliers**ANTARA**

Pursuant to the Company's license arrangement with Ethypharm, Ethypharm is responsible for the manufacture and supply of ANTARA finished product or ANTARA bulk product at the Company's option. The disruption or termination of the supply of ANTARA by Ethypharm or its third party contractors could have a material adverse effect on the Company's business, financial position and results of operations.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)***FACTIVE*

The Company currently obtains the active pharmaceutical ingredient (API) for its commercial requirements for FACTIVE from LG Life Sciences. The Company purchases the API pursuant to a long-term supply agreement. The disruption or termination of the supply of the commercial requirement for FACTIVE or a significant increase in the cost of the API from this source could have a material adverse effect on the Company's business, financial position and results of operations.

(k) Concentration of Credit Risk

SFAS No. 105, Disclosure of Information about Financial Instruments with Off-Balance-Sheet Risk and Financial Instruments with Concentrations of Credit Risk, (SFAS No. 105) requires disclosure of any significant off-balance-sheet and credit risk concentrations. The Company has no off-balance-sheet or credit risk concentrations such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains its cash and cash equivalents balances with several unaffiliated institutions.

The following table summarizes the number of customers that individually comprise greater than 10% of total revenues and their aggregate percentage of the Company's total product revenues:

Year-Ended December 31,	Number of Significant Customers	Percentage of Total Product Revenues by Customer		
		A	B	C
2008	3	32%	41%	19%
2007	3	36%	38%	15%
2006	3	41%	32%	12%

The following table summarizes the number of customers that individually comprise greater than 10% of total accounts receivable and their aggregate percentage of the Company's total trade accounts receivable:

As of December 31,	Number of Significant Customers	Percentage of Total Trade Accounts Receivable by Customer		
		A	B	C
2008	3	31%	32%	30%
2007	3	45%	34%	12%

To date, the Company has not written off any significant customer receivable balances.

(l) Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates include the following: reserves for inventory obsolescence, rebate reserves, special promotional programs reserves, product returns reserves, the valuation of derivatives and the useful lives, expected future cash flows for intangible assets and impairment analysis.

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

(m) Financial Instruments

The estimated fair value of the Company's financial instruments, including cash, cash equivalents and accounts receivable, approximates the carrying values of these instruments.

In connection with financing the acquisition of ANTARA, the Company recognized an embedded derivative instrument related to a put/call liability. In connection with the convertible notes issued in 2007, the Company recognized an embedded derivative instrument related to an interest make-whole provision. In connection with the convertible notes issued in 2008, the Company recognized an embedded derivative related to the conversion option and an interest make-whole provision. These instruments are recognized in the accompanying consolidated financial statements at fair value and are recorded as accrued expenses and other current liabilities in the accompanying consolidated balance sheets. Changes in fair value are recorded in the accompanying consolidated statements of operations. See Note 11.

In connection with the Amendment of the Revenue Interest Assignment disclosed in Note 11, the Company is committed to make milestone payments based on certain contingent events occurring. These contingent payments are considered financial instruments and recognized in the accompanying financial statements at fair value.

(n) Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs were approximately \$2,607,000, \$2,735,000 and \$3,260,000 for the fiscal years ended December 31, 2008, 2007 and 2006, respectively.

(o) Comprehensive Loss

The Company follows the provisions of SFAS No. 130, *Reporting Comprehensive Income* (SFAS No. 130). SFAS No. 130 requires disclosure of all components of comprehensive loss on an annual and interim basis. Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. In 2008, 2007 and 2006, the net loss, is equal to the comprehensive net loss.

(p) Segment Reporting

The Company follows the provisions of SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information* (SFAS No. 131). SFAS No. 131 establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. SFAS No. 131 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions as to how to allocate resources and assess performance. The Company's chief decision makers, as defined under SFAS No. 131, are the chief executive officer and the chief financial officer. All of the Company's assets are located in the United States. Approximately 98% of the Company's product revenues are generated from customers based in the United States.

The Company believes it operates in one segment called *Pharmaceutical*. Product sales and the financial information disclosed herein represent all of the material financial information related to the Company's one operating segment.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

Sales by product within the Company's operating segment are as follows:

	Year- Ended December 31,		
	2008	2007	2006
ANTARA	\$ 70,330	\$ 58,571	\$ 16,778
FACTIVE	15,995	19,887	21,466
Total Product Sales	\$ 86,325	\$ 78,458	\$ 38,244

(q) Long-Lived Assets

The Company follows the provisions of SFAS No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets* (SFAS No. 144). Under SFAS No. 144, long-lived assets and identifiable intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, recoverability of assets to be held and used is assessed by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating the undiscounted cash flows are each done at the lowest possible level for which there are identifiable assets. If the aggregate undiscounted cash flows are less than the carrying value of the asset, then the resulting impairment charge to be recorded is calculated based on the amount by which the carrying amount of the asset exceeds its fair value. Any write-downs are recorded as permanent reductions in the carrying amount of the asset.

During the fourth quarter of 2008, events and circumstances, primarily a significant reduction in projected worldwide long-term revenues and the associated cash flows indicated that the ANTARA and FACTIVE intangible assets could be impaired. The decrease in forecasted long-term revenues and cash flows was related to the planned reduction in the sales force, the receipt of the Paragraph IV Notice from Lupin Limited (as described in Note 10 (c)) and the overall economic and regulatory conditions and developments in the United States and abroad. The Company's estimate of undiscounted cash flows performed during the quarter ended December 31, 2008 indicated that the carrying amount of the ANTARA intangible assets are expected to be recovered and therefore the intangible assets are not impaired. The Company's estimate of undiscounted cash flows performed during the quarter ended December 31, 2008 indicated that the carrying amount of the FACTIVE intangible assets are not expected to be recovered and therefore the assets are impaired. The estimate of undiscounted cash flows is based upon several significant assumptions including, but not limited to, estimated worldwide sales levels, forecasted size of the Company's sales force and strategic plans to control costs, including a significant reduction of the Company's sales force. The Company calculated the fair value of the FACTIVE intangible assets by using a relief from royalty method. The relief from royalty method is based on the assumption that, in lieu of ownership of an intangible asset, a company would be willing to pay a royalty in order to enjoy the benefits of the asset. Under this method, fair value is estimated by discounting the hypothetical royalty payments to their present value over the economic life of the assets. The Company has recorded a non-cash impairment charge of approximately \$50,759,000 in the accompanying consolidated statements of operations for the year ended December 31, 2008 in order to write-down the FACTIVE intangible assets to fair value.

The Company also follows the provisions of SFAS No. 142, *Goodwill and Other Intangible Assets*, (SFAS No. 142). Under SFAS No. 142, goodwill and purchased intangible assets with indefinite lives are not amortized but are reviewed periodically for impairment. The Company performs an annual evaluation of goodwill at the end of each fiscal year to test for impairment or more frequently if events or circumstances indicate that goodwill may be impaired. Because the Company has a single operating segment, which is its sole reporting unit, the Company performs this test by comparing the fair value of the entity with its book value,

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

including goodwill. If the fair value exceeds the book value, goodwill is not impaired. If the book value exceeds the fair value, then the Company would calculate the potential impairment loss by comparing the implied fair value of goodwill with the book value. If the implied fair value of goodwill is less than the book value, then an impairment charge would be recorded. Because the book value of the Company, as represented by stockholders' deficit, is negative as of December 31, 2008, the Company does not believe that any of its goodwill is impaired.

(s) Stock-Based Compensation

Effective January 1, 2006, the Company adopted SFAS No. 123 (Revised 2004), Share-Based Payment (SFAS No. 123R) using the modified prospective transition method. SFAS No. 123R requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. Under the modified prospective transition method, compensation cost recognized during the year ended December 31, 2006 includes (1) compensation cost for all share-based payments granted prior to, but not vested as of December 31, 2005, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, Accounting for Stock-Based Compensation (SFAS No. 123), and (2) compensation cost for all share-based payments granted subsequent to December 31, 2005, based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123R. Such amounts have been reduced by an estimate of forfeitures on all unvested awards. Stock-based compensation expense primarily relates to stock options, restricted stock, and stock issued under the Company's employee stock purchase plan.

The compensation expense under SFAS No. 123R is recorded in cost of product sales, research and development expense, selling and marketing expense, and general and administrative expense based on the specific allocation of employees receiving the equity awards. Additionally, the Company eliminated the January 1, 2006 deferred compensation balance against additional paid-in capital upon adoption of SFAS No. 123R.

The fair value of each option award is estimated on the grant date using the Black-Scholes-Merton option-pricing model based on the assumptions noted in the following table:

	Year Ended December 31,					
	2008		2007		2006	
Expected volatility	60.86	71.66%	60.03	61.77%	52.14	62.18%
Risk-free interest rate	1.71	3.61%	3.77	5.04%	4.35	5.07%
Expected life (years)	5.59	5.84	5.55	6.17	5.55	6.25
Expected dividend						

Expected volatility is determined based on historical volatility data of the Company's common stock from the period of time beginning with the Company's merger with GeneSoft in February 2004 and other factors through the month of grant. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The expected life of the stock options granted was estimated based on the historical exercise patterns over the option lives while considering employee exercise strategy and cancellation behavior. The Company has not paid and does not anticipate paying cash dividends; therefore, the expected dividend yield is assumed to be 0%.

The total compensation cost that has been charged to income for the years ended December 31, 2008, 2007 and 2006 was approximately \$1,324,000, \$2,713,000 and \$3,876,000, respectively. The Company's policy is to recognize compensation cost for awards with service conditions and graded vesting using the straight-line

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

method. Additionally, the Company's policy is to issue authorized but previously unissued shares to satisfy share option exercises, the issuance of restricted stock and stock issued under the Employee Stock Purchase Plan (ESPP). The amount of stock-based compensation recognized during a period is based on the fair value of the portion of the awards that are ultimately expected to vest. In addition, the requisite service period is generally equal to the vesting term. SFAS No. 123R requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term forfeitures is distinct from cancellations or expirations and represents only the unvested portion of the surrendered option. The Company estimates forfeitures based on historical data, adjusted for known trends. The Company has applied an annual forfeiture rate of 21.39% to options in calculating total recognized compensation cost as of December 31, 2008. This analysis is re-evaluated annually and the forfeiture rate will be adjusted as necessary. Ultimately, the actual expense recognized over the vesting period will only be for those shares that vest.

Using the Black-Scholes-Merton option-pricing model, the weighted average grant date fair values of options granted during the years ended December 31, 2008, 2007 and 2006 were \$1.03, \$2.46 and \$7.36, respectively. For the year ended December 31, 2008, the Company granted 648,426 stock options with a weighted average exercise price of \$1.77. For the year ended December 31, 2007, the Company granted 605,661 stock options with a weighted average exercise price of \$4.17. For the year ended December 31, 2006, the Company granted 243,644 stock options with a weighted average exercise price of \$13.49. During the years ended December 31, 2008, 2007 and 2006, the total intrinsic value of options exercised was \$0, \$120,000 and \$754,000, respectively. The total amount of cash received from exercise of these options during the years ended December 31, 2008, 2007 and 2006 was \$0, \$17,000 and \$166,000, respectively.

The 2001 Incentive Plan also provides for awards of nontransferable shares of restricted common stock which are subject to forfeiture. All shares of restricted stock vest based on service conditions in two equal installments over a two-year period. Generally, the fair value of each restricted stock award is equal to the market price of the Company's stock at the date of grant. Certain restricted share awards provide for accelerated vesting if there is a change in control.

A summary of activity related to restricted stock under the Option Plans as of December 31, 2008, is indicated in the following table (in thousands, except weighted average data):

	Number of Shares	Weighted-Average Grant Date Fair Value
Nonvested at December 31, 2007	214	\$ 7.64
Granted	284	1.71
Vested	(128)	0.53
Forfeited	(66)	3.00
Nonvested at December 31, 2008	304	\$ 6.10

As of December 31, 2008, there is approximately \$1,967,000 of total unrecognized compensation cost related to unvested share based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 1.45 years. The Company expects approximately 484,000 unvested options to vest at some point in the future. Options expected to vest are calculated by applying an estimated forfeiture rate to the unvested options.

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

(t) Income Taxes

The Company applies SFAS No. 109, Accounting for Income Taxes (SFAS No. 109), which requires the Company to recognize deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. SFAS No. 109 requires deferred tax assets and liabilities to be adjusted when the tax rates or other provisions of the income tax laws change.

In accordance with the Financial Accounting Standards Board (FASB) Interpretation No. 48 Accounting for Uncertainty in Income Taxes and an Interpretation of FASB Statement No. 109 (the Interpretation) (FIN 48), the Company's historical practice was and will continue to be to recognize any interest and penalties related to unrecognized tax benefits in income tax expense. As of December 31, 2008, there were no unrecognized tax benefits, and as such, the Company has not recorded interest and penalties related to unrecognized tax benefits.

(u) Recent Accounting Pronouncements

Fair Value Measurement

In February 2008, the FASB issued FASB Staff Position No. SFAS 157-2, Effective Date of FASB Statement No. 157, which deferred the effective date of SFAS 157 for all non-financial assets and non-financial liabilities to fiscal years beginning after November 15, 2008. The implementation of SFAS 157 for financial assets and financial liabilities, effective for the Company on January 1, 2008, did not have a material effect on the Company's consolidated financial statements. The Company currently is evaluating the effect of SFAS 157 for non-financial assets and non-financial liabilities on the Company's consolidated financial statements.

In October 2008, the FASB issued FASB Staff Position No. SFAS 157-3, Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active, (FSP 157-3), to clarify the application of the provisions of SFAS 157 in an inactive market and how an entity would determine fair value in an inactive market. FSP 157-3 was effective upon issuance, including prior periods for which financial statements had not been issued. The implementation of FSP 157-3 did not have a material effect on the Company's consolidated financial statements.

Accounting for Convertible Debt Instruments that may be Settled Upon Conversion

In May 2008, the FASB issued Staff Position No. APB 14-1 Accounting for Convertible Debt Instruments that may be Settled in Cash Upon Conversion (FSP APB14-1). FSP APB 14-1 requires the issuer of certain convertible debt instruments that may be settled in cash (or other assets) on conversion to separately account for the liability and equity components of the instrument in a manner that reflects the issuer's nonconvertible debt borrowing rate. Further, FSP APB 14-1 clarifies the appropriate economics of the conversion options as borrowing costs and their potential dilutive effects in earnings per share. FSP APB 14-1 is effective for fiscal years beginning after December 15, 2008. The Company has not yet completed its evaluation of FSP APB 14-1, but does not currently believe that it will have a material impact on the results of operations, financial position or cash flows.

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133

In March 2008, the FASB issued FASB Statement No. 161, *Disclosures about Derivative Instruments and Hedging Activities* (SFAS No. 161). SFAS No. 161 requires entities to provide greater transparency about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133 *Accounting for Derivative Instruments and Hedging Activities* (SFAS No. 133) and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity's financial position, results of operations, and cash flows. SFAS No. 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. Management is in the process of studying the impact of this standard on the Company's financial accounting and reporting.

Business Combinations

In December 2007, the FASB issued Statement No. 141R, *Business Combinations* (SFAS No. 141R). SFAS No. 141R improves consistency and comparability of information about the nature and effect of a business combination by establishing principles and requirements for how an acquirer (a) recognizes and measures in its financial statements the identifiable assets acquired, liabilities assumed and any non-controlling interest in the acquiree; (b) recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and (c) determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS No. 141R applies prospectively to all business combination transactions for which the acquisition date is on or after January 1, 2009. The impact of the Company's adoption of SFAS No. 141R will depend upon the nature and terms of business combinations, if any, that it consummates on or after January 1, 2009.

Accounting for Collaborative Arrangements

In November 2007, EITF issued EITF Issue No. 07-01 *Accounting for Collaborative Arrangements* (EITF No. 07-01). EITF No. 07-01 requires collaborators to present the results of activities for which they act as the principal on a gross basis and report any payments received from (made to) other collaborators based on other applicable generally accepted accounting principles (GAAP) or, in the absence of other applicable GAAP, based on analogy to authoritative accounting literature or a reasonable, rational, and consistently applied accounting policy election. Further, EITF No. 07-01 clarified that the determination of whether transactions within a collaborative arrangement are part of a vendor-customer (or analogous) relationship subject to Issue No. 01-09, *Accounting for Consideration Given by a Vendor to a Customer*. EITF No. 07-01 is effective for fiscal years beginning after December 15, 2008. The Company has not yet completed its evaluation of EITF No. 07-01, but does not currently believe that it will have a material impact on the results of operations, financial position or cash flows.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****(3) Acquisition of ANTARA**

On August 18, 2006, the Company acquired the rights to ANTARA in the United States from Reliant Pharmaceuticals in a transaction accounted for as an acquisition of a business in accordance with SFAS No. 141, Business Combinations (SFAS No. 141) and accordingly, allocated the purchase price of ANTARA based upon the estimated fair value of net assets acquired and liabilities assumed. The Company performed a valuation study to determine the allocation of the purchase price of the ANTARA acquisition among the tangible and intangible assets acquired as well as their estimated amortization period. The estimated useful life of the intangible assets is assumed to be fourteen years which was based upon the remaining life of the patents covering ANTARA, the regulatory barriers to competition, and management's knowledge of existing competitors research activities. The Company completed an analysis of the fair values of the liabilities assumed in connection with the acquisition, including certain liabilities that qualify for recognition under EITF No. 95-3 Recognition of Liabilities in Connection with a Purchase Business Combination (EITF No. 95-3). ANTARA's operations, assumed as of the date of acquisition, are included in the Company's results of operations beginning on August 18, 2006.

The following is a summary of the Company's estimate of the fair values of the assets acquired and liabilities assumed at the date of acquisition (in thousands):

Estimate of the allocation of purchase price:	
Inventories	\$ 4,344
Prepaid expenses	2,656
Intangible assets	60,780
Goodwill	16,783
Total assets acquired	84,563
Liabilities assumed	(1,427)
Net assets acquired	\$ 83,136
Consideration and direct transaction costs:	
Cash	\$ 82,376
Direct transaction costs	760
Total purchase price	\$ 83,136

The following table presents the estimate of the fair value of the intangible assets acquired, their estimated useful lives and amortization expense (in thousands, except estimated useful lives data):

Intangible assets	Fair value of intangibles	Estimated life (in years)	Amortization for the year ended December 31, 2008
License Agreement	\$ 58,900	14	\$ 4,207
Manufacturing Relationship	1,880	14	134
Total	\$ 60,780		\$ 4,341

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

The valuation of the purchased intangible assets of \$60,780,000 was based on the result of a valuation using the income approach and applying a weighted average cost of capital of 17%. On an ongoing basis, the Company will evaluate the useful life of these intangible assets and determine if any competitive, governmental or regulatory event has impaired the value of the assets or modified their estimated useful lives.

F-24

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****(4) Reverse Stock Split**

Pursuant to an Amendment to the amended and restated articles of organization, the Company effectuated on November 15, 2006, a one-for-eight reverse stock split of its issued and outstanding common stock, par value \$0.10 per share and maintained the number of authorized shares of its common stock at 175,000,000. As a result of the reverse stock split, each eight shares of common stock issued and outstanding as of November 15, 2006 at the close of business, were automatically combined into and became one share of common stock. In cases in which the reverse stock split results in any shareholder holding a fraction of a share, such fractional share was rounded up to the nearest whole number.

Immediately after giving effect to the reverse stock split, the Company had approximately 13,552,125 shares of common stock outstanding (without giving effect to rounding due to fractional shares). The reverse stock split did not change the number of authorized shares of common stock, alter the par value of the common stock or modify any voting rights or other terms of the common stock. As a result of the reverse stock split, the per share exercise price of, and the number of shares of common stock underlying, Company stock options and warrants outstanding immediately prior were automatically proportionally adjusted, based on the one-for-eight reverse stock split ratio, in accordance with the terms of such options or warrants, as the case may be. All share and per share information in these consolidated financial statements have been retroactively restated to reflect the reverse stock split.

(5) Facility Lease Liability

At the time of merger with GeneSoft Pharmaceuticals (GeneSoft) in 2004, management approved a plan to integrate certain GeneSoft facilities into existing operations. In connection with the integration activities, the Company included in the purchase price allocation a restructuring liability of approximately \$18,306,000, which included \$1,419,000 in severance-related costs and \$16,887,000 in facility lease impairment costs pertaining to 68,000 square feet of leased space which expires on February 28, 2011. In 2008 and 2007, in accordance with EITF No. 95-3, the Company made adjustments to the facilities lease liability based on revisions made to estimates of future rental income related to additional subleased space of approximately \$1,552,000 and \$838,000, respectively. These adjustments were recorded as a reduction to goodwill.

The following tables summarize the restructuring liability activity recorded related to the GeneSoft merger (in thousands):

	Year Ended December 31, 2008				Balance at December 31, 2008
	Balance at December 31, 2007	Liability Adjustment	Net Cash Payments	Interest Accretion	
Assumed facility lease liability	\$ 10,959	\$ (1,552)	\$ (2,390)	\$ 390	\$ 7,407

	Year Ended December 31, 2007				Balance at December 31, 2007
	Balance at December 31, 2006	Liability Adjustment	Net Cash Payments	Interest Accretion	
Assumed facility lease liability	\$ 13,900	\$ (838)	\$ (2,618)	\$ 515	\$ 10,959

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

(6) Fair Value Measurements

In September 2006, the FASB issued SFAS No. 157, *Fair Value Measurements* (SFAS No. 157). SFAS No. 157 defines fair value, establishes a framework for measuring fair value in accordance with GAAP and expands disclosures about fair value measurements. SFAS No. 157 codifies the definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, clarifies the principle that fair value should be based on the assumptions market participants would use when pricing the asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007 and interim periods within those years. The Company adopted SFAS No. 157 on January 1, 2008. The three levels of the fair value hierarchy under SFAS No. 157 are described below:

Level 1 Relates to observable inputs such as quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2 Relates to other inputs that are observable, directly or indirectly, such as quoted prices for similar assets and liabilities or market corroborated inputs.

Level 3 Relates to unobservable inputs used when little or no market data is available and requires the Company to develop its own assumptions about how market participants would price the assets or liabilities. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The primary objective of the Company's investment activities is to preserve principal and fulfill liquidity needs while at the same time maximizing the income the Company receives from the Company's investments without significantly increasing risk. To achieve this objective, the Company maintains the majority of its portfolio of cash equivalents in money market funds to maximize investment income and minimize investment risk. As December 31, 2008, the Company believes that its cash equivalents reflect the carrying value which is not subject to any loss or write-down.

As of December 31, 2008, the Company's cash equivalents were classified as Level 1 assets where inputs are quotes in active markets for identical assets that the Company has the ability to assess on the measurement date. An active market for the Company's cash equivalents is available in which transactions occur with sufficient frequency and volume which provide pricing information on an ongoing basis.

For derivative liabilities that use Level 2 inputs, the Company utilizes information obtained directly from observable market inputs which include the Company's stock price, volatility, and market value of debt and risk free interest rate. For the year ended December 31, 2008, the Company has recorded approximately \$10,147,000 as a gain on derivative liabilities that use Level 2 inputs. For derivative liabilities that use Level 3 inputs, the Company developed its own assumptions and decision point related to a put/call premium that does not have any observable inputs or available market data to support the fair value. For the year ended December 31, 2008, the Company has recorded approximately \$333,000 as a gain on derivative liabilities that use Level 3 inputs. Both of these are recorded as gains in the accompanying consolidated statements of operations.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

The following table represents, by level within the fair value hierarchy, a summary of the fair market value of assets and liabilities the Company held as of December 31, 2008:

December 31, 2008	Level 1	Level 2	Level 3	Total
Assets:				
Cash equivalents	\$ 8,101,000	\$	\$	\$ 8,101,000
Liabilities:				
Derivative liabilities	\$	\$ 2,370,000	\$ 653,000	\$ 3,023,000

The reconciliation of the Company's liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:

	Derivative Liability
Balance at January 1, 2008	\$ 986,000
Gain on derivative	(333,000)
Balance at December 31, 2008	\$ 653,000

(7) Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following (in thousands):

	December 31,	
	2008	2007
Goodwill	\$ 75,408	\$ 76,960
License Agreements, net	49,436	105,285
Manufacturing Relationships, net	1,600	5,618
Total	\$ 126,444	\$ 187,863

(a) Goodwill

The Company's goodwill relates to the merger with GeneSoft, which occurred in February 2004 and totaled approximately \$62,495,000, and the product acquisition of ANTARA, which occurred in August 2006 and totaled approximately \$16,783,000. During 2008 and 2007, the Company recorded a reduction to goodwill associated with GeneSoft of approximately \$1,552,000 and \$838,000, respectively, primarily related to additional sublease income related to a facility lease liability. During 2007, the Company recorded a reduction to goodwill associated with the product acquisition of ANTARA of approximately \$395,000 primarily related to reductions in accruals originally recorded during the acquisition and subsequently reversed. As of December 31, 2008, the Company does not believe that its goodwill is impaired. No amount of the goodwill balance at December 31, 2008 will be deductible for income tax purposes.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****(b) Intangible Assets**

As of December 31, 2008, intangible assets consist of the following (in thousands):

Asset Classification	Cost	Accumulated Amortization	Net
License Agreements	\$ 59,411	\$ (9,975)	\$ 49,436
Manufacturing Relationships	1,918	(318)	1,600
Total	\$ 61,329	\$ (10,293)	\$ 51,036

The ANTARA and FACTIVE intangible assets are amortized on a straight-line basis over the remaining legal life of the underlying patents of approximately 14.0 and 15.7, years respectively, which also corresponds to the estimated useful life of such assets. The weighted average amortization period for the license agreements is approximately 14.9 years and the weighted average amortization period for the manufacturing relationships is approximately 15.2 years, respectively. During 2008, 2007 and 2006, the Company recorded approximately \$9,108,000, \$9,108,000 and \$6,376,000 of amortization expense, respectively. As discussed in Note 2, during the year ended December 31, 2008, the Company recorded an impairment charge of \$50,759,000 on the intangible assets of FACTIVE. The remaining value of \$549,000 will be amortized on a straight-line basis over 10.75 years.

The remaining amortization in future periods is as follows (in thousands):

Year-Ending December 31,	
2009	\$ 4,393
2010	\$ 4,393
2011	\$ 4,393
2012	\$ 4,393
2013	\$ 4,393
Thereafter	\$ 29,071
Total	\$ 51,036

(8) Notes Receivable

In connection with a lease agreement associated with vehicles for the Company's sales representatives, the Company was issued notes by the lessor totaling approximately \$2,926,000 related to the repayment of security deposits made by the Company. The notes bear interest at rates ranging from 5.5% to 7.75% and have expiration dates ranging from February 2008 to November 2008. Principal and interest are repaid by the lessor to the Company over the 36 month lease term as lease payments are made on the vehicles. There was no balance remaining on these notes receivable as of December 31, 2008.

(9) Income Taxes

The Company applies SFAS No. 109, Accounting for Income Taxes (SFAS No. 109), which requires the Company to recognize deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is recorded

when it is more likely than not that the deferred tax asset will not be recovered.

F-28

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

The Company's income tax expense of approximately \$420,000, \$384,000 and \$179,000 for the years ended December 31, 2008, 2007 and 2006, respectively, is comprised of deferred federal and state taxes related to the tax effects of the Company's indefinite lived intangible asset that cannot be offset against the Company's deferred tax assets. This resulted from the ANTARA asset acquisition whereby the goodwill is tax deductible. Therefore, the corresponding tax amortization expense generates a deferred tax liability without the ability to recognize an equal amount of deferred tax asset due to the determination that a valuation allowance is required on all of the Company's gross deferred tax assets.

The Company's income tax provision (benefit) as of the years ended December 31, 2008, 2007 and 2006 differed from the expected US federal statutory income tax rate as set forth below (in thousands):

	December 31, 2008	December 31, 2007	December 31, 2006
Expected federal tax expense	\$ (21,874)	\$ (10,019)	\$ (26,621)
Permanent differences	423	898	1,766
State taxes, net of federal benefit	(2,973)	(1,428)	(3,627)
Tax Credits		(500)	2,252
Expiring net operating losses	194	2,165	843
Change in valuation allowance	24,650	9,268	25,566
Income tax expense	\$ 420	\$ 384	\$ 179

The components of the Company's net deferred tax asset at the respective dates are as follows (in thousands):

	December 31,	
	2008	2007
Net operating loss carryforwards	\$ 4,494	\$ 153,368
Research and development and other credits	161	12,648
Capitalized research and development costs	5,508	6,401
Depreciation	1,044	1,071
Facility impairment liability related to merger	2,847	4,213
Sale reserves and allowances	6,294	4,269
Intangible assets acquired at merger	(1,569)	(22,237)
Other intangibles	(661)	(352)
Advanced payments	15,378	15,378
Deferred revenue	1,509	
Deferred compensation	2,962	2,620
Accrued expenses	1,867	4,100
Other temporary differences	1,505	1,563
Net deferred tax asset	41,339	183,042
Valuation allowance	(42,322)	(183,605)
Net deferred tax liability	\$ (983)	\$ (563)

The valuation allowance has been provided due to the uncertainty surrounding the realization of the deferred tax assets. The valuation allowance decreased by approximately \$141,283,000 from December 31, 2007 to

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

December 31, 2008, primarily as a result of the reduction of net operating loss carryforwards and tax credits as a result of the limitations under Sections 382 and 383 of the Internal Revenue Code (IRC) and after the application of IRC Section 108 as described more fully below. The valuation allowance increased by approximately \$6,140,000 from December 31, 2006 to December 31, 2007, primarily due to an increase in net operating loss carryforwards.

At December 31, 2008, the Company had net operating loss carryforwards of approximately \$11,956,000 and \$7,149,000 available to reduce federal and state taxable income, respectively, if any. The federal net operating losses will begin to expire in 2027 and the state net operating losses will begin to expire in 2013. The Company does not have any net operating losses that are attributable to excess stock option deductions which would be recorded as an increase in additional paid in-capital. The Company also had research and development tax credit carryforwards of approximately \$244,000 to reduce state income tax, if any, which will expire in 2021. During 2008 in connection with the debt exchange completed on November 25, 2008 as described in Note 11, the Company experienced a greater than 50% ownership change as defined under IRC Sections 382 and 383. This limits the annual amount of net operating losses and tax credit carryforwards that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The net operating losses and tax credits that will expire unused in the future as a result of the Section 382 and 383 limitations which was applied after the application of Section 108 of the IRC as it related to the cancellation of indebtedness income resulting from the debt exchange, have been eliminated from the amounts disclosed herein as of December 31, 2008.

Effective January 1, 2007, the Company adopted the provisions of FASB Interpretation No. 48, *Accounting for Uncertainty in Income Taxes* (FIN 48). At December 31, 2008, the Company had \$18,042,000 of gross unrecognized tax benefits, with no effect to the effective tax rate, if recognized as a result of the Company's full valuation allowance against its deferred tax assets. At December 31, 2007, the Company had \$20,804,000 of gross unrecognized tax benefits, with no effect to the effective tax rate, if recognized as a result of the Company's full valuation allowance against its deferred tax assets. The gross unrecognized tax benefits decreased at December 31, 2008, as compared to December 31, 2007, due to the elimination of previously unrecognized tax benefits resulting from the current year IRC Section 383 limitation offset by an increase in new positions taken during the current period. A reconciliation of the beginning and ending amount of unrecognized tax benefits (which are not recorded as a liability in the statement of financial position because they are offset by net operating loss carryforwards with a full valuation allowance) are as follows (in thousands):

	2008	2007
Balance, January 1	\$ 20,804	\$ 20,804
Increases (decreases) for tax positions taken during a prior period	(3,404)	
Increases (decreases) for tax positions taken during the current period	642	
Decreases relating to settlements		
Decreases resulting from the expiration of the statute of limitations		
Balance, December 31	\$ 18,042	\$ 20,804

The Company files income tax returns in the United States federal jurisdiction and multiple state jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination for years before 2004, except to the extent that in the future it utilizes net operating losses or tax credit carryforwards that originated before 2004. The Company is currently not under examination by the Internal Revenue Service of other jurisdictions for any tax years.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

In accordance with FIN 48, the Company's practice was and continues to be to recognize any interest and penalties related to unrecognized tax benefits in income tax expense. The Company has not recorded any interest and penalties related to the unrecognized tax benefits as of December 31, 2008 and 2007.

It is reasonably possible that within the next twelve months, the Company's liability for unrecognized tax benefits could increase by approximately \$10,600,000 due primarily to additional accruals for continuance of filing positions taken in prior periods. However the increase is not anticipated to impact the Company's statement of operations or statement of financial position due to expected net operating losses and corresponding valuation allowance.

(10) Commitments and Contingencies**(a) Lease Commitments**

The Company's headquarters in Waltham, MA, consisting of approximately 36,000 square feet, is under an operating lease which expires on March 31, 2012 and includes an option to renew for an additional five years. The rent payments include lease escalation clauses. In addition, for the months of November and December in 2007 and 2006, total rental payments are abated by approximately \$131,000 and \$121,000, respectively. The rent differential related to the rent holidays and escalation provisions is accounted for as deferred rent.

The Company assumed a lease obligation in South San Francisco, California when it merged with GeneSoft. The leased space is approximately 68,000 square feet and the lease expires on February 28, 2011. Portions of the facility in South San Francisco, California had been subleased to third parties in 2008, 2007 and 2006.

In 2007, the Company moved its commercial sales and marketing office to Skillman, New Jersey. The Company's new commercial sales and marketing facility of approximately 10,000 square feet is under an operating lease, the term of which begins in early 2008 and expires on January 31, 2013. The rent payments under the Company's commercial sales and marketing facility lease include lease escalation clauses. In addition, for the first four months of the lease term, total rental payments are abated by approximately \$68,300. The rent differential related to the rent holidays and escalation provisions are accounted for as deferred rent.

The future minimum lease payments under the operating leases at December 31, 2008 are as follows (in thousands):

Year-Ending December 31,	Restructuring/Impaired Facility	Facility Leases
2009	\$ 4,677	\$ 1,143
2010	4,821	1,190
2011	807	1,195
2012		467
2013		112
Thereafter		
Total	\$ 10,305	\$ 4,107

Rent expense relating to the Company's facility leases in 2008, 2007, and 2006 amounted to approximately \$1,020,000, \$833,000 and \$833,000, respectively. Rent payments for facilities accounted for in the restructuring and facility impairment accruals amounted to \$4,519,000, \$4,366,000 and \$5,255,000 in 2008, 2007 and 2006,

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

respectively. Rental payments received from subleasing arrangements were approximately \$2,796,000, \$2,565,000 and \$3,922,000 in 2008, 2007, and 2006, respectively, and were accounted for as part of the Company's restructuring and impairment accruals.

(b) Employment Agreements

The Company has employment agreements with its executive officers and several key employees, which provide for bonuses, as defined, and severance benefits upon termination of employment, as defined.

(c) Litigation

On December 2, 2008, the Company and its licensor, Ethypharm, S.A. (Ethypharm) received notice of a Paragraph IV certification from Lupin Limited (Lupin), notifying the Company of the filing of an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market a generic version of ANTARA prior to the August 2020 expiration date of U.S. Patent No. 7,101,574 (the 574 Patent). The 574 Patent, which is owned by Ethypharm, exclusively licensed to Oscient and listed in the FDA Orange Book for ANTARA relates to pharmaceutical compositions containing fenofibrate and methods of preparing the same. Lupin's certification notice alleges that the 574 Patent is invalid and/or will not be infringed by Lupin's commercial manufacture, use or sale of the drug product described in Lupin's ANDA.

In response to the filing of Lupin's ANDA, on January 14, 2009, the Company, along with its wholly owned subsidiary Guardian II Acquisition Corporation and Ethypharm, filed a lawsuit in the United States District Court for the District of Maryland against Lupin and its subsidiary Lupin Pharmaceuticals, Inc. for infringement of the 574 Patent.

In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Lupin, FDA approval of Lupin's ANDA will be stayed until the earlier of thirty months from the date of receipt of the Paragraph IV certification notice, or the date of a District Court decision finding that the 574 Patent is either invalid, unenforceable or not infringed by the drug product which is the subject of Lupin's ANDA. If the litigation is still ongoing after thirty months, the termination of the stay could result in the introduction of one or more generic products to ANTARA prior to resolution of the litigation.

The Company is involved in other various legal matters, which arise in the ordinary course of business. The Company does not believe that the ultimate resolution of these other matters will have a material adverse effect on its financial condition, results of operations or cash flows.

(d) Other Contingencies

On May 30, 2008 the Company received notice of a Paragraph IV certification from Orchid Healthcare, a Division of Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), notifying it of the filing of an ANDA with the FDA for a generic version of FACTIVE. Orchid's notice sets forth allegations that eight of the nine FDA Orange Book listed patents are invalid and/or will not be infringed by Orchid's manufacture, importation, use, or sale of the product for which the ANDA was submitted. The notice does not, however, include a Paragraph IV certification with respect to U.S. Patent No. 5,633,262, which is also listed in the FDA Orange Book. Accordingly, the FDA cannot finally approve Orchid's ANDA until the expiry of U.S. Patent No. 5,633,262 in June 2015.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

The Company has not commenced a lawsuit against Orchid relating to these eight patents and is continuing to evaluate whether to commence litigation in response to Orchid's Paragraph IV certification. In the event Orchid elects to amend its ANDA to include a Paragraph IV certification with respect to the ninth patent, U.S. Patent No. 5,633,262, the Company believes that it will be entitled to an automatic thirty-month stay of FDA approval of the ANDA if either the Company and/or LG Life Sciences initiate a timely patent infringement lawsuit against Orchid, which could be a substantial cost and there are no assurances that it would be successful.

(11) Debt Obligations

Debt obligations consist of the following (in thousands):

	As of December 31,	
	2008	2007
12.50% Senior convertible guaranteed notes due 2011	\$ 112,424	\$
3.50% Senior convertible promissory notes due 2011, net of discount	10,796	179,508
3 1/2% Senior convertible promissory notes due 2011	829	829
5% Convertible promissory notes due 2009	13,300	13,300
Revenue interest assignment	39,229	39,129
12% Senior secured note	20,000	20,000
Capital lease	245	131
	196,823	252,897
Less current maturities of long-term debt	13,413	38
current debt obligations	183,278	
	\$ 132	\$ 252,859

(a) Convertible Notes

On February 6, 2004, the Company issued approximately \$22,310,000 in principal amount of 5% convertible five year promissory notes due February 2009 (the "5% Notes"). Following the exchange offer completed in May 2007 described below, there are approximately \$13,300,000 principal amount of the 5% Notes outstanding at December 31, 2008. As of December 31, 2008, the 5% Notes are convertible into the Company's common stock at the option of the holders, at a conversion price of \$53.13 per share. The maturity date of these notes was extended to December 1, 2009 and the conversion price was reduced to approximately \$1.10 effective on the date of the January 2009 Extension and Exchange offers that are discussed further in Note 22.

On June 26, 2004, the Company issued \$152,750,000 in principal amount of its 3 1/2% senior convertible promissory notes due in April 2011 (the "3 1/2% Notes"). Following the exchange offer completed in May 2007 described below, there are approximately \$829,000 principal amount of the 3 1/2% Notes outstanding at December 31, 2008. These notes are convertible into the Company's common stock at the option of the holders at a conversion price of \$53.14 per share. The Company may not redeem the outstanding 3 1/2% Notes at its election before May 10, 2010. After this date, the Company can redeem all or part of the 3 1/2% Notes for cash at a price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest. The holders' right of repurchase under the 3 1/2% Notes is identical to the right of repurchase under the 3.50% Notes (defined below) and is described below.

In May 2007, the Company completed (i) an exchange offer with certain holders of the 3 1/2% Notes in which the Company exchanged \$151,921,000 aggregate principal amount of its new 3.50% Convertible Senior

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

Notes due 2011 (the 3.50% Notes) for \$151,921,000 aggregate principal amount of its then outstanding 3 1/2% Notes; and (ii) an exchange offer with holders of the 5% Notes in which the Company exchanged approximately \$10,574,000 aggregate principal and accrued interest amount of its then outstanding 5% Notes for approximately \$13,746,000 aggregate principal amount of the 3.50% Notes. The Company also issued an additional \$60,000,000 of 3.50% Notes to the public for cash at a public offering price of 77.50% of principal, resulting in \$46,500,000 in gross proceeds to the Company.

The 3.50% Notes are initially convertible at a conversion price of approximately \$13.50 per common share. The 3.50% Notes are convertible at any time by the holder. In the event of a fundamental change, holders of the 3 1/2% Notes and the 3.50% Notes have the right to require the Company to repurchase all or any portion of their notes at a price equal to 100% of the principal amount plus accrued and unpaid interest. Under the indenture for the 3 1/2% Notes and the 3.50% Notes, a fundamental change will be deemed to occur if (i) a change of control transaction occurs in which substantially all of the Company's common stock is exchanged either for consideration other than common stock that is listed on a U.S. national securities exchange or is exchanged for consideration other than common stock that is approved for quotation on a U.S. system of automated dissemination of quotations of securities or (ii) the Company's common stock is neither listed for trading on a U.S. national securities exchange nor approved for listing on any U.S. system of automated dissemination of quotations of securities prices. In the event the Company's shares are delisted from the NASDAQ Global Market (as discussed in Note 1), this event may be considered a fundamental change and the holders of the 3 1/2% Notes and the 3.50% Notes would have the ability to demand the Company to repurchase the outstanding notes.

Before May 10, 2010, the Company may not redeem the 3.50% Notes. On or after May 10, 2010, the Company may redeem any or all of the 3.50% Notes at 100% of the principal amount, plus accrued and unpaid interest. In addition, the Company may automatically convert some or all of the 3.50% Notes on or prior to the maturity date if the closing price of its common shares has exceeded 130% of the conversion price then in effect for at least 20 trading days during any consecutive 30 trading day period ending within five trading days prior to the notice of auto-conversion (the auto-conversion feature). If a holder elects to voluntarily convert their 3.50% Notes or the Company elects to automatically convert some or all of the 3.50% Notes on or prior to May 10, 2010, the Company will pay additional interest to holders of 3.50% Notes being converted. This additional interest will be equal to the amount of interest that would have been payable on the 3.50% Notes from the last day interest was paid on the 3.50% Notes, through and including May 10, 2010. Additional interest, if any, will be paid in cash or in common shares of the Company, at the Company's option. If the Company pays additional interest upon a voluntary conversion with its common shares, such shares will be valued at the conversion price that is in effect at that time. If the Company pays additional interest upon an automatic conversion with its common shares, such shares will be valued at 90% of the automatic conversion price that is in effect at that time.

The Company has accounted for the 3.50% Notes in accordance with the guidance as set forth in EITF No. 96-19, Debtor's Accounting for a Modification or Exchange of Debt Instruments (EITF No. 96-19), SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, as amended (SFAS No. 133), EITF No. 05-7, Accounting for Modifications to Conversion Options Embedded in Debt Instruments and Related Issues (EITF No. 05-7), EITF No. 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock (EITF No. 00-19), EITF No. 05-02, Meaning of Conventional Convertible Debt Instrument (EITF No. 05-02) and EITF No. 01-6, The Meaning of Indexed to a Company's Own Stock (EITF No. 01-6), and determined that the exchange represents an extinguishment of existing debt rather than a modification. Accordingly, the Company recorded a gain of approximately \$30,824,000 upon the extinguishment of debt, which was a result of exchanging a majority of the 3 1/2% Notes and a portion of the 5% Notes that were issued at par value, for the 3.50% Notes that were issued at 77.50% of par (i.e. a 22.50%

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

discount). The gain arose due to the fact that the fair value of the 3 1/2% Notes exceeded that of the 3.50% Notes. The debt issuance costs related to the 3 1/2% Notes in the amount of approximately \$3,285,000 are netted against the gain.

The additional 3.50% Notes generated gross proceeds of \$46,500,000. Debt issuance costs, related to these notes, of approximately \$6,057,000 were being amortized to interest expense, on a straight-line basis over 48 months. After the 2008 Exchange Offer, discussed below, the Company wrote off deferred financing costs associated with the 3.50% Notes exchanged. There is approximately \$206,000 of deferred financing costs related to the 3.50% Notes remaining which will be amortized to interest expense on a straight-line basis over the remaining 30 months until the maturity of the notes.

On November 25, 2008, the Company completed its 2008 Exchange Offer (the 2008 Exchange Offer) in which the Company issued an aggregate principal amount of \$85,184,000 12.50% Convertible Guaranteed Senior Notes due 2011 (the 12.50% Notes) and 21,310,549 shares of the Company s common stock in exchange for \$212,979,000 in aggregate principal amount of the 3.50% Notes. The Company also issued \$2,000,000 of 12.50% Notes due 2011 to Paul Capital Partners as part of the Amendment to the Revenue Interest Assignment Agreement discussed below.

The 12.50% Notes will mature on January 15, 2011. Interest on the 12.50% Notes is payable at a rate of 12.50% per year, payable semiannually on April 15 and October 15 of each year, commencing April 15, 2009, except that the final interest payment date will be payable January 15, 2011. The Company may elect to pay interest on the 12.50% Notes in cash or by increasing the principal amount of the 12.50% Notes or by issuing additional 12.50% Notes in an amount equal to the amount of interest for the applicable interest payment period.

The 12.50% Notes are guaranteed by Guardian II and this guarantee is secured by a second priority lien on substantially all of the assets of Guardian II. The second priority lien is subject to the first priority lien on substantially all of the assets of Guardian II which is held by Paul Royalty Fund Holdings II, LP (Paul Capital), an affiliate of Paul Capital Partners, and secures the Company s and Guardian II s payment obligations to Paul Capital under the First Lien Obligations (as defined below).

The 12.50% Notes are convertible, at the option of the holder, at anytime on or prior to maturity, into shares of the Company s common stock at an initial conversion rate equal to a conversion price of approximately \$1.10 per share. If a holder of 12.50% Notes elects to voluntarily convert some or all of its 12.50% Notes on or prior to November 25, 2010, the Company will pay additional interest to such holder. This additional interest will be equal to the amount of interest that would have been payable on the 12.50% Notes from the last day interest was paid on the 12.50% Notes, through and including November 25, 2010. Additional interest, if any, will be paid in cash or, solely at the Company s option, in common shares or a combination of cash and common shares. If the Company pays additional interest upon a voluntary conversion with the Company s common shares, such shares will be valued at the conversion price that is in effect at that time.

The Company also has the right to automatically convert some or all of the 12.50% Notes on or prior to January 15, 2011 if the closing price of the Company s common shares has exceeded 130% of the conversion price then in effect for at least 20 trading days during any consecutive 30 trading day period ending within five trading days prior to the notice of automatic conversion. If the Company elects to automatically convert some or all of the 12.50% Notes on or prior to November 25, 2009, the Company will pay additional interest to holders of 12.50% Notes being converted. This additional interest will be equal to the amount of interest that would have been payable on the 12.50% Notes from the last day interest was paid on the 12.50% Notes, through and

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

including November 25, 2009. Additional interest, if any, will be paid in cash or, solely at the Company's option, in common shares or a combination of cash and common shares. If the Company pays additional interest upon an automatic conversion with the Company's common shares, such shares will be valued at 90% of the automatic conversion price that is in effect at that time.

Prior to October 15, 2010, the 12.50% Notes are not redeemable. On or after October 15, 2010, the Company may redeem some or all of the 12.50% Notes for cash at 100% of the principal amount of the 12.50% Notes to be redeemed, plus accrued and unpaid interest, to but excluding the redemption date.

In the event of a fundamental change, holders of the 12.50% Notes have the same right as holders of the 3.50% Notes to require the Company to repurchase all or any portion of their notes at a price equal to 100% of the principal amount plus accrued and unpaid interest. In the event the Company's shares are delisted from the NASDAQ Global Market (as discussed in Note 1), this event may be considered a fundamental change and the holders of the 12.50% Notes could have the ability to demand the Company to repurchase the outstanding notes. If holders of the Company's 12.50% Notes elect to convert their notes in connection with a fundamental change that occurs on or prior to January 15, 2011, pursuant to which 10% or more of the consideration for our common stock (other than cash payments for fractional shares) in such fundamental change transaction consists of cash or securities (or other property) that are not traded immediately following such transaction on a United States national securities exchange, the Company will increase the conversion rate for the 12.50% Notes surrendered by the applicable amount as set forth in the Indenture. In some circumstances, this adjusted conversion rate may entitle the holders of the 12.50% Notes to receive more common shares than are authorized. In the event that the Company is required to issue more shares than are authorized, shareholder approval would be required to increase the amount of the Company's authorized shares. In no event should the conversion rate be less than \$0.47. The definition of fundamental change is the same as under the indenture which governs the 3.50% Notes described above.

The Indenture also provides that the Company may not incur additional indebtedness in excess of \$50 million (Permitted Indebtedness) from the earlier of (i) the date that is one year from the date on which the Company's common stock has traded at a price which exceeds the conversion price then in effect for at least 20 trading days during any consecutive 30 trading day period, and (ii) the first anniversary of the maturity date of the 12.50% Notes. Any indebtedness incurred to finance new product acquisitions or in connection with refinancing Permitted Indebtedness, the Company's existing indebtedness or obligations or the 12.50% Notes would not be counted toward the aforementioned limit.

If an event of default occurs under the Indenture, the Trustee or the holders of at least 25% in principal amount of the notes may declare 100% of the principal of and accrued and unpaid interest on all the notes to be due and payable immediately.

The 2008 Exchange Offer is being accounted for as a troubled debt restructuring in accordance with EITF Issue No. 02-4 Determining Whether a Debtor's Modification or Exchange of Debt Instruments is within the Scope of FASB Statement No. 15 and Statement of Financial Accounting Standards No. 15, Accounting by Debtors and Creditors for Troubled Debt Restructurings (SFAS No. 15). As a result, the carrying value of the 12.50% Notes is equal to the sum of all future cash flows on the notes due, including interest payments. Accordingly, all future interest expense and debt issuance costs were accrued upon the date of the Exchange Offer as a reduction to the gain on extinguishment of the 3.50% Notes and no future interest or amortization expense associated with the 12.50% Notes will be recognized. The Company recognized a gain of approximately \$35,357,000 associated with the debt restructuring which is approximately \$2.20 per weighted average common

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

share outstanding. As of December 31, 2008, the carrying value of the 12.50% Notes due 2011 consisted of \$86,684,000 of principal and approximately \$25,740,000 of future interest payable on these notes. As a result of the exchange being accounted for as a troubled debt restructuring, the Company will recognize no interest expense related to the 12.50% Notes in future periods.

On December 5, 2008 one holder of the 12.50% Notes exercised the conversion feature of their notes for approximately 454,500 shares of common stock. Additionally, the Company elected to pay the additional interest upon conversion by issuing 113,636 common shares.

In accordance with SFAS No. 133, the Company has separately accounted for the additional interest payment features of the 3.50% Notes as an embedded derivative instrument. The Company is also accounting for the conversion option and the additional interest payment feature of the 12.50% Notes as a compound embedded derivative. Embedded derivatives are measured at fair value and classified in the accompanying consolidated balance sheets as other long term liabilities. Changes in the fair value of the embedded derivatives are recognized in earnings. The derivative liabilities are revalued quarterly and changes in their fair value are recorded as other expense or income. For the purpose of accounting for the 3.50% Notes issued in the exchange offer, the fair value of the embedded derivative upon issuance was subtracted from the carrying value of the debt and reflected as a debt discount. The debt discount is amortized as interest expense using the effective interest method through the date the notes are scheduled to mature. The embedded derivative contained in the 12.50% Notes was initially valued at \$12,474,000 on November 25, 2008 and was recorded as a component to the gain on exchange of convertible notes. As of December 31, 2008, the fair value of the derivatives for the 3.50% Notes and the 12.50% Notes are approximately \$0 and \$2,370,000, respectively, which reflects a change in the fair value of approximately \$10,104,000 for the year ended December 31, 2008 which is included as gain on derivative in the accompanying consolidated statements of operations.

Security Agreements

Guardian II and Paul Capital previously entered into a security agreement in August 2006 under which Guardian II granted to Paul Capital a senior security interest in and to substantially all assets owned by Guardian II (the First Priority Lien) in order to secure the Company's and Guardian II's payment obligations (the First Lien Obligations) to Paul Capital under the Revenue Interests Assignment Agreement dated as of July 21, 2006 by and among the Company, Guardian II and Paul Capital and Guardian II's obligations of payment under the \$20,000,000 aggregate principal amount of 12% senior secured note issued to Paul Capital at the time the Company entered into the Revenue Interests Assignment Agreement.

On November 25, 2008, Guardian II and the Trustee, in its capacity as collateral agent for the holders of 12.50% Notes entered into a Security Agreement under which Guardian II granted to the Trustee a second priority security interest in and to substantially all assets owned by Guardian II (the Second Priority Lien) in order to secure Guardian II's guarantee of the Company's obligations with respect to the 12.50% Notes, the 2008 Paul Capital Note (as defined below) and any additional 12.50% Notes that may be issued under the Indenture (the Second Lien Obligations).

For the year ended December 31, 2008, the Company incurred approximately \$7,907,000 in interest expense on its convertible debt. Additionally, the Company amortized approximately \$11,290,000 as non-cash interest expense related to the accretion of the bond discount and approximately \$1,416,000 amortization of debt issuance costs.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****(b) Other Financial Arrangements**

In August 2006, the Company, together with its wholly-owned subsidiary Guardian II (the entity which holds all of the ANTARA assets), entered into several financing agreements with Paul Royalty Fund Holdings II, LP (Paul Capital), an affiliate of Paul Capital Partners, including the Revenue Interests Assignment Agreement, the Note Purchase Agreement and the Common Stock and Warrant Purchase Agreement, in consideration for an aggregate amount of \$70 million.

Revenue Interests Assignment Agreement

The Company and Guardian II entered into the Revenue Interests Assignment Agreement (the Revenue Agreement), pursuant to which the Company sold to Paul Capital the right to receive specified royalties on Oscient's net sales in the United States (and the net sales of its affiliates and licensees) of FACTIVE tablets and Guardian II sold to Paul Capital the right to receive specified royalties on Guardian II's net sales in the United States (and the net sales of its affiliates and licensees) of ANTARA capsules, in each case until December 31, 2016 in exchange for an aggregate of \$40 million from Paul Capital. The royalty payable to Paul Capital on net sales of ANTARA and FACTIVE is tiered as follows: 9% for the first \$75 million in annual net revenues, 6% for annual net revenues in excess of \$75 million, but less than \$150 million, and 2% for annual net revenues which exceed \$150 million. Once the cumulative royalty payments to Paul Capital exceed \$100 million, the royalties become nominal. In November of 2008, the Company entered into an amendment to the Revenue Agreement which is discussed in detail below under the subheading Amendment to Revenue Interests Assignment Agreement .

In connection with the Revenue Agreement, the Company recorded a liability, referred to as the revenue interest liability, of approximately \$40 million in accordance with EITF No. 88-18, Sales of Future Revenues (EITF No. 88-18). The Company imputes interest expense associated with this liability using the effective interest rate method and has recorded a corresponding accrued interest liability. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of ANTARA and FACTIVE sales. Payments made to Paul Capital as a result of ANTARA and FACTIVE sales levels will reduce the accrued interest liability and the principal amount of the revenue interest liability. The Company currently estimates that the imputed interest rate associated with this liability will be approximately 17.39%. The Company recorded approximately \$7,138,000 and \$8,020,000 in interest expense related to this agreement in 2008 and 2007, respectively.

In the event of (i) a change of control of Oscient or Guardian II, (ii) a bankruptcy of Oscient or Guardian II, (iii) a transfer by Oscient or any of its subsidiaries of substantially all of either ANTARA or FACTIVE, (iv) subject to a cure period, breach of certain material covenants and representations in the Revenue Agreement and (v) in the event the sale of ANTARA is suspended due to a court issued injunction or the Company elects to suspend sales of ANTARA, in each case as a result of a lawsuit by certain third parties (each a Put Event), Paul Capital has the right to require the Company and Guardian II to repurchase from Paul Capital its royalty interest at a price in cash which equals the greater of (a) 200% of cumulative payments made by Paul Capital under the Revenue Agreement less the cumulative royalties previously made to Paul Capital; or (b) the amount which will provide Paul Capital, when taken together with the royalties previously paid, a 22% internal rate of return (the Put/Call Price). During the term of the agreement through December 31, 2008, the Company and Guardian II have paid approximately \$16,313,000 in royalty payments to Paul Capital. Upon a bankruptcy event, the Company and Guardian II are automatically required to repurchase the Paul Capital royalty interest at the Put/Call Price. In the event of a change of control of Oscient, the Company has the right to repurchase the Paul

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

Capital royalty interest for an amount equal to the Put/ Call Price. The Company has determined that Paul Capital's put option and the Company's call option meet the criteria to be considered an embedded derivative and should be accounted for as such. In 2006, the Company initially recorded a net liability of \$1,005,000 related to the put/call option to reflect its estimated fair value as of the date of the agreement, in accordance with SFAS No. 133. This liability is revalued on a quarterly basis to reflect any changes in the fair value and any gain or loss resulting from the revaluation is recorded in earnings. As of December 31, 2008, the fair value of the derivative is approximately \$653,000 which reflects a change in the fair value of approximately \$333,000 for the year ended December 31, 2008 which has been recorded as a gain on derivative in the accompanying consolidated statements of operations.

During the first two fiscal years immediately following the fiscal year in which combined annual net sales of ANTARA and FACTIVE are equal to or greater than \$125 million, the Company and Guardian II have the right, but not the obligation, to reduce the royalty percentages due under the Revenue Agreement to Paul Capital by fifty percent (50%) by paying Paul Capital a price in cash which will provide Paul Capital, when taken together with the royalties previously paid, a 22% internal rate of return. During the first two fiscal years immediately following the fiscal year in which combined annual net sales of ANTARA and FACTIVE are equal to or greater than \$250 million, the Company and Guardian II have the right, but not the obligation, to repurchase the Paul Capital royalty interest at a price in cash which will provide Paul Capital, when taken together with the royalties previously paid, a 22% internal rate of return.

Note Purchase Agreement

Guardian II entered into a Note Purchase Agreement (the "Note Purchase Agreement") with Paul Capital pursuant to which Guardian II issued and sold a \$20,000,000 aggregate principal amount of 12% senior secured note (the "Note"), due on the fourth anniversary of the closing date, subject to Guardian II's option to extend the maturity to the sixth anniversary of the closing date, provided (i) there are no defaults under the Note at the time, and (ii) the Company issues to Paul Capital, at the time of the exercise of such option, a warrant for a number of shares of common stock equal to 10% of the principal balance plus accrued interest divided by \$6.94, with an exercise price of \$6.94 per share. If the Company exercises such option, the number of shares subject to the warrant issuable to Paul Capital would be between 288,018 shares and 367,529 shares, depending upon the amount, if any, of the interest payable on the Note the Company elects to have added to the principal of the Note rather than paid in cash as described below.

Interest is payable semi-annually in arrears on the last day of each of March and September. Guardian II has the option to pay interest in cash or to have 50% of the interest paid in cash and 50% of the interest added to principal. In the event of a change of control of Oscient or on or after the second anniversary of the closing, the Company may at its option prepay all or any part of the Note at a premium which declines over time. In the event of default, with "event of default" defined as a continuing Put Event under the Revenue Agreement as described in more detail above, the outstanding principal and interest in the Note will become immediately due and payable. As of December 31, 2008, the Company had exercised its option to add approximately \$3,015,000 of interest expense payable to the principal of the Note. This amount is recorded as accrued expenses and other current liabilities in the accompanying consolidated balance sheets.

Subject to the Revenue Agreement and the Note Purchase Agreement, without the prior written consent of Paul Capital, the Company has agreed not to (i) amend, waive any rights under, or terminate any material license agreements, including the agreements relating to the ANTARA products and FACTIVE products, (ii) enter into any new agreement or amend or fail to exercise any of its material rights under existing agreements that would

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

adversely affect Paul Capital's royalty interest, and (iii) sell any material assets related to ANTARA or FACTIVE.

Pursuant to the terms of the Revenue Agreement and the Note Purchase Agreement, Guardian II and Paul Capital entered into a Security Agreement (the "Security Agreement") under which Guardian II granted to Paul Capital a security interest in and to substantially all assets owned by Guardian II (including rights to the ANTARA products) in order to secure its performance under each of the Revenue Agreement, the Note Purchase Agreement and the Note. To the extent the indebtedness under certain of its pre-existing debt obligations is refinanced or replaced and such replacement or refinancing indebtedness is secured, the Company has agreed to equally and ratably secure its obligations under the Revenue Agreement.

Amendment to Revenue Interests Assignment Agreement

On November 25, 2008 the First Amendment (the "Amendment") by and among the Company, Guardian II and Paul Capital dated November 5, 2008 to the Revenue Interests Assignment Agreement dated as of July 21, 2006 and restated August 18, 2006 became effective in accordance with its terms upon the completion of the 2008 Exchange Offer. The Amendment was entered into in order to secure Paul Capital's consent to the grant of the Second Priority Lien.

In accordance with the terms of the Amendment, the Company issued Paul Capital (i) a \$2.0 million aggregate principal amount note (the "2008 Paul Capital Note") with terms substantially identical to the Company's 12.50% Notes issued in the 2008 Exchange Offer, and (ii) 500,000 shares of the Company's common stock. The Company also granted certain registration rights to Paul Capital with respect to the 2008 Paul Capital Note and the common shares issued. Additionally, the Company agreed to amend the exercise price of the Common Stock Purchase Warrant dated August 18, 2006 issued to Paul Capital to purchase 288,018 shares of the Company's common stock from \$6.94 to \$0.45, the closing price of the Company's common stock on the NASDAQ Global Market on the date immediately preceding the closing of the 2008 Exchange Offer.

Under the terms of the Amendment, in the event that the sum of the net sales of ANTARA and FACTIVE in the U.S. and the gross margin received by the Company from sales of FACTIVE within its territory outside of the U.S. (for which the definition of Net Revenues has been expanded to include in the Amendment) is less than 85% of certain specified annual sales thresholds, then Paul Capital will be entitled to a (i) 3% increase in the applicable royalty percentage payable on the first \$75 million of sales of such products in the applicable year and (ii) 2% increase in the applicable royalty percentage payable on net sales of such products in excess of \$75 million and less than \$150 million in the applicable year. The specified sales thresholds are \$115 million in 2009, \$135 million in 2010, \$150 million in 2011 and \$175 million thereafter through the term. Furthermore, the Amendment provides that in the event that the Company fails to achieve the specified sales threshold in any applicable year, the increased applicable royalty percentage shall also be payable on the net sales of any future drug products acquired or in-licensed by the Company or its subsidiaries. The increase in the applicable percentage payable on net sales shall be limited to a maximum payment to Paul Capital of \$2.25 million per year and \$15 million during the term of the Revenue Agreement, and in no event shall such payment exceed the amount which Paul Capital would have received in the applicable year had the specified sales threshold for that year been achieved.

The Amendment also provides that in the event that the Company or its subsidiaries acquires or in-licenses additional drug products, the Company shall make a one-time milestone payment to Paul Capital of \$1.25 million on the second anniversary of the Company's first commercial sale of any such product.

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

Under the terms of the Amendment, in the event that Paul Capital and the Company determine that the fair market value of the collateral in which Paul Capital has been granted a security interest by Guardian II is less than the Put/Call Price (as defined in the Revenue Agreement), the Company will elect, in its sole discretion, to either grant Paul Capital a security interest in 25% of each additional drug product acquired or in-licensed by the Company or its subsidiaries, or pay Paul Capital \$1.5 million on the second year anniversary of the Company's first commercial sale of each such product.

Both the \$1.25 million milestone payment on the second anniversary of an acquired or in-licensed additional drug product and the \$1.5 million payment for any additional drug product acquired or in-licensed in which Paul Capital is not granted at least a 25% security interest are considered to be free standing financial instruments. These items are required to be recorded at fair value on the Company's balance sheet. As of December 31, 2008, the Company has determined that the fair value of these financial instruments is \$0. The Company will evaluate the valuation of these financial instruments at each balance sheet date.

The Amendment also provides that any acceleration or failure to pay the 12.50% Notes shall be considered a Put Event as further described above, whereby Paul Capital could have the right to demand the Company repurchase the revenue interest assignment at the Put/Call Price and the amounts outstanding under the Note Purchase Agreement would become immediately due and payable.

Common Stock and Warrant Purchase Agreement

As part of the financing, the Company and Paul Capital also entered into a Common Stock and Warrant Purchase Agreement (the "Stock and Warrant Purchase Agreement"), pursuant to which, in exchange for \$10 million, the Company sold to Paul Capital 1,388,889 shares (the "Shares") of the Company's Common Stock, at a price of \$7.20 per share (the "Private Placement") and issued Paul Capital a warrant (the "Warrant") to purchase 288,018 shares of Common Stock (the "Warrant Shares") at an exercise price of \$6.94 per share. In accordance with the Amendment noted above, the Company amended the exercise price on the Warrant Shares to \$0.45 per share, the closing price of the Company's common stock on the NASDAQ Global Market on the date immediately preceding the closing of the 2008 Exchange Offer. The Warrant is exercisable for seven years from the date of closing. The Warrant contains a net share settlement feature and penalties if the Company does not deliver the applicable amount of Warrant Shares within three trading days of exercise of a Warrant by Paul Capital. The Warrant also contains provisions providing that, at Paul Capital's election, the Company must repurchase the Warrant from Paul Capital upon a sale of the Company in which the consideration for such sale is solely cash. The warrant has not been exercised as of December 31, 2008.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

As discussed in Note 1, the Company has classified the amounts due for the convertible notes due 2011, the Revenue Agreement, and the Note due to Paul Capital as current due to various repurchase features that may occur in 2009. If the delisting does not occur or if the delisting does occur but the holders of the 2011 Notes do not require the Company to repurchase the Notes, the following table presents future maturities of debt (in thousands):

Year-Ending December 31, 2008	
2009	\$ 13,413
2010	20,113
2011	124,066
2012	
2013	
Thereafter	39,231
Total	\$ 196,823

(12) Stockholders Equity**(a) Equity Plans**

The Company granted stock options to key employees and consultants under its 1991, 1993, 1995 and 1997 Stock Option Plans, and continues to grant stock-based awards under its 2001 Incentive Plan (collectively, the Option Plans). On August 13, 2007, the Board of Directors approved the Company's 2007 Employment Inducement Award Plan (the 2007 Inducement Plan) and authorized 500,000 shares of common stock for issuance under the 2007 Inducement Plan. The Compensation Committee of the Board of Directors determines the purchase price and vesting schedule applicable to each option grant. As of December 31, 2007, there were no shares reserved for future grants under the 1991, 1993, 1995 and 1997 Plans. The 2001 Incentive Plan, as amended and restated, provides for the grant of non-qualified stock options, incentive stock options, restricted stock, stock appreciation rights, unrestricted stock, deferred stock, convertible securities, and cash and equity-based performance awards. The 2007 Inducement Plan provides for the grant of non-qualified stock options and restricted stock. As of December 31, 2008, 2,577,246 shares were authorized and 1,057,558 shares were available for future issuance under the 2001 Incentive Plan and 485,043 shares were authorized and 107,956 shares were available for future issuance under the 2007 Inducement Plan. In addition, under separate agreements not covered by any plan, the Company has granted certain key employees and directors of the Company an aggregate of 65,506 options to purchase common stock.

The Company also had an Employee Stock Purchase Plan (ESPP), which was adopted in February 2000. Under the ESPP, eligible employees may contribute up to 15% of their earnings toward the semi-annual purchase of the Company's common stock. The employees' purchase price is 85% of the fair market value of the common stock at the time of grant of option or the time at which the option is deemed exercised, whichever is less. The most recently completed offering period began July 1, 2007 and ended on December 31, 2007; therefore, July 1, 2007 is considered the grant date for the purposes of recognizing the stock-based compensation expense for this offering period. The Company projects the estimated contributions at the beginning of the period and uses the Black-Scholes-Merton option-pricing model in order to determine the estimated fair value of the stock to be issued. At the end of the offering period, the Company adjusts the estimated contributions to actual. The Company recognizes stock-based compensation expense related to the ESPP in accordance with SFAS No. 123R. However, effective the beginning of the most recently completed offering in 2007, the Company reduced the discount from 15% to 5% for employees to purchase shares, resulting in a purchase price of 95% of the fair

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

market value of the common stock at the time of grant of option or the time at which the option is deemed exercised, whichever is less. Under SFAS 123R, no compensation expense is required to be recorded when the employee discount is 5% or less. As of December 31, 2008, 431,250 shares were authorized and 25 shares were available for future issuance under this plan. In 2008, the Company suspended the ESPP.

A summary of activity related to stock options under the Option Plans as of December 31, 2008 is presented below (in thousands, except weighted average data):

	Number of Shares (in thousands)	Exercise Price Range	Weighted Average Exercise Price	Weighted- Average Remaining Contractual Term (in Years)	Aggregate Intrinsic Value
Outstanding, December 31, 2007	1,263	\$ 1.76-221.25	\$ 20.75		
Granted	648	\$ 0.23-2.16	\$ 1.77		
Exercised					
Canceled/Forfeited	(319)	\$ 1.15-50.16	\$ 13.34		
Outstanding, December 31, 2008	1,592	\$ 0.23-221.25	\$ 14.50	7.60	
Exercisable, December 31, 2008	926	\$ 2.02-221.25	\$ 23.36	6.57	
Exercisable & expected to vest, December 31, 2008	1,410		\$ 16.29	0.42	

The range of exercise prices for options outstanding and options exercisable under the Option Plans at December 31, 2008 are as follows:

Range of Exercise Prices	Options Outstanding			Options Exercisable	
	Weighted Average Remaining Contractual Life of Options Outstanding (in years)	Number of Shares (in thousands)	Weighted Average Exercise Price	Number of Shares (in thousands)	Weighted Average Exercise Price
\$ 0.23 1.27	9.41	176	\$ 1.11		
\$ 1.33 2.07	9.21	220	1.87	19	2.02
\$ 2.12 2.16	9.15	254	2.16	129	2.16
\$ 2.62 4.54	8.15	153	3.75	50	3.69
\$ 4.54 4.94	8.19	201	4.93	177	4.94
\$ 4.96 14.24	6.25	163	11.56	130	11.83
\$ 14.36 21.80	6.64	163	18.06	160	18.08
\$ 23.32 47.28	5.27	179	36.81	178	36.88
\$ 49.24 164.75	1.90	82	111.43	82	111.43
\$ 221.25 221.25	1.55	1	221.25	1	221.25
Total		1,592	\$ 14.50	926	\$ 23.36

(b) Sale of Common Stock

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

On April 11, 2006, the Company completed a private placement of its common stock with institutional investors and other accredited investors. The Company sold an aggregate of 2,254,402 shares of its common stock at a price of \$15.44 per share and warrants to purchase up to 1,149,745 shares of common stock at a price of \$1.00 per warrant. The warrants have an exercise price of \$17.76 per share and a term of five years.

F-43

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****(c) Warrants**

As of December 31, 2008, the Company had warrants outstanding for the purchase of 1,443,820 shares of common stock at exercise prices ranging from \$0.45 - \$90.64, as adjusted for the reverse stock split effectuated by the Company in November 2006. These warrants are fully vested at December 31, 2008 and are as follows (in thousands, except exercise price data):

Warrants Outstanding	Exercise Price	Expiration
23	\$ 17.76	April 11, 2011
1,127	\$ 17.76	April 11, 2011
6	\$ 90.64	June 13, 2011
288	\$ 0.45	August 18, 2013

(e) Common Stock Reserved

Common stock reserved for future issuance at December 31, 2008 consists of the following (in thousands):

Stock option and incentive plans	3,062
Employee stock purchase plan	1
Warrants	1,444
Conversion of convertible notes	80,078
Total	84,585

The Company has entered into several instruments which can be settled in the Company's common shares. In some future scenarios, the Company may be required to issue more common shares than are currently authorized. Consistent with the guidance provided by EITF Issue No. 00-19 *Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock* (EITF 00-19), the Company will reclassify instruments, which the Company does not have sufficient common shares to settle the obligation to deliver common shares, as liabilities in order to determine the appropriate accounting treatment of the affected instruments. The Company will perform this reclassification by evaluating the instruments with the latest inception date first.

(13) Incentive Savings 401(k) Plan

The Company maintained an incentive savings 401(k) plan (the 401(k) Plan) for the benefit of all employees. The Company matched 50% of the first 6% of salary, which for 2008 was limited to the first \$230,000 of annual salary. The Company contributed approximately \$603,000, \$424,000 and \$356,000 to the 401(k) Plan for the years ended December 31, 2008, 2007 and 2006, respectively. The Company has suspended the Company match as of December 31, 2008.

(14) Supply Agreement for ANTARA

In accordance with the acquisition of ANTARA in August of 2006, the Company was assigned rights to and assumed obligations under an exclusive license to the rights to ANTARA licensed from Ethypharm S.A. In order to maintain the exclusivity of these rights, the Company must achieve minimum annual sales in the United States and Canada until February 2012 or pay amounts to Ethypharm to compensate for any shortfall. On or about February 27, 2009, the Company received notice from Ethypharm that it had not achieved the minimum sales

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

threshold, and accordingly within 60 days of receipt of such notice, on or approximately April 28, 2009, the Company may elect to maintain the exclusivity of the license by compensating Ethypharm for any shortfall, or to convert the exclusive license to a non-exclusive license. As of December 31, 2008, the Company recorded approximately \$621,000 as additional royalties related to the potential shortfall owed to Ethypharm and which would be payable in the event we elect to maintain the exclusivity of the license. During the term of the agreement, the Company is obligated to pay a royalty on sales of ANTARA in the U.S. including a royalty on other fenofibrate monotherapy products in formulation and dosage forms that may be substantially similar or identical to ANTARA developed by the Company. The license term expires in February 2020 and, absent notice of termination by either party, automatically renews for consecutive periods of two (2) years each. Under the terms of the agreement, at the Company's option, Ethypharm is obligated to either manufacture and deliver to the Company finished fenofibrate product or deliver bulk product to the Company for encapsulation and packaging. Ethypharm also has a right of first refusal on any divestiture of the ANTARA rights by the Company. Additional Company obligations under the Ethypharm agreement include funding a portion of the active pharmaceutical ingredient safety stock that Ethypharm is required to maintain

In addition to the exclusive license from Ethypharm, S.A. which the Company assumed in accordance with the terms of the asset purchase agreement with Reliant Pharmaceuticals, Inc. (Reliant), whereby the Company acquired ANTARA, the Company also assumed certain of Reliant's liabilities relating to ANTARA. Those obligations include a responsibility to make certain royalty and milestone payments based on sales of ANTARA. Under the terms of one of the licenses not including the Ethypharm license the Company is obligated to make certain royalty payments to a third party licensor based on sales of ANTARA, which royalty payments are subject to a low single digit increase in the event of a change in control of the Company. The Company has engaged the third party licensor to renegotiate the terms of that license and on December 12, 2008 has suspended further royalty payments while the terms of such license are being renegotiated. As of December 31, 2008 the Company has accrued approximately \$2,798,000 related to this unpaid royalty based on sales through December 31, 2008.

(15) Supply Agreement for FACTIVE

The Company licenses from LG Life Sciences the right to develop and commercialize gemifloxacin (FACTIVE), a fluoroquinolone antibiotic, in North America, France, Germany, the United Kingdom, Luxembourg, Ireland, Italy, Spain, Portugal, Belgium, the Netherlands, Austria, Greece, Sweden, Denmark, Finland, Norway, Iceland, Switzerland, Andorra, Monaco, San Marino, Vatican City, Poland, Czech Republic, Slovakia, Slovenia, Hungary, Estonia, Latvia, Lithuania, Liechtenstein, Malta, Cyprus, Romania, Bulgaria, Croatia, Serbia and Montenegro, Bosnia and Herzegovina, Albania and the Former Yugoslav Republic of Macedonia. The term of the agreement with respect to each country extends at least through the life of the patents covering gemifloxacin in such country. In the United States, the last of the issued patents for composition of matter expires in 2018. The patent term could extend further in countries outside of the U.S. depending upon several factors, including whether the Company obtains patent extensions and the timing of its commercial sale of the product in a particular country.

Under the terms of the agreement, LG Life Sciences has agreed to supply and the Company is obligated to purchase from LG Life Sciences all of its anticipated commercial requirements for the FACTIVE API. LG Life Sciences currently supplies the FACTIVE API from its manufacturing facility in South Korea.

The agreement with LG Life Sciences also required the Company to achieve minimum gross sales levels of \$30 million from its licensed territories over a 12-month period of time starting in approximately the third quarter

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

of 2007 to the third quarter of 2008, which if not met, LG Life Sciences could elect to terminate the agreement and have the technology be returned to LG Life Sciences. After LG Life Sciences' review of the Company's financial information during the fourth quarter of 2008, concluded that it will not terminate the agreement based on the minimum gross sales level of \$30 million. Under this agreement, the Company is responsible, at its expense and through consultation with LG Life Sciences, for the clinical and commercial development of gemifloxacin in the countries covered by the license, including conducting clinical trials, filing drug approval applications with the FDA and other applicable regulatory authorities and marketing, distributing and selling of gemifloxacin in its territory.

The Company is obligated to pay a royalty on sales of FACTIVE in North America and the territories covered by the license in Europe. These royalty obligations expire with respect to each country covered by the agreement on the later of (i) the expiration of the patents covering FACTIVE in such country or (ii) the expiration of data exclusivity in Mexico, Canada or the European Union respectively, or 2014 in the U.S. The Company is also obligated to make aggregate milestone payments of up to \$40 million (not including payments previously made pursuant to up-front obligations or achievements of certain milestones) to LG Life Sciences including milestone payments required by the amendments described below upon achievement of additional regulatory approvals and sales thresholds.

On March 31, 2005, the Company amended its license and option agreement with LG Life Sciences. As part of the amendment of the agreement, the Company made a one-time, up-front payment of \$2 million to LG Life Sciences which was expensed and agreed to make certain additional milestone payments upon obtaining regulatory approvals and sales thresholds. The amended agreement also includes a reduction of future royalties payable to LG Life Sciences at certain FACTIVE revenue levels in territories covered by the agreement.

The Company further amended its agreement with LG Life Sciences on February 3, 2006, pursuant to which LG Life Sciences agreed to a reduction of future royalties payable for sales of FACTIVE tablets in Mexico and Canada and the termination of LG Life Sciences' co-promotion rights in these countries. The modified agreement also calls for additional milestone payments to be made to LG Life Sciences upon consummation of sublicense agreements in Mexico and Canada (which payments were made to LG in February 2006 and August 2006, respectively) as well as upon receipt of regulatory approval of FACTIVE in each of such countries. Additionally, on December 27, 2006, the Company amended its agreement with LG Life Sciences to reduce future royalties payable to LG Life Sciences for sales of FACTIVE tablets in Europe and to provide for a reduction in the supply price for the active pharmaceutical ingredient for FACTIVE for product to be sold in Europe. In lieu of milestone payments previously agreed to by the parties, this amendment also requires the Company to pay LG Life Sciences a portion of any milestone or license fee payments the Company receives from its European partner.

(16) Co-Promotion of TESTIM

On April 11, 2005, the Company entered into a co-promotion agreement with Auxilium Pharmaceuticals, Inc. (Auxilium), under which the Company and Auxilium co-promoted in the United States Auxilium's product, TESTIM gel, a topical 1% testosterone gel indicated for the treatment of male hypogonadism. On August 31, 2006, the Company and Auxilium mutually agreed to conclude this co-promotion arrangement and agreed to share profits from primary care sales, as provided for under the co-promotion agreement, through August 31, 2006. As part of the termination of the co-promotion agreement, the Company received \$1,800,000 from Auxilium as additional compensation for commercialization efforts by its sales force through August 31, 2006, which has been recognized as revenue at December 31, 2006.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****(17) Partnering Arrangements for FACTIVE***Sublicense Agreement with Pfizer, S.A. de C.V.*

On February 6, 2006, the Company entered into a Sublicensing and Distribution Agreement with Pfizer, S.A. de C.V. (Pfizer Mexico), pursuant to which the Company sublicensed its rights to sell FACTIVE tablets in Mexico to Pfizer Mexico. In exchange for those rights, Pfizer Mexico has paid the Company an up-front payment and has agreed to pay milestone payments upon obtaining certain regulatory approvals and sales goals, as well as royalties on future sales. The up-front payment is being recognized as revenue over the term of the Company's continuing obligations under the agreement of approximately eighteen months. These royalty rates are subject to reduction upon expiration of certain patents in Mexico for FACTIVE or if a generic form of gemifloxacin has a material impact on Pfizer Mexico's sales volumes in Mexico. Pfizer Mexico is obligated to exclusively purchase from the Company, and the Company must exclusively supply, all active pharmaceutical ingredients for FACTIVE. The agreement with Pfizer Mexico may be terminated by either party upon the occurrence of certain termination events, including Pfizer Mexico's right to terminate at any time after the first anniversary of launch of FACTIVE tablets in Mexico upon nine months prior written notice. Upon termination, Pfizer Mexico is obligated to assign any and all rights to regulatory approvals in Mexico to the Company or its designee. Pfizer Mexico is currently marketing FACTIVE-5 in Mexico for the treatment of CAP, AECB, ABS and uUTI.

Supply and Marketing Agreement with Abbott Laboratories

On August 9, 2006, the Company granted the commercialization rights of FACTIVE tablets in Canada to Abbott Laboratories, Ltd. (Abbott Canada), the Canadian affiliate of Abbott. In exchange for those rights, Abbott Canada agreed to a transfer price on product purchases and to make certain payments to the Company upon achievement of certain regulatory and sales milestones. The Company subsequently amended the agreement on January 31, 2008 whereby Abbott Canada's development and commercialization obligations were substantially reduced. In December 2008, the Company's license agreement with Abbott Canada was terminated. Abbott Canada has ceased all development and commercialization of FACTIVE in Canada.

Menarini International Operation Luxembourg S.A.

The Company entered into a License, Supply and Marketing Agreement with Menarini International Operation Luxembourg S.A. (Menarini), a wholly-owned subsidiary of Menarini Industrie Farmaceutiche Riunite S.r.l. dated December 28, 2006, whereby the Company sublicensed its rights to sell FACTIVE tablets in the European Union to Menarini. Under the terms of the Company's agreement with Menarini, Menarini is responsible for obtaining regulatory approval for FACTIVE in the European Union, and the Company has agreed to reimburse Menarini for expenses associated with such regulatory development up to an agreed limit. Menarini has paid the Company an up-front payment which is being recognized as revenue over the term of the Company's continuing obligations under the agreement of approximately thirty-three months. Menarini has also agreed to pay the Company milestone payments upon obtaining certain regulatory and reimbursement approvals and upon achieving certain annual net sales goals, which could total up to \$23.0 million, if all the milestones are achieved. Menarini will pay the Company a transfer price on purchases of the API, for FACTIVE, which is determined based on a percentage of quarterly sales of FACTIVE by Menarini in Europe. Menarini is also obligated to exclusively purchase from the Company, and the Company must exclusively supply, all API for FACTIVE to be sold in Europe for the earlier of (1) the expiration of the life of certain patents covering the product or (ii) the expiration of data exclusivity. The Company's agreement with Menarini may be terminated by either party upon the occurrence of certain termination events, including Menarini's right to terminate if the

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

European regulatory authorities do not recommend approval of FACTIVE at various stages of the approval process with a package insert, or label, that meets certain requirements as to the safety, dosing and indications for which FACTIVE may be prescribed. Menarini may also terminate the agreement if it does not receive approval for reimbursement from European member countries that is above a certain minimum price per tablet. Upon termination, Menarini is obligated to assign any and all rights to regulatory approvals in the European Union to the Company or its designee.

In recent years, the FDA has made the approval process for new antibiotics more challenging, sometimes requesting placebo-controlled or superiority design clinical studies for certain indications. It is possible that the European Medicines Agency (EMEA) could adopt a similar position regarding the approval of new antibiotics for certain indications. Menarini may not be able to obtain regulatory approval for FACTIVE, which could delay or prevent us from receiving revenue from sales of FACTIVE in Europe, and/or may require additional expenditures. Menarini can terminate this agreement if the EMEA does not recommend approval of FACTIVE with a package insert or label that meets certain requirements for safety, dosing and indications for which FACTIVE may be prescribed. Moreover, the Company's predecessor's original regulatory filing in the United Kingdom was rejected.

(18) Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,	
	2008	2007
Sales reserves and allowances	\$ 16,526	\$ 10,734
Derivative liabilities	3,023	
Payroll and related expenses	3,460	5,244
Deferred rent	499	502
Professional fees	1,255	512
Interest related to convertible notes payable	8,186	2,189
Royalty interest payable	124	371
Other	1,025	1,376
	\$ 34,098	\$ 20,928

(19) Guarantor and Non-Guarantor Financial Information

Guardian II Acquisition Corporation (Guarantor Subsidiary), a wholly owned subsidiary of Oscient Pharmaceuticals Corporation (Parent Company), has guaranteed the notes issued in the exchange offer described in Note 11 (a). As described in Note 11 (b), Guarantor Subsidiary was formed during 2006 in connection with the Company's acquisition of ANTARA. Separate financial statements and other disclosures concerning the Parent Company and Guarantor Subsidiary are not presented because Guarantor Subsidiary is 100% wholly owned by the Parent Company and has fully and unconditionally guaranteed such debt. The following tables present consolidating financial information for the Parent Company, Guarantor Subsidiary and Non-Guarantor Subsidiary of Oscient Pharmaceutical Corporation. The equity method of accounting is used to reflect investments of the Parent Company in its Guarantor and Non-Guarantor Subsidiary. Costs and expenses are recorded by the entities on a specific basis, or where necessary, allocated based upon net revenues. All intercompany transactions are eliminated in consolidation. The Company is presenting the condensed balance sheets of the Parent Company and Guarantor Subsidiary separately as of December 31, 2008 and 2007, and the condensed statements of operations and the condensed statements of cash flows for the years ended December 31, 2008, 2007, and 2006 in accordance with Rule 3-10(e) of Regulation S-X.

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****Condensed Supplemental Consolidated Balance Sheet**

As of December 31, 2008

(in thousands)

	Parent Company	Guarantor Subsidiary	Non-Guarantor Subsidiary	Eliminations	Consolidated
ASSETS					
Current Assets:					
Cash and cash equivalents	\$ 2,295	\$ 10,248	\$ 52	\$	\$ 12,595
Accounts receivable	4,210	13,392			17,602
Inventories, net	3,567	4,133			7,700
Intercompany receivable	10,063	114,819		(124,882)	
Prepaid expenses and other current assets	3,005	592			3,597
Total current assets	23,140	143,184	52	(124,882)	41,494
Property and Equipment, net	768				768
Restricted cash	4,598				4,598
Other assets	415	314			729
Investment in subsidiaries	52			(52)	
Intangible assets, net	549	50,487			51,036
Goodwill	59,021	16,387			75,408
Total Assets	\$ 88,543	\$ 210,372	\$ 52	\$ (124,934)	\$ 174,033
LIABILITIES AND SHAREHOLDERS (DEFICIT)					
EQUITY					
Current Liabilities:					
Current maturities of long-term obligations	\$ 13,413	\$	\$	\$	\$ 13,413
Debt obligations	11,625	171,653			183,278
Intercompany debt obligation	114,819			(114,819)	
Accounts payable	7,371	4,608			11,979
Intercompany payable		49,874		(49,874)	
Accrued expenses and other current liabilities	14,687	19,411			34,098
Current portion of accrued facilities impairment charge	3,152				3,152
Deferred revenue	273	3,653			3,926
Total current liabilities	165,340	249,199		(164,693)	249,846
Long-term liabilities:					
Long-term obligations, net of current maturities	132				132
Noncurrent portion of accrued facilities impairment charge	4,255				4,255
Other long-term liabilities		984			984
Shareholders' (Deficit) Equity:					
Series B restricted common stock					
Common stock	3,664		12	(12)	3,664
Additional paid-in-capital	425,665	23,136	40	(23,176)	425,665
Accumulated deficit	(510,513)	(62,947)		62,947	(510,513)

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Total shareholders (deficit) equity	(81,184)	(39,811)	52	39,759	(81,184)
Total Liabilities and Shareholders (Deficit) Equity	\$ 88,543	\$ 210,372	\$ 52	\$ (124,934)	\$ 174,033

F-49

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

As of December 31, 2007

(in thousands)

	Parent Company	Guarantor Subsidiary	Non-Guarantor Subsidiary	Eliminations	Consolidated
ASSETS					
Current Assets:					
Cash and cash equivalents	\$ 29,226	\$ 13,693	\$ 5,349	\$	\$ 48,268
Notes receivable	486				486
Accounts receivable	4,444	10,588			15,032
Inventories, net	5,429	3,630			9,059
Intercompany receivable	26,240			(26,240)	
Prepaid expenses and other current assets	1,777	1,087	22		2,886
Total current assets	67,602	28,998	5,371	(26,240)	75,731
Property and Equipment, net	807				807
Restricted cash	4,198				4,198
Other assets	5,230	355			5,585
Investment in subsidiaries	5,371			(5,371)	
Intangible assets, net	56,075	54,828			110,903
Goodwill	60,573	16,387			76,960
Total Assets	\$ 199,856	\$ 100,568	\$ 5,371	\$ (31,611)	\$ 274,184
LIABILITIES AND SHAREHOLDERS (DEFICIT) EQUITY					
Current Liabilities:					
Current maturities of long-term obligations	\$ 38	\$	\$	\$	\$ 38
Accounts payable	7,582	2,680			10,262
Intercompany payable		46,903		(46,903)	
Accrued expenses and other current liabilities	12,774	8,154			20,928
Current portion of accrued facilities impairment charge	2,128				2,128
Accrued restructuring charge	364				364
Total current liabilities	22,886	57,737		(46,903)	33,720
Long-term liabilities:					
Long-term obligations, net of current maturities	193,730	59,129			252,859
Noncurrent portion of accrued facilities impairment charge	8,831				8,831
Other long-term liabilities	2,851	4,365			7,216
Deferred revenue	273				273
Shareholders' (Deficit) Equity:					
Series B restricted common stock					
Common stock	1,389		12	(12)	1,389
Additional paid-in-capital	415,654	23,136	4,735	(27,871)	415,654
Accumulated deficit	(445,758)	(43,799)	624	43,175	(445,758)

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Total shareholders (deficit) equity	(28,715)	(20,663)	5,371	15,292	(28,715)
Total Liabilities and Shareholders (Deficit) Equity	\$ 199,856	\$ 100,568	\$ 5,371	\$ (31,611)	\$ 274,184

F-50

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****Condensed Supplemental Consolidated Statements of Operations****(in thousands)**

	For the year ended December 31, 2008				
	Parent Company	Guarantor Subsidiary	Non-Guarantor Subsidiary	Eliminations	Consolidated
Net revenues	\$ 16,518	\$ 70,330	\$	\$	\$ 86,848
Total costs and expenses	83,839	83,371			167,210
Loss from operations	(67,321)	(13,041)			(80,362)
Other income (expense):					
Interest income	386	183	81		650
Interest expense	(21,080)	(9,802)			(30,882)
Gain on disposition of investment	413				413
Gain on exchange of convertible notes	35,357				35,357
Gain on derivative related to long-term debt	67	10,413			10,480
Intercompany income (expense)	10,079	(10,079)			
Loss from subsidiaries	(19,066)			19,066	
Other Income	9				9
Net other income (expense)	6,165	(9,285)	81	19,066	16,027
(Loss) income from operations before income tax	(61,156)	(22,326)	81	19,066	(64,335)
Provision for income tax	(3,599)	3,179			(420)
Net (loss) income	\$ (64,755)	\$ (19,147)	\$ 81	\$ 19,066	\$ (64,755)

	For the year ended December 31, 2007				
	Parent Company	Guarantor Subsidiary	Non-Guarantor Subsidiary	Eliminations	Consolidated
Net revenues	\$ 21,398	\$ 58,571	\$	\$	\$ 79,969
Total costs and expenses	42,618	75,347			117,965
Loss from operations	(21,220)	(16,776)			(37,996)
Other income (expense):					
Interest income	1,783	553	205		2,541
Interest expense	(17,588)	(10,618)			(28,206)
Gain on disposition of investment	231				231
Gain on exchange of convertible notes	30,824				30,824
Gain on derivative related to long-term debt	3,004	19			3,023
Loss from subsidiaries	(19,688)			19,688	
Other Income	114				114
Net other income (expense)	(1,320)	(10,046)	205	19,688	8,527

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 10-K

Income (loss) from operations before income tax	(22,540)	(26,822)	205	19,688	(29,469)
Provision for income tax	(7,313)	6,929			(384)
Net income (loss)	\$ (29,853)	\$ (19,893)	\$ 205	\$ 19,688	\$ (29,853)

F-51

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

	For the year ended December 31, 2006				
	Parent Company	Guarantor Subsidiary	Non-Guarantor Subsidiary	Eliminations	Consolidated
Net revenues	\$ 29,374	\$ 16,778	\$	\$	\$ 46,152
Total costs and expenses	94,373	23,698			118,071
Loss from operations	(64,999)	(6,920)			(71,919)
Other income (expense):					
Interest income	2,533	45	417		2,995
Interest expense	(8,057)	(2,999)			(11,056)
Gain on disposition of investment	1,617				1,617
Income from subsidiary	(9,636)			9,636	
Other Income	65				65
Net other income (expense)	(13,478)	(2,954)	417	9,636	(6,379)
Income (loss) from operations before income tax	(78,477)	(9,874)	417	9,636	(78,298)
Provision for income tax		(179)			(179)
Net income (loss)	\$ (78,477)	\$ (10,053)	\$ 417	\$ 9,636	\$ (78,477)

F-52

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****Condensed Supplemental Consolidated or Combined Statement of Cash Flows**

	For the year ended December 31, 2008				
	Parent Company	Guarantor Subsidiary	Non-Guarantor Subsidiary	Eliminations	Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES	\$ (27,839)	\$ (3,445)	\$ 103	\$	\$ (31,181)
CASH FLOWS FROM INVESTING ACTIVITIES:					
Proceeds from disposition of investment	413				413
Purchase of property and equipment	(190)				(190)
Proceeds from sale of property and equipment	3				3
Decrease (increase) in restricted cash	(400)				(400)
(Increase) decrease in other assets	(35)				(35)
Distribution from subsidiary	5,400			(5,400)	
Proceeds from notes receivable	486				486
Net cash provided by (used in) investing activities	5,677			(5,400)	(277)
CASH FLOWS FROM FINANCING ACTIVITIES:					
Proceeds from issuance of notes					
Proceeds from exercise of stock options					
Proceeds from issuance of stock under employee stock purchase plan	193				193
Exchange costs	(4,924)				(4,924)
Distribution to parent			(5,400)	5,400	
Payments on long-term obligations	(38)				(38)
Net cash provided by financing activities	(4,769)		(5,400)	5,400	(4,769)
NET INCREASE IN CASH AND CASH EQUIVALENTS	(26,931)	(3,445)	(5,297)		(35,673)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	29,226	13,693	5,349		48,268
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 2,295	\$ 10,248	\$ 52		\$ 12,595

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

	For the year ended December 31, 2007				
	Parent Company	Guarantor Subsidiary	Non-Guarantor Subsidiary	Eliminations	Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES	\$ (39,132)	\$ 4,275	\$ 196	\$	\$ (34,661)
CASH FLOWS FROM INVESTING ACTIVITIES:					
Proceeds from disposition of investment	231				231
Purchase of property and equipment	(56)				(56)
Proceeds from sale of property and equipment	7				7
Decrease (increase) in restricted cash	2,414				2,414
(Increase) decrease in other assets	14	(77)			(63)
Investment in subsidiary	(2,500)			2,500	
Proceeds from notes receivable	1,373				1,373
Net cash provided by (used in) investing activities	1,483	(77)		2,500	3,906
CASH FLOWS FROM FINANCING ACTIVITIES:					
Proceeds from issuance of notes	40,444				40,444
Proceeds from exercise of stock options	17				17
Proceeds from issuance of stock under employee stock purchase plan	404				404
Advances from parent			2,500	(2,500)	
Payments on long-term obligations	(38)				(38)
Net cash provided by financing activities	40,827		2,500	(2,500)	40,827
NET INCREASE IN CASH AND CASH EQUIVALENTS	3,178	4,198	2,696		10,072
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	26,048	9,495	2,653		38,196
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 29,226	\$ 13,693	\$ 5,349	\$	\$ 48,268

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

	For the year ended December 31, 2006				
	Parent Company	Guarantor Subsidiary	Non-Guarantor Subsidiary	Eliminations	Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES	\$ (68,405)	\$ 4,256	\$ 514	\$	\$ (63,635)
CASH FLOWS FROM INVESTING ACTIVITIES:					
Proceeds from disposition of investment	1,617				1,617
Purchase of property and equipment	(263)				(263)
Proceeds from sale of property and equipment	1				1
Decrease (increase) in restricted cash	5,118				5,118
Decrease (increase) in other assets	5	(334)			(329)
Investment in subsidiary	(23,136)			23,136	
Distribution from subsidiary	22,800			(22,800)	
Proceeds from maturities of marketable securities			2,696		2,696
Proceeds from notes receivable	790				790
Issuance of notes receivable	(186)				(186)
Cash flows related to acquisition of ANTARA		(77,563)			(77,563)
Net cash provided by (used in) investing activities	6,746	(77,897)	2,696	336	(68,119)
CASH FLOWS FROM FINANCING ACTIVITIES:					
Proceeds from private placement of common stock, net	33,477				33,477
Proceeds from issuance of stock in connection with acquisition	9,958				9,958
Proceeds from issuance of notes		20,000			20,000
Proceeds from assignment of revenue interest		40,000			40,000
Proceeds from exercise of stock options	166				166
Proceeds from issuance of stock under employee stock purchase plan	740				740
Investment from parent		23,136		(23,136)	
Distribution to parent			(22,800)	22,800	
Payments on long-term obligations	(9)				(9)
Net cash provided by financing activities	44,332	83,136	(22,800)	(336)	104,332
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(17,327)	9,495	(19,590)		(27,422)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	43,375		22,243		65,618
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 26,048	\$ 9,495	\$ 2,653	\$	\$ 38,196

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)****(20) Quarterly Consolidated Statements of Operations (unaudited)**

The following table sets forth unaudited quarterly statement of operations data for each of the eight quarters in the two year period ended December 31, 2008. In the opinion of management, this information has been prepared on the same basis as the audited financial statements appearing elsewhere in this Form 10-K, and all necessary adjustments, consisting only of normal recurring adjustments, have been included in the amounts stated below to present fairly the unaudited quarterly results of operations (in thousands, except per share data).

	Year	Quarter Ended December 31,	Quarter Ended September 30,	Quarter Ended June 30,	Quarter Ended March 31,
2008					
Revenues:					
Product sales	\$ 86,325	\$ 26,168	\$ 21,695	\$ 20,193	\$ 18,269
Biopharmaceutical/other revenues	523	242	92	92	97
Total revenues	86,848	26,410	21,787	20,285	18,366
Costs and expenses:					
Cost of product sales	29,013	8,567	7,082	6,348	7,016
Research and development	2,875	331	680	521	1,343
Selling and marketing	71,150	14,945	18,263	18,190	19,752
General and administrative	13,413	2,713	2,874	3,936	3,890
Impairment of intangibles	50,759	50,759			
Total costs and expenses	167,210	77,315	28,899	28,995	32,001
Loss from operations	(80,362)	(50,905)	(7,112)	(8,710)	(13,635)
Other income (expense):					
Interest income	650	36	111	147	356
Interest expense	(30,882)	(6,234)	(7,961)	(8,373)	(8,314)
Gain on disposition of investment	413			96	317
Gain on exchange of convertible debt	35,357	35,357			
Gain (loss) on derivative related to convertible notes	10,480	10,329	37	158	(44)
Other income	9	(4)	3	2	8
Net other income (expense)	(16,027)	39,484	(7,810)	(7,970)	(7,677)
(Loss) Income before income tax	(64,335)	(11,421)	(14,922)	(16,680)	(21,312)
Provision for income tax	(420)	(105)	(105)	(105)	(105)
Net (loss) income	\$ (64,755)	\$ (11,526)	\$ (15,027)	\$ (16,785)	\$ (21,417)
Net loss per common share:					
Basic and diluted	\$ (4.03)	\$ (0.50)	\$ (1.09)	\$ (1.20)	\$ (1.53)
Weighted average common shares outstanding:					
Basic and diluted	16,051	22,825	13,839	13,970	13,969

Table of Contents**OSCIENT PHARMACEUTICALS CORPORATION****Notes to Consolidated Financial Statements (Continued)**

	Year	Quarter Ended December 31,	Quarter Ended September 30,	Quarter Ended June 30,	Quarter Ended March 31,
2007					
Revenues:					
Product sales	\$ 78,458	\$ 25,196	\$ 15,457	\$ 15,762	\$ 22,043
Biopharmaceutical/other revenues	1,511	92	111	151	1,156
Total revenues	79,969	25,288	15,568	15,913	23,199
Costs and expenses:					
Cost of product sales	31,269	7,995	7,929	6,591	8,754
Research and development	5,845	1,573	1,476	1,292	1,505
Selling and marketing	66,278	16,842	17,632	14,348	17,455
General and administrative	14,573	4,732	3,367	2,914	3,559
Total costs and expenses	117,965	31,142	30,404	25,145	31,273
Loss from operations	(37,996)	(5,854)	(14,836)	(9,232)	(8,074)
Other income (expense):					
Interest income	2,541	559	771	720	491
Interest expense	(28,206)	(9,540)	(7,818)	(6,369)	(4,478)
Gain on disposition of investment	231		73		158
Gain on exchange of convertible debt	30,824			30,824	
Gain on derivative related to convertible notes	3,023	223	2,406	394	
Other income	114	2	15	48	49
Net other income (expense)	8,527	(8,756)	(4,553)	25,617	(3,780)
(Loss) Income before income tax	(29,469)	(14,610)	(19,389)	16,385	(11,854)
Provision for income tax	(384)	(62)	(108)	(108)	(108)
Net (loss) income	\$ (29,853)	\$ (14,672)	\$ (19,497)	\$ 16,277	\$ (11,962)
Net loss per common share:					
Basic	\$ (2.19)	\$ (1.08)	\$ (1.43)	\$ 1.20	\$ (0.88)
Diluted	\$ (2.19)	\$ (1.08)	\$ (1.43)	\$ 0.70	\$ (0.88)
Weighted average common shares outstanding:					
Basic	13,601	13,629	13,605	13,588	13,582
Diluted	13,601	13,629	13,605	26,051	13,582

Table of Contents

OSCIENT PHARMACEUTICALS CORPORATION

Notes to Consolidated Financial Statements (Continued)

(22) Subsequent Events

Extension of 2009 Notes

On January 28, 2009, the Company entered into a first amendment (the "2009 Amendment") to its Note Amendment and Exchange Agreement dated November 17, 2003 with the holders of approximately \$16.8 million of the \$17.0 million outstanding principal and accrued interest of the Company's 5% Convertible Promissory Notes due in 2009. The 2009 Amendment extends for these holders the maturity date of the 5% Convertible Promissory Notes due 2009 from February 6, 2009 to December 1, 2009 and lowers the conversion price at which such holders may convert such notes into shares of the Company's common stock to \$1.10 (the "New 2009 Notes"). The Amendment also provides these holders the option, at their election, to exchange the New 2009 Notes for the Company's 12.50% Convertible Guaranteed Senior Notes due 2011 in a principal amount equal to the principal amount of the New 2009 Notes plus accrued interest thereon. The 12.50% Convertible Guaranteed Senior Notes due 2011 will have the same terms and security interest and be issued under the same indenture as the notes issued in the Company's exchange offer completed on November 25, 2008, as described above.

In the 2009 Amendment, the Company also agreed to file a registration statement within 20 business days of the date of the 2009 Amendment relating to the resale of the 12.50% Convertible Guaranteed Senior Notes due 2011 and the common stock issuable upon conversion thereof. If (i) the Company fails to file the registration statement within 20 business days, (ii) the registration statement does not become effective within 120 days, or (iii) the effectiveness of the registration statement is suspended for more than 90 days, the Company will incur liquidated damages in the form of increased principal in the amount of 0.5% of the aggregate principal amount of the New 2009 Notes for each 20 day period beyond such time periods under (i), (ii) or (iii). In no event will the Company be liable for liquidated damages payments for a time period of greater than 180 days. The Company filed the registration statement on February 13, 2009. However, it has not yet become effective.

The Company also agreed to reimburse the holders party to the 2009 Amendment for their reasonable legal fees relating to the transaction and registration rights up to a specified cap.

Restructuring Plan

On February 11, 2009 the Company announced that it is reducing its workforce by approximately 32% under a plan of termination. The workforce reduction is part of a restructuring of the Company's commercial organization designed to more aggressively preserve the Company's financial resources. The Company commenced notification of employees affected by the workforce reduction on February 11, 2009, and the workforce reduction is expected to be completed by the end of the quarter ended March 31, 2009.

As a result of this restructuring plan, the Company estimates it will record a restructuring charge of approximately \$2 million in the first quarter of 2009, primarily representing cash payments for severance and benefits expenses and equipment lease related expenses. The majority of these payments will be made in the first and second quarters of 2009.

Conversion of 12.50% Notes

At various dates in 2009, a holder of the 12.50% Notes voluntarily converted \$2,129,000 principal of notes. The Company issued 1,935,453 common shares for the converted notes and elected to issue 483,862 common shares to settle the additional interest that was due upon conversion. Had this conversion occurred on December 31, 2008, the net loss per common share would have been \$3.51.